
<html lang="en"     class="pb-page"  data-request-id="7058f69c-52e2-4c56-bc0f-eca98d0d24bf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.9b00864;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor" /></meta><meta name="dc.Creator" content="Tim J.  Fyfe" /></meta><meta name="dc.Creator" content="Barrie  Kellam" /></meta><meta name="dc.Creator" content="David A.  Sykes" /></meta><meta name="dc.Creator" content="Ben  Capuano" /></meta><meta name="dc.Creator" content="Peter J.  Scammells" /></meta><meta name="dc.Creator" content="J. Robert  Lane" /></meta><meta name="dc.Creator" content="Steven J.  Charlton" /></meta><meta name="dc.Creator" content="Shailesh N.  Mistry" /></meta><meta name="dc.Description" content="Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both dr..." /></meta><meta name="Description" content="Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both dr..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 3, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00864" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00864" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00864" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00864" /></link>
        
    
    

<title>Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00864" /></meta><meta property="og:title" content="Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0029.jpeg" /></meta><meta property="og:description" content="Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure–kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00864"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00864">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00864&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00864&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00864&amp;href=/doi/10.1021/acs.jmedchem.9b00864" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 9488-9520</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00846" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00870" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D<sub>2</sub> Receptor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tim J. Fyfe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tim J. Fyfe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry,  Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia</div><div class="loa-info-affiliations-info">School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tim+J.++Fyfe">Tim J. Fyfe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barrie Kellam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barrie Kellam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barrie++Kellam">Barrie Kellam</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0030-9908" title="Orcid link">http://orcid.org/0000-0003-0030-9908</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David A. Sykes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David A. Sykes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+A.++Sykes">David A. Sykes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ben Capuano</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ben Capuano</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Monash University, Parkville, Victoria 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ben++Capuano">Ben Capuano</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5434-0180" title="Orcid link">http://orcid.org/0000-0001-5434-0180</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter J. Scammells</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter J. Scammells</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Monash University, Parkville, Victoria 3052, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+J.++Scammells">Peter J. Scammells</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2930-895X" title="Orcid link">http://orcid.org/0000-0003-2930-895X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Robert Lane</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Robert Lane</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#6e1c010c40020f000b2e00011a1a070009060f03400f0d401b05"><span class="__cf_email__" data-cfemail="f98b969bd79598979cb997968d8d90979e919894d7989ad78c92">[email protected]</span></a>. Phone: +44 115 8230468 (J.R.L.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Robert++Lane">J. Robert Lane</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7361-7875" title="Orcid link">http://orcid.org/0000-0002-7361-7875</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven J. Charlton</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven J. Charlton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Centre of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</div><div class="loa-info-affiliations-info">Excellerate Bioscience Ltd., BioCity, Nottingham NG1 1GF, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0e7d7a6b786b60206d666f7c627a61604e60617a7a676069666f63206f6d207b65"><span class="__cf_email__" data-cfemail="d5a6a1b0a3b0bbfbb6bdb4a7b9a1babb95bbbaa1a1bcbbb2bdb4b8fbb4b6fba0be">[email protected]</span></a>. Phone: +44 115 8230165 (S.J.C.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven+J.++Charlton">Steven J. Charlton</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shailesh N. Mistry</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shailesh N. Mistry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#cbb8a3aaa2a7aeb8a3e5a6a2b8bfb9b28ba5a4bfbfa2a5aca3aaa6e5aaa8e5bea0"><span class="__cf_email__" data-cfemail="87f4efe6eeebe2f4efa9eaeef4f3f5fec7e9e8f3f3eee9e0efe6eaa9e6e4a9f2ec">[email protected]</span></a>. Phone: +44 115 8467983 (S.N.M.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shailesh+N.++Mistry">Shailesh N. Mistry</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2252-1689" title="Orcid link">http://orcid.org/0000-0002-2252-1689</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00864&amp;href=/doi/10.1021%2Facs.jmedchem.9b00864" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 9488–9520</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 3, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 May 2019</li><li><span class="item_label"><b>Published</b> online</span>3 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00864" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00864</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9488%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTim%2BJ.%2BFyfe%252C%2BBarrie%2BKellam%252C%2BDavid%2BA.%2BSykes%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D21%26contentID%3Dacs.jmedchem.9b00864%26title%3DStructure%25E2%2580%2593Kinetic%2BProfiling%2Bof%2BHaloperidol%2BAnalogues%2Bat%2Bthe%2BHuman%2BDopamine%2BD2%2BReceptor%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9520%26publicationDate%3DNovember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00864"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1565</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00864" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure–Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tim&quot;,&quot;last_name&quot;:&quot;J. Fyfe&quot;},{&quot;first_name&quot;:&quot;Barrie&quot;,&quot;last_name&quot;:&quot;Kellam&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;A. Sykes&quot;},{&quot;first_name&quot;:&quot;Ben&quot;,&quot;last_name&quot;:&quot;Capuano&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;J. Scammells&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Robert Lane&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;J. Charlton&quot;},{&quot;first_name&quot;:&quot;Shailesh&quot;,&quot;last_name&quot;:&quot;N. Mistry&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;9488-9520&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00864&quot;},&quot;abstract&quot;:&quot;Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure–kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of th&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00864&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00864" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00864&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00864" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00864&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00864" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00864&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00864&amp;href=/doi/10.1021/acs.jmedchem.9b00864" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00864" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00864" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00864%26sid%3Dliteratum%253Aachs%26pmid%3D31580666%26genre%3Darticle%26aulast%3DFyfe%26date%3D2019%26atitle%3DStructure%25E2%2580%2593Kinetic%2BProfiling%2Bof%2BHaloperidol%2BAnalogues%2Bat%2Bthe%2BHuman%2BDopamine%2BD2%2BReceptor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D21%26spage%3D9488%26epage%3D9520%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291456" title="Hydrocarbons">Hydrocarbons</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292526" title="Equilibrium">Equilibrium</a>,</li><li><a href="/action/doSearch?ConceptID=290905" title="Kinetics">Kinetics</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/jmcmar.2019.62.issue-21/20191114/jmcmar.2019.62.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D<sub>2</sub> receptor (D<sub>2</sub>R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D<sub>2</sub>R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D<sub>2</sub>R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D<sub>2</sub>R action. Our results suggest an optimal kinetic profile for D<sub>2</sub>R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure–kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05013" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05013" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Haloperidol (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is an effective, typical antipsychotic drug (APD) used in the treatment of schizophrenia (SCZ). As for all current APDs, its mechanism of action is primarily through antagonism of dopamine (DA) D<sub>2</sub> receptors (D<sub>2</sub>R) in the mesolimbic pathway, where excessive DA activity is thought to underlie the positive symptoms of schizophrenia.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Unfortunately, <b>1</b>, along with other typical APDs, is associated with severe on-target side effects including extrapyramidal side effect (EPS) (e.g., Parkinsonian symptoms such as bradykinesia and tremor) and hyperprolactinemia.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> These symptoms are mediated by blockade of D<sub>2</sub>R signaling in the nigrostriatal and tuberoinfundibular DA pathways, respectively.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2−7)</a> Tardive dyskinesia is also associated with long-term exposure to typical APDs such as <b>1</b>.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0001.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Typical APD haloperidol (<b>1</b>) and atypical APD clozapine (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Atypical APDs display a diminished incidence of EPS and hyperprolactinemia relative to typical APDs.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> While the primary distinction between typicality and atypicality is based on such clinical observations, the mechanism(s) that might drive this distinction remains unclear. Clozapine (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is a prototypical atypical antipsychotic. It has a complex pharmacological profile with high affinity for other members of the biogenic amine receptor family and, in particular, a relatively high affinity for the serotonin 2A receptor (5-HT<sub>2A</sub>R).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Many atypical APDs have similar pharmacology, leading to the hypothesis that a relatively high affinity for the 5HT<sub>2A</sub>R as compared to the D<sub>2</sub>R confers atypicality.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13−16)</a> However, not all atypical APDs share this profile, suggesting that this theory cannot account for all examples of atypicality.<a onclick="showRef(event, 'ref13 ref17'); return false;" href="javascript:void(0);" class="ref ref13 ref17">(13,17)</a> Unfortunately, this lack of selectivity across aminergic receptors is associated with off-target side effects, including sedation, metabolic disorders, weight gain, urinary incontinence and constipation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Compound <b>2</b> can also cause acute agranulocytosis, a potentially life-threatening white blood cell disorder.</div><div class="NLM_p">The relatively fast rate at which <b>2</b> and other related APDs dissociate from the D<sub>2</sub>R has also been suggested to be the basis for an atypical profile.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Rapid dissociation of an antagonist might allow a fraction of D<sub>2</sub>Rs to be occupied by transiently high concentrations of DA released into the synapse, whereas an antagonist with a slow dissociation rate would cause insurmountable antagonism. Central to this hypothesis was the consensus that APDs exhibit similar association rates (<i>k</i><sub>on</sub>) for the D<sub>2</sub>R, meaning that affinity is largely mediated by differences in dissociation rate (<i>k</i><sub>off</sub>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Olanzapine, however, which has a similar high affinity for the D<sub>2</sub>R as many typical antipsychotics, displays an atypical profile.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The incorporation of drug–receptor kinetic binding parameters into drug discovery programs is seen as increasingly important for the development of next-generation therapeutics.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28">(20−28)</a> Previous efforts to derive estimates of APD kinetic rate constants have used radiometric detection methods with limited assay throughput.<a onclick="showRef(event, 'ref19 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref19 ref29 ref30">(19,29,30)</a> We have recently developed a competition association assay using time-resolved fluorescence resonance energy transfer (TR-FRET) to determine ligand kinetic parameters of unlabeled D<sub>2</sub>R agonists<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> and profiled an extensive series of APDs to explore the kinetic basis for on-target side effects.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> We found that the association rates of the APDs varied over 3 orders of magnitude and that association rates, rather than dissociation rates, correlated with EPS. These observations led us to propose a revised kinetic hypothesis whereby a rapid association rate leads to drug rebinding at the D<sub>2</sub>R, maintaining a higher concentration of APD in the synaptic compartment. This causes increased competition with DA, leading to EPS. In contrast, hyperprolactinaemia was correlated with APD dissociation rate.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Optimizing D<sub>2</sub>R binding kinetics may permit the design of novel tools to test this kinetic hypothesis, as well as facilitate the generation of new APDs with an improved therapeutic profile.</div><div class="NLM_p">Although clozapine (<b>2</b>) appears to possess the desired slow on/fast off kinetic profile for reduced on-target side effects [<i>k</i><sub>on</sub> = (8.23 ± 1.42) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.67 ± 0.25 min<sup>–1</sup>],<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> it displays affinity for many aminergic G protein-coupled receptors (GPCRs), contributing to its off-target side effects. Haloperidol (<b>1</b>), in contrast, has a better off-target selectivity profile, but an undesirable fast on/slow off kinetic profile at the D<sub>2</sub>R [<i>k</i><sub>on</sub> = (1.29 ± 0.21) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.61 ± 0.04 min<sup>–1</sup>] that contributes to its on-target side effects.</div><div class="NLM_p">The aim of the current study was to optimize the kinetic binding parameters of the more selective scaffold of haloperidol toward a slow on/fast off profile. To this end, we herein describe the design and synthesis of 50 analogues of <b>1</b>, focusing on structural modification of four key moieties (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and use competition association kinetic binding methodology to determine their association and dissociation rates and equilibrium affinities at the D<sub>2</sub>R. We reveal that both the association and dissociation kinetics of this scaffold can vary considerably with subtle structural modification. Interestingly, we have identified previous analogues of <b>1</b>, among others, that may have been overlooked on the basis of affinity-driven scaffold optimization, that possess favorable kinetic profiles. These data reveal the structure–kinetic relationships (SKRs) of <b>1</b>, as well as identify novel tool compounds with which to interrogate the relationship between APD kinetic binding parameters and on-target side-effect profiles. Although the structure–activity relationships (SARs) surrounding the butyrophenone scaffold of APDs have been extensively studied in previous years,<a onclick="showRef(event, 'ref34 ref35 ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37 ref38 ref39">(34−39)</a> to our knowledge, these data represent the first reported SKR relating to analogues of <b>1</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0002.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural regions of haloperidol (<b>1</b>) investigated as part of the SKR study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">To begin our structure–kinetic study, we focused on modifying four distinct regions of <b>1</b>, namely, the <i>para</i>-fluorophenyl (red box), keto-alkyl linker (green box), piperidinol (orange box), and <i>para</i>-chlorophenyl (blue box) moieties, as depicted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. For completeness, we included both established and novel analogues of <b>1</b> in our approach, covering 50 compounds in totality.</div><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5"> Variation of <i>para</i>-Chlorophenyl Moiety of <b>1</b></h4><div class="NLM_p">In evaluating the positional effects of halogen substitution on the <i>p</i>-chlorophenyl moiety, we initially synthesized analogues bearing the chloro substituent in the <i>ortho</i> (<b>8n</b>) and <i>meta</i> (<b>8a</b>) positions, as well as incorporation of all possible dichloro substitution patterns [2,3-diCl (<b>8b</b>); 2,4-diCl (<b>8c</b>); 2,5-diCl (<b>8d</b>); 2,6-diCl (<b>8e</b>); 3,4-diCl (<b>8f</b>);<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and 3,5-diCl (<b>8g</b>)]. In addition, we wanted to assess the effects of halogen removal through the unsubstituted analogue (<b>8h</b>),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> as well as alternative para substituents, including methyl (<b>8i</b>),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> trifluoromethyl (<b>8j</b>), <i>N</i>,<i>N</i>-dimethylamino (<b>8k</b>), and fluoro (<b>8l</b>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The synthesis of these compounds is summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, the appropriately substituted bromobenzene (<b>3a</b>–<b>l</b>) underwent lithiation using <i>n</i>-BuLi, followed by treatment with commercially available <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (<b>4</b>) to afford the corresponding <i>N</i>-Boc-protected phenylpiperidinols (<b>5a</b>–<b>l</b>). HCl-mediated <i>N</i>-Boc-deprotection afforded the corresponding hydrochloride salts or free amines following basic work-up (<b>6a</b>–<b>l</b>). Finally, nucleophilic displacement of key intermediate 4-chloro-1-(4-fluorophenyl)butan-1-one (<b>7a</b>) with the appropriate substituted phenylpiperidinol (<b>6a</b>–<b>l</b>) was achieved by refluxing in toluene in the presence of KI and NaHCO<sub>3</sub>, to afford the desired final analogues (<b>8a</b>–<b>l</b>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Haloperidol (<b>1</b>) Analogues with Modification to the <i>para</i>-Chlorophenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, tetrahydrofuran (THF), −78 °C, 3–8 h, 50–88% (<b>5a</b>–<b>l</b>); (ii) HCl (4 M), 1,4-dioxane, 1–3 h, 75–98% (<b>6a</b>, <b>6c</b>, <b>6e</b>, <b>6f</b>, <b>6h</b>–<b>l</b> (free base) <b>6b</b>, <b>6d</b>, <b>6g</b> (HCl salt)); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 45–70% (<b>8a</b>–<b>l</b>).</p></p></figure><div class="NLM_p">Although established, the employed lithiation chemistry proved to be problematic toward the synthesis of the <i>o</i>-chloro analogue (<b>8n</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Standard conditions failed to deliver the desired <i>N</i>-Boc-protected piperidinol intermediate from <b>3m</b>, instead producing the biphenyl piperidinol (<b>5m</b>). While unintended, this molecule would still provide additional information to our study and was <i>N</i>-Boc-deprotected to give <b>6m</b>, followed by N-alkylation with <b>7a</b> using conditions outlined previously, to furnish a biphenyl analogue (<b>8m</b>). In contrast, the desired <i>o</i>-chloro analogue was accessed in three steps using an alternative approach (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Grignard addition of <b>3m</b> to <b>4</b> yielded <i>o</i>-chlorophenyl piperidinol intermediate <b>5n</b>, which underwent <i>N</i>-Boc deprotection to give <b>6n</b>. Final N-alkylation with <b>7a</b> furnished <b>8n</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Biphenyl Side Product and <i>ortho</i>-Cl Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, THF, −78 °C, 6 h, 55% (<b>5m</b>); (ii) Mg, I<sub>2(cat.)</sub>, Et<sub>2</sub>O, 0 °C to reflux, 3 h, 54% (<b>5n</b>); (iii) HCl, 1,4-dioxane, room temperature (rt), 2 h, 72–96% (<b>6m</b>, <b>6n</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 62–76% (<b>8m</b>, <b>8n</b>).</p></p></figure></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> Variation of the <i>p</i>-Fluorophenyl Moiety of <b>1</b></h4><div class="NLM_p">To investigate positional effects of fluorine substitution on the butyrophenone phenyl ring on the kinetics of <b>1</b>, we generated analogues with all possible mono and difluoro substituents [2-F (<b>14a</b>);<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> 3-F (<b>14b</b>);<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> 2,3-diF (<b>14c</b>); 2,4-diF (<b>14d</b>); 2,5-diF (<b>14e</b>); 2,6-diF (<b>14f</b>); 3,4-diF (<b>14g</b>);<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and 3,5-diF (<b>14h</b>)], as well as two <i>ortho</i>-substituted analogues [2-Cl (<b>14i</b>) and 2-Me (<b>14j</b>)], a para-substituted analogue [4-Cl (<b>16k</b>)]<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and a <i>des</i>-fluoro variant (<b>14l</b>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> As detailed in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, commercially available 3-butynol (<b>9</b>) was treated with SOCl<sub>2</sub> and catalytic pyridine at reflux temperature, followed by distillation to afford 4-chlorobut-1-yne (<b>10</b>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The appropriate iodobenzene (<b>11a</b>–<b>j</b>) was then employed in a Pd-catalyzed Sonogashira cross-coupling reaction<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> with <b>10</b>, affording the corresponding internal aryl alkynes (<b>12a</b>–<b>j</b>). Next, we utilized a TfOH-catalyzed metal-free regioselective Markovnikov-type hydration protocol<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> with 2,2,2-trifluoroethanol as solvent in the presence of H<sub>2</sub>O, furnishing the corresponding aryl ketones (<b>13a</b>–<b>j</b>). Finally, N-alkylation of commercially available key intermediate <b>7b</b> with each synthesized alkyl chloride (<b>13a</b>, <b>13b</b>, <b>13d</b>, <b>13e</b>, <b>13g</b>–<b>j</b>) furnished final analogues <b>14a</b>, <b>14b</b>, <b>14d</b>, <b>14e</b>, and <b>14g</b>–<b>j</b>. Alternatively, 4-chloro-1-(4-chlorophenyl)butan-1-one (<b>13l</b>) was accessed via Friedel–Crafts acylation, followed by N-alkylation of <b>7b</b> to afford <b>14k</b>. Finally, commercially available 4-chloro-1-phenylbutan-1-one (<b>13l</b>) was aminated with <b>7b</b> to afford the <i>des</i>-fluoro analogue <b>14l</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Analogues of <b>1</b> with Modification to the <i>p</i>-Fluorophenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SOCl<sub>2</sub>, pyridine, 0 °C to reflux, 30 min, 82%; (ii) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, Et<sub>3</sub>N, 1,4-dioxane, 50 °C, 1–3 h, 45–85% (<b>12a</b>–<b>j</b>); (iii) TfOH, H<sub>2</sub>O, CF<sub>3</sub>CH<sub>2</sub>OH, 60 °C, 3–8 h, 50–90% (<b>13a</b>–<b>j</b>); (iv) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 50–82% (<b>14a</b>, <b>14b</b>, <b>14d</b>, <b>14e</b>, <b>14g</b>–<b>l</b>); <b>14c</b> and <b>14f</b> were detected but unable to be isolated in appreciable yield.</p></p></figure><div class="NLM_p">The synthesis of analogues containing 2,3-difluorophenyl (<b>14c</b>) and 2,6-difluorophenyl (<b>14f</b>) substituents was problematic. When attempting to N-alkylate key intermediate <b>7b</b> with the corresponding alkyl halides (<b>13c</b>, <b>13f</b>), major side products due to a competing nucleophilic aromatic substitution (S<sub>N</sub>Ar) reaction were observed, making purification of the target compounds by flash column chromatography (FCC) and preparative high-performance liquid chromatography (HPLC) extremely challenging. These side products are believed to arise due to activation of the position <i>ortho</i> to the ketone moiety, when a fluoro substituent is present. To circumvent the S<sub>N</sub>Ar reaction, syntheses of the affected analogues were modified to incorporate ketal protection/deprotection of the ketone, permitting nucleophilic displacement of the alkyl halide only (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Beginning with ketal protection of <b>13c</b>, we employed a <i>p-</i>TsOH-catalyzed reaction with trimethyl orthoformate in MeOH at room temperature, to afford the corresponding dimethyl ketal (<b>15c</b>). Alternatively, <b>13f</b> was reacted with 1,2-ethanediol in the presence of catalytic <i>p-</i>TsOH in toluene under Dean–Stark conditions, to afford the corresponding 1,3-dioxolane (<b>15f</b>). These compounds were then subjected to nucleophilic displacement using <b>7b</b> to furnish <b>16c</b> and <b>16f</b>, followed by acid-catalyzed hydrolysis in acetone at reflux, affording final compounds <b>14c</b> and <b>14f</b>.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 2,3- and 2,6-Difluoro Analogues of <b>1</b> Using Various Protection Strategies<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) trimethylorthoformate, <i>p</i>-TsOH·H<sub>2</sub>O, MeOH, rt, 12 h, 77% (<b>15c</b>); (ii) ethylene glycol, <i>p</i>-TsOH·H<sub>2</sub>O, toluene, reflux (Dean–Stark), 16 h, 83% (<b>15f</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 71–77% (<b>16c</b>, <b>16f</b>); (iv) <i>p</i>-TsOH·H<sub>2</sub>O, 15:1 acetone/H<sub>2</sub>O, reflux, 48 h, 76–82% (<b>14c</b>, <b>14f</b>).</p></p></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Variation of Ketone and Linker Moiety of <b>1</b></h4><div class="NLM_p">We focused on replacement of the ketone group of <b>1</b> with a range of moieties, including ether, thioether, and the corresponding carbinol (racemic). The ether- and thioether-variants of <b>1</b> were accessed using a literature procedure in three steps<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>17a</b> and <b>17b</b>, respectively; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 1</a>), while the corresponding secondary alcohol was afforded in two steps, also through the literature procedure (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>)<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 2</a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0003.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Literature analogues of <b>1</b> synthesized using various methodologies. Ether- and thioether analogues<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>17a</b> and <b>17b</b>, respectively); racemic alcohol analogue<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (<b>18</b>); tropanyl analogue<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>42</b>); piperazinyl analogue<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>43</b>); phenyl- and <i>p</i>-chlorophenylpiperidine analogues<a onclick="showRef(event, 'ref38 ref47'); return false;" href="javascript:void(0);" class="ref ref38 ref47">(38,47)</a> (<b>47</b> and <b>48</b>, respectively); reverse substitution analogue<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (<b>53</b>); and <i>des</i>-halo analogue<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our subsequent focus was to further understand the importance and effect of geometry on the kinetics of conformationally restricted analogues of <b>1</b>, via synthesis of both olefin geometric isomers. The <i>trans</i>-olefin <b>23</b> was accessed through a five-step chemical synthesis as outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, beginning with a one-pot base-mediated intramolecular enolate alkylation of key intermediate <b>7a</b>, to furnish cyclopropyl(4-fluorophenyl)methanone (<b>19</b>) in quantitative yield. Subsequent reduction with NaBH<sub>4</sub> afforded secondary alcohol <b>20</b>, followed by a vanadyl acetylacetonate-catalyzed stereoselective isomerization in chlorobenzene to yield (<i>E</i>)-4-(4-fluorophenyl)but-3-en-1-ol (<b>21</b>) as the exclusive geometric isomer. Compound <b>21</b> was subsequently activated with methanesulfonyl chloride to give mesylate <b>22</b>. This was followed by N-alkylation of <b>7b</b> using standard conditions, affording final olefin analogue <b>23</b>.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>trans-</i>Olefin Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, MeOH, 60 °C, 5 h, quantitative; (ii) NaBH<sub>4</sub>, MeOH, 0 °C to rt, 3 h, 99%; (iii) VO(acac)<sub>2</sub>, butylated hydroxytoluene, PhCl, 80 °C, 48 h, 35%; (iv) MsCl, dichloromethane (DCM), Et<sub>3</sub>N, rt, 3 h, 88%; (v) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 82%.</p></p></figure><div class="NLM_p">The <i>cis</i>-isomer <b>28</b> was accessed through a three-step synthesis as outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Initially, Ni-catalyzed stereoselective arylation of 2,3-dihydrofuran <b>24</b> with (4-fluorophenyl)magnesium bromide (<b>25</b>) at −30 °C successfully afforded the <i>cis</i>-olefin <b>26</b><a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> as the exclusive isomer. This compound was then mesylated using standard conditions to afford <b>27</b>, followed by N-alkylation of <b>7b</b> using conditions outlined previously, furnishing <b>28</b>. As outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>, both trans- and cis-isomers (<b>21</b> and <b>26</b>, respectively) were treated with diethylzinc and diiodomethane using Simmons–Smith<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> conditions to access the corresponding racemic <i>trans</i>- and <i>cis</i>-cyclopropanes (<b>29</b> and <b>30</b>, respectively). This was followed by mesylation to give <b>29a</b> and <b>30a</b> and subsequent N-alkylation of <b>7b</b> to afford racemic <b>29b</b> and <b>30b</b>.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0013.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>cis-</i>Olefin Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Ni[COD]<sub>2</sub>, 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride, LiCl, THF, −30 °C, 8 h, 31%; (ii) MsCl, Et<sub>3</sub>N, DCM, rt, 24 h, 90%; (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 75%.</p></p></figure><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0014.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Both <i>trans</i>- and <i>cis</i>-Cyclopropane Enantiomers of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Et<sub>2</sub>Zn, CH<sub>2</sub>I<sub>2</sub>, DCM, 0 °C to rt, 24 h, 95–98% (<b>29</b>, <b>30</b>); (ii) MsCl, Et<sub>3</sub>N, DCM, rt, 90–95% (<b>29a</b>, <b>30a</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 67–70% (<b>29b</b>, <b>30b</b>).</p></p></figure><div class="NLM_p">Next, we focused on the synthesis of both propiophenone and valerophenone analogues of <b>1</b> that maintained the ketone functionality (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Beginning with Friedel–Crafts acylation chemistry, the appropriate commercially available acyl chloride (<b>31a</b>, <b>31c</b>) was reacted with fluorobenzene <b>32</b> in the presence of stoichiometric AlCl<sub>3</sub> to afford the corresponding phenones (<b>33a</b>,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><b>33c</b><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a>). This was followed by N-alkylation of <b>7b</b> to afford final analogues (<b>34a</b>, <b>34c</b><a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>). In addition, we wanted to access the 1,3-propylene, 1,4-butylene, and 1,5-pentylene analogues of <b>1</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). To achieve this, phenones <b>33a</b>, <b>7a</b>, and <b>33c</b> were treated with triethylsilane in trifluoroacetic acid (TFA), followed by evaporation and direct chromatographic purification to furnish the corresponding reduced intermediates <b>35a</b>–<b>c</b>. Finally, N-alkylation of key intermediate <b>7b</b> furnished alkane analogues <b>36a</b>–<b>c</b>.</div><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0015.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Ketone and Alkane Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) AlCl<sub>3</sub>, DCM, 0 °C to rt, 6 h, 85% (<b>33a</b>, <b>33c</b>); (ii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 75–90% (<b>34a</b>, <b>34c</b>); (iii) triethylsilane, trifluoroacetic acid, 0 °C, 2–3 h, 75–85% (<b>35a</b>–<b>c</b>); (iv) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 72–91% (<b>36a</b>–<b>c</b>).</p></p></figure><div class="NLM_p">To assess analogues of <b>1</b> incorporating internal aromatic alkynes (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>), 1-fluoro-4-iodobenzene (<b>37</b>) was initially subjected to modified Sonagashira conditions<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> using commercially available alcohols (<b>38a</b>, <b>38c</b>), affording aryl alkynes (<b>39a</b>,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a><b>39c</b>). Next, the alcohols were converted to their corresponding mesylates (<b>40a</b>,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><b>40c</b>), followed by N-alkylation of <b>7b</b> with the appropriate mesylate to afford the corresponding final propynyl and pentynyl analogues (<b>41a</b> and <b>41c</b>, respectively). The butynyl analogue <b>41b</b> was accessed via the cross-coupling reaction between key intermediate <b>10</b> and 1-fluoro-4-iodobenzene (<b>37</b>), providing aryl alkyne intermediate <b>40b</b>, which underwent amination with <b>7b</b>.</div><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0016.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Internal Alkyne Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Et<sub>3</sub>N, MeCN, rt, 5 h, 94% (<b>39a</b>, <b>39c</b>); (ii) methanesulfonyl chloride, Et<sub>3</sub>N, DCM, 24 h, 93% (<b>40a</b>, <b>40c</b>); (iii) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Et<sub>3</sub>N, 1,4-dioxane, 50 °C, 3 h, 75% (<b>40b</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 68–74% (<b>41a</b>–<b>c</b>).</p></p></figure></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Variation of the Piperidinol Moiety of <b>1</b></h4><div class="NLM_p">Modification to the piperidinol moiety of <b>1</b> was another key interest in our SKR investigation. To observe the kinetic effect of introducing an ethylene bridge on the piperidinol, we synthesized tropanyl analogue <b>42</b> according to a literature procedure<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 3</a>), utilizing <i>n</i>-BuLi in place of Grignard chemistry. We then sought to modify the tertiary alcohol group, beginning with synthesis of piperazinyl analogue <b>43</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This compound was accessed in two steps via the construction of the piperazine ring and subsequent N-alkylation with <b>7a</b><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 4</a>).</div><div class="NLM_p">Removing the tertiary alcohol within <b>1</b> to generate the corresponding 3,6-dihydropyridine (<b>45</b>) was our next focus, as well as further elaboration of the olefin to yield the corresponding cycloalkane derivative (<b>46</b>) (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>). Key piperidinol intermediate <b>7b</b> was first dehydrated using neat concentrated HCl followed by an alkaline work-up to afford the 1,2,3,6-tetrahydropyridine (<b>44</b>). Displacement of <b>7a</b> with <b>44</b> furnished olefin <b>45</b>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> This molecule was subsequently treated using Simmons–Smith<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> conditions, as outlined previously, to afford the corresponding cyclopropane analogue <b>46</b>.</div><figure id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0017.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Dihydropyridyl and Fused Cyclopropane Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HCl (conc.), reflux, 5 h, quantitative; (ii) <b>7a</b>, NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 65% (<b>45</b>); (iii) Et<sub>2</sub>Zn, CH<sub>2</sub>I<sub>2</sub>, DCM, 0 °C to rt, 24 h, 75% (<b>46</b>).</p></p></figure><div class="NLM_p">In addition, we synthesized two analogues of <b>1</b> containing modified phenyl piperidine (<b>47</b>)<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and <i>p</i>-chlorophenyl piperidine (<b>48</b>)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> cores (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), of which the synthesis is detailed in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 5</a>.</div><div class="NLM_p">Further emphasis was placed on the tertiary alcohol contained within <b>1</b>, where we sought to assess the impact of O-methylation (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). <i>N</i>-Boc-protection of key intermediate <b>7b</b> gave <b>49</b>, followed by O-alkylation with methyl iodide to afford the corresponding methyl ether <b>50</b>. This was followed by <i>N</i>-Boc-deprotection to give the secondary amine hydrochloride <b>51</b>. Final N-alkylation with key intermediate <b>7a</b> afforded compound <b>52</b>.</div><figure id="sch11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0018.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Methyl Ether Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt, 4 h, 85%; (ii) NaH, MeI, DMF, rt, 24 h, 80%; (iii) HCl, 1,4-dioxane, rt, 2 h, 95%; (iv) <b>7a</b>, NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 70%.</p></p></figure></div><div id="sec2_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Dual Modification to Halo-Aryl Moieties of <b>1</b></h4><div class="NLM_p last">Recent molecular dynamics (MD) simulations by Thomas et al.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> were used to understand the ligand binding pathways of <b>1</b> and <b>2</b> at the D<sub>2</sub>R/D<sub>3</sub>R. The final stable pose of <b>1</b> was shown to occupy the same space as predicted in a number of molecular docking studies;<a onclick="showRef(event, 'ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61">(59−61)</a> however, the molecular orientation was contradictory to these data by 180°, with the butyrophenone moiety buried most deeply in the receptor. Therefore, and due to confounding studies regarding the orientation of <b>1</b> at the D<sub>2</sub>R, it was of interest to investigate the kinetic effects of modifying both phenyl moieties of <b>1</b> simultaneously. Accordingly, we synthesized a further two structural analogues of <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). These modifications included swapping both aromatic termini (<b>53</b>), as well as removal of these aromatic substituents (<b>54</b>). <b>53</b> was synthesized according to a literature procedure following Friedel–Crafts acylation and N-alkylation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 6</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Compound <b>54</b> was similarly accessed through literature methods (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Scheme 7</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Pharmacology</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Characterization of PPHT-Red Binding</h4><div class="NLM_p last">Specific equilibrium binding of the agonist PPHT-red (Cisbio Bioassays) to the human D<sub>2L</sub> receptor (hD<sub>2L</sub>R) was saturable and best described by the interaction of PPHT-red with a single population of binding sites, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Figure 1A</a>. From these studies, the equilibrium dissociation constant (<i>K</i><sub>d</sub>) of the fluorescent ligand was determined to be 43.2 ± 0.37 nM. The binding kinetics of PPHT-red were characterized by monitoring the observed association rates at six different ligand concentrations (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Figure 1B</a>). The observed rate of association was related to the PPHT-red concentration in a linear fashion (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Figure 1C</a>). Kinetic rate parameters for PPHT-red were calculated by globally fitting the association time courses, resulting in a <i>k</i><sub>on</sub> of (9.21 ± 0.24) × 10<sup>6</sup> M<sup>–1</sup> min<sup>–1</sup> and <i>k</i><sub>off</sub> of 0.35 ± 0.01 min<sup>–1</sup>. The resulting <i>K</i><sub>d</sub> (<i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>) of 46.3 ± 0.15 nM was comparable to that obtained from equilibrium studies.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Characterization of Kinetic Binding Parameters of Unlabeled Analogues of <b>1</b> at the D<sub>2</sub>R</h4><div class="NLM_p">The competition association binding method allows the characterization of the kinetic rate parameters of unlabeled compounds (<i>k</i><sub>on</sub>, <i>k</i><sub>off</sub>) and the subsequent calculation of a kinetically derived (<i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>) equilibrium dissociation constant (<i>K</i><sub>d</sub>). The binding affinity of the various ligands for the hD<sub>2L</sub>R was measured at equilibrium at 37 °C in a buffer containing 5′-guanylyl imidodiphosphate (GppNHp) (0.1 mM) to ensure that antagonist and tracer binding only occurred to the G protein-uncoupled form of the receptor. <i>K</i><sub>i</sub> values for compound <b>1</b> and the 50 structural analogues studied are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, and representative competition curves are presented in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A. In these tables, we have separated the analogues into five groups, those that have been modified at the <i>para</i>-chlorophenyl, <i>para</i>-fluorophenyl, piperidinol, ketone/alkyl linker, and concurrent phenyl ring moiety modification, as indicated in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. Representative kinetic competition curves for selected analogues are given in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B–D. Association curves for PPHT-red alone and in the presence of competitor were globally fitted to <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a> enabling the calculation of both <i>k</i><sub>on</sub> (<i>k</i><sub>3</sub>) and <i>k</i><sub>off</sub> (<i>k</i><sub>4</sub>) for each of the ligands, as reported in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. To validate the rate constants, we compared the kinetically derived dissociation constant (<i>K</i><sub>d</sub>) values (<i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>) with the dissociation constant (<i>K</i><sub>i</sub>) obtained from equilibrium competition binding experiments (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). There was a good correlation between these two values for all compounds tested (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.99, <i>p</i> < 0.0001), indicating that the parameters determined in the kinetic assay were in agreement with those determined at equilibrium.</div><figure id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0004.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Equilibrium and competition association binding. (A) Competition between PPHT-red (12.5 nM) and increasing concentrations of <b>1</b> and representative analogues (<b>8b</b>, <b>8d</b>, <b>8g</b>, <b>8l</b>, <b>14j</b>, <b>14k</b>, <b>45</b>, <b>46</b>, <b>48</b>, <b>52</b>, <b>53</b>) at the hD<sub>2L</sub>R. PPHT-red competition association curves in the presence of (B) <b>30b</b>, (C) <b>34c</b>, and (D) <b>42</b>. All binding reactions were performed at 37 °C in the presence of GppNHp (100 μM) with nonspecific binding levels determined by inclusion of haloperidol (10 μM). Kinetic and equilibrium data were fitted to the equations described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> to calculate <i>K</i><sub>i</sub>, <i>K</i><sub>d</sub>, <i>k</i><sub>on</sub>, and <i>k</i><sub>off</sub> values for the unlabeled ligands: these are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as singlet values from a representative of four experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0005.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlating equilibrium and kinetically derived parameters for haloperidol (<b>1</b>) and 51 structural analogues at the dopamine D<sub>2</sub> receptor. Correlation between p<i>K</i><sub>i</sub> and kinetically derived p<i>K</i><sub>d</sub> for the 51 test ligands including haloperidol. p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium as exemplified in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A. The values composing the kinetically derived p<i>K</i><sub>d</sub> (−log (<i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>)) were taken from competition kinetic association experiments as exemplified in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B–D. All data used in these plots are detailed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as mean ± S.E.M. from four separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Kinetic Binding Parameters for Haloperidol (<b>1</b>) and Unlabeled Analogues of <b>1</b> for Human D<sub>2L</sub> Receptors Estimated Using TR-FRET Assay<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0019.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0020.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The rate constants <i>k</i><sub>off</sub> and <i>k</i><sub>on</sub>, the half-life (<i>t</i><sub>1/2</sub>), and the kinetically derived p<i>K</i><sub>d</sub> were obtained from competition kinetic association experiments using PPHT-red.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium. Data are presented as mean ± standard error of the mean (S.E.M.) from four experiments performed in singlet.</p></div></div><div></div></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Characterization of the Kinetic Profile of <b>1</b> at the hD<sub>2L</sub>R</h4><div class="NLM_p">The equilibrium affinities and kinetic rate constants of <b>1</b> and <b>2</b> have recently been determined using the aforementioned TR-FRET assay.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Prior to initiating an investigation into <b>1</b>, we also assessed its parameters and determined similar estimates in agreement with the literature<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> [<i>k</i><sub>off</sub> = 0.61 ± 0.04 min<sup>–1</sup>, <i>k</i><sub>on</sub> = (1.29 ± 0.21) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, p<i>K</i><sub>d</sub> = 9.31 ± 0.05, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>], validating our experimental conditions and further demonstrating that <b>1</b> is indeed a high-affinity, fast <i>k</i><sub>on</sub>/slow <i>k</i><sub>off</sub> compound at the hD<sub>2L</sub>R. Kinetic estimates for <b>1</b> are outlined in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, and all experimental structure–kinetic data will make specific reference to these data as a comparison. Furthermore, compounds with fast <i>k</i><sub>off</sub> values approaching >1.0 min<sup>–1</sup> were reassessed using a modified injection protocol, whereby the hD<sub>2L</sub>R membrane homogenates were introduced using an online injector while simultaneously measuring TR-FRET binding. This is to avoid any delay between membrane addition and initial TR-FRET measurement, improving the quality of the nonlinear fit for compounds with rapid equilibration kinetics and thus increasing our confidence in the rate parameter estimate. Characterization of <b>1</b> using this methodology returned comparable estimates to the offline injection protocol. Additional data acquired for selected compounds using this methodology are located in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinetic Binding Parameters of Unlabeled Analogues of <b>1</b> with Modification to the <i>para</i>-Fluorophenyl Moiety for Human D<sub>2L</sub> Receptors Estimated Using TR-FRET assay<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0021.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0022.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The rate constants <i>k</i><sub>off</sub> and <i>k</i><sub>on</sub>, the half-life (<i>t</i><sub>1/2</sub>), and the kinetically derived p<i>K</i><sub>d</sub> were obtained from competition kinetic association experiments using PPHT-red.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Completed using the online injection protocol.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Kinetic Binding Parameters of Unlabeled Analogues of <b>1</b> with Modifications to the Ketone and Linker Moieties for Human D<sub>2L</sub> Receptors Estimated Using TR-FRET Assay<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0023.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0024.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The rate constants <i>k</i><sub>off</sub> and <i>k</i><sub>on</sub>, the half-life (<i>t</i><sub>1/2</sub>), and the kinetically derived p<i>K</i><sub>d</sub> were obtained from competition kinetic association experiments using PPHT-red.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Completed using the online injection protocol.</p></div></div><div></div></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Measurement of the Functional Activity of Analogues of <b>1</b></h4><div class="NLM_p last"><b>1</b> is a hD<sub>2L</sub>R antagonist. It is possible, however, that modification of this structure may yield agonists. We measured the activity of all analogues in an assay measuring inhibition of intracellular adenosine cyclic 3′,5′-phosphate (cAMP) production stimulated by forskolin using a bioluminescence resonance energy transfer (BRET) biosensor. This is a measurement of Gi/o G protein activation by the hD<sub>2L</sub>R. We performed two types of measurements. In the first, we tested the ability of a 10 μM concentration of each analogue alone to activate the hD<sub>2L</sub>R, and in the second, we measured the ability of each analogue to antagonize the action of an EC<sub>80</sub> (30 nM) concentration of the agonist dopamine. The results of these experiments revealed that none of the compounds displayed agonist activity apart from <b>47</b>, which displayed 20% of the maximal effect of dopamine at a concentration of 10 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Table 1</a>). All compounds antagonized the effect of dopamine to a basal (unstimulated) level except for <b>47</b>, which reduced the effect of dopamine to a level consistent with the intrinsic activity determined in the agonist assay protocol (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Table 1</a>).</div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Kinetic Effects of Variation of the <i>para</i>-Chlorophenyl Moiety of <b>1</b></h4><div class="NLM_p">Initially focusing on modification of the <i>para</i>-chlorophenyl moiety of <b>1</b>, we sought to assess the kinetic effect of all possible mono- (<b>8a</b>, <b>8n</b>) and dichlorophenyl substituents (<b>8b</b>–<b>g</b>), as well as variation of the para substituent (<b>8h</b>–<b>m</b>) through the synthesis of 14 structural analogues (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These compounds exhibited a 17-fold variation in affinity, which was driven by interesting changes in kinetic parameters, spanning a >10-fold variation in the association rate [<i>k</i><sub>on</sub> = (1.22 ± 0.20) × 10<sup>8</sup>–(2.95 ± 0.30) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>] and a ∼4-fold variation in the dissociation rate (<i>k</i><sub>off</sub> = 0.30 ± 0.01–1.25 ± 0.09 min<sup>–1</sup>).</div><div class="NLM_p">The data show that analogues lacking an electron-withdrawing group (EWG), (chloro) substituent, at the <i>meta</i>- and para-positions have reduced binding affinity, and this loss is mirrored by a decrease in <i>k</i><sub>on</sub> and an increase in <i>k</i><sub>off</sub> relative to <b>1</b>. For example, the <i>ortho</i>-Cl analogue (<b>8n</b>) displayed an ∼8-fold reduction in affinity resulting from a decreased <i>k</i><sub>on</sub> and increased <i>k</i><sub>off</sub> [<i>k</i><sub>on</sub> = (3.54 ± 0.16) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.16 ± 0.11 min<sup>–1</sup>]. This was also evident for the 2,6-diCl analogue (<b>8e</b>) losing ∼6-fold affinity, also mediated by a slowed association and an increased dissociation rate [<i>k</i><sub>on</sub> = (5.07 ± 0.47) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.05 ± 0.05 min<sup>–1</sup>]. This trend continued with the <i>des</i>-Cl analogue <b>8h</b>, as it also revealed a similar change in rate constants [<i>k</i><sub>on</sub> = (1.22 ± 0.20) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.02 ± 0.10 min<sup>–1</sup>].</div><div class="NLM_p">Addition of a strong electron-donating group (EDG) (<i>N</i>,<i>N</i>-dimethylamino, <b>8k</b>) results in a >10-fold decrease in affinity (p<i>K</i><sub>d</sub> = 8.12 ± 0.04) and again appears to be driven by a decrease in <i>k</i><sub>on</sub> and an increase in <i>k</i><sub>off</sub> [<i>k</i><sub>on</sub> = (1.64 ± 0.12) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.25 ± 0.09 min<sup>–1</sup>]. Furthermore, other analogues bearing weakly electron-donating substituents (e.g., <i>para</i>-tolyl analogue <b>8i</b>) saw a smaller decrease in affinity (∼3-fold), similarly mediated by a change in both rate constants toward a slow on, fast off profile [<i>k</i><sub>on</sub> = (1.00 ± 0.06) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.98 ± 0.02 min<sup>–1</sup>].</div><div class="NLM_p">Conversely, insertion of a <i>meta</i>-Cl substituent (exemplified by <b>8a</b>), despite decreasing affinity ∼8-fold, acts only to decrease the <i>k</i><sub>on</sub> whilst having no effect on <i>k</i><sub>off</sub> [<i>k</i><sub>on</sub> = (3.62 ± 0.94) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.64 ± 0.10 min<sup>–1</sup>], and this similarly applies to <i>para</i>-Cl substituents. The trend continued with 2,4-dichloro (<b>8c</b>) and 2,5-dichloro (<b>8d</b>) analogues, losing ∼7-fold and 3-fold affinity, respectively. Again, this loss was largely mediated by a decreased association rate [<b>8c</b>: <i>k</i><sub>on</sub> = (2.87 ± 0.56) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.70 ± 0.16 min<sup>–1</sup>; <b>8d</b>: <i>k</i><sub>on</sub> = (5.29 ± 0.36) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.56 ± 0.06 min<sup>–1</sup>] relative to <b>1</b>. Interestingly, when the <i>ortho</i>- and <i>meta</i>-chloro substituents are combined [2,3-diCl analogue (<b>8b</b>)], affinity increases ∼5-fold, and this is now predominantly mediated by both a ∼2-fold increase in association rate and ∼2-fold decrease in dissociation rate [p<i>K</i><sub>d</sub> = 9.84 ± 0.08, <i>k</i><sub>on</sub> = (2.20 ± 0.30) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.30 ± 0.01 min<sup>–1</sup>]. Substitution with a strongly electron-withdrawing <i>para</i>-CF<sub>3</sub> substituent (<b>8j</b>) maintained affinity, with no effect on the kinetic profile of the analogue relative to <b>1</b> [<i>k</i><sub>on</sub> = (1.36 ± 0.07) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.62 ± 0.02 min<sup>–1</sup>]. Furthermore, replacing the <i>para</i>-chloro substituent for a <i>para</i>-fluoro (<b>8l</b>) predominantly decreased <i>k</i><sub>on</sub>.</div><div class="NLM_p last">All compounds bearing an <i>ortho</i> substituent (<b>8n</b>, <b>8c</b>, <b>8d</b>, <b>8e</b>, <b>8m</b>), with the exception of <b>8b</b>, displayed a reduced on-rate, indicating potential sensitivity to steric bulk at this position through resulting rotation of the phenyl group relative to the piperidinol. Interestingly, the 2,3-diCl analogue (<b>8b</b>) contains the privileged 2,3-dichlorophenylpiperidine pharmacophore known to confer high affinity in other molecules at both the D<sub>2</sub>-like and 5HT receptors. This particular substitution pattern may therefore support a different binding mode. Both increased lipophilicity and steric bulk are preferred at the <i>meta</i>- and <i>para</i>-positions of the ring, with the 4-position being optimal, which is supported by <b>8h</b> (4-fluoro) and <b>8l</b> (4-H) being less favored. For the off rate, the substituent effect is reversed in terms of increasing <i>k</i><sub>off</sub> (o > m > p). This parameter appears to be less impacted by steric factors, and instead, the electronics may play a greater role (<b>8k</b>, <b>8i</b>, <b>8h</b>). In summary, these initial data provide insight into how structural modifications of haloperidol (<b>1</b>) impact upon individual kinetic parameters, demonstrating the potential for differential modification of rate constants toward a slow on, fast off profile, depending on the position and nature of the aryl substituents of the 4-phenylpiperidin-4-ol moiety.</div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Kinetic Effects of Variation of the <i>para</i>-Fluorophenyl Moiety of <b>1</b></h4><div class="NLM_p">We examined the effect of fluoro substituents at both <i>ortho</i>-(<b>14a</b>) and <i>meta</i>-(<b>14b</b>) positions of the phenone moiety, as well as all possible difluorophenyl substituents (<b>14c</b>–<b>h</b>), together with three additional <i>ortho</i>-analogues [<i>o</i>-Cl (<b>14i</b>), <i>o</i>-CH<sub>3</sub> (<b>14j</b>), <i>o</i>-Cl (<b>14k</b>)], and an unsubstituted analogue (<b>14l</b>). Modification to this moiety caused large decreases in affinity relative to <b>1</b>, spanning over 100-fold from p<i>K</i><sub>d</sub> = 6.67 ± 0.01 (<b>14h</b>) to 8.75 ± 0.02 (<b>14l</b>), and is associated with a wide range of association and dissociation rate constants. These losses in affinity are mediated through concurrent changes in both <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub>. This applies to all but the <i>para</i>-Cl analogue (<b>14k</b>), as it lost affinity 10-fold relative to <b>1</b>, but this was largely mediated by a decreased rate of association [<i>k</i><sub>on</sub> = (1.38 ± 0.05) × 10<sup>8</sup>  M<sup>−1</sup> min<sup>−1</sup>, <i>k</i><sub>off</sub> = 0.70 ± 0.03 min<sup>–1</sup>]. The <i>des</i>-fluoro analogue (<b>14l</b>) maintained the highest affinity, and similar to the previous series, this was facilitated by a shift in both rate constants [p<i>K</i><sub>d</sub> = 8.75 ± 0.02, <i>k</i><sub>on</sub> = (6.33 ± 1.06) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.12 ± 0.18 min<sup>–1</sup>]. Of the three <i>ortho</i>-substituted analogues <b>[14a</b> (<i>m</i>-F), <b>14i</b> (<i>m</i>-Cl), <b>14j</b> (<i>m</i>-CH<sub>3</sub>)], the fluoro substituent was the least favorable in terms of affinity, decreasing ∼13-fold relative to <b>1</b>, whereas the <i>ortho</i>-tolyl substituent only reduces affinity by 6-fold. However, these changes are likewise mediated by a decreased association rate and increased rate of dissociation. Notably, the <i>m</i>-Cl (<b>14i</b>) and <i>m</i>-CH<sub>3</sub> (<b>14j</b>) substituents have similar van der Waals radii but very different electronic effects, thus highlighting a steric factor as being important. The <i>meta</i>-fluoro-substituted analogue (<b>14b</b>) also dramatically reduced the affinity and was similarly driven by a decreased <i>k</i><sub>on</sub> and increased <i>k</i><sub>off</sub> [<i>k</i><sub>on</sub> = (2.55 ± 0.27) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.08 ± 0.21 min<sup>–1</sup>].</div><div class="NLM_p last">Difluoro substitution of the phenyl ring revealed no clear SKR and commonly caused substantial losses in binding affinity. However, unlike the previous chloro series, greater increases in the rate of dissociation were observed. Interestingly, using our online injection protocol, we identified compounds with even slower <i>k</i><sub>on</sub> values relative to <b>2</b>, coupled with equal to or faster <i>k</i><sub>off</sub> values, despite their affinities being lower than <b>2</b>. For example, the 2,3-(<b>14c</b>), 2,4-(<b>14d</b>) and 2,5-difluoro (<b>14e</b>) analogues of <b>1</b> (p<i>K</i><sub>d</sub> = 7.28 ± 0.04, 6.92 ± 0.05, and 6.85 ± 0.04, respectively) showed dissociation rates faster than any compound identified in the previous series (<i>k</i><sub>off</sub> = 1.70 ± 0.09, 1.36 ± 0.21, and 1.49 ± 0.36 min<sup>–1</sup>, respectively). In conclusion, these preliminary data suggest that different fluorine substitution patterns dramatically reduce binding affinities, mediated through changes in both kinetic parameters. However, the relationship among the nature of substituents, the substitution pattern, and the corresponding kinetic profile is unclear.</div></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Kinetic Effects of Variation of Ketone and Linker Moieties of <b>1</b></h4><div class="NLM_p">We next examined the effect of modification to the linker and ketone moieties of <b>1</b> through synthesis of a further 15 analogues. Specific linker-modified compounds included propiophenone (<b>34a</b>) and valerophenone (<b>34c</b>) analogues of <b>1</b>, alongside 3–5-carbon alkyl (<b>36a</b>–<b>c</b>) and alkyne analogues (<b>41a</b>–<b>c</b>). In addition, a thorough analysis of modification to the ketone moiety was undertaken via synthesis of geometric olefin isomers (<b>23</b>, <b>26</b>) and their corresponding cyclopropane derivatives (<b>29b</b>, <b>30b</b>), through to isosteric replacement with sulfur (<b>17a</b>) or oxygen (<b>17b</b>), as well as conversion of the ketone to the corresponding secondary alcohol (<b>18</b>).</div><div class="NLM_p">All compounds in this series lost binding affinity relative to <b>1</b> and, for the most part, this was mediated through a decrease in <i>k</i><sub>on</sub> and an increase in <i>k</i><sub>off</sub>. Converting the ketone to its corresponding secondary alcohol (<b>18</b>) (racemic), while engendering a 13-fold reduction in affinity compared to <b>1</b>, was exclusively caused by a slowed <i>k</i><sub>on</sub> [p<i>K</i><sub>d</sub> = 7.04 ± 0.01, <i>k</i><sub>on</sub> = (6.19 ± 0.41) × 10<sup>6</sup> M<sup>–1</sup> min<sup>–1</sup>]. Replacement of the carbonyl moiety with sulfur (<b>17a</b>) or oxygen (<b>17b</b>) modulated both kinetic binding parameters, though their respective association rates varied ∼6-fold [<i>k</i><sub>on</sub> = (4.99 ± 0.59) × 10<sup>8</sup> and (1.22 ± 0.35) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, respectively]. This difference may be due to a number of factors, including the electronegativity and size difference between the sulfur and oxygen atoms, the relatively longer S–C bond length compared to that of the O–C bond, and the orbital arrangement around each heteroatom (resulting in considerably smaller bond angles in the thioether compared to the ether). The <i>trans</i>-alkene (<b>23</b>) lost ∼10-fold affinity relative to <b>1</b>, and this was again predominantly due to a decreased <i>k</i><sub>on</sub> [<i>k</i><sub>on</sub> = (6.39 ± 0.88) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>]. Interestingly, the cis-isomer (<b>26</b>) saw a further 5-fold reduction in affinity (p<i>K</i><sub>d</sub> = 7.49 ± 0.12); however, this was predominantly due to a change in association rate, displaying a <i>k</i><sub>on</sub> almost 20-fold slower and a <i>k</i><sub>off</sub> 2-fold faster than <b>1</b> [<i>k</i><sub>on</sub> = (3.35 ± 0.72) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.25 ± 0.16 min<sup>–1</sup>]. Analysis of the racemic cycloalkane diastereomers was also interesting; introduction of the <i>trans</i>-cyclopropane (<b>29b</b>) resulted in a ∼10-fold increase in affinity relative to the parent <i>trans</i>-olefin <b>23</b>, which was predominantly due to a ∼10-fold increase in association rate [<i>k</i><sub>on</sub> = (6.07 ± 0.87) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup>]. Conversely, introduction of the <i>cis</i>-cyclopropane (<b>30b</b>) had no effects on affinity relative to the parent <i>cis</i>-olefin <b>28</b>; however, this substituent marginally decreased <i>k</i><sub>on</sub> while increasing the <i>k</i><sub>off</sub> [<i>k</i><sub>on</sub> = (4.47 ± 0.47) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.37 ± 0.09 min<sup>–1</sup>]. These data indicate that cis-geometry is preferred as opposed to trans-geometry with respect to this subset of compounds in reference to tuning the kinetic profile toward “slow on, fast off” characteristics and demonstrate the importance of geometry in the corresponding pharmacological profile of APDs. Analysis of the propiophenone and valerophenone analogues of <b>1</b> returned further intriguing results. Decreasing the linker length by just one carbon (<b>34a</b>) relative to <b>1</b> resulted in dramatic changes in both association and dissociation rate constants [<i>k</i><sub>on</sub> = (1.33 ± 0.17) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.95 ± 0.32 min<sup>–1</sup>], resulting in a loss of affinity at the D<sub>2</sub>R by >20-fold (p<i>K</i><sub>d</sub> = 6.84 ± 0.05).</div><div class="NLM_p last">Perhaps, the most exciting compound to arise from our study was the valerophenone analogue (<b>34c</b>). Despite losing affinity by >10-fold relative to <b>1</b>, this compound displayed a ∼10-fold slower <i>k</i><sub>on</sub> and a >3.5-fold faster <i>k</i><sub>off</sub> than <b>1</b>. Both the kinetic profile and affinity are similar to those of <b>2</b>, which our previous studies predict would confer a low propensity to cause extrapyramidal side effects.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The alkane analogues of <b>1</b> (<b>36a</b>–<b>c</b>) exhibited a 10-fold variation in affinity with respect to one another, with the butylene analogue (<b>36b</b>) found to be optimal in terms of affinity conservation relative to <b>1</b> (p<i>K</i><sub>d</sub><b>=</b> 8.17 ± 0.03), despite all having >10-fold losses in affinity relative to <b>1</b>. Despite having a >20-fold lower affinity compared to <b>1</b>, the propylene analogue (<b>36a</b>) was found to have a slow on, fast off kinetic profile [p<i>K</i><sub>d</sub> = 7.18 ± 0.06, <i>k</i><sub>on</sub> = (2.29 ± 0.15) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 1.54 ± 0.07 min<sup>–1</sup>]. Finally, analysis of the 3–5-carbon alkyne analogues (<b>41a</b>–<b>c</b>) saw a 10-fold variation in affinity, with the pentyne analogue (<b>41c</b>) being optimal (p<i>K</i><sub>d</sub> = 7.75 ± 0.03), as well as displaying the largest change in both rate constants toward a slow on, fast off profile [<i>k</i><sub>on</sub> = (6.41 ± 0.80) × 10<sup>7</sup>  M<sup>−1</sup> min<sup>−1</sup>, <i>k</i><sub>off</sub> = 1.15 ± 0.15 min<sup>–1</sup>].</div></div><div id="sec2_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Kinetic Effects of Variation of the Piperidinol Moiety of <b>1</b></h4><div class="NLM_p">The kinetic effect of structural modifications to the 4-phenylpiperidin-4-ol moiety of <b>1</b> was explored through the synthesis of eight additional analogues. We observed the effects of introducing an ethylene bridge (<b>42</b>), as well as modification primarily to the tertiary alcohol through methyl ether formation (<b>52</b>) and its subsequent removal, generating a variety of compounds containing piperazinyl (<b>43</b>), dihydropyridinyl (<b>45</b>), cyclopropyl (<b>46</b>), and piperidinyl (<b>47</b>, <b>48</b>) functionalities. We observed a wide range of affinities that spanned a ∼30-fold difference, and unlike the previous chemical series, modification to the piperidinol moiety for the most part had relatively negligible effects on the <i>k</i><sub>off</sub>, with the majority maintaining similar values to those of <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Instead, a decrease in affinity relative to <b>1</b> was largely facilitated by a decreased <i>k</i><sub>on</sub>. Notably, of the two analogues with higher affinities relative to <b>1</b>, these were instead largely mediated by an increase in <i>k</i><sub>on</sub> and decrease in <i>k</i><sub>off</sub>. For example, introducing the tropanyl moiety (<b>42</b>) conferred a ∼10-fold increase in affinity, which was equally driven by an increase in <i>k</i><sub>on</sub> and decrease in <i>k</i><sub>off</sub> [p<i>K</i><sub>d</sub> = 10.26 ± 0.06, <i>k</i><sub>on</sub> = (3.68 ± 0.64) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.19 ± 0.02 min<sup>–1</sup>]. The cyclopropane variant (<b>46</b>) 5-fold improved affinity relative to <b>1</b> was also mediated by an increased <i>k</i><sub>on</sub> and decreased <i>k</i><sub>off</sub> [p<i>K</i><sub>d</sub> = 9.84 ± 0.02, <i>k</i><sub>on</sub> = (2.03 ± 0.09) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>, <i>k</i><sub>off</sub> = 0.30 ± 0.01 min<sup>–1</sup>]. The improved affinities and decreased dissociation rates of <b>42</b> and <b>46</b> (tropanyl and cyclopropane analogues, respectively) can perhaps be rationalized through a major conformational difference induced by these substituents, resulting in a more entropically favorable binding event. From these preliminary data, it appears that modification to the piperidinol moiety is not particularly amenable to significant increases in the corresponding compounds rate of dissociation (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinetic Binding Parameters of Unlabeled Analogues of <b>1</b> with Modifications to the Piperidinol Moiety for Human D<sub>2L</sub> Receptors Estimated Using TR-FRET Assay<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0025.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0026.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The rate constants <i>k</i><sub>off</sub> and <i>k</i><sub>on</sub>, the half-life (<i>t</i><sub>1/2</sub>), and the kinetically derived p<i>K</i><sub>d</sub> were obtained from competition kinetic association experiments using PPHT-red.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet.</p></div></div><div></div></div></div><div id="sec2_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Dual Modifications to Both Phenyl Moieties of <b>1</b></h4><div class="NLM_p">Finally, we assessed the effect of swapping the halogen substituents on each end of haloperidol (<b>1</b>) through compound (<b>53</b>), as well as their simultaneous removal as exemplified by the <i>des</i>-halo analogue <b>54</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These structural changes all decreased affinity, which was reflected by decreases in the corresponding <i>k</i><sub>on</sub>, with only minor effects on <i>k</i><sub>off</sub> relative to <b>1</b>. Swapping the halogen atoms on each ring (<b>53</b>) caused a 16-fold loss in affinity (p<i>K</i><sub>d</sub> = 7.73 ± 0.02), which was predominantly driven by a 16-fold decrease in <i>k</i><sub>on</sub> [<i>k</i><sub>on</sub> = (4.17 ± 0.28) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>]. Finally, removal of both halogen atoms (<b>54</b>) simultaneously caused a ∼18-fold loss in affinity (p<i>K</i><sub>d</sub> = 7.51 ± 0.01), driven by a sole ∼18-fold decrease in <i>k</i><sub>on</sub> relative to <b>1</b> [<i>k</i><sub>on</sub> = (2.28 ± 0.13) × 10<sup>7</sup> M<sup>–1</sup> min<sup>–1</sup>]. This effect is unlike that of previous analogues bearing a <i>para</i>-halo substituent on only one of the two phenyl rings (<b>8h</b> and <b>14l</b>), whereby both <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> are altered (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, respectively).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinetic Binding Parameters of Unlabeled Bifunctionalized Analogues of <b>1</b> for Human D<sub>2L</sub> Receptors Estimated Using TR-FRET Assay<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0027.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0028.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The rate constants <i>k</i><sub>off</sub> and <i>k</i><sub>on</sub>, the half-life (<i>t</i><sub>1/2</sub>), and the kinetically derived p<i>K</i><sub>d</sub> were obtained from competition kinetic association experiments using PPHT-red.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium. Data are presented as mean ± S.E.M. from four experiments performed in singlet.</p></div></div><div></div></div><div class="NLM_p">Our studies show that modifying the scaffold of <b>1</b> produces compounds with a wide range of both association rates [spanning ∼3 orders of magnitude, from <i>k</i><sub>on</sub> = (3.37 ± 0.62) × 10<sup>6</sup> to (3.68 ± 0.64) × 10<sup>9</sup> M<sup>–1</sup> min<sup>–1</sup>] and dissociation rates (spanning >10-fold, from <i>k</i><sub>off</sub> = 0.19 ± 0.02 to 2.35 ± 0.19 min<sup>–1</sup>), which constituted large variations in hD<sub>2L</sub>R affinities (spanning over 3 orders of magnitude from <i>K</i><sub>d</sub> = 288 to 0.0549 nM). To further understand the relationship between kinetic rate constants and the affinity of D<sub>2</sub>R ligands, we have correlated the kinetic binding data of these 50 compounds (<i>k</i><sub>on</sub>, <i>k</i><sub>off</sub>) with the derived equilibrium affinity estimates (p<i>K</i><sub>d</sub>) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Our data confirms that p<i>K</i><sub>d</sub> is robustly correlated with the association rate (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, Spearman’s <i>r</i><sup>2</sup> = 0.96, <i>p</i> > 0.0001), whereas p<i>K</i><sub>d</sub> is, to a much lesser extent, correlated with the dissociation rate (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). These data are in contrast to previous studies claiming that the differences in APD affinities are determined entirely by how fast they dissociate from the D<sub>2</sub>R.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> This is due to the fact that association rates have widely been assumed to be diffusion-limited. Indeed, studies conducted at other systems, namely, the M<sub>3</sub> muscarinic acetylcholine and A<sub>2A</sub> adenosine receptors, have found correlations between <i>k</i><sub>off</sub> values and affinity.<a onclick="showRef(event, 'ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64">(62−64)</a> However, the association rate constants of a series of metabotropic glutamate receptor 2 positive allosteric modulators were found to be strongly correlated to affinity, whereas dissociation rate constants were not.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This correlation has also been observed at the orexin OX<sub>2</sub> receptor and β<sub>2</sub>-adrenoreceptors for ligands with distinct chemotypes.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a></div><figure id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0006.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Correlating kinetically derived equilibrium dissociation constants vs kinetic rate constants of haloperidol (<b>1</b>) and 50 structural analogues at the dopamine D<sub>2</sub> receptor. (A) A plot of log <i>k</i><sub>on</sub> vs p<i>K</i><sub>d</sub> demonstrates a statistically significant correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.96, <i>p</i> < 0.0001) between these two variables. (B) Conversely, a plot of p<i>K</i><sub>d</sub> vs log <i>k</i><sub>off</sub> demonstrates a much poorer correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.34, <i>p</i> < 0.0001) despite the traditional scientific consensus that APD affinity is solely driven by changes in <i>k</i><sub>off</sub>. (C) Observed association rate (log <i>k</i><sub>on</sub>) and calculated partition coefficient (cLog <i>P</i>) show no correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.007, <i>p</i> = 0.562). The central line corresponds to the linear regression of the data, and the dotted lines represent the 95% confidence intervals for the regression. (D) Representing the diversity in affinity and corresponding kinetic profiles for analogues of <b>1</b>. A plot of log <i>k</i><sub>off</sub> vs log <i>k</i><sub>on</sub> represents a spectrum of compounds with various kinetic profiles (∼10-fold difference in <i>k</i><sub>off</sub>, ∼30-fold difference in <i>k</i><sub>on</sub>) identified from this study. Clozapine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (<b>2</b>) and typical APD chlorpromazine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> are also included as reference points. These data identify several compounds with interesting slow on, fast off kinetic profiles (<b>14c</b>, <b>30b</b>, <b>34c</b>, <b>36a</b>). Combinations of <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> that result in identical affinity (<i>K</i><sub>d</sub>) values are represented by diagonal dotted lines. All data used in these plots apart from chlorpromazine are detailed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as mean from at least four separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is evident that modification to the scaffold of <b>1</b> and the corresponding changes in affinity are principally mediated by a change in the rate of association (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). However, our study highlights that particular structural moieties of <b>1</b> are more appropriate for the modification of both kinetic parameters toward a slow on, fast off profile. For example, when modification to the piperidinol moiety caused a loss in binding affinity relative to <b>1</b>, this was predominantly <i>k</i><sub>on</sub>-mediated, while having negligible effects on <i>k</i><sub>off</sub>. However, modification of the <i>p</i>-fluorophenyl or linker moieties and subsequent losses in affinity saw greater changes in both kinetic rate constants, highlighting these areas as a focal point for future SKR investigations. In addition, we were able to derive preliminary SKR for the <i>p</i>-chlorophenyl moiety of <b>1</b>. From our kinetic data obtained from a limited amount of compound structural/chemical diversity, we determined that both the electronic nature and position of substituents on the aromatic ring dictate the corresponding kinetic profile. We found that <i>meta</i>- and para-EWG groups (depending on compound affinity) can either slow the <i>k</i><sub>on</sub> while having no effect on <i>k</i><sub>off</sub> (<b>8a</b>, <b>8c</b>, <b>8d</b>) or, equally, slow the <i>k</i><sub>on</sub> while increasing <i>k</i><sub>off</sub> (<b>8b</b>, <b>8f</b>, <b>8g</b>). Conversely, compounds bearing <i>ortho</i>-Cl substituents and that are not <i>meta</i>- or para-substituted act to slow the <i>k</i><sub>on</sub> but increase the <i>k</i><sub>off</sub> (<b>8e</b>, <b>8n</b>). This is also true for para-EDG substituents at these positions (<b>8h</b>, <b>8i</b>, <b>8k</b>). It may be possible to use such molecules as templates in an attempt to further increase affinity via decoration of the aromatic termini, while maintaining an “attractive” or slow on, fast off kinetic profile.</div><div class="NLM_p">The derived association rate of all compounds was further assessed for any potential correlation with physicochemical parameters such as clog <i>P</i> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) and topological polar surface area (TPSA) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">Supplementary Figure 2</a>), to which there was found to be no relationship. This is unsurprising as this study places particular emphasis on the kinetics of not only positional isomers between subsets of compounds but also close structural analogues that display very similar properties of size, lipophilicity, and polarity. This further provides evidence that the observed changes to affinity and kinetic profile are not simply due to modification of physicochemical properties. These data are in contrast to previous observations at the D<sub>2</sub>R reporting that compounds with fast dissociation rates are less lipophilic and have lower molecular weights.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> This is notable as additional micro-pharmacokinetic/pharmacodynamic mechanisms, such as ligand binding to the cell membrane, are known to play a role in target binding kinetics.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Although it is widely accepted that increasing lipophilicity results in increased affinity, this study shows that for this subset of compounds this is not the case, highlighting that careful analysis of kinetic parameters is essential and also likely to be context-/target-dependent.</div><div class="NLM_p">Our recent proposal to expand the kinetic hypothesis for APD side effects considers not only the dissociation rate (and therefore the propensity to display insurmountable antagonism) but also the association rate and subsequent potential for receptor rebinding.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Based on this hypothesis, we proposed three broad classes of APDs in an attempt to explain how different kinetic characteristics have the potential to influence on-target side effects. Class 1: fast on/slow off compounds exemplified by haloperidol (<b>1</b>), class 2: fast on/fast off compounds, namely, chlorpromazine, an early typical APD, and class 3: slow on/fast off compounds exemplified by clozapine (<b>2</b>). A fast association rate will result in a higher D<sub>2</sub>R rebinding potential in the striatum and consequently high EPS potential. In contrast, slow dissociation from D<sub>2</sub>Rs expressed on pituitary lactotrophs results in insurmountable antagonism, leading to increased prolactin release (e.g., <b>1</b>). These data suggest that the profile of <b>1</b>, i.e., slow <i>k</i><sub>on</sub>/fast <i>k</i><sub>off</sub> kinetics as exhibited by <b>2</b>, is optimal for APDs targeting D<sub>2</sub>Rs. Using the scaffold of <b>1</b>, we have shown that single structural modifications to one of four moieties produce structurally similar molecules with a spectrum of association and dissociation kinetic rate constants (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D), and several molecules have been identified (<b>14c</b>, <b>30b</b>, <b>34c</b>, <b>36a</b>) that display interesting profiles resembling that of <b>2</b>. Of the known literature compounds that were tested (<b>8f</b>, <b>8h</b>, <b>8i</b>, <b>8l</b>, <b>14a</b>, <b>14b</b>, <b>14g</b>, <b>14k</b>, <b>14l</b>, <b>17a</b>, <b>17b</b>, <b>18</b>, <b>42</b>, <b>43</b>, <b>47</b>, <b>48</b>, <b>53</b>, <b>54</b>), information regarding their EPS and hyperprolactinemia liabilities is absent. Our data highlights the importance of employing kinetic analyses in conjunction with other parameters toward the optimization of APD leads.</div><div class="NLM_p last">The identification of substituents and structural drivers that modulate kinetic profiles for the butyrophenone scaffold through a concurrent increase in <i>k</i><sub>on</sub> and decrease in <i>k</i><sub>off</sub>, such as EDGs on the <i>p</i>-chlorophenyl moiety, difluoro substituents on the <i>p</i>-fluorophenyl moiety, replacing the ketone for a <i>cis</i>-cyclopropane, or the simple alteration of the alkyl linker length, may be used to ‘fine tune’ the design of novel compounds structurally similar to <b>1</b> with optimized kinetic parameters similar to that of atypical APD <b>2</b>. Collectively, these data represent the first reported kinetic characterization of analogues of <b>1</b> and clearly demonstrate that incorporation of kinetic binding parameter analyses into APD discovery programs may facilitate the identification of D<sub>2</sub>R antagonist APDs with an improved therapeutic window.</div></div><div id="sec2_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Structural Basis for Structure–Kinetic Relationships</h4><div class="NLM_p">Given the focused nature of our SKR study, with modifications grouped by different moieties present on <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), it is possible to conduct a global analysis of the kinetic binding parameters obtained, in relation to these modifications. Such analysis might be a useful indicator in determining whether specific regions of the haloperidol scaffold are more sensitive to structural modification in terms of <i>k</i><sub>on</sub>, <i>k</i><sub>off</sub>, and <i>K</i><sub>i</sub> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0007.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Summary of the range of kinetic binding parameters obtained for each region of structural modification to haloperidol (<b>1</b>). Values describe the fold-difference between the largest and smallest values for each parameter and grouped by the moiety of <b>1</b> that was modified.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is interesting to note that modification of the <i>p</i>-fluorophenyl and butyrophenone moieties results in a broader range of <i>k</i><sub>on</sub> values compared to those observed with the piperidinol and chlorophenyl moiety analogues. This may indicate that these regions play an important role in guiding ligand entry to the binding site. In contrast, the chlorophenyl moiety seems to be a relatively less important determinant of <i>k</i><sub>on</sub> and affinity.</div><div class="NLM_p">The recently published structure of the D<sub>2</sub>R<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> offers insight into the observed binding pose of the atypical APD risperidone at a thermostabilized D<sub>2</sub>R. Co-crystal structures offer a wealth of structural information about the interaction between the co-crystallized ligand and receptor under specific experimental conditions and are useful in correlating pharmacologically determined measurements of affinity with such interactions. Furthermore, ligand docking studies into such structures can identify receptor–ligand interactions that in part might determine kinetic parameters (particularly, <i>k</i><sub>off</sub>).</div><div class="NLM_p">However, co-crystal structures only offer a static snapshot of a low energy ligand-bound conformation of the receptor, which may not represent the conformation stabilized by a structurally distinct ligand scaffold. In contrast, entry and egress is a complex process that involves the interaction of both a flexible receptor and the ligand and the journey of that ligand from the extracellular milieu to the binding site. Recent MD simulations have revealed that residues in the extracellular loop regions of GPCRs play an important role in this process.<a onclick="showRef(event, 'ref58 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref58 ref70 ref71">(58,70,71)</a> This is a highly dynamic region of the receptor, and the static conformation observed in a crystal structure cannot provide the complete picture of the role of this region; thus, future studies using long time scale MD simulations are needed to allow us to reconcile our present findings with this structural data.</div><div class="NLM_p">Recently, MD simulations have been carried out, attempting to explore the ligand binding journeys of both haloperidol (<b>1</b>) and clozapine (<b>2</b>) at the D<sub>2</sub>R/D<sub>3</sub>R.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Interestingly, the binding of <b>1</b> at the D<sub>2</sub>R has been proposed to arise via a “handover” mechanism, whereby an initial key π-stacking interaction with Tyr<sup>7.35</sup> (Ballesteros–Weinstein numbering scheme)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> allows this residue to act as a pivot point from which the ligand can explore the extracellular vestibule, followed by formation of a salt-bridge with Asp<sup>3.32</sup>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This mechanism appears to be reliant upon an optimal intramolecular distance between the <i>p</i>-fluorophenyl moiety of <b>1</b> and the protonated piperidinyl amine; thus, changes in this distance through linker extension might be expected to influence orthosteric binding and the corresponding kinetic profile of the ligand (particularly <i>k</i><sub>on</sub>). Our findings correlate with this observation, as homologues of <b>1</b> bearing either a propiophenone (<b>34a</b>) or a valerophenone (<b>34c</b>) moiety both exhibit relatively lower <i>k</i><sub>on</sub> values [(1.03 ± 0.18) × 10<sup>7</sup> and (1.42 ± 0.24) × 10<sup>8</sup> M<sup>–1</sup> min<sup>–1</sup> respectively]. This is further reflected in the corresponding alkyl linker analogues (<b>36a</b>–<b>c</b>), whereby <b>36b</b> (bearing a butylene linker—the corresponding deoxo analogue of <b>1</b>) retained the highest <i>k</i><sub>on</sub> value compared to its homologues (<b>36a</b> and <b>36c</b>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p">However, while these simulations were unbiased, only two of those reported resulted in a complete binding trajectory (determined by the presence of an ionic interaction between Asp<sup>3.32</sup> on each receptor and the protonated nitrogen atom of each ligand), which occurred at the D<sub>3</sub>R only. The D<sub>2</sub>R structure was not available at the time of this study, and a D<sub>3</sub>R crystal structure<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> was used as the basis for both simulations, with generation of a D<sub>2</sub>R homology model for the D<sub>2</sub>R simulations. Notably, comparison of the D<sub>2</sub>R and D<sub>3</sub>R crystal structures reveals a considerably different arrangement of the extracellular domains.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p last">To further our understanding about the SKR reported in our study, our future work will focus on conducting advanced MD simulations using the recently reported D<sub>2</sub>R structure, with a view to correlating how subtle structural changes in the haloperidol analogues (imbuing distinct kinetic profiles) described above might influence interaction with specific residues, which line the entry to and exit from the ligand binding site.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30844" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30844" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we report the chemical synthesis and extensive kinetic profiling of 50 analogues of haloperidol (<b>1</b>) at the hD<sub>2L</sub>R, using a TR-FRET competition association kinetic binding assay, permitting the derivation of multiple equilibrium and kinetic parameters (p<i>K</i><sub>i</sub>, p<i>K</i><sub>d</sub>, <i>k</i><sub>on</sub>, and <i>k</i><sub>off</sub>). All analogues retained the hD<sub>2L</sub>R antagonist action of <b>1</b> apart from <b>47</b> that gave a partial response relative to dopamine at a concentration of 10 μM. The kinetic profile was assessed with respect to predominantly single modification of one of four structural moieties of <b>1</b>, namely, the <i>p</i>-fluorophenyl, ketone and alkyl linker, piperidinol, and <i>p</i>-chlorophenyl moieties. Specifically, we observed the effect of both mono- and dihalogen substituents on individual phenyl rings, as well as ketone and linker modified variants, incorporating <i>cis</i>- and <i>trans-</i>olefins and their corresponding cyclopropanes, together with numerous alkanes and alkynes. In addition, we investigated the effect of modification to the tertiary alcohol, as well as incorporation of piperazinyl, tetrahydropyridinyl, and other piperidinyl moieties. Importantly, we show that there is no correlation between <i>k</i><sub>on</sub> and the physicochemical parameters clog <i>P</i> and TPSA, meaning that differences in kinetic profiles and corresponding compound affinities are not simply due to nonspecific effects such as cell membrane binding. Moreover, we reveal that <i>k</i><sub>on</sub> is significantly correlated with p<i>K</i><sub>d</sub> and is contrary to previous reports at the D<sub>2</sub>R. Thus, we found that a loss in binding affinity is generally associated with a decrease in <i>k</i><sub>on</sub>. However, preliminary SKR derived for the <i>p</i>-chlorophenyl moiety of <b>1</b> demonstrates that particular substitution patterns and the nature of aromatic substituents are more likely to concurrently decrease <i>k</i><sub>on</sub> while increasing <i>k</i><sub>off</sub>. For example, chloro substituents at the <i>ortho</i>-position modulate the kinetic parameters toward a slow <i>k</i><sub>on</sub>/fast <i>k</i><sub>off</sub> profile, whereas <i>meta</i> and/or <i>para</i>-chloro substituents can either decrease the <i>k</i><sub>on</sub>, while having no effect on <i>k</i><sub>off</sub>, or, equally, also simultaneously decrease <i>k</i><sub>on</sub>/<i>k</i><sub>off</sub>. The <i>p</i>-fluorophenyl and ketone/alkyl linker structural moieties of <b>1</b> were found to be important for mediating changes in both kinetic rate parameters, particularly, the <i>k</i><sub>off</sub>, while the piperidinol moiety was more linked to changes in <i>k</i><sub>on</sub> only. For example, converting the aryl ketone to a <i>cis</i>-cyclopropane group or increasing/decreasing the linker length significantly modulates both rate constants, whereas most modifications to the piperidinol ring simply modulate the <i>k</i><sub>on</sub>. We show that with minimal variation this scaffold can be converted to the slow on, fast off kinetic profile that we hypothesize is characteristic of APDs with reduced on-target side-effect profiles (e.g., <b>14c</b>, <b>30b</b>, <b>34c</b>, <b>36a</b>). These compounds may be used as tools to further explore the influence of kinetic rate parameters and their role in the corresponding clinical profile of APDs toward the development of novel efficacious treatments devoid of EPS and hyperprolactinemia.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> General Chemistry</h3><div class="NLM_p">Chemicals and solvents of analytical and HPLC grade were purchased from commercial suppliers and used without further purification. Reactions were monitored by thin-layer chromatography on commercially available silica precoated aluminum-backed plates (Merck Kieselgel 60 F<sub>254</sub>). Visualization was under UV light (254 and 366 nm), followed by staining with ninhydrin or KMnO<sub>4</sub> dips. Flash column chromatography was performed using silica gel 60, 230–400 mesh particle size (Sigma-Aldrich). NMR spectra were recorded on Bruker-AV 400. <sup>1</sup>H spectra were recorded at 400.13 Hz and <sup>13</sup>C NMR spectra at 101.62 Hz. All <sup>13</sup>C NMR are <sup>1</sup>H broadband decoupled. Solvents used for NMR analysis (reference peaks listed) were CDCl<sub>3</sub> supplied by Cambridge Isotope Laboratories Inc. (δ<sub>H</sub> = 7.26 ppm, δ<sub>C</sub> = 77.16 ppm) and CD<sub>3</sub>OD supplied by VWR (δ<sub>H</sub> = 3.31 ppm and δ<sub>C</sub> = 49.00 ppm). Chemical shifts (δ) are recorded in parts per million (ppm), and coupling constants are recorded in hertz (Hz). The following abbreviations are used to describe signal shapes and multiplicities: singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), dd (doublet of doublets), ddd (double doublet of doublets), dtd (double triplet of doublets), and multiplet (m). Spectra were assigned using appropriate correlated spectroscopy and heteronuclear multiple quantum correlation experiments. Processing of the NMR data was carried out using NMR software Topspin 3.0. Reverse phase (RP)-HPLC-mass spectra (MS) were recorded on a Shimadzu UFLCXR system coupled to Applied Biosystems API2000 and visualized at 254 nm (channel 1) and 220 nm (channel 2). RP-HPLC-MS was carried out using a Phenomenex Gemini NX-C18 110 Å column (50 mm × 2 mm × 3 μm) at a flow rate 0.5 mL min<sup>–1</sup> over a 5 min period (method A). The retention time (<i>t</i><sub>R</sub>) of the final product is reported using a gradient method of 5–95% solvent B in solvent A over 12 min. [Solvent A = 0.01% trifluoroacetic acid in H<sub>2</sub>O, solvent B = 0.01% trifluoroacetic acid in CH<sub>3</sub>CN (method B).] All screening compounds were one single peak and determined to be >95% pure at both 254 and 220 nm using method B. All high-resolution mass spectra (HRMS) were recorded on a Bruker microTOF mass spectrometer using MS electrospray ionization operating in positive ion mode. Preparative RP-HPLC was performed on a Waters 515 LC system and monitored using a Waters 996 photodiode array detector at wavelengths between 190 and 800 nm. Spectra were analyzed using Millenium 32 software. Preparative RP-HPLC was performed using a Gemini NX-C18 110 Å column (250 mm × 21.2 mm × 5 μm) at a flow rate of 20.0 mL min<sup>–1</sup> using a gradient method of 5–95% B over 15 min [solvent A = 0.01% trifluoroacetic acid in H<sub>2</sub>O, solvent B = 0.01% trifluoroacetic in CH<sub>3</sub>CN (method C)]. Predicted partition coefficient (cLog <i>P</i>) values were calculated using Data Warrior 4.7.2, Actelion Pharmaceutical Ltd.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedure A: <i>n</i>-Butyllithium-Mediated Addition of Aryllithiums to Ketones for the Preparation of <b>5a</b>–<b>m</b></h4><div class="NLM_p last">To a stirred solution of substituted bromobenzene (<b>3a</b>–<b>l</b>) (1.35 equiv) in THF at −78 °C was added <i>n</i>-butyllithium (1.30 equiv), and the reaction was maintained at −78 °C for 30 min. After this, a solution of ketone (1 equiv) in THF was slowly introduced into the reaction and stirred at −78 °C for 2 h. The reaction was quenched with the addition of a saturated solution of NH<sub>4</sub>Cl, and the reaction mixture was transferred to a separating funnel and extracted with DCM (3 × 40 mL). The organic extracts were dried (anhydrous Na<sub>2</sub>SO<sub>4</sub>), and the residue was purified by column chromatography using petroleum ether (PE)/EtOAc in a ratio as indicated to afford the desired compound.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> General Procedure B: <i>N</i>-Boc Deprotection for the Preparation of <b>6a</b>–<b>n</b></h4><div class="NLM_p last">The <i>N</i>-Boc-protected amine was taken up in 4 M HCl in 1,4-dioxane (20 mL) and stirred at rt for 2 h. The solvents were evaporated in vacuo to afford the corresponding amine hydrochloride. Alternatively, the residue could be taken up in H<sub>2</sub>O (20 mL) and added to a separating funnel. The aqueous (aq) solution was washed with Et<sub>2</sub>O (3 × 30 mL), and the aqueous phase was made alkaline with the addition of 2 M NaOH solution. This phase was then extracted with DCM (3 × 30 mL), and the organic extracts were collected, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated in vacuo to afford the corresponding amine-free base.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure C: N-Alkylation for the Preparation of <b>8a</b>–<b>n</b>, <b>14a</b>–<b>l</b>, <b>17a</b>, <b>17b</b>, <b>18</b>, <b>23</b>, <b>26</b>, <b>29b</b>, <b>30b</b>, <b>34a</b>, <b>34c</b>, <b>36a</b>–<b>c</b>, <b>41a</b>–<b>c</b>, <b>42</b>–<b>43</b>, <b>45</b>–<b>48</b>, <b>52</b>, <b>53</b>, <b>and 54</b></h4><div class="NLM_p last">To a round-bottom flask or sealed microwave vessel was added the amine (1.1 equiv), alkyl halide or mesylate (1 equiv), KI (0.1 equiv), and NaHCO<sub>3</sub> (2 equiv) followed by toluene. This suspension was then heated at reflux temperature for 24 h. The reaction was filtered and evaporated to dryness followed by direct chromatographic purification using an appropriate eluent as indicated.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> General Procedure D: Sonogashira Cross-Coupling of Aryl Iodides for the Preparation of <b>12a</b>–<b>j and 40b</b></h4><div class="NLM_p last">PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (1 mol %) and copper(I) iodide (2 mol %) were placed in a 50 mL round-bottomed flask equipped with a magnetic bar, and then nondried 1,4-dioxane (10 mL), the corresponding iodide (1.0 equiv), 4-chloro-1-butyne (1.2 equiv), and triethylamine (5.0 equiv) were added. The flask was capped with a rubber septum, and the resulting mixture was magnetically stirred at 50 °C for 2–6 h. The reaction was diluted with Et<sub>2</sub>O (100 mL) after cooling, removing the solids by filtration. The resulting solution was purified by column chromatography (petroleum ether) to yield the corresponding alkyne product.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> General Procedure E: Sonogashira Cross-Coupling of Aryl Iodides for the Preparation of <b>39a</b> and <b>39c</b></h4><div class="NLM_p last">To a N<sub>2</sub>-degassed solution of CH<sub>3</sub>CN and triethylamine (2.0 equiv) were added alkyne (1.1 equiv), the appropriate iodobenzene (1.0 equiv), Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (2 mol %), and CuI (2 mol %), and the mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with Et<sub>2</sub>O, filtered, concentrated, and purified on silica gel (<i>n</i>-hexanes).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> General Procedure F: Triflic Acid-Catalyzed Markovnikov-Type Hydration of Internal Alkynes for the Preparation of <b>13a</b>–<b>j</b></h4><div class="NLM_p last">The purified alkyne was treated with triflic acid (0.5 equiv) and H<sub>2</sub>O (2 equiv) in 2,2,2-trifluoroethanol in a sealed vial equipped with a magnetic stirring bar and stirred at 60 °C for 6 h. The reaction mixture was concentrated under reduced pressure, and the corresponding ketone was directly purified by FCC with an appropriate eluent as indicated.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> General Procedure G: Alcohol Mesylation for the Preparation of <b>22</b>, <b>27</b>, <b>29a</b>, <b>30a</b>, <b>40a</b>, and <b>40c</b></h4><div class="NLM_p last">To a solution of alcohol (1 equiv) and Et<sub>3</sub>N (2.5 equiv) in DCM was added at room temperature MsCl (1.3 equiv). The mixture was stirred at room temperature for 1.5–24 h until complete consumption of starting material was evident. The mixture was diluted with EtOAc and washed with H<sub>2</sub>O and brine, and the organic fraction was dried (Na<sub>2</sub>SO<sub>4</sub>). The solvents were removed in vacuo, and the residue was chromatographed on silica eluting with the appropriate solvent as indicated. Similarly, and in many cases, the residue could be used for the next reaction without the need for purification.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5a</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 7.64 g of a white foam (74%). LCMS (<i>m</i>/<i>z</i>): 312.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.95 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43–7.38 (m, 2H), 7.34–7.30 (m, 2H), 4.08–3.91 (m, 2H), 3.21 (td, <i>J</i> = 13.0, 2.7 Hz, 2H), 1.94 (td, <i>J</i> = 13.3, 4.9 Hz, 2H), 1.75 (s, 1H), 1.69 (dq, <i>J</i> = 14.2, 2.8 Hz, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 146.7, 133.2, 128.7, 126.2, 79.8, 71.5, 39.9, 38.2, 28.6.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>tert</i>-Butyl 4-(3-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5b</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.25 g of a white solid (69.1%). LCMS (<i>m</i>/<i>z</i>): 312.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.95 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.51 (t, <i>J</i> = 1.8 Hz, 1H), 7.35 (dt, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (dt, <i>J</i> = 7.7, 1.7 Hz, 1H), 4.03 (ddt, <i>J</i> = 13.4, 4.2, 1.7 Hz, 2H), 3.23 (td, <i>J</i> = 13.0, 2.7 Hz, 2H), 2.03 (s, 1H), 1.96 (td, <i>J</i> = 13.3, 4.9 Hz, 2H), 1.77–1.66 (m, 2H), 1.49 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 150.4, 134.5, 129.8, 127.4, 125.2, 122.9, 79.8, 71.5, 39.9, 38.1, 28.6.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl 4-(2,3-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5c</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.87 g of a white solid (65.9%). LCMS (<i>m</i>/<i>z</i>): 346.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.05 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.49 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.35–7.26 (m, 1H), 4.15–4.05 (m, 2H), 3.33 (td, <i>J</i> = 13.0, 2.7 Hz, 2H), 2.38–2.27 (m, 2H), 2.07–1.98 (m, 2H), 1.54 (s, 9H), 1.51 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.0, 145.7, 135.2, 130.2, 129.9, 127.7, 125.4, 79.7, 72.9, 39.9, 35.3, 28.6.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 4-(2,4-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5d</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.30 g of a transparent oil (71%). LCMS (<i>m</i>/<i>z</i>): 346.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.02 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.27 (d, <i>J</i> = 8.0 Hz, 2H), 7.03 (t, <i>J</i> = 8.0 Hz, 1H), 4.01 (s, 2H), 3.42 (s, 1H), 3.23 (s, 2H), 2.76 (td, <i>J</i> = 13.2, 5.0 Hz, 2H), 1.90 (d, <i>J</i> = 12.9 Hz, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.0, 145.2, 133.4, 133.0, 129.9, 128.7, 127.7, 79.8, 72.4, 35.0, 28.6.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-(2,5-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5e</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.48 g of a white solid (68%). LCMS (<i>m</i>/<i>z</i>): 346.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.02 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.59 (d, <i>J</i> = 2.5 Hz, 1H), 7.29 (d, <i>J</i> = 8.5 Hz, 1H), 7.18 (dd, <i>J</i> = 8.4, 2.5 Hz, 1H), 4.09–4.00 (m, 2H), 3.28–3.21 (m, 2H), 2.83 (d, <i>J</i> = 1.0 Hz, 1H), 2.32 (td, <i>J</i> = 13.3, 4.9 Hz, 2H), 1.84 (d, <i>J</i> = 13.4 Hz, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.0, 145.2, 133.4, 133.0, 129.9, 128.7, 127.7, 79.8, 72.4, 35.0, 28.6.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 4-(2,6-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5f</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.72 g of a transparent oil (76%). LCMS (<i>m</i>/<i>z</i>): 346.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.03 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.32 (d, <i>J</i> = 8.0 Hz, 2H), 7.12–7.03 (m, 1H), 4.02 (dd, <i>J</i> = 13.2, 4.8 Hz, 2H), 3.26 (td, <i>J</i> = 12.9, 2.8 Hz, 2H), 2.81 (td, <i>J</i> = 13.2, 5.0 Hz, 2H), 2.01–1.89 (m, 2H), 1.48 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.1, 140.1, 133.8, 132.1, 128.4, 79.6, 76.1, 39.9, 35.7, 28.6.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>tert</i>-Butyl 4-(3,4-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5g</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.25 g of a white foam (73.4%). LCMS (<i>m</i>/<i>z</i>): 346.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.06 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.59 (d, <i>J</i> = 2.2 Hz, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.26 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 3.97 (dt, <i>J</i> = 12.9, 3.3 Hz, 2H), 3.19 (t, <i>J</i> = 12.9 Hz, 2H), 1.86 (td, <i>J</i> = 13.2, 4.8 Hz, 2H), 1.71–1.65 (m, 2H), 1.46 (s, 1H), 1.44 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 148.9, 132.4, 130.9, 130.3, 127.2, 124.3, 79.8, 70.9, 42.9, 36.6, 28.5.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 4-(3,5-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5h</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 2.22 g of a white solid (78.2%). LCMS (<i>m</i>/<i>z</i>): 345.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.09 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.35 (d, <i>J</i> = 1.9 Hz, 2H), 7.24 (t, <i>J</i> = 1.9 Hz, 1H), 4.01 (ddt, <i>J</i> = 13.5, 4.7, 1.8 Hz, 21H), 3.18 (td, <i>J</i> = 13.1, 2.7 Hz, 2H), 2.22 (s, 1H), 1.90 (td, <i>J</i> = 13.3, 4.9 Hz, 2H), 1.71–1.62 (m, 2H), 1.45 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 151.9, 135.2, 127.3, 123.7, 79.9, 71.5, 39.8, 38.1, 28.6.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 4-hydroxy-4-phenylpiperidine-1-carboxylate (<b>5i</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.49 g of a white foam (76%). LCMS (<i>m</i>/<i>z</i>): 278.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.83 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.53–7.45 (m, 2H), 7.43–7.33 (m, 2H), 7.34–7.24 (m, 1H), 4.03 (ddt, <i>J</i> = 13.3, 4.4, 1.8 Hz, 2H), 3.26 (td, <i>J</i> = 13.1, 2.7 Hz, 2H), 2.01 (td, <i>J</i> = 13.4, 4.9 Hz, 2H), 1.84 (s, 1H), 1.50 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 148.1, 128.5, 127.2, 124.5, 79.5, 71.5, 39.9, 38.1, 28.5.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>tert</i>-Butyl 4-hydroxy-4-(<i>p</i>-tolyl)piperidine-1-carboxylate (<b>5j</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.29 g of white foam (68%). LCMS (<i>m</i>/<i>z</i>): 292.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.93 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37–7.33 (m, 2H), 7.17 (dt, <i>J</i> = 7.9, 0.7 Hz, 2H), 3.99 (dt, <i>J</i> = 13.1, 2.6 Hz, 2H), 3.23 (td, <i>J</i> = 13.1, 2.7 Hz, 2H), 2.34 (s, 3H), 1.96 (td, <i>J</i> = 13.4, 4.9 Hz, 2H), 1.84–1.78 (m, 1H), 1.76–1.66 (m, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.0, 145.3, 136.9, 129.2, 124.5, 79.6, 71.4, 40.0, 38.3, 28.6, 21.1.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>tert</i>-Butyl 4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (<b>5k</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.43 g of a white foam (84%). LCMS (<i>m</i>/<i>z</i>): 346.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.00 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.60 (m, 4H), 4.04 (ddt, <i>J</i> = 13.7, 4.6, 1.8 Hz, 2H), 3.22 (td, <i>J</i> = 13.0, 2.6 Hz, 2H), 1.98 (td, <i>J</i> = 13.3, 4.9 Hz, 2H), 1.75–1.66 (m, 2H), 1.47 (s, 9H), 1.35–1.27 (m, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 152.2 (d, <i>J</i> = 1.5 Hz), 129.6 (q, <i>J</i> = 32.5 Hz), 125.5 (q, <i>J</i> = 3.8 Hz), 125.1, 124.2 (q, <i>J</i> = 272.1 Hz), 79.9, 71.7, 39.8, 38.1, 28.6.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>tert</i>-Butyl 4-(4-(dimethylamino)phenyl)-4-hydroxypiperidine-1-carboxylate (<b>5l</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.22 g of white solid (69%). LCMS (<i>m</i>/<i>z</i>): 321.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.51 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.34 (d, <i>J</i> = 8.9 Hz, 2H), 6.73 (d, <i>J</i> = 8.5 Hz, 2H), 3.96 (s, 2H), 3.25 (t, <i>J</i> = 11.6 Hz, 2H), 2.94 (s, 6H), 2.03–1.88 (m, 2H), 1.79–1.71 (m, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 155.1, 129.2, 128.3, 125.7, 112.6, 79.5, 71.1, 40.8, 28.6, 28.6.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>tert</i>-Butyl 4-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5m</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 1.24 g of transparent oil (71%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.42–7.35 (m, 2H), 6.94 (t, <i>J</i> = 8.7 Hz, 2H), 3.88 (dd, <i>J</i> = 12.8, 4.4 Hz, 2H), 3.22–3.09 (m, 2H), 3.07 (s, 1H), 1.83 (td, <i>J</i> = 13.2, 4.7 Hz, 2H), 1.64 (dd, <i>J</i> = 14.1, 2.5 Hz, 2H), 1.39 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.8 (d, <i>J</i> = 245.3 Hz), 154.9, 144.3 (d, <i>J</i> = 3.1 Hz), 126.4 (d, <i>J</i> = 7.9 Hz), 114.9 (d, <i>J</i> = 21.2 Hz), 79.6, 70.9, 38.1, 28.4.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl 4-(2′-chloro-[1,1′-biphenyl]-2-yl)-4-hydroxypiperidine-1-carboxylate (<b>5m</b>)</h4><div class="NLM_p last">General procedure A: Purification by FCC (eluent: EtOAc/hexane 0–40%) gave 700 mg of a white solid (55%). Reaction byproduct from the attempted synthesis of <i>tert</i>-butyl 4-(2-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5n</b>). LCMS (<i>m</i>/<i>z</i>): 388.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.12 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.51 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 7.49–7.41 (m, 1H), 7.40 (td, <i>J</i> = 7.7, 1.6 Hz, 1H), 7.29 (dtd, <i>J</i> = 10.5, 6.2, 5.6, 2.9 Hz, 4H), 7.01 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 3.89 (dddd, <i>J</i> = 15.5, 13.2, 5.0, 2.6 Hz, 2H), 3.06 (qd, <i>J</i> = 12.4, 2.7 Hz, 2H), 2.09–1.98 (m, 1H), 1.96–1.85 (m, 1H), 1.74 (ddd, <i>J</i> = 13.8, 11.4, 2.7 Hz, 2H), 1.44 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 145.0, 142.9, 137.3, 133.5, 132.3, 131.0, 129.5 128.8, 128.2, 126.9, 126.4, 126.3, 79.5, 73.6, 38.6, 38.2, 28.6.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>tert</i>-Butyl 4-(2-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>5n</b>)</h4><div class="NLM_p last">To a stirred solution of 1-bromo-2-chloro-benzene (<b>3m</b>) (609 μL, 5.22 mmol) in Et<sub>2</sub>O was added magnesium turnings (150 mg, 6.17 mmol), followed by catalytic iodide, and the reaction was stirred at room temperature for 2 h. This mixture was then cooled to 0 °C, treated with 4-oxopiperidine-1-carboxylic acid <i>tert</i>-butyl ester (946 mg, 4.75 mmol) dissolved in Et<sub>2</sub>O (10 mL), and added to the reaction mixture slowly. The reaction was heated at reflux temperature for 3 h. The reaction was quenched with a saturated solution of NH<sub>4</sub>Cl, and the aqueous phase was extracted with EtOAc. The organic extracts were combined and dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuo. The residue was purified by FCC (eluent: EtOAc/<i>n</i>-hexanes 0–40%) and gave 800 mg of a white foam (54%). LCMS (<i>m</i>/<i>z</i>): 312.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.97 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.56 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.30 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.21 (td, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.15 (td, <i>J</i> = 7.5, 1.7 Hz, 1H), 3.96 (dd, <i>J</i> = 13.4, 4.8 Hz, 2H), 3.22 (t, <i>J</i> = 12.9 Hz, 2H), 3.05 (s, 1H), 2.29 (td, <i>J</i> = 13.2, 4.9 Hz, 2H), 1.87–1.78 (m, 2H), 1.43 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 154.9, 143.5, 131.7, 131.5, 128.6, 127.2, 127.1, 79.5, 72.2, 39.8, 34.9, 28.5.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-(3-Chlorophenyl)piperidin-4-ol (<b>6a</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 660 mg of a white solid (97%). LCMS (<i>m</i>/<i>z</i>): 212.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.74 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.52 (t, <i>J</i> = 1.9 Hz, 1H), 7.37 (dt, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.29 (t, <i>J</i> = 7.8 Hz, 1H), 7.24 (dt, <i>J</i> = 7.9, 1.7 Hz, 1H), 3.10 (td, <i>J</i> = 12.3, 2.6 Hz, 2H), 2.99–2.90 (m, 2H), 2.42 (d, <i>J</i> = 9.1 Hz, 2H), 1.97 (td, <i>J</i> = 13.2, 4.6 Hz, 2H), 1.70 (dd, <i>J</i> = 14.1, 2.5 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 151.2, 134.4, 129.8, 127.1, 125.2, 122.9, 71.4, 42.2, 39.1.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-(2,3-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (<b>6b</b>)</h4><div class="NLM_p last">General procedure B: Concentration in vacuo gave 685 mg of a beige solid (94%). LCMS (<i>m</i>/<i>z</i>): 246.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.53 min. <sup>1</sup>H NMR [dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>] δ 9.19 (d, <i>J</i> = 55.0 Hz, 2H), 7.75 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 7.60 (dd, <i>J</i> = 8.0, 1.6 Hz, 1H), 7.40 (t, <i>J</i> = 8.0 Hz, 1H), 5.88 (s, 1H), 3.20 (s, 4H), 2.74 (dt, <i>J</i> = 14.1, 8.9 Hz, 2H), 1.80 (dd, <i>J</i> = 14.3, 2.4 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 146.4, 133.4, 129.7, 128.8, 128.0, 126.8, 69.8, 30.5.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(2,4-Dichlorophenyl)piperidin-4-ol (<b>6c</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 325 mg of a white solid (65%). LCMS (<i>m</i>/<i>z</i>): 246.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.65 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.27 (dd, <i>J</i> = 8.0, 1.9 Hz, 2H), 7.01 (td, <i>J</i> = 8.0, 2.1 Hz, 1H), 3.20–3.09 (m, 2H), 2.96–2.84 (m, 2H), 2.80–2.66 (m, 3H), 1.91 (dt, <i>J</i> = 14.0, 2.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 140.9, 133.9, 131.9, 131.9, 127.9, 76.0, 42.1, 36.6.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-(2,5-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (<b>6d</b>)</h4><div class="NLM_p last">General procedure B: Concentration in vacuo gave 180 mg of a white solid (98%). LCMS (<i>m</i>/<i>z</i>): 246.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 1.34 min. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.42–8.91 (m, 2H), 7.79 (d, <i>J</i> = 2.6 Hz, 1H), 7.45 (d, <i>J</i> = 8.4 Hz, 1H), 7.39 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 5.98 (s, 1H), 3.23–3.11 (m, 4H), 2.77 (dt, <i>J</i> = 14.1, 9.0 Hz, 2H), 1.70 (d, <i>J</i> = 13.9 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 146.1, 133.2, 132.1, 129.1, 128.8, 128.0, 69.4, 39.2, 30.3.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4-(2,6-Dichlorophenyl)piperidin-4-ol (<b>6e</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 682 mg of a white solid (96%). LCMS (<i>m</i>/<i>z</i>): 246.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.88 min. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.93 (d, <i>J</i> = 60.3 Hz, 2H), 7.45 (d, <i>J</i> = 7.9 Hz, 2H), 7.28 (dd, <i>J</i> = 8.4, 7.5 Hz, 1H), 5.67 (s, 1H), 3.21 (s, 4H), 2.90–2.76 (m, 2H), 2.16 (d, <i>J</i> = 13.7 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 139.9, 133.6, 132.0, 129.2, 72.0, 32.1.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 4-(3,4-Dichlorophenyl)piperidin-4-ol (<b>6f</b>)</h4><div class="NLM_p last">General procedure “B” Alkaline work-up afforded 702 mg of a white solid (98%). LCMS (<i>m</i>/<i>z</i>): 246.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 1.86 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.61 (d, <i>J</i> = 2.2 Hz, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 1H), 7.30 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 3.07 (td, <i>J</i> = 12.3, 2.7 Hz, 2H), 2.97–2.90 (m, 2H), 2.21 (s, 2H), 1.94 (ddd, <i>J</i> = 13.6, 12.2, 4.8 Hz, 2H), 1.70–1.63 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 149.3, 132.4, 130.8, 127.1, 124.2, 71.2, 42.1, 38.9.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-(3,5-Dichlorophenyl)-4-hydroxypiperidin-1-ium chloride (<b>6g</b>)</h4><div class="NLM_p last">General procedure B: Concentration in vacuo gave 755 mg of a white solid (93%). LCMS (<i>m</i>/<i>z</i>): 246.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.62 min. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.03 (s, 2H), 7.52 (t, <i>J</i> = 1.9 Hz, 1H), 7.45 (d, <i>J</i> = 1.9 Hz, 2H), 5.79 (s, 1H), 3.17 (dtd, <i>J</i> = 22.5, 12.8, 11.9, 7.0 Hz, 4H), 2.26 (td, <i>J</i> = 13.5, 5.0 Hz, 2H), 1.74 (dd, <i>J</i> = 13.9, 2.3 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 152.7, 134.0, 126.5, 123.7, 68.5, 33.9.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-Phenylpiperidin-4-ol (<b>6h</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 622 mg of a white solid (97%). LCMS (<i>m</i>/<i>z</i>): 178.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.42 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.55–7.48 (m, 2H), 7.41–7.32 (m, 2H), 7.31–7.22 (m, 1H), 3.10 (dd, <i>J</i> = 12.2, 2.6 Hz, 2H), 2.98–2.89 (m, 2H), 2.22 (s, 2H), 2.00 (ddd, <i>J</i> = 13.5, 12.2, 4.6 Hz, 2H), 1.75–1.69 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 149.1, 128.4, 126.9, 124.6, 71.5, 42.4, 39.3.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-(<i>p</i>-Tolyl)piperidin-4-ol (<b>6i</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 621 mg of a white solid (95%). LCMS (<i>m</i>/<i>z</i>): 192.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.62 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.37 (d, <i>J</i> = 8.3 Hz, 2H), 7.15 (d, <i>J</i> = 8.0 Hz, 2H), 3.07 (dd, <i>J</i> = 12.2, 2.7 Hz, 2H), 2.92–2.86 (m, 2H), 2.42–2.26 (m, 5H), 1.96 (td, <i>J</i> = 13.0, 4.6 Hz, 2H), 1.69 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 146.2, 136.5, 129.1, 124.6, 71.2, 42.4, 39.3, 21.0.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-(4-(Trifluoromethyl)phenyl)piperidin-4-ol (<b>6j</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 702 mg of a light yellow solid (92%). LCMS (<i>m</i>/<i>z</i>): 246.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 1.41–1.82 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.66–7.56 (m, 4H), 3.11 (td, <i>J</i> = 12.3, 2.6 Hz, 2H), 3.01–2.92 (m, 2H), 2.20–2.07 (m, 2H), 2.01 (ddd, <i>J</i> = 13.5, 12.3, 4.8 Hz, 2H), 1.74–1.65 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 152.9, 129.3 (q, <i>J</i> = 32.4 Hz), 125.4 (q, <i>J</i> = 3.7 Hz), 125.1, 71.7, 42.3, 39.2.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-(4-(Dimethylamino)phenyl)piperidin-4-ol (<b>6k</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 675 mg of a light orange solid (98%). LCMS (<i>m</i>/<i>z</i>): 221.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.31 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.40–7.31 (m, 2H), 6.76–6.68 (m, 2H), 3.09 (td, <i>J</i> = 12.1, 2.7 Hz, 2H), 2.93 (s, 6H), 2.90 (dt, <i>J</i> = 11.9, 3.5 Hz, 2H), 2.07 (s, 2H), 1.96 (ddd, <i>J</i> = 13.3, 11.9, 4.5 Hz, 2H), 1.77–1.68 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 149.6, 136.9, 125.4, 112.4, 70.9, 42.5, 40.7, 39.3.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 4-(4-Fluorophenyl)piperidin-4-ol (<b>6l</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 600 mg of a light yellow solid (92%). LCMS (<i>m</i>/<i>z</i>): 196.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.42 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47–7.42 (m, 2H), 7.01 (t, <i>J</i> = 8.7 Hz, 2H), 3.07 (td, <i>J</i> = 12.2, 2.6 Hz, 2H), 2.91 (ddd, <i>J</i> = 12.6, 4.2, 2.1 Hz, 2H), 1.95 (td, <i>J</i> = 13.0, 4.7 Hz, 2H), 1.69 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.9 (d, <i>J</i> = 245.2 Hz), 144.9 (d, <i>J</i> = 3.0 Hz), 126.4 (d, <i>J</i> = 8.0 Hz), 115.1 (d, <i>J</i> = 21.1 Hz), 71.4, 42.5, 39.5.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 4-(2′-Chloro-[1,1′-biphenyl]-2-yl)piperidin-4-ol (<b>6m</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 200 mg of a white solid (95%). LCMS (<i>m</i>/<i>z</i>): 288.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.06 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.61 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.49–7.41 (m, 1H), 7.44–7.37 (m, 1H), 7.35–7.25 (m, 4H), 7.02 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 3.05–2.95 (m, 2H), 2.90–2.81 (m, 2H), 2.37 (s, 2H), 2.09 (ddd, <i>J</i> = 13.9, 12.2, 4.6 Hz, 1H), 1.98 (ddd, <i>J</i> = 13.7, 12.2, 4.7 Hz, 1H), 1.78 (ddt, <i>J</i> = 13.5, 10.5, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 145.6, 143.1, 137.2, 133.4, 132.2, 131.1, 129.4, 128.6, 128.2, 126.7, 126.5, 126.2, 73.5, 39.2, 38.8.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 4-(2-Chlorophenyl)piperidin-4-ol (<b>6n</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 285 mg of a white solid (72%). LCMS (<i>m</i>/<i>z</i>): 2121 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.48 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.57 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 7.34 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.25 (td, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.18 (td, <i>J</i> = 7.6, 1.8 Hz, 1H), 3.15 (td, <i>J</i> = 12.4, 2.7 Hz, 2H), 2.99–2.89 (m, 2H), 2.63 (s, 1H), 2.29 (ddd, <i>J</i> = 13.4, 12.3, 4.7 Hz, 2H), 1.96–1.86 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 144.2, 131.9, 131.8, 128.5, 127.3, 127.2, 72.4, 42.2, 36.3.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 4-(4-Chlorophenyl)piperidin-4-ol (<b>7b</b>)</h4><div class="NLM_p last">General procedure B: Alkaline work-up afforded 1.62 g of a beige solid (96%). LCMS (<i>m</i>/<i>z</i>): 311.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 0.76 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43–7.38 (m, 2H), 7.32–7.27 (m, 2H), 3.05 (td, <i>J</i> = 12.3, 2.7 Hz, 2H), 2.91–2.84 (m, 2H), 2.18 (s, 2H, broad), 1.91 (ddd, <i>J</i> = 13.4, 12.2, 4.7 Hz, 2H), 1.71–1.60 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 147.7, 132.7, 128.5, 126.2, 71.3, 42.3, 39.3.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 4-(4-(3-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8a</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 91 mg of the title compound as a white solid (68%). LCMS (<i>m</i>/<i>z</i>): 376.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.37 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub>: requires 376.1505 [M + H]<sup>+</sup>; found 376.1546. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.02 (t, <i>J</i> = 6.7 Hz, 2H), 7.44 (s, 1H), 7.35–7.18 (m, 3H), 7.14 (t, <i>J</i> = 8.4 Hz, 2H), 2.98 (t, <i>J</i> = 7.0 Hz, 2H), 2.78 (d, <i>J</i> = 11.4 Hz, 2H), 2.55–2.35 (m, 4H), 2.06–1.90 (m, 5H), 1.67 (d, <i>J</i> = 13.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.5 Hz), 150.7, 134.4, 133.8 (d, <i>J</i> = 3.1 Hz), 130.8 (d, <i>J</i> = 9.2 Hz), 129.7, 127.2, 125.2, 122.9, 115.8 (d, <i>J</i> = 21.7 Hz), 71.3, 57.9, 49.4, 38.5, 36.4, 22.1.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 4-(4-(2,3-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 82 mg of the title compound as a white solid (68%). LCMS (<i>m</i>/<i>z</i>): 410.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.58 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1118 [M + H]<sup>+</sup>; found 410.1151. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.99 (dd, <i>J</i> = 8.6, 5.6 Hz, 2H), 7.41 (ddd, <i>J</i> = 16.5, 8.0, 1.5 Hz, 2H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 7.11 (t, <i>J</i> = 8.6 Hz, 2H), 2.98 (t, <i>J</i> = 7.1 Hz, 3H), 2.94 (s, 1H), 2.81 (dt, <i>J</i> = 11.9, 3.2 Hz, 2H), 2.58–2.45 (m, 4H), 2.26 (td, <i>J</i> = 13.0, 4.4 Hz, 2H), 2.04–1.93 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.4 Hz), 145.9, 134.9, 133.7 (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.2 Hz), 129.7, 127.5, 125.5, 115.7 (d, <i>J</i> = 21.8 Hz), 72.4, 57.7, 49.1, 36.3, 35.4, 21.8.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 4-(2,4-Dichlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>8c</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (Method C) afforded the title compound as a white solid (44 mg, 60%). LCMS (<i>m</i>/<i>z</i>): 410.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.47 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1012 [M + H]<sup>+</sup>; found 410.1094. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.05 (s, 1H), 8.00–7.92 (m, 2H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H), 7.12 (td, <i>J</i> = 8.2, 4.1 Hz, 2H), 5.59 (s, 1H), 3.58 (d, <i>J</i> = 11.3 Hz, 2H), 3.36 (q, <i>J</i> = 11.2 Hz, 2H), 3.28–3.10 (m, 6H), 2.35 (d, <i>J</i> = 14.1 Hz, 2H), 2.22 (p, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.78, 166.1 (d, <i>J</i> = 255.6 Hz), 137.8, 133.8, 132.7 (d, <i>J</i> = 3.1 Hz), 132.2, 130.8 (d, <i>J</i> = 9.5 Hz), 129.2, 116.0 (d, <i>J</i> = 21.9 Hz), 73.3, 56.7, 48.5, 35.1, 33.7, 18.2.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 4-(4-(2,5-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8d</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 91 mg of the title compound as a white solid (70%). LCMS (<i>m</i>/<i>z</i>): 410.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.65 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1012 [M + H]<sup>+</sup>; found 410.1093. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.04–7.94 (m, 2H), 7.53 (d, <i>J</i> = 2.5 Hz, 1H), 7.25 (d, <i>J</i> = 8.5 Hz, 1H), 7.17–7.07 (m, 3H), 2.97 (t, <i>J</i> = 7.0 Hz, 2H), 2.77 (dt, <i>J</i> = 10.8, 2.8 Hz, 3H), 2.51–2.42 (m, 4H), 2.28 (td, <i>J</i> = 13.0, 4.4 Hz, 2H), 1.96 (p, <i>J</i> = 7.1 Hz, 2H), 1.86 (dd, <i>J</i> = 13.7, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.7, 165.7 (d, <i>J</i> = 254.4 Hz), 145.6, 133.8 (d, <i>J</i> = 3.1 Hz), 133.2, 132.8, 130.8 (d, <i>J</i> = 9.1 Hz), 130.1, 128.4, 127.7, 115.7 (d, <i>J</i> = 21.8 Hz), 72.0, 57.7, 49.1, 36.3, 35.2, 21.9.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 4-(4-(2,6-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8e</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 69 mg of the title compound as a white solid (73%). LCMS (<i>m</i>/<i>z</i>): 410.72 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.50 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1111 [M + H]<sup>+</sup>; found 410.1066. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (dd, <i>J</i> = 8.7, 5.6 Hz, 2H), 7.29 (d, <i>J</i> = 7.9 Hz, 2H), 7.12 (t, <i>J</i> = 8.6 Hz, 2H), 7.04 (t, <i>J</i> = 8.0 Hz, 1H), 3.24 (s, 1H), 2.98 (t, <i>J</i> = 7.1 Hz, 2H), 2.81–2.69 (m, 4H), 2.54–2.48 (m, 2H), 2.45 (t, <i>J</i> = 7.1 Hz, 2H), 2.06 (d, <i>J</i> = 13.6 Hz, 2H), 1.97 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.8, 165.7 (d, <i>J</i> = 254.1 Hz), 140.7, 134.0, 133.8 (d, <i>J</i> = 3.0 Hz), 132.0, 130.8 (d, <i>J</i> = 9.2 Hz), 128.2, 115.7 (d, <i>J</i> = 21.7 Hz), 75.8, 57.8, 49.2, 36.4, 36.2, 22.1.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 4-(4-(3,4-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8f</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 84 mg of the title compound as a white solid (70%). LCMS (<i>m</i>/<i>z</i>): 410.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.69 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1111 [M + H]<sup>+</sup>; found 410.1066. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.03 (dd, <i>J</i> = 8.7, 5.5 Hz, 2H), 7.55 (d, <i>J</i> = 2.1 Hz, 1H), 7.40 (d, <i>J</i> = 8.5 Hz, 1H), 7.31–7.23 (m, 1H), 7.16 (t, <i>J</i> = 8.6 Hz, 2H), 2.99 (t, <i>J</i> = 7.0 Hz, 2H), 2.80 (dt, <i>J</i> = 11.4, 2.9 Hz, 2H), 2.54–2.37 (m, 4H), 2.08–1.91 (m, 4H), 1.66 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.4, 167.0, 164.5, 148.9, 133.8, 133.8, 132.5, 130.9, 130.8, 130.7, 130.3, 127.2, 124.3, 115.9, 115.7, 77.5, 77.2, 76.8, 71.1, 57.9, 49.3, 38.4, 36.3, 22.0.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4-(4-(3,5-Dichlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8g</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 92 mg of the title compound as a white solid (62%). LCMS (<i>m</i>/<i>z</i>): 410.7 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.59 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>Cl<sub>2</sub>FNO<sub>2</sub>: requires 410.1084 [M + H]<sup>+</sup>; found 410.1097. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.08 (dd, <i>J</i> = 8.5, 5.6 Hz, 2H), 7.41 (t, <i>J</i> = 1.9 Hz, 1H), 7.35 (t, <i>J</i> = 8.7 Hz, 2H), 7.28 (d, <i>J</i> = 1.9 Hz, 2H), 5.04 (s, 1H), 2.95 (t, <i>J</i> = 6.6 Hz, 2H), 2.57 (d, <i>J</i> = 10.9 Hz, 2H), 2.35 (t, <i>J</i> = 6.8 Hz, 2H), 2.29 (t, <i>J</i> = 11.4 Hz, 2H), 1.85 (t, <i>J</i> = 6.7 Hz, 2H), 1.58 (dt, <i>J</i> = 12.9, 6.4 Hz, 2H), 1.42 (d, <i>J</i> = 12.9 Hz, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 198.2, 164.7 (d, <i>J</i> = 251.1 Hz), 154.7, 134.1 (d, <i>J</i> = 2.9 Hz), 133.7, 130.8 (d, <i>J</i> = 9.4 Hz), 125.8, 123.8, 115.6 (d, <i>J</i> = 21.7 Hz), 69.9, 57.2, 48.7, 37.5, 35.6, 22.2.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 1-(4-Fluorophenyl)-4-(4-hydroxy-4-phenylpiperidin-1-yl)butan-1-one (<b>8h</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 101 mg of the title compound as a white solid (88%). LCMS (<i>m</i>/<i>z</i>): 342.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.92 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>24</sub>FNO<sub>2</sub>: requires 342.1864 [M + H]<sup>+</sup>; found 342.1873. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.08–7.99 (m, 2H), 7.48 (dd, <i>J</i> = 7.6, 1.7 Hz, 2H), 7.36 (t, <i>J</i> = 7.7 Hz, 2H), 7.31–7.22 (m, 1H), 7.15 (t, <i>J</i> = 8.6 Hz, 2H), 3.00 (t, <i>J</i> = 7.1 Hz, 2H), 2.81 (dt, <i>J</i> = 11.7, 3.1 Hz, 2H), 2.56–2.42 (m, 4H), 2.05 (ddd, <i>J</i> = 28.3, 13.9, 5.8 Hz, 4H), 1.89 (s, 1H), 1.73 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H).<sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.3 Hz), 148.5, 133.8 (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.3 Hz), 128.4, 127.1, 124.6, 115.7 (d, <i>J</i> = 21.7 Hz), 71.4, 57.9, 49.5, 38.5, 36.4, 22.0.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 1-(4-Fluorophenyl)-4-(4-hydroxy-4-(<i>p</i>-tolyl)piperidin-1-yl)butan-1-one (<b>8i</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 84 mg of the title compound as a white solid (80%). LCMS (<i>m</i>/<i>z</i>): 356.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.22 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>26</sub>FNO<sub>2</sub>: requires 356.2067 [M + H]<sup>+</sup>; found 356.2068. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (dd, <i>J</i> = 8.7, 5.6 Hz, 2H), 7.34 (d, <i>J</i> = 8.0 Hz, 2H), 7.18–7.08 (m, 4H), 2.98 (t, <i>J</i> = 7.1 Hz, 2H), 2.78 (dt, <i>J</i> = 12.1, 3.3 Hz, 2H), 2.52–2.40 (m, 4H), 2.33 (s, 3H), 2.09–1.94 (m, 5H), 1.70 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.3 Hz), 145.6, 136.7, 133.8 (d, <i>J</i> = 3.1 Hz), 130.8 (d, <i>J</i> = 9.3 Hz), 129.1, 124.6, 115.7 (d, <i>J</i> = 21.8 Hz), 71.1, 57.9, 49.6, 38.5, 36.4, 21.9, 21.1. CDCl<sub>3</sub></div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 1-(4-Fluorophenyl)-4-(4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one (<b>8j</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 65 mg of the title compound as a white solid (69%). LCMS (<i>m</i>/<i>z</i>): 410.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.59 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>23</sub>F<sub>4</sub>NO<sub>2</sub>: requires 410.1756 [M + H]<sup>+</sup>; found 410.1778. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.00 (dd, <i>J</i> = 8.6, 5.5 Hz, 2H), 7.57 (s, 4H), 7.13 (t, <i>J</i> = 8.6 Hz, 2H), 2.99 (t, <i>J</i> = 7.0 Hz, 2H), 2.85 (d, <i>J</i> = 11.2 Hz, 2H), 2.57–2.45 (m, 4H), 2.17–1.90 (m, 5H), 1.79–1.63 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.4, 165.8 (d, <i>J</i> = 254.7 Hz), 152.3, 133.7 (d, <i>J</i> = 3.1 Hz), 129.4 (d, <i>J</i> = 32.4 Hz), 125.4 (q, <i>J</i> = 3.7 Hz), 125.2, 124.3 (q, <i>J</i> = 272.9 Hz), 115.8 (d, <i>J</i> = 21.9 Hz), 71.3, 57.9, 49.3, 38.2, 36.3, 21.7.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 4-(4-(4-(Dimethylamino)phenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>8k</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 60 mg of the title compound as a light orange solid (62%). LCMS (<i>m</i>/<i>z</i>): 385.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 1.41 min. HRMS (<i>m</i>/<i>z</i>): C<sub>23</sub>H<sub>29</sub>FN<sub>2</sub>O<sub>2</sub>: requires 385.2310 [M + H]<sup>+</sup>; found 385.2274. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.99 (dd, <i>J</i> = 8.7, 5.6 Hz, 2H), 7.32 (d, <i>J</i> = 8.8 Hz, 2H), 7.12 (t, <i>J</i> = 8.6 Hz, 2H), 6.70 (d, <i>J</i> = 8.9 Hz, 2H), 3.01 (t, <i>J</i> = 7.0 Hz, 2H), 2.92 (s, 6H), 2.93–2.86 (m, 2H), 2.60 (dt, <i>J</i> = 14.8, 8.4 Hz, 4H), 2.14 (td, <i>J</i> = 13.3, 4.3 Hz, 2H), 2.02 (p, <i>J</i> = 7.3 Hz, 2H), 1.94 (s, 1H), 1.77 (dd, <i>J</i> = 14.3, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.2, 165.8 (d, <i>J</i> = 254.4 Hz), 149.8, 135.8, 133. (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.2 Hz), 125.5, 115.7 (d, <i>J</i> = 21.8 Hz), 112.5, 70.4, 57.5, 49.4, 40.7, 37.7, 36.3, 21.2.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 1-(4-Fluorophenyl)-4-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (<b>8l</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 80 mg of the title compound as a white solid (74%). LCMS (<i>m</i>/<i>z</i>): 360.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.09 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>F<sub>2</sub>NO<sub>2</sub>: requires 360.1697 [M + H]<sup>+</sup>; found 360.1777. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.12–7.96 (m, 2H), 7.44–7.36 (m, 2H), 7.13 (t, <i>J</i> = 8.6 Hz, 2H), 7.00 (t, <i>J</i> = 8.7 Hz, 2H), 2.98 (t, <i>J</i> = 7.0 Hz, 2H), 2.80 (dt, <i>J</i> = 11.7, 3.0 Hz, 2H), 2.55–2.41 (m, 4H), 2.02 (dt, <i>J</i> = 14.3, 10.2 Hz, 5H), 1.70 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.8 (d, <i>J</i> = 254.4 Hz), 161.9 (d, <i>J</i> = 245.3 Hz), 144.2 (d, <i>J</i> = 2.6 Hz), 133.8 (d, <i>J</i> = 3.3 Hz), 130.8 (d, <i>J</i> = 9.2 Hz), 126.4 (d, <i>J</i> = 8.0 Hz), 115.7 (d, <i>J</i> = 21.8 Hz), 115.1 (d, <i>J</i> = 21.1 Hz), 71.1, 57.9, 49.5, 38.5, 36.4, 21.9.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 4-(2′-Chloro-[1,1′-biphenyl]-2-yl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>8m</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 95 mg of the title compound as a transparent oil (76%). LCMS (<i>m</i>/<i>z</i>): 452.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 4.00 min. HRMS (<i>m</i>/<i>z</i>): C<sub>27</sub>H<sub>27</sub>ClFNO<sub>2</sub>: requires 452.1787 [M + H]<sup>+</sup>; found 452.1811. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.19 (s, 1H), 7.94 (dd, <i>J</i> = 8.6, 5.3 Hz, 2H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.49–7.38 (m, 2H), 7.33 (ddd, <i>J</i> = 7.5, 5.1, 2.7 Hz, 2H), 7.25 (d, <i>J</i> = 7.6 Hz, 2H), 7.12 (t, <i>J</i> = 8.5 Hz, 2H), 7.02 (d, <i>J</i> = 7.5 Hz, 1H), 3.44 (dd, <i>J</i> = 26.7, 11.6 Hz, 2H), 3.22–2.99 (m, 6H), 2.71–2.58 (m, 1H), 2.46 (td, <i>J</i> = 14.0, 4.1 Hz, 1H), 2.35 (s, 1H), 2.15 (t, <i>J</i> = 7.2 Hz, 2H), 2.01 (dd, <i>J</i> = 30.5, 14.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.7, 166.1 (d, <i>J</i> = 255.6 Hz), 142.3, 142.1, 137.1, 133.4, 132.8 (d, <i>J</i> = 3.0 Hz), 132.4, 130.9, 130.8 (d, <i>J</i> = 9.5 Hz), 129.6, 129.2, 128.8, 127.8, 126.7, 126.4, 116.0 (d, <i>J</i> = 21.9 Hz), 71.4, 56.6, 48.6, 35.9, 35.6, 35.1, 18.2.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 4-(2-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>8n</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 88 mg of the title compound as a white solid (62%). LCMS (<i>m</i>/<i>z</i>): 376.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.37 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO: requires 376.1474 [M + H]<sup>+</sup>; found 376.1479. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 12.14 (s, 1H), 8.01–7.92 (m, 2H), 7.46 (dd, <i>J</i> = 7.7, 1.9 Hz, 1H), 7.37 (dd, <i>J</i> = 7.5, 1.8 Hz, 1H), 7.32–7.19 (m, 2H), 7.13 (t, <i>J</i> = 8.5 Hz, 2H), 4.05 (s, 1H), 3.58 (d, <i>J</i> = 11.5 Hz, 2H), 3.36 (q, <i>J</i> = 11.2 Hz, 2H), 3.15 (q, <i>J</i> = 6.5, 5.2 Hz, 4H), 2.67 (td, <i>J</i> = 13.9, 4.1 Hz, 2H), 2.31 (d, <i>J</i> = 14.1 Hz, 2H), 2.22 (p, <i>J</i> = 6.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.6, 166.0 (d, <i>J</i> = 255.5 Hz), 140.6, 132.6 (d, <i>J</i> = 3.0 Hz), 131.9, 131.5, 130.7 (d, <i>J</i> = 9.4 Hz), 129.5, 127.7, 127.1, 115.9 (d, <i>J</i> = 22.0 Hz), 69.8, 56.6, 48.4, 35.0, 32.9, 18.1.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 4-Chlorobut-1-yne (<b>10</b>)</h4><div class="NLM_p last">3-Butynol (<b>9</b>) (25.0 mL, 330 mmol) and pyridine (2.66 mL, 33 mmol) were placed in a 100 mL round-bottomed flask, and the mixture was cooled in an ice bath. Then, thionyl chloride (24.4 mL, 334 mmol) was added dropwise for 10 min. The flask was shaken occasionally during the addition, and after the thionyl chloride was added, the mixture was heated under reflux for 30 min. Fractional distillation of the products gave 4-chloro-1-butyne as a light yellow liquid (24 mL, 82%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 3.58 (t, <i>J</i> = 7.1 Hz, 2H), 2.63 (td, <i>J</i> = 7.1, 2.6 Hz, 2H), 2.07 (t, <i>J</i> = 2.7 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 80.2, 70.5, 41.9, 22.8.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-(4-Chlorobut-1-yn-1-yl)-2-fluorobenzene (<b>12a</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.24 g of a yellow oil (72%). LCMS (<i>m</i>/<i>z</i>): 183.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.05 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47–7.40 (m, 1H), 7.34–7.26 (m, 1H), 7.15–7.03 (m, 2H), 3.73 (t, <i>J</i> = 7.2 Hz, 2H), 2.95 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.9 (d, <i>J</i> = 251.0 Hz), 133.8 (d, <i>J</i> = 1.5 Hz), 129.9 (d, <i>J</i> = 7.9 Hz), 124.0 (d, <i>J</i> = 3.8 Hz), 115.6 (d, <i>J</i> = 21.0 Hz), 111.7 (d, <i>J</i> = 15.7 Hz), 91.2 (d, <i>J</i> = 3.3 Hz), 75.9 (d, <i>J</i> = 1.1 Hz), 42.1, 24.1.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 1-(4-Chlorobut-1-yn-1-yl)-3-fluorobenzene (<b>12b</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.55 g of a yellow oil (90%). LCMS (<i>m</i>/<i>z</i>): 183.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.02 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.32–7.25 (m, 1H), 7.22 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.14 (ddd, <i>J</i> = 9.5, 2.6, 1.4 Hz, 1H), 7.03 (tdd, <i>J</i> = 8.4, 2.7, 1.2 Hz, 1H), 3.71 (t, <i>J</i> = 7.2 Hz, 2H), 2.91 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.6 (d, <i>J</i> = 246.3 Hz), 129.9 (d, <i>J</i> = 8.5 Hz), 127.7 (d, <i>J</i> = 3.1 Hz), 125.1 (d, <i>J</i> = 9.5 Hz), 118.6 (d, <i>J</i> = 22.7 Hz), 115.6 (d, <i>J</i> = 21.2 Hz), 86.9, 81.5 (d, <i>J</i> = 3.4 Hz), 42.1, 23.9.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 1-(4-Chlorobut-1-yn-1-yl)-2,3-difluorobenzene (<b>12c</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.65 g of a yellow oil (87%). LCMS (<i>m</i>/<i>z</i>): 201.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.02 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.20–7.11 (m, 1H), 7.15–7.05 (m, 1H), 7.00 (dddd, <i>J</i> = 8.3, 7.8, 4.9, 1.6 Hz, 1H), 3.70 (t, <i>J</i> = 7.2 Hz, 2H), 2.93 (td, <i>J</i> = 7.2, 0.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 151.3 (dd, <i>J</i> = 252.7, 13.4 Hz), 150.7 (dd, <i>J</i> = 248.3, 12.2 Hz), 128.5 (d, <i>J</i> = 3.4 Hz), 123.9 (dd, <i>J</i> = 7.3, 4.9 Hz), 117.4 (d, <i>J</i> = 17.5 Hz), 113.9 (dd, <i>J</i> = 12.3, 1.8 Hz), 92.6 (d, <i>J</i> = 3.8 Hz), 74.9 (dd, <i>J</i> = 4.6, 1.3 Hz), 41.9, 24.1.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 1-(4-Chlorobut-1-yn-1-yl)-2,4-difluorobenzene (<b>12d</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.72 g of a yellow oil (82.3%). LCMS (<i>m</i>/<i>z</i>): 201.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.99 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.42–7.35 (m, 1H), 6.86–6.78 (m, 2H), 3.69 (t, <i>J</i> = 7.2 Hz, 2,H), 2.91 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 163.3 (dd, <i>J</i> = 253.7, 12.2 Hz), 162.6 (dd, <i>J</i> = 251.7, 11.3 Hz), 134.6 (dd, <i>J</i> = 9.7, 2.8 Hz), 111.6 (dd, <i>J</i> = 21.9, 3.8 Hz), 108.1 (dd, <i>J</i> = 16.0, 4.1 Hz), 104.3 (dd, <i>J</i> = 24.9, 0.2 Hz), 90.9 (dd, <i>J</i> = 3.4, 1.8 Hz), 75.0 (d, <i>J</i> = 1.4 Hz), 42.04, 24.1.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 2-(4-Chlorobut-1-yn-1-yl)-1,4-difluorobenzene (<b>12e</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.45 g of a yellow oil (70%). LCMS (<i>m</i>/<i>z</i>): 201.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.00 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.10 (ddd, <i>J</i> = 8.5, 5.4, 2.9 Hz, 1H), 7.04–6.93 (m, 2H), 3.69 (t, <i>J</i> = 7.2 Hz, 2H), 2.92 (t, <i>J</i> = 7.2 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 159.3 (d, <i>J</i> = 249.6 Hz), 158.2 (d, <i>J</i> = 242.8 Hz), 128.8 (d, <i>J</i> = 81.5 Hz), 119.8 (dd, <i>J</i> = 25.2, 1.9 Hz), 116.7 (dd, <i>J</i> = 10.6, 8.6 Hz), 116.5 (dd, <i>J</i> = 10.5, 8.5 Hz), 92.3 (d, <i>J</i> = 3.4 Hz), 75.1 (d, <i>J</i> = 2.6 Hz), 41.9, 24.1.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 2-(4-Chlorobut-1-yn-1-yl)-1,3-difluorobenzene (<b>12f</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 992 mg of a pink oil (53%). LCMS (<i>m</i>/<i>z</i>): 200.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.97 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.32–7.20 (m, 1H), 6.96–6.86 (m, 2H), 3.74 (t, <i>J</i> = 7.3 Hz, 2H), 2.99 (t, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 163.5 (d, <i>J</i> = 253.2 Hz), 163.4 (d, <i>J</i> = 253.3 Hz), 129.6 (t, <i>J</i> = 10.0 Hz), 111.4 (dd, <i>J</i> = 4.5, 0.3 Hz), 111.2 (dd, <i>J</i> = 4.5, 1.2 Hz), 102.2 (t, <i>J</i> = 19.8 Hz), 96.2 (t, <i>J</i> = 3.1 Hz), 69.6 (t, <i>J</i> = 1.4 Hz), 41.8, 24.3.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 4-(4-Chlorobut-1-yn-1-yl)-1,2-difluorobenzene (<b>12g</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.53 g of a yellow oil (81%). LCMS (<i>m</i>/<i>z</i>): 200.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.03 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.21 (ddd, <i>J</i> = 10.9, 7.5, 2.0 Hz, 1H), 7.13 (dd, <i>J</i> = 4.6, 1.6 Hz, 1H), 7.08 (dt, <i>J</i> = 10.2, 8.2 Hz, 1H), 3.67 (t, <i>J</i> = 7.1 Hz, 2H), 2.86 (t, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 150.6 (dd, <i>J</i> = 250.9, 12.5 Hz), 150.0 (dd, <i>J</i> = 248.7, 13.0 Hz), 128.4 (dd, <i>J</i> = 6.4, 3.6 Hz), 120.8 (d, <i>J</i> = 18.3 Hz), 117.5 (d, <i>J</i> = 17.8 Hz), 86.5 (d, <i>J</i> = 1.9 Hz), 80.6 (t, <i>J</i> = 2.3 Hz), 42.1, 23.8.</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 1-(4-Chlorobut-1-yn-1-yl)-3,5-difluorobenzene (<b>12h</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (<i>n</i>-hexanes) gave 1.61 g of a yellow oil (85%). LCMS (<i>m</i>/<i>z</i>): 200.9 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.03 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.98–6.91 (m, 2H), 6.79 (tt, <i>J</i> = 9.0, 2.4 Hz, 1H), 3.70 (t, <i>J</i> = 7.1 Hz, 2H), 2.90 (t, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.8 (d, <i>J</i> = 248.5 Hz), 162.7 (d, <i>J</i> = 248.6 Hz), 125.9 (t, <i>J</i> = 11.8 Hz), 114.9 (d, <i>J</i> = 7.4 Hz), 114.7 (d, <i>J</i> = 7.4 Hz), 104.5 (t, <i>J</i> = 25.4 Hz), 88.2, 80.6 (t, <i>J</i> = 3.9 Hz), 41.94, 23.8.</div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 1-Chloro-2-(4-chlorobut-1-yn-1-yl)benzene (<b>12i</b>)</h4><div class="NLM_p last">General procedure E: Purification by FCC (<i>n</i>-hexanes) gave 1.12 g of a light yellow liquid (88%). LCMS (<i>m</i>/<i>z</i>): 200.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.02 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.45 (dd, <i>J</i> = 7.5, 1.9 Hz, 1H), 7.38 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.21 (dtd, <i>J</i> = 16.1, 7.4, 1.6 Hz, 2H), 3.72 (t, <i>J</i> = 7.3 Hz, 2H), 2.95 (t, <i>J</i> = 7.3 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 136.0, 133.5, 129.3, 129.2, 126.5, 123.1, 91.3, 79.5, 42.1, 24.1.</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 1-(4-Chlorobut-1-yn-1-yl)-2-methylbenzene (<b>12j</b>)</h4><div class="NLM_p last">General procedure E: Purification by FCC (<i>n</i>-hexanes) gave 1.32 g of a transparent liquid (92%). LCMS (<i>m</i>/<i>z</i>): 179.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.03 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.39 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.23–7.17 (m, 2H), 7.17–7.07 (m, 1H), 3.71 (t, <i>J</i> = 7.2 Hz, 2H), 2.93 (t, <i>J</i> = 7.2 Hz, 2H), 2.44 (s, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 140.4, 132.0, 129.5, 128.2, 125.6, 123.0, 89.7, 81.5, 42.5, 24.1, 20.8.</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 4-Chloro-1-(2-fluorophenyl)butan-1-one (<b>13a</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 1.12 g of a yellow oil (82%). LCMS: <i>t</i><sub>R</sub> 2.91 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.87 (td, <i>J</i> = 7.6, 1.9 Hz, 1H), 7.52 (dddd, <i>J</i> = 8.3, 7.1, 5.0, 1.9 Hz, 1H), 7.23 (ddd, <i>J</i> = 7.8, 7.3, 1.1 Hz, 1H), 7.14 (ddd, <i>J</i> = 11.3, 8.3, 1.1 Hz, 1H), 3.66 (t, <i>J</i> = 6.4 Hz, 2H), 3.18 (td, <i>J</i> = 6.9, 3.1 Hz, 2H), 2.27–2.17 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.4 (d, <i>J</i> = 4.0 Hz), 162.2 (d, <i>J</i> = 254.6 Hz), 134.8 (d, <i>J</i> = 9.1 Hz), 130.7 (d, <i>J</i> = 2.7 Hz), 125.6 (d, <i>J</i> = 13.0 Hz), 124.6 (d, <i>J</i> = 3.4 Hz), 116.9 (d, <i>J</i> = 24.0 Hz), 44.6, 40.5 (d, <i>J</i> = 7.8 Hz), 26.8 (d, <i>J</i> = 2.1 Hz).</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 4-Chloro-1-(3-fluorophenyl)butan-1-one (<b>13b</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 449 mg of a dark red oil (41%). LCMS (<i>m</i>/<i>z</i>): 201.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.91 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.77 (ddd, <i>J</i> = 7.8, 1.6, 1.0 Hz, 1H), 7.66 (ddd, <i>J</i> = 9.5, 2.6, 1.5 Hz, 1H), 7.46 (td, <i>J</i> = 8.0, 5.5 Hz, 1H), 7.28 (tdd, <i>J</i> = 8.3, 2.7, 1.0 Hz, 1H), 3.69 (t, <i>J</i> = 6.2 Hz, 2H), 3.17 (t, <i>J</i> = 6.9 Hz, 2H), 2.27–2.20 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.7 (d, <i>J</i> = 2.0 Hz), 162.9 (d, <i>J</i> = 248.0 Hz), 138.9 (d, <i>J</i> = 6.0 Hz), 130.4 (d, <i>J</i> = 7.6 Hz), 123.9 (d, <i>J</i> = 3.0 Hz), 120.3 (d, <i>J</i> = 21.4 Hz), 114.8 (d, <i>J</i> = 22.3 Hz), 44.6, 35.5, 26.7.</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 4-Chloro-1-(2,3-difluorophenyl)butan-1-one (<b>13c</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 745 mg of a yellow oil (81%). LCMS: <i>t</i><sub>R</sub> 2.94 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.61 (ddt, <i>J</i> = 7.8, 6.0, 1.7 Hz, 1H), 7.36 (dddd, <i>J</i> = 9.8, 8.2, 7.4, 1.8 Hz, 1H), 7.17 (tdd, <i>J</i> = 8.1, 4.6, 1.5 Hz, 1H), 3.66 (t, <i>J</i> = 6.3 Hz, 2H), 3.18 (td, <i>J</i> = 6.9, 3.1 Hz, 2H), 2.22 (dddd, <i>J</i> = 13.3, 6.9, 6.2, 0.8 Hz, 32H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.2 (dd, <i>J</i> = 3.8, 2.6 Hz), 151.1 (dd, <i>J</i> = 250.1, 14.0 Hz), 150.5 (dd, <i>J</i> = 256.7, 13.7 Hz), 127.5 (d, <i>J</i> = 9.9 Hz), 125.1 (dd, <i>J</i> = 3.6, 1.6 Hz), 124.5 (dd, <i>J</i> = 6.6, 4.5 Hz), 121.6 (dd, <i>J</i> = 17.5, 1.4 Hz), 44.4, 40.5 (d, <i>J</i> = 7.0 Hz), 26.6 (d, <i>J</i> = 2.0 Hz).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 4-Chloro-1-(2,4-difluorophenyl)butan-1-one (<b>13d</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 294 mg of a yellow oil (58%). LCMS: <i>t</i><sub>R</sub> 2.91 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.94 (td, <i>J</i> = 8.6, 6.6 Hz, 1H), 7.01–6.91 (m, 1H), 6.87 (ddd, <i>J</i> = 11.1, 8.6, 2.4 Hz, 1H), 3.65 (t, <i>J</i> = 6.3 Hz, 2H), 3.14 (td, <i>J</i> = 6.9, 3.3 Hz, 2H), 2.20 (dddd, <i>J</i> = 13.3, 6.9, 6.2, 0.8 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 195.7 (d, <i>J</i> = 4.8 Hz), 165.9 (dd, <i>J</i> = 257.2, 12.4 Hz), 162.9 (dd, <i>J</i> = 257.5, 12.6 Hz), 132.7 (dd, <i>J</i> = 10.5, 4.3 Hz), 122.0 (dd, <i>J</i> = 13.2, 3.6 Hz), 112.4 (dd, <i>J</i> = 21.4, 3.4 Hz), 104.9 (dd, <i>J</i> = 27.9, 25.4 Hz), 44.5 (s), 40.3 (d, <i>J</i> = 7.8 Hz), 26.7 (d, <i>J</i> = 2.2 Hz).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 4-Chloro-1-(2,5-difluorophenyl)butan-1-one (<b>13e</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 384 mg of a clear oil (82%). LCMS: <i>t</i><sub>R</sub> 2.90 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.50 (ddd, <i>J</i> = 8.7, 5.5, 3.3 Hz, 1H), 7.18 (ddt, <i>J</i> = 9.0, 7.0, 3.6 Hz, 1H), 7.10 (ddd, <i>J</i> = 10.1, 9.0, 4.2 Hz, 1H), 3.62 (t, <i>J</i> = 6.3 Hz, 2H), 3.13 (td, <i>J</i> = 6.9, 3.2 Hz, 2H), 2.17 (pd, <i>J</i> = 6.6, 0.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 195.8 (dd, <i>J</i> = 4.8, 1.3 Hz), 158.7 (dd, <i>J</i> = 244.6, 2.2 Hz), 158.1 (dd, <i>J</i> = 250.8, 2.4 Hz), 126.4 (dd, <i>J</i> = 15.8, 6.2 Hz), 121.4 (dd, <i>J</i> = 24.6, 9.4 Hz), 118.3 (dd, <i>J</i> = 27.4, 7.9 Hz), 116.4 (dd, <i>J</i> = 25.0, 3.3 Hz), 44.4, 40.3 (d, <i>J</i> = 8.2 Hz), 26.6 (d, <i>J</i> = 2.3 Hz).</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 4-Chloro-1-(2,6-difluorophenyl)butan-1-one (<b>13f</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 408 mg of a clear oil (79%). LCMS (<i>m</i>/<i>z</i>): 219.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.90 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.39 (tt, <i>J</i> = 8.4, 6.3 Hz, 1H), 6.94 (t, <i>J</i> = 8.2 Hz, 2H), 3.63 (t, <i>J</i> = 6.3 Hz, 2H), 3.06 (t, <i>J</i> = 7.0 Hz, 2H), 2.20 (p, <i>J</i> = 6.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.6, 159.9 (d, <i>J</i> = 253.5 Hz), 159.9 (d, <i>J</i> = 253.7 Hz), 132.6 (t, <i>J</i> = 10.5 Hz), 112.4–112.3 (m), 112.21–112.06 (m), 44.2, 41.9 (t, <i>J</i> = 2.3 Hz), 26.5.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 4-Chloro-1-(3,4-difluorophenyl)butan-1-one (<b>13g</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 1.27 g of a yellow oil (78%). LCMS (<i>m</i>/<i>z</i>): 219.5 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.94 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.87–7.78 (m, 1H), 7.78 (dtd, <i>J</i> = 6.5, 2.1, 1.0 Hz, 1H), 7.34–7.22 (m, 1H), 3.71–3.67 (m, 2H), 3.16 (t, <i>J</i> = 6.9 Hz, 2H), 2.30–2.20 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.5, 153.8 (dd, <i>J</i> = 257.1, 13.0 Hz), 150.6 (dd, <i>J</i> = 251.0, 13.0 Hz), 133.9 (t, <i>J</i> = 3.8 Hz), 125.1 (dd, <i>J</i> = 7.5, 3.6 Hz), 117.7 (d, <i>J</i> = 17.8 Hz), 117.4 (dd, <i>J</i> = 17.9, 1.9 Hz), 44.6, 35.3, 26.7.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-Chloro-1-(3,5-difluorophenyl)butan-1-one (<b>13h</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 309 mg of a red oil (72%). LCMS: <i>t</i><sub>R</sub> 2.96 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.53–7.42 (m, 2H), 7.02 (tt, <i>J</i> = 8.4, 2.4 Hz, 1H), 3.67 (t, <i>J</i> = 6.2 Hz, 2H), 3.13 (t, <i>J</i> = 6.9 Hz, 2H), 2.22 (tt, <i>J</i> = 6.8, 6.0 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.47 (t, <i>J</i> = 2.4 Hz), 163.20 (dd, <i>J</i> = 251.1, 11.7 Hz), 139.71 (t, <i>J</i> = 7.4 Hz), 111.07 (dd, <i>J</i> = 18.9, 7.3 Hz), 108.63 (t, <i>J</i> = 25.4 Hz), 44.46, 35.61, 26.57.</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 4-Chloro-1-(2-chlorophenyl)butan-1-one (<b>13i</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 1.12 g of a yellow oil (80%). LCMS (<i>m</i>/<i>z</i>): 217.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.90 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.48 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.44–7.36 (m, 2H), 7.32 (td, <i>J</i> = 7.2, 1.8 Hz, 1H), 3.65 (t, <i>J</i> = 6.3 Hz, 2H), 3.14 (t, <i>J</i> = 7.0 Hz, 2H), 2.21 (p, <i>J</i> = 6.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 202.2, 139.3, 131.9, 130.9, 130.7, 128.9, 127.1, 44.4, 39.9, 26.9.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 4-Chloro-1-(<i>o</i>-tolyl)butan-1-one (<b>13j</b>)</h4><div class="NLM_p last">General procedure F: Purification by FCC (<i>n</i>-hexanes/EtOAc 10:0.1) gave 900 mg of a yellow oil (74%). LCMS (<i>m</i>/<i>z</i>): 197.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.90 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.68 (dd, <i>J</i> = 7.8, 1.4 Hz, 1H), 7.38 (td, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.30–7.23 (m, 2H), 3.67 (t, <i>J</i> = 6.3 Hz, 2H), 3.10 (t, <i>J</i> = 6.9 Hz, 2H), 2.50 (s, 3H), 2.20 (p, <i>J</i> = 6.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 203.1, 138.2, 137.8, 132.1, 131.5, 128.6, 125.9, 44.7, 38.3, 27.0, 21.5.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 4-(4-Chlorophenyl)-1-(4-(2-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridin-1-ium 2,2,2-trifluoroacetate (<b>14a</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 49 mg of white solid (45%). LCMS (<i>m</i>/<i>z</i>): 376.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.34 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub>: requires 376.1401 [M + H]<sup>+</sup>; found 376.1483. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.71 (s, 1H), 7.87 (td, <i>J</i> = 7.6, 1.8 Hz, 1H), 7.57 (tdd, <i>J</i> = 7.3, 5.0, 1.8 Hz, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 2H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.29–7.22 (m, 1H), 7.17 (dd, <i>J</i> = 11.4, 8.3 Hz, 1H), 3.88 (s, 1H), 3.55 (d, <i>J</i> = 11.6 Hz, 2H), 3.34 (q, <i>J</i> = 11.2 Hz, 2H), 3.14 (tt, <i>J</i> = 6.6, 3.3 Hz, 4H), 2.53 (td, <i>J</i> = 14.1, 4.1 Hz, 2H), 2.26–2.14 (m, 2H), 1.94 (d, <i>J</i> = 14.4 Hz, 2H).</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(3-fluorophenyl)butan-1-one (<b>14b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 55 mg of a white solid (39%). LCMS (<i>m</i>/<i>z</i>): 376.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.21 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub>: requires 376.1474 [M + H]<sup>+</sup>; found 376.1480. <sup>1</sup>H NMR (methanol-<i>d</i><sub>4</sub>) δ 7.89 (dt, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.75 (ddd, <i>J</i> = 9.7, 2.7, 1.6 Hz, 1H), 7.63–7.51 (m, 3H), 7.45–7.35 (m, 3H), 3.61 (d, <i>J</i> = 11.9 Hz, 2H), 3.49 (td, <i>J</i> = 12.7, 2.8 Hz, 2H), 3.34–3.24 (m, 4H), 2.43 (td, <i>J</i> = 14.5, 4.4 Hz, 2H), 2.31–2.18 (m, 2H), 2.01 (dq, <i>J</i> = 15.3, 2.9 Hz, 2H). <sup>13</sup>C NMR (methanol-<i>d</i><sub>4</sub>) δ 198.9 (d, <i>J</i> = 2.3 Hz), 164.3 (d, <i>J</i> = 246.3 Hz), 147.0, 140.1 (d, <i>J</i> = 6.2 Hz), 134.23, 131.8 (d, <i>J</i> = 7.7 Hz), 129.5, 127.5, 125.2 (d, <i>J</i> = 3.0 Hz), 121.3 (d, <i>J</i> = 21.7 Hz), 115.5 (d, <i>J</i> = 22.8 Hz), 69.3, 50.3, 49.6, 36.4, 36.3, 19.6.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(2,3-difluorophenyl)butan-1-one (<b>14c</b>)</h4><div class="NLM_p last">A solution of 4-(4-chlorophenyl)-1-(4-(2,3-difluorophenyl)-4,4-dimethoxybutyl)piperidin-4-ol (<b>16c</b>) (110 mg, 250 μmol) in 15 mL of 15:1 acetone/H<sub>2</sub>O was treated with <i>p-</i>TsOH (61.8 mg, 326 μmol), and the mixture was heated at reflux for 48 h. The mixture was concentrated under reduced pressure. The residue was dissolved in EtOAC (20 mL) and poured into saturated NaHCO<sub>3</sub> (20 mL). The aqueous phase was extracted with EtOAc (2 × 20 mL), and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue was purified by FCC (SiO<sub>2</sub>, 98:1 EtOAc/MeOH), affording the title compound as a beige solid (75 mg, 76%). LCMS (<i>m</i>/<i>z</i>): 394.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.37 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1380 [M + H]<sup>+</sup>; found 394.1390. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.62 (ddt, <i>J</i> = 7.9, 6.1, 1.8 Hz, 1H), 7.38–7.32 (m, 3H), 7.32–7.25 (m, 2H), 7.16 (tdd, <i>J</i> = 8.1, 4.5, 1.5 Hz, 1H), 3.01 (td, <i>J</i> = 7.0, 2.8 Hz, 2H), 2.82–2.76 (m, 2H), 2.51–2.38 (m, 4H), 2.05–1.79 (m, 5H), 1.66 (dd, <i>J</i> = 14.0, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.0 (dd, <i>J</i> = 6.3, 2.6 Hz), 151.1 (dd, <i>J</i> = 250.4, 14.8 Hz), 150.4 (dd, <i>J</i> = 256.2, 13.6 Hz), 147.0, 132.8, 128.5, 128.1 (d, <i>J</i> = 9.9 Hz), 126.2, 125.2 (dd, <i>J</i> = 3.5, 1.3 Hz), 124.3 (dd, <i>J</i> = 6.6, 4.5 Hz), 121.2 (d, <i>J</i> = 17.4 Hz), 71.2, 57.8, 49.4, 41.4 (d, <i>J</i> = 6.8 Hz), 38.5, 21.9.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 4-(4-Chlorophenyl)-1-(4-(2,4-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>14d</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 68 mg of a white solid (66%). LCMS (<i>m</i>/<i>z</i>): 394.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.35 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1380 [M + H]<sup>+</sup>; found 394.1387. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.54 (s, 1H), 7.53 (ddd, <i>J</i> = 8.6, 5.4, 3.3 Hz, 1H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.31–7.20 (m, 3H), 7.15 (td, <i>J</i> = 9.5, 4.1 Hz, 1H), 4.83 (s, 1H), 3.47 (d, <i>J</i> = 10.2 Hz, 2H), 3.33 (q, <i>J</i> = 11.3 Hz, 2H), 3.11 (td, <i>J</i> = 6.4, 3.2 Hz, 4H), 2.45 (td, <i>J</i> = 14.0, 4.2 Hz, 2H), 2.18 (dq, <i>J</i> = 13.7, 6.7 Hz, 2H), 1.93 (d, <i>J</i> = 14.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 195.1, 158.7 (dd, <i>J</i> = 245.1, 1.9 Hz), 158.3 (dd, <i>J</i> = 251.3, 2.2 Hz), 144.8, 133.6, 128.8, 126.1, 125.6 (dd, <i>J</i> = 15.4, 6.4 Hz), 122.1 (dd, <i>J</i> = 24.5, 9.6 Hz), 118.6 (dd, <i>J</i> = 27.2, 7.8 Hz), 116.4 (d, <i>J</i> = 27.9 Hz), 68.8, 56.5, 48.9, 39.9 (d, <i>J</i> = 9.0 Hz), 35.4, 18.1.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 4-(4-Chlorophenyl)-1-(4-(2,5-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>14e</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 60 mg of a white solid (66%). LCMS (<i>m</i>/<i>z</i>): 394.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.35 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1380 [M + H]<sup>+</sup>; found 394.1385. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.15 (s, 1H), 7.53 (ddd, <i>J</i> = 8.7, 5.4, 3.3 Hz, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 2H), 7.31 (d, <i>J</i> = 8.4 Hz, 2H), 7.23 (dq, <i>J</i> = 6.9, 3.1 Hz, 1H), 7.14 (td, <i>J</i> = 9.6, 4.1 Hz, 1H), 3.55 (d, <i>J</i> = 11.4 Hz, 2H), 3.33 (q, <i>J</i> = 11.3 Hz, 2H), 3.21–3.05 (m, 4H), 2.53–2.42 (m, 2H), 2.19 (t, <i>J</i> = 7.9 Hz, 2H), 1.9 (d, <i>J</i> = 14.5 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 195.1, 158.6 (dd, <i>J</i> = 245.1, 1.9 Hz), 158.2 (dd, <i>J</i> = 251.0, 2.3 Hz), 144.2, 133.8, 128.9, 125.8, 122.0 (dd, <i>J</i> = 24.5, 9.8 Hz), 118.5 (dd, <i>J</i> = 27.5, 8.0 Hz), 116.4 (d, <i>J</i> = 3.1 Hz), 116.2 (d, <i>J</i> = 2.8 Hz), 69.0, 56.5, 48.9, 39. 8 (d, <i>J</i> = 8.9 Hz), 35.3, 18.1.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(2,6-difluorophenyl)butan-1-one (<b>14f</b>)</h4><div class="NLM_p last">A solution of 4-(4-chlorophenyl)-1-(3-(2-(2,6-difluorophenyl)-1,3-dioxolan-2-yl)propyl)piperidin-4-ol (<b>16f</b>) (150 mg, 342 μmol) in 15 mL of 15:1 acetone/H<sub>2</sub>O was treated with <i>p-</i>TsOH (84.7 mg, 445 μmol), and the mixture was heated at reflux for 48 h. The mixture was concentrated under reduced pressure. The residue was dissolved in EtOAC (20 mL) and poured into saturated NaHCO<sub>3</sub> (20 mL). The aqueous phase was extracted with EtOAc (2 × 20 mL), and the combined extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure. The residue was purified by FCC (eluent, 98:1 EtOAc/MeOH), affording the title compound as a beige solid (110 mg, 82%). LCMS (<i>m</i>/<i>z</i>): 394.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.27 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1418 [M + H]<sup>+</sup>; found 394.1465. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.45–7.37 (m, 2H), 7.36 (td, <i>J</i> = 8.4, 7.3, 5.3 Hz, 1H), 7.32–7.25 (m, 2H), 6.94 (t, <i>J</i> = 8.1 Hz, 2H), 2.92 (t, <i>J</i> = 7.1 Hz, 2H), 2.79 (dt, <i>J</i> = 11.7, 3.1 Hz, 2H), 2.50–2.37 (m, 4H), 2.07 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.94 (p, <i>J</i> = 7.2 Hz, 3H), 1.69 (dd, <i>J</i> = 14.0, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.6, 159.9 (dd, <i>J</i> = 253.1, 7.5 Hz), 147.1, 132.8, 132.3 (t, <i>J</i> = 10.4 Hz), 128.5, 126.2, 118.5 (t, <i>J</i> = 19.6 Hz), 112.4–112.2 (m), 112.2–111.9 (m), 71.12, 57.6, 49.4, 42.9, 38.5, 21.3.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(3,4-difluorophenyl)butan-1-one (<b>14g</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 48 mg of a white solid (74%). LCMS (<i>m</i>/<i>z</i>): 364.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.51 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1380 [M + H]<sup>+</sup>; found 394.1388. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.82 (ddd, <i>J</i> = 10.5, 7.7, 2.1 Hz, 1H), 7.76 (ddd, <i>J</i> = 8.8, 4.1, 1.8 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.28 (d, <i>J</i> = 8.7 Hz, 2H), 7.28–7.18 (m, 1H), 2.95 (t, <i>J</i> = 7.0 Hz, 2H), 2.76 (d, <i>J</i> = 12.2 Hz, 2H), 2.49–2.34 (m, 4H), 2.03–1.90 (m, 4H), 1.80 (s, 1H), 1.66 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.5, 153.6 (dd, <i>J</i> = 256.7, 13.0 Hz), 150.5 (dd, <i>J</i> = 250.7, 12.9 Hz), 147.0, 134.5 (t, <i>J</i> = 3.8 Hz), 132.9, 128.5, 126.2, 125.1 (dd, <i>J</i> = 7.3, 3.6 Hz), 117.7–117.6 (m), 117.5–117.4 (m), 71.1, 57.8, 49.4, 38.4, 36.3, 21.9.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 4-(4-Chlorophenyl)-1-(4-(3,5-difluorophenyl)-4-oxobutyl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>14h</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 42 mg of a white solid (44%). LCMS (<i>m</i>/<i>z</i>): 394.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.44 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>22</sub>ClF<sub>2</sub>NO<sub>2</sub>: requires 394.1307 [M + H]<sup>+</sup>; found 394.1371. <sup>1</sup>H NMR (methanol-<i>d</i><sub>4</sub>) δ 7.64–7.53 (m, 2H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.28–7.17 (m, 1H), 3.71–3.54 (m, 2H), 3.44 (td, <i>J</i> = 12.8, 2.8 Hz, 2H), 2.34 (td, <i>J</i> = 14.1, 4.3 Hz, 2H), 2.27–2.15 (m, 2H), 2.04–1.94 (m, 2H). <sup>13</sup>C NMR (methanol-<i>d</i><sub>4</sub>) δ 197.6, 164.6 (d, <i>J</i> = 249.3 Hz), 164.5 (d, <i>J</i> = 249.3 Hz), 147.0, 141.1 (t, <i>J</i> = 7.5 Hz), 134.2, 129.5, 127.4, 112.1 (d, <i>J</i> = 7.2 Hz), 111.9 (d, <i>J</i> = 7.4 Hz), 109.3 (t, <i>J</i> = 26.0 Hz), 69.2, 57.5, 36.6, 36.3, 19.4.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 1-(2-Chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (<b>14i</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 89 mg of a white solid (70%). LCMS (<i>m</i>/<i>z</i>): 392.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.40 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>Cl<sub>2</sub>NO<sub>2</sub>: requires 392.1106 [M + H]<sup>+</sup>; found 392.1184. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 7.42–7.34 (m, 4H), 7.33–7.25 (m, 3H), 2.97 (t, <i>J</i> = 7.1 Hz, 2H), 2.77 (dt, <i>J</i> = 11.9, 3.0 Hz, 2H), 2.47–2.36 (m, 4H), 2.10–1.98 (m, 3H), 1.93 (p, <i>J</i> = 7.2 Hz, 2H), 1.68 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 203.4, 147.1, 139.7, 132.8, 131.7, 130.9, 130.6, 128.9, 128.4, 126.9, 126.2, 71.1, 57.7, 49.4, 40.9, 38.5, 21.7.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(<i>o</i>-tolyl)butan-1-one (<b>14j</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 90 mg of a white solid (70%). LCMS (<i>m</i>/<i>z</i>): 372.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.47 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>26</sub>ClNO<sub>2</sub>: requires 372.1652 [M + H]<sup>+</sup>; found 372.1626. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.66 (d, <i>J</i> = 7.6 Hz, 1H), 7.39 (d, <i>J</i> = 8.5 Hz, 2H), 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.6 Hz, 2H), 7.24 (d, <i>J</i> = 7.5 Hz, 2H), 2.92 (t, <i>J</i> = 7.1 Hz, 2H), 2.78 (dt, <i>J</i> = 12.0, 3.1 Hz, 2H), 2.49 (s, 3H), 2.50–2.36 (m, 4H), 2.04 (td, <i>J</i> = 13.3, 4.5 Hz, 2H), 1.93 (p, <i>J</i> = 7.2 Hz, 3H), 1.68 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 204.4, 147.1, 138.3, 138.0, 132.8, 132.0, 131.2, 128.6, 128.4, 126.2, 125.7, 71.2, 57.9, 49.5, 39.5, 38.6, 21.9, 21.4.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-phenylbutan-1-one (<b>14k</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 75 mg of a white solid (75 mg, 79%). LCMS (<i>m</i>/<i>z</i>): 358.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.21 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>24</sub>ClNO<sub>2</sub>: requires 358.1558 [M + H]<sup>+</sup>; found 358.1579. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.98 (d, <i>J</i> = 8.3 Hz, 2H), 7.60–7.51 (m, 1H), 7.51–7.42 (m, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.32–7.22 (m, 2H), 3.00 (t, <i>J</i> = 7.0 Hz, 2H), 2.79 (dt, <i>J</i> = 12.0, 3.0 Hz, 2H), 2.51–2.37 (m, 4H), 2.07–1.92 (m, 5H), 1.65 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 200.1, 147.1, 137.4, 132.9, 132.8, 128.7, 128.5, 128.2, 126.2, 71.2, 58.0, 49.4, 38.5, 36.4, 22.1.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 1-(4-Chlorophenyl)-4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (<b>14l</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 68 mg of the title compound as a yellow solid (80%). LCMS (<i>m</i>/<i>z</i>): 392.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.68 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>Cl<sub>2</sub>NO<sub>2</sub>: requires 392.1106 [M + H]<sup>+</sup>; found 392.1174. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.92 (d, <i>J</i> = 8.6 Hz, 2H), 7.43 (d, <i>J</i> = 8.6 Hz, 2H), 7.35 (d, <i>J</i> = 8.7 Hz, 2H), 7.28 (d, <i>J</i> = 8.7 Hz, 2H), 2.96 (t, <i>J</i> = 7.0 Hz, 2H), 2.75 (dt, <i>J</i> = 12.2, 3.2 Hz, 2H), 2.50–2.35 (m, 4H), 2.06–1.90 (m, 4H), 1.73 (s, 1H), 1.65 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.8, 147.1, 139.4, 135.7, 132.8, 129.7, 128.9, 128.5, 126.2, 71.2, 57.9, 49.4, 38.5, 36.4, 22.1.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 1-(4-Chloro-1,1-dimethoxybutyl)-2,3-difluorobenzene (<b>15c</b>)</h4><div class="NLM_p last">4-Chloro-1-(2,3-difluorophenyl)butan-1-one (<b>13c</b>) (450 mg, 2.06 mmol) was taken up in MeOH (15 mL), treated with trimethyl orthoformate (450 mL, 4.12 mmol) and <i>p</i>-toluenesulfonic acid monohydrate (7.83 mg, 41.2 mmol), and stirred for 3 h at rt. This was diluted with sat. aq NaHCO<sub>3</sub> (20 mL) and H<sub>2</sub>O (20 mL) and extracted with EtOAc (3 × 15 mL). The organic extracts were combined, washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford 425 mg of the title compound as a light green oil (77%). LCMS (<i>m</i>/<i>z</i>): 265.8 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.08 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.35 (ddt, <i>J</i> = 8.1, 6.4, 1.7 Hz, 1H), 7.14 (dddd, <i>J</i> = 9.9, 8.7, 7.1, 1.8 Hz, 1H), 7.06 (tdd, <i>J</i> = 8.1, 5.0, 1.6 Hz, 1H), 3.42 (t, <i>J</i> = 6.6 Hz, 2H), 3.19 (s, 6H), 2.22–2.13 (m, 2H), 1.54–1.42 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 151.1 (dd, <i>J</i> = 247.4, 13.6 Hz), 147.9 (dd, <i>J</i> = 253.0, 13.5 Hz), 129.8 (d, <i>J</i> = 7.3 Hz), 125.1 (dd, <i>J</i> = 3.7, 2.2 Hz), 123.5 (dd, <i>J</i> = 6.8, 4.8 Hz), 117.3 (d, <i>J</i> = 17.2 Hz), 101.8 (d, <i>J</i> = 3.2 Hz), 48.8, 44.8, 32.4 (d, <i>J</i> = 3.1 Hz), 27.3.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 2-(3-Chloropropyl)-2-(2,6-difluorophenyl)-1,3-dioxolane (<b>15f</b>)</h4><div class="NLM_p last">A solution of 4-chloro-1-(2,6-difluorophenyl)butan-1-one (<b>13f</b>) (250 mg, 1.14 mmol), ethylene glycol (320 μL, 5.72 mmol), and <i>p</i>-TsOH·H<sub>2</sub>O (10.9 mg, 57.2 μmol) in toluene (15 mL) was heated at reflux temperature using a Dean–Stark water trap for 16 h. The cooled reaction mixture was washed with NaOH (3 × 20 mL), followed by H<sub>2</sub>O (2 × 20 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). The organic layer was removed in vacuo, and the residue was purified by FCC (5:95 EtOAc/PE) to afford 249 mg of a clear oil (83%). LCMS (<i>m</i>/<i>z</i>): 263.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.91 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.23 (tt, <i>J</i> = 8.2, 5.3 Hz, 1H), 6.85 (t, <i>J</i> = 8.7 Hz, 2H), 4.12–4.03 (m, 2H), 3.93–3.84 (m, 2H), 3.56 (t, <i>J</i> = 6.8 Hz, 2H), 2.25–2.19 (m, 2H), 1.93 (dt, <i>J</i> = 14.1, 6.9 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 160.6 (dd, <i>J</i> = 252.0, 7.6 Hz), 129.9 (t, <i>J</i> = 11.1 Hz), 117.7 (t, <i>J</i> = 14.7 Hz), 112.7–112.6 (m), 112.5–112.4 (m), 109.1 (t, <i>J</i> = 3.5 Hz), 64.9, 45.1, 36.5 (t, <i>J</i> = 1.8 Hz), 26.8.</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> 4-(4-Chlorophenyl)-1-(4-(2,3-difluorophenyl)-4,4-dimethoxybutyl)piperidin-4-ol (<b>16c</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 130 mg of a transparent oil (71%). LCMS (<i>m</i>/<i>z</i>): 440.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.39 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.40 (d, <i>J</i> = 8.7 Hz, 2H), 7.38–7.33 (m, 1H), 7.29 (d, <i>J</i> = 8.6 Hz, 2H), 7.12 (dtd, <i>J</i> = 9.6, 7.9, 1.8 Hz, 1H), 7.04 (tdd, <i>J</i> = 8.1, 5.0, 1.4 Hz, 1H), 3.18 (s, 6H), 2.66 (d, <i>J</i> = 11.4 Hz, 2H), 2.38–2.19 (m, 4H), 2.11–1.97 (m, 4H), 1.76 (s, 1H), 1.65 (dd, <i>J</i> = 14.1, 2.6 Hz, 2H), 1.29–1.16 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 151.1 (dd, <i>J</i> = 246.8, 13.8 Hz), 147.9 (dd, <i>J</i> = 252.8, 13.3 Hz), 146.9, 132.9, 130.1 (d, <i>J</i> = 7.1 Hz), 128.5, 126.2, 125.2 (t, <i>J</i> = 4.9, 2.3 Hz), 123.4 (dd, <i>J</i> = 12.0, 5.1 Hz), 117.1 (d, <i>J</i> = 17.2 Hz), 102.2 (t, <i>J</i> = 3.1 Hz), 71.1, 58.2, 49.4, 48.8, 38.4, 32.7 (d, <i>J</i> = 2.9 Hz), 21.4.</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> 4-(4-Chlorophenyl)-1-(3-(2-(2,6-difluorophenyl)-1,3-dioxolan-2-yl)propyl)piperidin-4-ol (<b>16f</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 325 mg of a transparent oil (77%). LCMS (<i>m</i>/<i>z</i>): 438.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.39 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 8.6 Hz, 2H), 7.29 (d, <i>J</i> = 8.6 Hz, 2H), 7.25–7.17 (m, 1H), 6.89–6.79 (m, 2H), 4.12–4.02 (m, 2H), 3.93–3.86 (m, 2H), 2.78 (d, <i>J</i> = 11.3 Hz, 2H), 2.44–2.34 (m, 4H), 2.15–2.01 (m, 4H), 1.85 (s, 1H), 1.68 (d, <i>J</i> = 11.5 Hz, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ160.7 (d, <i>J</i> = 251.7 Hz), 160.7 (d, <i>J</i> = 251.9 Hz), 147.1, 132.8, 129.7 (t, <i>J</i> = 11.0 Hz), 128.5, 126.2, 117.9 (t, <i>J</i> = 14.8 Hz), 112.6 (d, <i>J</i> = 7.2 Hz), 112.4 (d, <i>J</i> = 7.2 Hz), 109.5 (t, <i>J</i> = 3.5 Hz), 71.2, 64.9, 58.5, 49.4, 38.5, 37.2, 20.9.</div></div><div id="sec4_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 4-(4-Chlorophenyl)-1-(3-((4-fluorophenyl)thio)propyl)piperidin-4-ol (<b>17a</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 67 mg of a white solid (77%). LCMS (<i>m</i>/<i>z</i>): 380.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.73 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>23</sub>ClFNOS: requires 380.1276 [M + H]<sup>+</sup>; found 380.1308. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43 (d, <i>J</i> = 8.6 Hz, 2H), 7.39–7.31 (m, 2H), 7.34–7.24 (m, 2H), 6.99 (t, <i>J</i> = 8.6 Hz, 2H), 2.92 (t, <i>J</i> = 7.3 Hz, 2H), 2.75 (dt, <i>J</i> = 11.8, 3.0 Hz, 2H), 2.50 (t, <i>J</i> = 7.3 Hz, 2H), 2.40 (td, <i>J</i> = 12.0, 2.4 Hz, 2H), 2.08 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.82 (p, <i>J</i> = 7.3 Hz, 2H), 1.70 (dd, <i>J</i> = 14.2, 2.6 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.8 (d, <i>J</i> = 246.1 Hz), 146.9, 132.9, 132.3 (d, <i>J</i> = 8.0 Hz), 131.5 (d, <i>J</i> = 3.4 Hz), 128.5, 126.2, 116.1 (d, <i>J</i> = 21.8 Hz), 71.2, 57.4, 49.6, 38.6, 33.2, 26.8.</div></div><div id="sec4_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> 4-(4-Chlorophenyl)-1-(3-(4-fluorophenoxy)propyl)piperidin-4-ol (<b>17b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 77 mg of a white solid (80%). LCMS (<i>m</i>/<i>z</i>): 364.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.51 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>23</sub>ClFNO<sub>2</sub>: requires 380.1474 [M + H]<sup>+</sup>; found 364.1492. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44 (d, <i>J</i> = 8.7 Hz, 2H), 7.31 (d, <i>J</i> = 8.6 Hz, 2H), 6.96 (dd, <i>J</i> = 9.6, 7.7 Hz, 2H), 6.84 (dd, <i>J</i> = 9.1, 4.3 Hz, 2H), 3.98 (t, <i>J</i> = 6.3 Hz, 2H), 2.88–2.76 (m, 2H), 2.58 (t, <i>J</i> = 7.5 Hz, 2H), 2.51–2.39 (m, 2H), 2.11 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 2.03–1.93 (m, 2H), 1.73 (dd, <i>J</i> = 14.2, 2.7 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 157.3 (d, <i>J</i> = 238.0 Hz), 155.2 (d, <i>J</i> = 2.1 Hz), 147.0, 132.9, 128.5, 126.3, 115.9 (d, <i>J</i> = 23.0 Hz), 115.6 (d, <i>J</i> = 7.8 Hz), 71.2, 67.1, 55.4, 49.6, 38.6, 27.1.</div></div><div id="sec4_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> 4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)-4-hydroxybutyl)piperidin-4-ol (<b>18</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 60 mg of the title compound as a white solid (67%). LCMS (<i>m</i>/<i>z</i>): 378.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.05 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>25</sub>ClFNO<sub>2</sub>: requires 378.1558 [M + H]<sup>+</sup>; found 378.1643. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.48–7.38 (m, 2H), 7.36–7.23 (m, 4H), 6.99 (t, <i>J</i> = 8.7 Hz, 2H), 4.67–4.61 (m, 1H), 3.07–2.99 (m, 1H), 2.89–2.79 (m, 1H), 2.64 (td, <i>J</i> = 12.1, 2.7 Hz, 1H), 2.58–2.47 (m, 3H), 2.22 (ddt, <i>J</i> = 18.7, 12.9, 4.7 Hz, 2H), 2.00–1.88 (m, 1H), 1.81–1.65 (m, 6H), 1.25 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.9 (d, <i>J</i> = 244.1 Hz), 146.4, 141.6 (d, <i>J</i> = 3.1 Hz), 133.2, 128.6, 127.4 (d, <i>J</i> = 8.0 Hz), 126.3, 115.1 (d, <i>J</i> = 21.2 Hz), 73.3, 70.9, 58.9, 50.2, 48.6, 40.2, 37.9, 37.7, 24.1.</div></div><div id="sec4_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Cyclopropyl(4-fluorophenyl)methanone (<b>19</b>)</h4><div class="NLM_p last">To a stirred solution of NaOH (1.82 g, 45.6 mmol) in H<sub>2</sub>O (30 mL) at room temperature was added a solution of 4-chloro-1-(4-fluorophenyl)butan-1-one (<b>7a</b>) (5.00 mL, 30.4 mmol) in THF (10 mL). After addition, the reaction temperature was increased to 60 °C followed by stirring for a further 5 h. EtOAc and H<sub>2</sub>O were added, and the organic phase was washed with additional H<sub>2</sub>O and brine and dried (Na<sub>2</sub>SO<sub>4</sub>) followed by concentration in vacuo to yield the product as a light yellow oil (5.00 g, quantitative). LCMS: <i>t</i><sub>R</sub> 2.73 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.08–7.99 (m, 2H), 7.19–7.09 (m, 2H), 2.62 (tt, <i>J</i> = 7.8, 4.6 Hz, 1H), 1.23 (ddt, <i>J</i> = 6.8, 4.6, 2.2 Hz, 2H), 1.04 (dq, <i>J</i> = 7.3, 3.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 199.1, 165.7 (d, <i>J</i> = 254.0 Hz), 134.5 (d, <i>J</i> = 3.0 Hz), 130.7 (d, <i>J</i> = 9.2 Hz), 115.7 (d, <i>J</i> = 21.8 Hz), 17.2, 11.8.</div></div><div id="sec4_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Cyclopropyl(4-fluorophenyl)methanol (<b>20</b>)</h4><div class="NLM_p last">To a stirred solution of cyclopropyl(4-fluorophenyl)methanone (<b>19</b>) (5.00 g, 30.5 mmol) in MeOH (40 mL) at 0 °C was added NaBH<sub>4</sub> (1.50 g, 39.6 mmol) portion-wise. The reaction mixture was allowed to come to room temperature and stirred for a further 4 h. To the reaction mixture was added sat. aqueous NH<sub>4</sub>Cl solution and EtOAc, the phases were separated, the aqueous phase was extracted twice with EtOAc, and the combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to afford 5.01 g of a gold oil (99%). LCMS (<i>m</i>/<i>z</i>): <i>t</i><sub>R</sub> 2.73 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.08–7.99 (m, 1H), 7.19–7.09 (m, 1H), 2.62 (tt, <i>J</i> = 7.8, 4.6 Hz, 1H), 1.23 (ddt, <i>J</i> = 6.8, 4.6, 2.2 Hz, 2H), 1.04 (dq, <i>J</i> = 7.3, 3.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 199.1, 165.7 (d, <i>J</i> = 254.0 Hz), 134.5 (d, <i>J</i> = 3.0 Hz), 130.7 (d, <i>J</i> = 9.2 Hz), 115.7 (d, <i>J</i> = 21.8 Hz), 17.2, 11.8.</div></div><div id="sec4_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> (<i>E</i>)-4-(4-Fluorophenyl)but-3-en-1-ol (<b>21</b>)</h4><div class="NLM_p last">To a mixture of vanadyl acetylacetonate (639 mg, 2.41 mmol), 2,6-di-<i>tert</i>-butyl-<i>p</i>-cresol (265 mg, 1.20 mmol), and chlorobenzene (40 mL) in a round-bottom flask was added a solution of cyclopropyl(4-fluorophenyl)methanol (<b>20</b>) (4.00 g, 24.1 mmol) in chlorobenzene (5.00 mL), and the resulting mixture was stirred at 80 °C. After 48 h, the reaction mixture was cooled to rt and filtered through a pad of Florisil. The solvent was evaporated, and the residue was purified by FCC (eluent, 4:1 <i>n</i>-hexanes/EtOAc) to yield 1.41 g of a transparent oil (35%). LCMS: <i>t</i><sub>R</sub> 2.73 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.35–7.26 (m, 2H), 6.98 (t, <i>J</i> = 8.7 Hz, 2H), 6.45 (d, <i>J</i> = 15.9 Hz, 1H), 6.11 (dt, <i>J</i> = 15.8, 7.1 Hz, 1H), 3.74 (t, <i>J</i> = 6.3 Hz, 2H), 2.46 (qd, <i>J</i> = 6.4, 1.4 Hz, 2H), 2.04 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.2 (d, <i>J</i> = 246.2 Hz), 133.5 (d, <i>J</i> = 3.2 Hz), 131.6, 127.6 (d, <i>J</i> = 8.0 Hz), 126.3 (d, <i>J</i> = 2.3 Hz), 115.5 (d, <i>J</i> = 21.5 Hz), 62.1, 36.4.</div></div><div id="sec4_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> (<i>E</i>)-4-(4-Fluorophenyl)but-3-en-1-yl methanesulfonate (<b>22</b>)</h4><div class="NLM_p last">General procedure G: Purification by FCC (eluent 4:1, PE/EtOAc) gave 152 mg of a transparent oil (83%). LCMS (<i>m</i>/<i>z</i>): <i>t</i><sub>R</sub> 2.79 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.35–7.28 (m, 2H), 6.99 (t, <i>J</i> = 8.7 Hz, 2H), 6.48 (dt, <i>J</i> = 15.8, 1.5 Hz, 1H), 6.07 (dt, <i>J</i> = 15.8, 7.0 Hz, 1H), 4.33 (t, <i>J</i> = 6.6 Hz, 2H), 3.01 (s, 3H), 2.65 (qd, <i>J</i> = 6.7, 1.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.4 (d, <i>J</i> = 246.7 Hz), 133.1 (d, <i>J</i> = 3.2 Hz), 132.5, 127.8 (d, <i>J</i> = 7.9 Hz), 123.7 (d, <i>J</i> = 2.3 Hz), 115.6 (d, <i>J</i> = 21.6 Hz), 69.1, 37.7, 32.9.</div></div><div id="sec4_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (<i>E</i>)-4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-en-1-yl)piperidin-4-ol (<b>23</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 80 mg of a white solid (82%). LCMS (<i>m</i>/<i>z</i>): 360.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.62 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO: requires 360.1452 [M + H]<sup>+</sup>; found 360.1541. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.48–7.40 (m, 2H), 7.35–7.26 (m, 4H), 6.98 (t, <i>J</i> = 8.7 Hz, 2H), 6.40 (d, <i>J</i> = 15.8 Hz, 1H), 6.12 (dt, <i>J</i> = 15.7, 6.9 Hz, 1H), 2.85 (dt, <i>J</i> = 11.9, 3.0 Hz, 2H), 2.59–2.51 (m, 2H), 2.49–2.39 (m, 4H), 2.13 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.91 (s, 1H), 1.73 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.1 (d, <i>J</i> = 245.8 Hz), 147.1, 133.9 (d, <i>J</i> = 3.2 Hz), 132.9, 129.9, 128.5, 128.2 (d, <i>J</i> = 2.3 Hz), 127.5 (d, <i>J</i> = 7.8 Hz), 126.2, 115.5 (d, <i>J</i> = 21.5 Hz), 71.1, 58.5, 49.5, 38.6, 30.9.</div></div><div id="sec4_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> (<i>Z</i>)-4-(4-Fluorophenyl)but-3-en-1-ol (<b>26</b>)</h4><div class="NLM_p last">An oven-dried round-bottom flask containing a stirring bar was charged with Ni(COD)<sub>2</sub> (319 mg, 10 mol %), 1,3-bis(2,6-diisopropylphenyl)imidazolinium chloride (492 mg, 10 mol%), and LiCl (491 mg, 11.6 mmol). The flask was fitted with a rubber septum, evacuated, and back-filled with argon (this sequence was repeated an additional two times). 2,3-Dihydrofuran (<b>24</b>) (875 μL, 11.6 mmol) was added to the flask along with THF (15 mL). The reaction mixture was then cooled to −30 °C and stirred for 2 min. Then, (4-fluorophenyl)magnesium bromide (<b>25</b>) (0.8 M solution in THF; 28.9 mL, 23.1 mmol) was added via a syringe. The mixture was stirred at this temperature for 6 h and then diluted with EtOAc (30 mL) and a solution of aqueous sat. NH<sub>4</sub>Cl (20 mL). The separated organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude material was purified by FCC (eluent 4:1 <i>n</i>-hexanes/EtOAc) to afford 600 mg of a transparent oil (31%). LCMS: <i>t</i><sub>R</sub> 2.73 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.35–7.26 (m, 2H), 6.98 (t, <i>J</i> = 8.7 Hz, 2H), 6.45 (d, <i>J</i> = 15.9 Hz, 1H), 6.11 (dt, <i>J</i> = 15.8, 7.1 Hz, 1H), 3.74 (t, <i>J</i> = 6.3 Hz, 2H), 2.46 (qd, <i>J</i> = 6.4, 1.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.8 (d, <i>J</i> = 246.1 Hz), 133.3 (d, <i>J</i> = 3.4 Hz), 130.6, 130.4 (d, <i>J</i> = 7.8 Hz), 128.3 (d, <i>J</i> = 1.5 Hz), 115.2 (d, <i>J</i> = 21.1 Hz), 62.5, 31.9.</div></div><div id="sec4_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (<i>Z</i>)-4-(4-Fluorophenyl)but-3-en-1-yl methanesulfonate (<b>27</b>)</h4><div class="NLM_p last">General procedure G: Compound degraded after attempted FCC purification (eluent 4:1 EtOAc/PE). Therefore, the compound was used for the next reaction without purification.</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> (<i>Z</i>)-4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-en-1-yl)-4-hydroxypiperidin-1-ium 2,2,2-trifluoroacetate (<b>28</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) gave 65 mg of a white solid (75%). LCMS (<i>m</i>/<i>z</i>): 360.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.65 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO: requires 360.1452 [M + H]<sup>+</sup>; found 360.1533. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.28 (s, 1H), 7.36 (d, <i>J</i> = 8.5 Hz, 2H), 7.29 (d, <i>J</i> = 8.5 Hz, 2H), 7.20 (dd, <i>J</i> = 8.5, 5.4 Hz, 2H), 7.05 (t, <i>J</i> = 8.6 Hz, 2H), 6.59 (d, <i>J</i> = 11.5 Hz, 1H), 5.89 (s, 1H), 5.50 (dt, <i>J</i> = 11.5, 7.1 Hz, 1H), 3.37 (d, <i>J</i> = 11.4 Hz, 2H), 3.23 (q, <i>J</i> = 11.2 Hz, 2H), 3.05 (dq, <i>J</i> = 9.2, 4.4 Hz, 2H), 2.75 (q, <i>J</i> = 7.7 Hz, 2H), 2.41 (td, <i>J</i> = 14.0, 4.2 Hz, 2H), 1.87 (d, <i>J</i> = 14.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.9 (d, <i>J</i> = 247.4 Hz), 144.4, 133.6, 132.2, 132.1 (d, <i>J</i> = 3.6 Hz), 130.2 (d, <i>J</i> = 8.0 Hz), 128.8, 125.9, 124.4, 115.5 (d, <i>J</i> = 21.5 Hz), 68.7, 56.5, 48.9, 35.2, 23.1.</div></div><div id="sec4_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> <i>trans</i>-2-(2-(4-Fluorophenyl)cyclopropyl)ethan-1-ol (<b>29</b>)</h4><div class="NLM_p last">A solution of (<i>E</i>)-4-(4-fluorophenyl)but-3-en-1-ol (<b>21</b>) (250 mg, 1.50 mmol) in DCM (30 mL) was treated with Et<sub>2</sub>Zn (0.9 M in hexanes; 8.36 mL, 7.52 mmol). After 10 min, the reaction mixture was cooled to 0 °C, treated with a solution of CH<sub>2</sub>I<sub>2</sub> (607 μL, 7.52 mmol) in DCM (10 mL) dropwise over 10 min, and allowed to warm to ambient temperature. After 24 h, the reaction mixture was quenched slowly with sat. aqueous NH<sub>4</sub>Cl and stirred for 10 min. The reaction mixture was extracted with DCM (3 × 20 mL), and the combined organic phases were washed with sat. aqueous NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to yield the desired cyclopropane as a transparent oil (265 mg, 98%). LCMS: <i>t</i><sub>R</sub> 2.67 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.00 (dd, <i>J</i> = 8.6, 5.5 Hz, 2H), 6.93 (dd, <i>J</i> = 9.8, 7.6 Hz, 2H), 3.76 (t, <i>J</i> = 6.5 Hz, 2H), 1.72–1.57 (m, 4H), 1.09–1.00 (m, 1H), 0.87 (dt, <i>J</i> = 8.5, 5.0 Hz, 1H), 0.80 (dt, <i>J</i> = 8.7, 5.2 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.1 (d, <i>J</i> = 243.0 Hz), 139.0 (d, <i>J</i> = 3.0 Hz), 127.2 (d, <i>J</i> = 7.9 Hz), 115.1 (d, <i>J</i> = 21.3 Hz), 62.9, 37.3, 22.2, 20.1, 15.5.</div></div><div id="sec4_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> <i>trans</i>-2-(2-(4-Fluorophenyl)cyclopropyl)ethyl methanesulfonate (<b>29a</b>)</h4><div class="NLM_p last">General procedure G: No purification required post work-up, giving 366 mg of a transparent oil (95%). LCMS (<i>m</i>/<i>z</i>): 259.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.83 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.04–6.98 (m, 2H), 6.93 (dd, <i>J</i> = 9.9, 7.6 Hz, 2H), 4.32 (td, <i>J</i> = 6.5, 1.5 Hz, 2H), 2.96 (s, 3H), 1.83 (qd, <i>J</i> = 6.7, 3.3 Hz, 2H), 1.71 (dt, <i>J</i> = 9.2, 4.9 Hz, 1H), 1.10–1.00 (m, 1H), 0.92 (dt, <i>J</i> = 8.5, 5.1 Hz, 1H), 0.83 (dt, <i>J</i> = 8.7, 5.3 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.2 (d, <i>J</i> = 243.4 Hz), 138.3 (d, <i>J</i> = 3.1 Hz), 127.3 (d, <i>J</i> = 7.7 Hz), 115.2 (d, <i>J</i> = 21.3 Hz), 69.8, 37.4, 33.8, 22.3, 19.4, 15.2.</div></div><div id="sec4_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> <i>trans</i>-4-(4-Chlorophenyl)-1-(2-(2-(4-fluorophenyl)cyclopropyl)ethyl)piperidin-4-ol (<b>29b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 72 mg of a white solid (80%). LCMS (<i>m</i>/<i>z</i>): 374.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.73 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>25</sub>ClFNO: requires 374.1609 [M + H]<sup>+</sup>; found 374.1690. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.46–7.39 (m, 2H), 7.33–7.26 (m, 2H), 7.00 (dd, <i>J</i> = 8.6, 5.5 Hz, 2H), 6.97–6.88 (m, 2H), 2.81 (dt, <i>J</i> = 11.5, 3.3 Hz, 2H), 2.54 (dd, <i>J</i> = 8.9, 6.9 Hz, 2H), 2.43 (ddd, <i>J</i> = 11.8, 9.7, 2.0 Hz, 2H), 2.10 (td, <i>J</i> = 13.3, 4.4 Hz, 3H), 1.71 (dd, <i>J</i> = 14.2, 2.7 Hz, 2H), 1.66–1.55 (m, 3H), 1.01–0.91 (m, 1H), 0.85 (dt, <i>J</i> = 8.4, 5.0 Hz, 1H), 0.77 (dt, <i>J</i> = 8.6, 5.2 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.1 (d, <i>J</i> = 243.0 Hz), 147.1, 139.2 (d, <i>J</i> = 3.1 Hz), 132.8, 128.5, 127.2 (d, <i>J</i> = 7.7 Hz), 126.2, 115.1 (d, <i>J</i> = 21.3 Hz), 71.1, 58.5, 49.7, 49.6, 38.5 (d, <i>J</i> = 1.5 Hz), 32.1, 22.6, 21.6, 15.8.</div></div><div id="sec4_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> <i>cis</i>-2-(2-(4-Fluorophenyl)cyclopropyl)ethan-1-ol (<b>30</b>)</h4><div class="NLM_p last">A solution of (<i>Z</i>)-4-(4-fluorophenyl)but-3-en-1-ol (<b>26</b>) (250 mg, 1.50 mmol) in DCM (30 mL) was treated with Et<sub>2</sub>Zn (0.9 M in hexanes; 8.36 mL, 7.52 mmol). After 10 min, the reaction mixture was cooled to 0 °C, treated with a solution of CH<sub>2</sub>I<sub>2</sub> (607 μL, 7.52 mmol) in DCM (10 mL) dropwise over 10 min, and allowed to warm to ambient temperature. After 24 h, the reaction mixture was quenched slowly with sat. aqueous NH<sub>4</sub>Cl and stirred for 10 min. The reaction mixture was extracted with DCM (3 × 20 mL), and the combined organic phases were washed with sat. aqueous NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo to yield the desired cyclopropane as a yellow oil (271 mg, quantitative). LCMS (<i>m</i>/<i>z</i>): 181.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.65 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.16–7.11 (m, 2H), 6.95 (t, <i>J</i> = 8.7 Hz, 2H), 3.56 (td, <i>J</i> = 6.3, 2.5 Hz, 2H), 2.11 (td, <i>J</i> = 8.3, 5.8 Hz, 1H), 1.58 (s, 1H), 1.43–1.31 (m, 1H), 1.19–1.05 (m, 2H), 1.01 (td, <i>J</i> = 8.2, 4.9 Hz, 1H), 0.65 (q, <i>J</i> = 5.3 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.4 (d, <i>J</i> = 243.7 Hz), 134.8 (d, <i>J</i> = 3.2 Hz), 130.5 (d, <i>J</i> = 7.8 Hz), 114.8 (d, <i>J</i> = 21.1 Hz), 62.8, 31.9, 19.8, 15.4, 9.6.</div></div><div id="sec4_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> <i>cis</i>-2-(2-(4-Fluorophenyl)cyclopropyl)ethyl methanesulfonate (<b>30a</b>)</h4><div class="NLM_p last">General procedure G: Purification by FCC (eluent 4:1, PE/EtOAc) gave 274 mg of a transparent oil (83%). LCMS: <i>t</i><sub>R</sub> 2.83 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.19–7.10 (m, 2H), 6.96 (t, <i>J</i> = 8.7 Hz, 2H), 4.20–4.04 (m, 2H), 2.92 (s, 3H), 2.18 (td, <i>J</i> = 8.6, 6.0 Hz, 1H), 1.56 (dq, <i>J</i> = 13.2, 6.6 Hz, 1H), 1.31 (dt, <i>J</i> = 14.4, 7.2 Hz, 1H), 1.22–1.15 (m, 1H), 1.05 (td, <i>J</i> = 8.4, 5.3 Hz, 1H), 0.69 (q, <i>J</i> = 5.6 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.5 (d, <i>J</i> = 244.2 Hz), 134.1 (d, <i>J</i> = 3.1 Hz), 130.5 (d, <i>J</i> = 7.9 Hz), 115.1 (d, <i>J</i> = 21.2 Hz), 69.8, 37.3, 28.6, 19.9, 14.7, 9.5.</div></div><div id="sec4_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> <i>cis</i>-4-(4-Chlorophenyl)-1-(2-(2-(4-fluorophenyl)cyclopropyl)ethyl)piperidin-4-ol (<b>30b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 49 mg of a white solid (66%). LCMS (<i>m</i>/<i>z</i>): 374.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.73 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>25</sub>ClFNO: requires 374.1609 [M + H]<sup>+</sup>; found 374.1687. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44–7.37 (m, 2H), 7.33–7.26 (m, 2H), 7.21–7.12 (m, 2H), 6.97 (t, <i>J</i> = 8.7 Hz, 2H), 2.70–2.59 (m, 2H), 2.51–2.40 (m, 1H), 2.42–2.29 (m, 2H), 2.25 (td, <i>J</i> = 13.3, 11.7, 3.8 Hz, 1H), 2.16–1.98 (m, 3H), 1.86 (s, 1H), 1.65 (dq, <i>J</i> = 14.2, 2.8 Hz, 2H), 1.34 (td, <i>J</i> = 11.9, 11.2, 5.4 Hz, 1H), 1.20–0.97 (m, 3H), 0.64 (q, <i>J</i> = 5.3 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.2 (d, <i>J</i> = 243.5 Hz), 146.9, 134.8 (d, <i>J</i> = 3.0 Hz), 132.7, 130.4 (d, <i>J</i> = 7.7 Hz), 128.4, 126.1, 114.7 (d, <i>J</i> = 21.2 Hz), 70.9, 58.3, 49.6, 48.9, 38.2, 26.0, 20.1, 16.9, 9.7.</div></div><div id="sec4_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> 3-Chloro-1-(4-fluorophenyl)propan-1-one (<b>33a</b>)</h4><div class="NLM_p last">To a stirred suspension of AlCl<sub>3</sub> (3.40 g, 25.5 mmol) in DCM (100 mL) at 0 °C was added fluorobenzene (<b>32</b>) (2.00 mL, 21.2 mmol) dropwise. After 30 min, 3-chloropropionyl chloride (<b>31a</b>) (2.81 mL, 25.5 mmol) was added dropwise. The reaction was brought to room temperature, stirred for a further 6 h, poured out on ice, and extracted with DCM (2 × 30 mL). The organic fractions were collected, washed with sat. aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered, and the solvent was removed in vacuo. The residue was purified by FCC (eluent, 99:1 PE/EtOAc) to afford 3.68 g of beige crystals (93%). LCMS (<i>m</i>/<i>z</i>): 187.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.75 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.07–7.90 (m, 2H), 7.19–7.09 (m, 2H), 3.91 (t, <i>J</i> = 6.8 Hz, 2H), 3.43 (t, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 195.2, 166.1 (d, <i>J</i> = 255.6 Hz), 132.9 (d, <i>J</i> = 3.1 Hz), 130.9 (d, <i>J</i> = 9.4 Hz), 116.0 (d, <i>J</i> = 21.9 Hz), 41.3, 38.7.</div></div><div id="sec4_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> 5-Chloro-1-(4-fluorophenyl)pentan-1-one (<b>33c</b>)</h4><div class="NLM_p last">To a stirred suspension of AlCl<sub>3</sub> (2.12 g, 15.9 mmol) in DCM (75 mL) at 0 °C was added fluorobenzene (<b>32</b>) (1.25 mL, 13.3 mmol) dropwise. After 30 min, 5-chloropentanoyl chloride (<b>31c</b>) (2.06 mL, 15.9 mmol) was added dropwise. The reaction was brought to room temperature, stirred overnight, poured out on ice, and extracted with DCM (2 × 30 mL). The organic fractions were collected, washed with sat. aqueous NaHCO<sub>3</sub> and H<sub>2</sub>O, dried (Na<sub>2</sub>SO<sub>4</sub>), and filtered, and the solvent was removed in vacuo. The residue was purified by FCC (eluent, 1:99 PE/EtOAc) to afford 2.55 g of a light brown oil (90%). LCMS (<i>m</i>/<i>z</i>): 215.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.91 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01–7.92 (m, 2H), 7.12 (t, <i>J</i> = 8.6 Hz, 2H), 3.57 (t, <i>J</i> = 6.0 Hz, 2H), 2.98 (t, <i>J</i> = 6.5 Hz, 2H), 1.91–1.79 (m, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.0, 165.8 (d, <i>J</i> = 254.7 Hz), 133.4 (d, <i>J</i> = 3.1 Hz), 130.7 (d, <i>J</i> = 9.4 Hz), 115.8 (d, <i>J</i> = 21.9 Hz), 44.8, 37.6, 32.1, 21.6.</div></div><div id="sec4_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> 3-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)propan-1-one (<b>34a</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 110 mg of a white solid (77%). LCMS (<i>m</i>/<i>z</i>): 362.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.42 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>21</sub>ClFNO<sub>2</sub>: requires 362.1245 [M + H]<sup>+</sup>; found 362.1357. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01–7.95 (m, 2H), 7.46–7.39 (m, 2H), 7.34–7.26 (m, 2H), 7.13 (t, <i>J</i> = 8.6 Hz, 2H), 3.18 (dd, <i>J</i> = 7.9, 6.7 Hz, 2H), 2.89 (dd, <i>J</i> = 8.0, 6.7 Hz, 2H), 2.82 (dt, <i>J</i> = 11.6, 3.2 Hz, 2H), 2.54 (td, <i>J</i> = 12.0, 2.5 Hz, 2H), 2.09 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.89–1.83 (s, 1H), 1.73 (dt, <i>J</i> = 14.0, 2.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.7, 165.9 (d, <i>J</i> = 254.8 Hz), 146.9, 133.5 (d, <i>J</i> = 3.0 Hz), 132.9, 130.8 (d, <i>J</i> = 9.2 Hz), 128.6, 126.2, 115.9 (d, <i>J</i> = 21.9 Hz), 70.9, 53.3, 49.6, 38.5, 36.4.</div></div><div id="sec4_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> 5-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)pentan-1-one (<b>34c</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:1:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 115 mg of a white solid (75%). LCMS (<i>m</i>/<i>z</i>): 390.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.42 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>25</sub>ClFNO<sub>2</sub>: requires 390.1558 [M + H]<sup>+</sup>; found 390.1640. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.02–7.92 (m, 2H), 7.45–7.37 (m, 2H), 7.31–7.24 (m, 2H), 7.11 (t, <i>J</i> = 8.6 Hz, 2H), 2.96 (t, <i>J</i> = 7.2 Hz, 2H), 2.79 (dt, <i>J</i> = 11.9, 3.0 Hz, 2H), 2.50–2.35 (m, 4H), 2.26 (s, 1H), 2.08 (td, <i>J</i> = 13.1, 4.4 Hz, 2H), 1.80–1.65 (m, 4H), 1.66–1.53 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.6, 165.8 (d, <i>J</i> = 254.6 Hz), 147.1, 133.5 (d, <i>J</i> = 3.0 Hz), 132.8, 130.8 (d, <i>J</i> = 9.3 Hz), 128.5, 126.2, 115.8 (d, <i>J</i> = 21.8 Hz), 71.1, 58.5, 49.5, 38.5, 38.4, 26.6, 22.4.</div></div><div id="sec4_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> 1-(3-Chloropropyl)-4-fluorobenzene (<b>35a</b>)</h4><div class="NLM_p last">3-Chloro-1-(4-fluorophenyl)propan-1-one (<b>33a</b>) (600 mg, 3.22 mmol) was taken up in trifluoroacetic acid (5 mL), and the solution was cooled to 0 °C. To this solution was added dropwise triethylsilane (1.44 mL, 9.00 mmol), and the reaction was stirred at 0 °C for 5 h. The solvents were removed in vacuo, and the crude product was purified by FCC (eluent, <i>n</i>-hexanes) to afford 437 mg of a transparent oil (79%). LCMS: <i>t</i><sub>R</sub> 3.00 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.20–7.12 (m, 2H), 7.03–6.94 (m, 2H), 3.52 (t, <i>J</i> = 6.4 Hz, 2H), 2.77 (t, <i>J</i> = 7.4 Hz, 2H), 2.13–2.01 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.6 (d, <i>J</i> = 243.8 Hz), 136.4 (d, <i>J</i> = 3.1 Hz), 130.0 (d, <i>J</i> = 7.9 Hz), 115.4 (d, <i>J</i> = 21.1 Hz), 44.2, 34.2, 32.0.</div></div><div id="sec4_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> 1-(4-Chlorobutyl)-4-fluorobenzene (<b>35b</b>)</h4><div class="NLM_p last">4-Chloro-1-(4-fluorophenyl)butan-1-one (<b>7a</b>) (1.25 mL, 7.66 mmol) was taken up in trifluoroacetic acid (10 mL), and the solution was cooled to 0 °C. To this solution was added dropwise triethylsilane (3.42 mL, 21.5 mmol), and the reaction was stirred at 0 °C for 2 h. The solvents were removed in vacuo, and the crude product was purified by FCC (eluent, <i>n</i>-hexanes) to afford 1.27 g of a transparent oil (89%). LCMS (<i>m</i>/<i>z</i>): 187.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.10 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.19–7.09 (m, 1H), 7.03–6.92 (m, 1H), 3.55 (t, <i>J</i> = 6.3 Hz, 1H), 2.63 (t, <i>J</i> = 7.1 Hz, 1H), 1.87–1.70 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.41 (d, <i>J</i> = 243.4 Hz), 137.55 (d, <i>J</i> = 3.1 Hz), 129.80 (d, <i>J</i> = 7.8 Hz), 115.21 (d, <i>J</i> = 21.2 Hz), 44.95, 34.41, 32.10, 28.81.</div></div><div id="sec4_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> 1-(5-Chloropentyl)-4-fluorobenzene (<b>35c</b>)</h4><div class="NLM_p last">5-Chloro-1-(4-fluorophenyl)pentan-1-one (<b>33c</b>) (600 mg, 2.80 mmol) was taken up in trifluoroacetic acid (5 mL), and the solution was cooled to 0 °C. To this solution was added dropwise triethylsilane (1.25 mL, 7.83 mmol), and the reaction was stirred at 0 °C for 5 h. The solvents were removed in vacuo, and the crude product was purified by FCC (eluent, <i>n</i>-hexanes) to afford 472 mg of a transparent oil (84%). LCMS: <i>t</i><sub>R</sub> 3.15 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.13 (dd, <i>J</i> = 8.4, 5.6 Hz, 2H), 6.97 (t, <i>J</i> = 8.7 Hz, 2H), 3.53 (t, <i>J</i> = 6.7 Hz, 2H), 2.60 (t, <i>J</i> = 7.7 Hz, 2H), 1.81 (dd, <i>J</i> = 8.0, 6.7 Hz, 2H), 1.67–1.58 (m, 2H), 1.54–1.43 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.3 (d, <i>J</i> = 243.0 Hz), 138.0 (d, <i>J</i> = 3.2 Hz), 129.8 (d, <i>J</i> = 7.9 Hz), 115.1 (d, <i>J</i> = 21.0 Hz), 45.1, 35.1, 32.6, 30.9, 26.6.</div></div><div id="sec4_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> 4-(4-Chlorophenyl)-1-(3-(4-fluorophenyl)propyl)piperidin-4-ol (<b>36a</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 105 mg of a white solid (72 mg, 70%). LCMS (<i>m</i>/<i>z</i>): 348.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.52 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>23</sub>ClFNO: requires 348.1452 [M + H]<sup>+</sup>; found 348.1532. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47–7.40 (m, 2H), 7.35–7.27 (m, 2H), 7.18–7.10 (m, 2H), 7.01–6.91 (m, 2H), 2.82 (dd, <i>J</i> = 9.1, 3.2 Hz, 2H), 2.62 (t, <i>J</i> = 7.7 Hz, 2H), 2.49–2.37 (m, 4H), 2.13 (td, <i>J</i> = 13.2, 4.5 Hz, 3H), 1.84 (dq, <i>J</i> = 9.6, 7.7 Hz, 2H), 1.77–1.67 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.2 (d, <i>J</i> = 243.1 Hz), 146.8, 137.6 (d, <i>J</i> = 3.2 Hz), 132.8, 129.7 (d, <i>J</i> = 7.8 Hz), 128.4, 126.1, 115.1 (d, <i>J</i> = 21.1 Hz), 71.0, 57.9, 49.4, 38.4, 32.9, 28.7.</div></div><div id="sec4_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> 4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)butyl)piperidin-4-ol (<b>36b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 150 mg of a white solid (77%). LCMS (<i>m</i>/<i>z</i>): 362.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.72 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>25</sub>ClFNO: requires 362.1712 [M + H]<sup>+</sup>; found 362.1743. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43 (d, <i>J</i> = 8.6 Hz, 2H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.12 (dd, <i>J</i> = 8.4, 5.6 Hz, 2H), 6.95 (t, <i>J</i> = 8.7 Hz, 2H), 2.80 (dd, <i>J</i> = 9.1, 3.1 Hz, 2H), 2.61 (t, <i>J</i> = 7.3 Hz, 2H), 2.47–2.35 (m, 4H), 2.12 (td, <i>J</i> = 13.2, 4.4 Hz, 2H), 1.81 (s, 1H), 1.71 (dd, <i>J</i> = 14.1, 2.7 Hz, 2H), 1.58 (dtd, <i>J</i> = 23.0, 8.4, 3.3 Hz, 4H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.3 (d, <i>J</i> = 243.1 Hz), 147.0, 138.1 (d, <i>J</i> = 3.3 Hz), 132.9, 129.8 (d, <i>J</i> = 7.7 Hz), 128.5, 126.2, 115.1 (d, <i>J</i> = 21.0 Hz), 71.2, 58.8, 49.6, 38.5, 35.1, 29.7, 26.6.</div></div><div id="sec4_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> 4-(4-Chlorophenyl)-1-(5-(4-fluorophenyl)pentyl)piperidin-4-ol (<b>36c</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 116 mg of a white solid (80%). LCMS (<i>m</i>/<i>z</i>): 376.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.88 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>27</sub>ClFNO: requires 376.1765 [M + H]<sup>+</sup>; found 376.1846. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43 (d, <i>J</i> = 8.6 Hz, 2H), 7.30 (d, <i>J</i> = 8.6 Hz, 2H), 7.12 (dd, <i>J</i> = 8.4, 5.6 Hz, 2H), 6.95 (t, <i>J</i> = 8.7 Hz, 2H), 2.82 (dt, <i>J</i> = 11.6, 3.2 Hz, 2H), 2.58 (t, <i>J</i> = 7.7 Hz, 2H), 2.45–2.35 (m, 4H), 2.13 (td, <i>J</i> = 13.3, 4.5 Hz, 3H), 1.76–1.67 (m, 2H), 1.67–1.57 (m, 2H), 1.55 (ddt, <i>J</i> = 10.9, 7.8, 3.7 Hz, 2H), 1.40–1.29 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 161.3 (d, <i>J</i> = 243.0 Hz), 147.0, 138.3 (d, <i>J</i> = 3.1 Hz), 132.9, 129.8 (d, <i>J</i> = 7.7 Hz), 128.5, 126.2, 115.1 (d, <i>J</i> = 21.0 Hz), 71.2, 58.9, 49.6, 38.5, 35.2, 31.6, 27.3, 26.9.</div></div><div id="sec4_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> 3-(4-Fluorophenyl)prop-2-yn-1-ol (<b>39a</b>)</h4><div class="NLM_p last">General procedure E: Purification by FCC (eluent, 1:5 EtOAc/<i>n</i>-hexanes) gave 2.45 g of a brown oil (94%). LCMS (<i>m</i>/<i>z</i>): 151.1 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.47 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44–7.37 (m, 2H), 7.03–6.93 (m, 2H), 4.48 (s, 2H), 2.29 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.7 (d, <i>J</i> = 249.6 Hz), 133.7 (d, <i>J</i> = 8.4 Hz), 118.7 (d, <i>J</i> = 3.5 Hz), 115.7 (d, <i>J</i> = 22.1 Hz), 87.1 (d, <i>J</i> = 1.5 Hz), 84.7, 51.6.</div></div><div id="sec4_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> 4-(4-Fluorophenyl)but-3-yn-1-ol (<b>39b</b>)</h4><div class="NLM_p last">General procedure E: Purification by FCC (eluent, 1:5 EtOAc/<i>n</i>-hexanes) gave 3.41 g of a brown oil that solidified upon standing (96%). LCMS (<i>m</i>/<i>z</i>): 165.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.56 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.43–7.36 (m, 2H), 6.99 (t, <i>J</i> = 8.7 Hz, 2H), 3.82 (t, <i>J</i> = 6.3 Hz, 2H), 2.68 (t, <i>J</i> = 6.3 Hz, 2H), 2.14 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.4 (d, <i>J</i> = 248.8 Hz), 133.6 (d, <i>J</i> = 8.3 Hz), 119.5 (d, <i>J</i> = 3.5 Hz), 115.56 (d, <i>J</i> = 22.0 Hz), 86.2 (d, <i>J</i> = 1.4 Hz), 81.4, 61.2, 23.8.</div></div><div id="sec4_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 5-(4-Fluorophenyl)pent-4-yn-1-ol (<b>39c</b>)</h4><div class="NLM_p last">General procedure E: Purification by FCC (eluent, 1:5 EtOAc/<i>n</i>-hexanes) gave 2.05 g of a brown oil (94%). LCMS (<i>m</i>/<i>z</i>): 179.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.65 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.40–7.31 (m, 2H), 7.01–6.92 (m, 2H), 3.81 (t, <i>J</i> = 6.1 Hz, 2H), 2.52 (t, <i>J</i> = 7.0 Hz, 1H), 1.85 (p, <i>J</i> = 6.6 Hz, 2H), 1.72 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.2 (d, <i>J</i> = 248.3 Hz), 133.5 (d, <i>J</i> = 8.3 Hz), 119.91 (d, <i>J</i> = 3.5 Hz), 115.55 (d, <i>J</i> = 22.1 Hz), 89.1 (d, <i>J</i> = 1.5 Hz), 80.2, 61.9, 31.5, 16.1.</div></div><div id="sec4_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> 3-(4-Fluorophenyl)prop-2-yn-1-yl methanesulfonate (<b>40a</b>)</h4><div class="NLM_p last">General procedure G: Compound degraded after attempted FCC purification (eluent 4:1, PE/EtOAc). Therefore, the compound was used for the next reaction without purification.</div></div><div id="sec4_1_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> 1-(4-Chlorobut-1-yn-1-yl)-4-fluorobenzene (<b>40b</b>)</h4><div class="NLM_p last">General procedure D: Purification by FCC (eluent, <i>n</i>-hexanes) gave 2.56 g of a yellow oil (75%). LCMS (<i>m</i>/<i>z</i>): 183.0 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.00 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44–7.34 (m, 1H), 7.04–6.93 (m, 1H), 3.67 (t, <i>J</i> = 7.2 Hz, 1H), 2.87 (t, <i>J</i> = 7.2 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.5 (d, <i>J</i> = 249.1 Hz), 133.7 (d, <i>J</i> = 8.4 Hz), 119.3 (d, <i>J</i> = 3.5 Hz), 115.6 (d, <i>J</i> = 22.0 Hz), 85.5 (d, <i>J</i> = 1.5 Hz), 81.6, 42.3, 23.9.</div></div><div id="sec4_1_121" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> 5-(4-Fluorophenyl)pent-4-yn-1-yl methanesulfonate (<b>40c</b>)</h4><div class="NLM_p last">General procedure G: Purification by FCC (eluent 4:1, PE/EtOAc) gave 333 mg of a transparent oil (93%). LCMS (<i>m</i>/<i>z</i>): 257.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.83 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.40–7.33 (m, 2H), 6.97 (t, <i>J</i> = 8.7 Hz, 2H), 4.40 (t, <i>J</i> = 6.1 Hz, 2H), 3.03 (s, 3H), 2.56 (t, <i>J</i> = 6.8 Hz, 2H), 2.03 (p, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.3 (d, <i>J</i> = 248.7 Hz), 133.5 (d, <i>J</i> = 8.4 Hz), 119.5 (d, <i>J</i> = 3.6 Hz), 115.6 (d, <i>J</i> = 22.1 Hz), 87.32, 80.9, 37.4, 28.2, 15.8.</div></div><div id="sec4_1_122" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> 4-(4-Chlorophenyl)-1-(3-(4-fluorophenyl)prop-2-yn-1-yl)piperidin-4-ol (<b>41a</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 84 mg of a yellow solid (74%). LCMS (<i>m</i>/<i>z</i>): 344.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.46 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>19</sub>ClFNO: requires 344.1139 [M + H]<sup>+</sup>; found 344.1214. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.47–7.37 (m, 4H), 7.31 (d, <i>J</i> = 8.3 Hz, 2H), 6.98 (t, <i>J</i> = 8.5 Hz, 2H), 3.52 (s, 1H), 2.90 (dt, <i>J</i> = 11.6, 3.0 Hz, 2H), 2.71 (td, <i>J</i> = 12.0, 2.5 Hz, 2H), 2.18 (td, <i>J</i> = 13.2, 4.6 Hz, 2H), 1.84 (s, 1H), 1.77 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.5 (d, <i>J</i> = 249.1 Hz), 146.9, 133.7 (d, <i>J</i> = 8.3 Hz), 132.9, 128.6, 126.2, 119.2 (d, <i>J</i> = 3.5 Hz), 115.6 (d, <i>J</i> = 22.1 Hz), 84.4 (d, <i>J</i> = 6.1 Hz), 70.8, 48.7, 48.0, 38.5.</div></div><div id="sec4_1_123" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> 4-(4-Chlorophenyl)-1-(4-(4-fluorophenyl)but-3-yn-1-yl)piperidin-4-ol (<b>41b</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 45 mg of a light brown solid (45 mg, 80%). LCMS (<i>m</i>/<i>z</i>): 358.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.60 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>21</sub>ClFNO: requires 358.1400 [M + H]<sup>+</sup>; found 358.1440. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.37 (dd, <i>J</i> = 8.4, 5.5 Hz, 2H), 7.31 (d, <i>J</i> = 8.3 Hz, 2H), 6.97 (t, <i>J</i> = 8.5 Hz, 2H), 2.89–2.80 (m, 2H), 2.75 (t, <i>J</i> = 7.6 Hz, 2H), 2.66–2.57 (m, 2H), 2.55 (d, <i>J</i> = 11.9 Hz, 2H), 2.12 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.81 (s, 1H), 1.79–1.68 (m, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.3 (d, <i>J</i> = 248.5 Hz), 146.9, 133.5 (d, <i>J</i> = 8.3 Hz), 132.9, 128.6, 126.2, 119.9, 115.5 (d, <i>J</i> = 21.9 Hz), 88.1, 80.5, 71.1, 57.5, 49.2, 38.6, 17.9.</div></div><div id="sec4_1_124" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> 4-(4-Chlorophenyl)-1-(5-(4-fluorophenyl)pent-4-yn-1-yl)piperidin-4-ol (<b>41c</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 74 mg of a gold oil (68%). LCMS (<i>m</i>/<i>z</i>): 372.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.78 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>23</sub>ClFNO: requires 372.1452 [M + H]<sup>+</sup>; found 372.1532. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.45–7.38 (m, 2H), 7.39–7.31 (m, 2H), 7.32–7.25 (m, 2H), 6.96 (t, <i>J</i> = 8.7 Hz, 2H), 2.80 (dt, <i>J</i> = 11.9, 3.1 Hz, 2H), 2.57–2.48 (m, 2H), 2.49–2.38 (m, 4H), 2.25 (s, 1H), 2.10 (td, <i>J</i> = 13.2, 4.5 Hz, 2H), 1.80 (p, <i>J</i> = 7.2 Hz, 2H), 1.70 (dd, <i>J</i> = 14.1, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 162.1 (d, <i>J</i> = 248.3 Hz), 147.1, 120.0 (d, <i>J</i> = 3.5 Hz), 115.5 (d, <i>J</i> = 22.0 Hz), 89.45 (d, <i>J</i> = 1.5 Hz), 79.9, 71.1, 57.8, 49.5, 38.5, 26.2, 17.6.</div></div><div id="sec4_1_125" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> 3-(4-Chlorophenyl)-8-(4-(4-fluorophenyl)-4-oxobutyl)-3-hydroxy-8-azabicyclo[3.2.1]octan-8-ium 2,2,2-trifluoroacetate (<b>42</b>)</h4><div class="NLM_p last">General procedure C: Purification by preparative HPLC (method C) afforded 45 mg of the title compound as a white solid (68%). LCMS (<i>m</i>/<i>z</i>): 402.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.58 min. HRMS (<i>m</i>/<i>z</i>): C<sub>23</sub>H<sub>25</sub>ClFNO<sub>2</sub>: requires 402.1631 [M + H]<sup>+</sup>; found 402.1633. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.34 (s, 1H), 7.99 (dd, <i>J</i> = 8.6, 5.4 Hz, 2H), 7.52 (d, <i>J</i> = 8.3 Hz, 2H), 7.33–7.25 (m, 2H), 7.17 (t, <i>J</i> = 8.5 Hz, 2H), 4.71 (s, 1H), 4.00 (t, <i>J</i> = 4.1 Hz, 2H), 3.13 (t, <i>J</i> = 6.1 Hz, 2H), 3.06 (dt, <i>J</i> = 10.5, 5.8 Hz, 4H), 2.84–2.69 (m, 4H), 2.26–2.12 (m, 4H), 2.05 (d, <i>J</i> = 15.4 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 197.1, 166.2 (d, <i>J</i> = 256.0 Hz), 145.8, 133.5, 132.7 (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.4 Hz), 128.7, 126.3, 116.1 (d, <i>J</i> = 22.0 Hz), 71.9, 61.6, 50.9, 43.6, 34.9, 24.4, 18.8.</div></div><div id="sec4_1_126" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> 4-(4-(4-Chlorophenyl)piperazin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>43</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 115 mg of the title compound as a white solid (69%). LCMS (<i>m</i>/<i>z</i>): 361.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.41 min. HRMS (<i>m</i>/<i>z</i>): C<sub>20</sub>H<sub>22</sub>ClFN<sub>2</sub>O: requires 361.1405 [M + H]<sup>+</sup>; found 361.1487. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.05–7.93 (m, 2H), 7.20–7.14 (m, 2H), 7.11 (t, <i>J</i> = 8.6 Hz, 2H), 6.84–6.79 (m, 2H), 3.09 (dd, <i>J</i> = 6.2, 3.8 Hz, 4H), 2.99 (t, <i>J</i> = 7.0 Hz, 2H), 2.57 (t, <i>J</i> = 5.0 Hz, 4H), 2.45 (t, <i>J</i> = 7.0 Hz, 2H), 1.97 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.4, 165.7 (d, <i>J</i> = 254.4 Hz), 150.0, 133.7 (d, <i>J</i> = 3.0 Hz), 130.7 (d, <i>J</i> = 9.2 Hz), 128.9, 124.4, 117.2, 115.7 (d, <i>J</i> = 21.8 Hz), 57.7, 53.0, 49.1, 36.2, 21.6.</div></div><div id="sec4_1_127" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> 4-(4-Chlorophenyl)-1,2,3,6-tetrahydropyridine (<b>44</b>)</h4><div class="NLM_p last">To concentrated hydrochloric acid (10 mL) in a 25 mL round-bottom flask was added 4-(4-chlorophenyl)piperidin-4-ol (<b>7b</b>) (500 mg, 2.36 mmol), and the suspension was stirred at reflux for 5 h. The solution was allowed to cool, then slowly added to 5 M NaOH (20 mL), and extracted with DCM (3 × 20 mL). The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under reduced pressure to afford 457 mg of a white solid (quantitative yield). LCMS (<i>m</i>/<i>z</i>): 194.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 1.87 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.34–7.23 (m, 4H), 6.11 (dt, <i>J</i> = 3.5, 1.8 Hz, 1H), 3.51 (q, <i>J</i> = 3.0 Hz, 2H), 3.09 (t, <i>J</i> = 5.7 Hz, 2H), 2.41 (dddd, <i>J</i> = 6.9, 4.0, 2.7, 1.2 Hz, 2H), 1.65 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 139.9, 134.4, 132.7, 128.5, 126.2, 124.3, 45.7, 43.4, 27.9.</div></div><div id="sec4_1_128" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> 4-(4-(4-Chlorophenyl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)-1-(4-fluorophenyl)butan-1-one (<b>45</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 49 mg of the title compound as a white solid (80%). LCMS (<i>m</i>/<i>z</i>): 358.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.64 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>21</sub>ClFNO: requires 358.1296 [M + H]<sup>+</sup>; found 358.1379. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.04–7.94 (m, 2H), 7.33–7.23 (m, 4H), 7.11 (t, <i>J</i> = 8.6 Hz, 2H), 6.04 (t, <i>J</i> = 1.7 Hz, 1H), 3.14 (q, <i>J</i> = 3.0 Hz, 2H), 3.02 (t, <i>J</i> = 7.1 Hz, 2H), 2.69 (t, <i>J</i> = 5.7 Hz, 2H), 2.54 (t, <i>J</i> = 7.1 Hz, 2H), 2.49 (tt, <i>J</i> = 5.8, 2.5 Hz, 2H), 2.01 (p, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.6, 165.8 (d, <i>J</i> = 254.4 Hz), 139.4, 134.1, 133.7 (d, <i>J</i> = 3.0 Hz), 132.8, 130.8 (d, <i>J</i> = 9.3 Hz), 126.3, 122.6, 115.7 (d, <i>J</i> = 21.8 Hz), 57.5, 53.3, 50.3, 36.3, 28.1, 21.9.</div></div><div id="sec4_1_129" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> 4-(6-(4-Chlorophenyl)-3-azabicyclo[4.1.0]heptan-3-yl)-1-(4-fluorophenyl)butan-1-one (<b>46</b>)</h4><div class="NLM_p last">A solution of 4-(4-(4-chlorophenyl)-3,6-dihydropyridin-1(2<i>H</i>)-yl)-1-(4-fluorophenyl)butan-1-one (<b>45</b>) (110 mg, 307 μmol) in DCM (20 mL) was treated with Et<sub>2</sub>Zn (0.9 M in hexanes; 1.71 mL, 1.54 mmol). After 10 min, the reaction mixture was cooled to 0 °C, treated dropwise with a solution of CH<sub>2</sub>I<sub>2</sub> (124 μL, 1.54 mmol) in DCM (2 mL) over 10 min, and allowed to warm to ambient temperature. After 24 h, the reaction mixture was quenched slowly with sat. aqueous NH<sub>4</sub>Cl and stirred for 10 min. The reaction mixture was extracted with DCM (3 × 20 mL), and the combined organic phases were washed with sat. aqueous NaHCO<sub>3</sub>, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The resulting residue was purified by FCC (eluent, 5% MeOH/EtOAc) to yield 82 mg of the title compound as a white solid (72%). LCMS (<i>m</i>/<i>z</i>): 372.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.94 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>23</sub>FNO: requires 372.1452 [M + H]<sup>+</sup>; found 372.1517. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.05–7.95 (m, 2H), 7.24–7.17 (m, 2H), 7.18–7.07 (m, 4H), 2.97 (t, <i>J</i> = 7.1 Hz, 2H), 2.81 (dd, <i>J</i> = 11.3, 5.8 Hz, 1H), 2.69 (dd, <i>J</i> = 11.3, 1.7 Hz, 1H), 2.36 (t, <i>J</i> = 6.9 Hz, 2H), 2.26–2.20 (m, 2H), 2.03 (dq, <i>J</i> = 14.0, 7.4, 6.9 Hz, 2H), 1.92 (p, <i>J</i> = 7.1 Hz, 2H), 1.37–1.28 (m, 1H), 0.87 (dd, <i>J</i> = 9.2, 4.2 Hz, 1H), 0.79 (dd, <i>J</i> = 5.7, 4.3 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 196.7, 166.1 (d, <i>J</i> = 256.1 Hz), 142.7, 132.9, 132. 7 (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.3 Hz), 129.9, 128.9, 116.0 (d, <i>J</i> = 22.2 Hz), 56.3, 52.7, 48.1, 34.9, 28.7, 23.6, 18.1, 17.7, 15.1.</div></div><div id="sec4_1_130" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> 1-(4-Fluorophenyl)-4-(4-phenylpiperidin-1-yl)butan-1-one (<b>47</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 89 mg of the title compound as a white solid (75%). LCMS (<i>m</i>/<i>z</i>): 326.4 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.35 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>24</sub>FNO: requires 326.1842 [M + H]<sup>+</sup>; found 326.1930. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.08–7.97 (m, 2H), 7.33–7.25 (m, 2H), 7.20 (d, <i>J</i> = 7.3 Hz, 3H), 7.14 (t, <i>J</i> = 8.6 Hz, 2H), 3.07–2.95 (m, 4H), 2.51–2.41 (m, 3H), 2.10–2.02 (m, 2H), 2.01–1.94 (m, 2H), 1.84–1.77 (m, 2H), 1.71 (qd, <i>J</i> = 12.4, 3.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.6, 165.8 (d, <i>J</i> = 254.4 Hz), 146.5, 133.8 (d, <i>J</i> = 3.0 Hz), 130.8 (d, <i>J</i> = 9.2 Hz), 128.5, 126.9, 126.2, 115.7 (d, <i>J</i> = 21.8 Hz), 58.2, 54.4, 42.8, 36.5, 33.5, 22.1.</div></div><div id="sec4_1_131" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> 4-(4-(4-Chlorophenyl)piperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>48</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 59 mg of the title compound as a beige solid (68%). LCMS (<i>m</i>/<i>z</i>): 360.2 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.72 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO: requires 360.1452 [M + H]<sup>+</sup>; found 360.1539. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.01 (dd, <i>J</i> = 8.7, 5.5 Hz, 2H), 7.26–7.22 (m, 2H), 7.16–7.08 (m, 4H), 3.05–2.94 (m, 4H), 2.52–2.38 (m, 3H), 2.09–1.90 (m, 4H), 1.76 (dq, <i>J</i> = 12.6, 2.2 Hz, 2H), 1.63 (qd, <i>J</i> = 12.4, 3.8 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.2 Hz), 144.9, 133.8 (d, <i>J</i> = 3.0 Hz), 131.8, 130.8 (d, <i>J</i> = 9.2 Hz), 128.6, 128.3, 115.7(d, <i>J</i> = 21.7 Hz), 58.2, 54.3, 42.2, 36.4, 33.5, 22.0.</div></div><div id="sec4_1_132" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> <i>tert</i>-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>49</b>)</h4><div class="NLM_p last">To a suspension of 4-(4-chlorophenyl)piperidin-4-ol (<b>7b</b>) (500 mg, 2.36 mmol) and Et<sub>3</sub>N (823 μL, 5.90 mmol) in DCM (20 mL) was added di-<i>tert</i>-butyl dicarbonate (2.06 g, 9.45 mmol), and the reaction mixture was stirred at rt for 4 h. The solvent was evaporated under reduced pressure, and the residue was purified by FCC (eluent, 10:1 <i>n</i>-hexanes/EtOAc) to afford 715 mg of a clear oil (97%). LCMS (<i>m</i>/<i>z</i>): 312.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.09 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.38 (d, <i>J</i> = 7.2 Hz, 2H), 7.15 (d, <i>J</i> = 7.3 Hz, 2H), 3.94 (br s, 2H), 3.18 (br s, 2H), 1.89 (br s, 2H), 1.46 (s, 11H).</div></div><div id="sec4_1_133" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> <i>tert</i>-Butyl 4-(4-chlorophenyl)-4-methoxypiperidine-1-carboxylate (<b>50</b>)</h4><div class="NLM_p last">To a stirred suspension of sodium hydride (64.7 mg, 2.69 mmol) in dry DMF (15 mL) at rt was added <i>tert</i>-butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (<b>49</b>) (700 mg, 2.24 mmol). After 30 min, methyl iodide (168 <i>μ</i>L, 2.69 mmol) was added and the mixture was stirred overnight. The mixture was poured into an equal volume of H<sub>2</sub>O and extracted with EtOAc (2 × 30 mL). The EtOAc extracts were collected and washed with additional H<sub>2</sub>O (3 × 30 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated in vacuo to give an orange oil. The crude oil was purified by FCC (eluent, 10:1 <i>n</i>-hexanes/EtOAc) to afford 645 mg of a clear oil (88%). LCMS (<i>m</i>/<i>z</i>): 326.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.18 min. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.00 (dd, <i>J</i> = 8.7, 5.5 Hz, 2H), 7.33–7.25 (m, 4H), 7.16–7.06 (m, 2H), 2.97 (t, <i>J</i> = 7.1 Hz, 2H), 2.93 (s, 3H), 2.75–2.65 (m, 2H), 2.45 (t, <i>J</i> = 7.2 Hz, 2H), 2.38 (td, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.03–1.90 (m, 4H), 1.84 (dt, <i>J</i> = 13.1, 6.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.4 Hz), 143.6, 133.8 (d, <i>J</i> = 3.0 Hz), 133.0, 130.8 (d, <i>J</i> = 9.3 Hz), 128.6, 127.6, 115.7 (d, <i>J</i> = 21.8 Hz), 75.4, 49.2, 36.4, 34.7, 22.1.</div></div><div id="sec4_1_134" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> 4-(4-Chlorophenyl)-4-methoxypiperidin-1-ium chloride (<b>51</b>)</h4><div class="NLM_p last">General procedure B: Concentration in vacuo gave 296 mg of a white solid (95%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.30 (s, 2H), 7.53–7.45 (m, 2H), 7.45–7.36 (m, 2H), 3.18 (d, <i>J</i> = 12.5 Hz, 12H), 3.11–2.96 (m, 2H), 2.89 (s, 3H), 2.20–2.08 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 141.9, 132.4, 128.6, 127.8, 73.4, 49.6, 39.3, 30.5.</div></div><div id="sec4_1_135" class="NLM_sec NLM_sec_level_3"><div id="ac_i174" class="anchor-spacer"></div><h4 class="article-section__title" id="_i174"> 4-(4-(4-Chlorophenyl)-4-methoxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one (<b>52</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 88 mg of the title compound as a white solid (81%). LCMS (<i>m</i>/<i>z</i>): 390.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.82 min. HRMS (<i>m</i>/<i>z</i>): C<sub>22</sub>H<sub>25</sub>ClFNO<sub>2</sub>: requires 390.1558 [M + H]<sup>+</sup>; found 390.1639. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.00 (dd, <i>J</i> = 8.7, 5.5 Hz, 2H), 7.33–7.25 (m, 4H), 7.16–7.06 (m, 2H), 2.97 (t, <i>J</i> = 7.1 Hz, 2H), 2.93 (s, 3H), 2.75–2.65 (m, 2H), 2.45 (t, <i>J</i> = 7.2 Hz, 2H), 2.38 (td, <i>J</i> = 11.7, 2.5 Hz, 2H), 2.03–1.90 (m, 4H), 1.84 (dt, <i>J</i> = 13.1, 6.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.5, 165.7 (d, <i>J</i> = 254.4 Hz), 143.6, 133.8 (d, <i>J</i> = 3.0 Hz), 133.0, 130.8 (d, <i>J</i> = 9.3 Hz), 128.6, 127.6, 115.7 (d, <i>J</i> = 21.8 Hz), 75.4, 49.2, 36.4, 34.7, 22.1.</div></div><div id="sec4_1_136" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> 1-(4-Chlorophenyl)-4-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)butan-1-one (<b>53</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 75 mg of the title compound as a light yellow solid (71%). LCMS (<i>m</i>/<i>z</i>): 376.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 3.39 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub>: requires 376.1401 [M + H]<sup>+</sup>; found 376.1488. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.99–7.88 (m, 2H), 7.48–7.36 (m, 4H), 7.01 (t, <i>J</i> = 8.7 Hz, 2H), 2.98 (t, <i>J</i> = 7.0 Hz, 2H), 2.76 (dd, <i>J</i> = 9.1, 6.1 Hz, 2H), 2.51–2.38 (m, 4H), 2.03–1.92 (m, 5H), 1.69 (dd, <i>J</i> = 14.2, 2.6 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 198.9, 161.9 (d, <i>J</i> = 245.2 Hz), 144.3 (d, <i>J</i> = 3.1 Hz), 139.4, 135.7, 129.6, 128.9, 126.4 (d, <i>J</i> = 7.9 Hz), 115.0 (d, <i>J</i> = 21.2 Hz), 71.1, 57.9, 49.5, 38.6, 36.4, 22.1.</div></div><div id="sec4_1_137" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> 4-(4-Hydroxy-4-phenylpiperidin-1-yl)-1-phenylbutan-1-one (<b>54</b>)</h4><div class="NLM_p last">General procedure C: Purification by FCC (eluent 20:0.5:0.1, EtOAc/MeOH/NH<sub>4</sub>OH) gave 125 mg of the title compound as a white solid (88%). LCMS (<i>m</i>/<i>z</i>): 324.3 [M + H]<sup>+</sup>, <i>t</i><sub>R</sub> 2.72 min. HRMS (<i>m</i>/<i>z</i>): C<sub>21</sub>H<sub>25</sub>NO<sub>2</sub>: requires 324.1865 [M + H]<sup>+</sup>; found 324.1965. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.03–7.94 (m, 2H), 7.59–7.51 (m, 1H), 7.46 (dd, <i>J</i> = 8.4, 6.9 Hz, 4H), 7.33 (dd, <i>J</i> = 8.4, 6.8 Hz, 2H), 7.27–7.21 (m, 1H), 3.01 (t, <i>J</i> = 7.0 Hz, 2H), 2.82 (dt, <i>J</i> = 11.9, 3.2 Hz, 2H), 2.55–2.44 (m, 4H), 2.14–1.94 (m, 5H), 1.71 (dd, <i>J</i> = 14.1, 2.7 Hz, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 200.1, 148.4, 137.3, 132.9, 128.7, 128.4, 128.2, 127.1, 124.6, 71.3, 57.9, 49.5, 38.3, 36.5, 21.9.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i177" class="anchor-spacer"></div><h3 class="article-section__title" id="_i177"> Pharmacological Characterization</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i178" class="anchor-spacer"></div><h4 class="article-section__title" id="_i178"> Materials</h4><div class="NLM_p last">Tag-lite labeling medium (LABMED), SNAP-Lumi4-Tb, and the PPHT [(±)-2-(<i>N</i>-phenethyl-<i>N</i>-propyl)amino-5-hydroxytetralin hydrochloride; 1-naphthalenol,5,6,7,8-tetrahydro-6-[(2-phenylethyl)propylamino]] derivative labeled with a red fluorescent probe (PPHT-red) were obtained from Cisbio Bioassays (Bagnolssur-Cèze, France). Ninety-six-well polypropylene plates (Corning) were purchased from Fisher Scientific UK (Loughborough, U.K.), and 384-well Optiplate plates were purchased from PerkinElmer (Beaconsfield, U.K.). GppNHp used in competition assays was obtained from Sigma-Aldrich (Poole, U.K.).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i179" class="anchor-spacer"></div><h4 class="article-section__title" id="_i179"> Cell Culture</h4><div class="NLM_p last">The host Chinese hamster ovary (CHO) K1 cell line was transfected with the cDNA encoding a SNAP-tagged human dopamine D<sub>2L</sub> receptor (Genbank ref: <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_000795">NM_000795</a>), and a stable dilution-cloned cell line (CHO–hD<sub>2L</sub>) was established by zeocin resistance encoded by the plasmid vector (pcDNA3.1zeo<sup>+</sup>, Invitrogen, Paisley, U.K.). Cells were maintained in Dulbecco’s modified Eagle’s medium/Ham F12 (DMEM/F12) containing 2 mM glutamine (Sigma-Aldrich, Poole, U.K.) and supplemented with 10% fetal calf serum (Life Technologies, Paisley, U.K.).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i180" class="anchor-spacer"></div><h4 class="article-section__title" id="_i180"> Terbium Labeling of SNAP-Tagged D<sub>2L</sub> Cells</h4><div class="NLM_p last">Cell culture medium was removed from the T-175 cm<sup>2</sup> flasks containing confluent adherent CHO–D<sub>2L</sub> cells. Twelve milliliter of Tag-lite labeling medium containing 100 nM SNAP-Lumi4-Tb was added to the flask and incubated for 1 h at 37 °C under 5% CO<sub>2</sub>. Cells were washed 2× in phosphate-buffered saline (PBS) (GIBCO Carlsbad, CA) to remove the excess of SNAP-Lumi4-Tb, then detached using 5 mL of GIBCO enzyme-free Hank’s-based cell dissociation buffer (GIBCO, Carlsbad, CA), collected in a vial containing 5 mL of DMEM/F12 containing 2 mM glutamine (Sigma-Aldrich), and supplemented with 10% fetal calf serum. Cells were pelleted by centrifugation (5 min at 1500 rpm), and the pellets were frozen to −80 °C. To prepare membranes, homogenization steps were conducted at 4 °C (to avoid receptor degradation). Specifically, 20 mL per T-175 cm<sup>2</sup> flask of wash buffer [10 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES) and 10 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4] was added to the pellet. This was homogenized using an electrical homogenizer, Ultra-Turrax (Ika-Werk GmbH & Co. KG, Staufen, Germany) (position 6, 4 × 5 s bursts), and subsequently centrifuged at 48 000<i>g</i> and 4 °C (Beckman Avanti J-251 Ultracentrifuge; Beckman Coulter, Fullerton, CA) for 30 min. The supernatant was discarded, and the pellet was re-homogenized and centrifuged as described above in wash buffer. The final pellet was suspended in ice-cold 10 mM HEPES and 0.1 mM EDTA, pH 7.4, at a concentration of 5–10 mg mL<sup>–1</sup>. Protein concentration was determined using the bicinchoninic acid assay kit (Sigma-Aldrich), using bovine serum albumin as a standard, and aliquots were maintained at −80 °C until required. Prior to their use, the frozen membranes were thawed and the membranes were suspended in the assay buffer at a membrane concentration of 0.2 mg mL<sup>–1</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i181" class="anchor-spacer"></div><h4 class="article-section__title" id="_i181"> Fluorescent Ligand-Binding Assays</h4><div class="NLM_p last">All fluorescent binding experiments using PPHT-red were conducted in white 384-well Optiplate plates, in assay binding buffer, 20 mM HEPES, 138 mM NaCl, 6 mM MgCl<sub>2</sub>, 1 mM EGTA, 1 mM EDTA, and 0.02% pluronic acid pH 7.4, 100 μM GppNHp, and 0.1% ascorbic acid. GppNHp was included to remove the G protein-coupled population of receptors that can result in two distinct populations of binding sites in membrane preparations, since the Motulsky–Mahan model<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> is only appropriate for ligands competing at a single site. In all cases, nonspecific binding was determined in the presence of 10 μM haloperidol.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i182" class="anchor-spacer"></div><h4 class="article-section__title" id="_i182"> Determination of PPHT-Red Binding Kinetics</h4><div class="NLM_p last">To accurately determine association rate (<i>k</i><sub>on</sub>) and dissociation rate (<i>k</i><sub>off</sub>) values, the observed rate of association (<i>k</i><sub>ob</sub>) was calculated using at least four different concentrations of PPHT-red (50–1.56 nM). The appropriate concentration of PPHT-red was incubated with human D<sub>2L</sub> CHO cell membranes (2 μg per well) in assay binding buffer (final assay volume, 40 μL). The degree of PPHT-red bound to the receptor was assessed at multiple time points by homogeneous time resolved fluorescence (HTRF) detection to allow construction of association kinetic curves. The kinetic parameters of PPHT-red and those of unlabeled compounds were determined using a start time of ∼1 s and an interval time of 20 s. The resulting data were globally fitted to the association kinetic model <a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a> to derive a single best-fit estimate for <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> as described under data analysis. The expression level of the hD<sub>2L</sub>R recombinantly expressed in CHO cells was assessed, using [<sup>3</sup>H]-spiperone saturation binding and determined to be 1.13 ± 0.11 pmol mg<sup>–1</sup> protein.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i183" class="anchor-spacer"></div><h4 class="article-section__title" id="_i183"> Competition Binding Kinetics</h4><div class="NLM_p">To determine the association and dissociation rates of D<sub>2</sub>R ligands, we used a competition kinetic binding assay recently described to profile the kinetics of a series of D<sub>2</sub>R agonists<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and antipsychotic drugs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> This approach involves the simultaneous addition of both fluorescent ligand and competitor to the receptor preparation, so that at <i>t</i> = 0, all receptors are unoccupied. PPHT-red (12.5 nM, a concentration that avoids ligand depletion in this assay volume) was added simultaneously with the unlabeled compound of varying concentrations (at <i>t</i> = ∼1 s) to CHO cell membranes derived from cells stably expressing the human D<sub>2L</sub>R (2 μg per well) in 40 μL of assay buffer. The degree of PPHT-red bound to the receptor was assessed at multiple time points by HTRF detection.</div><div class="NLM_p last">Nonspecific binding was determined as the amount of HTRF signal detected in the presence of haloperidol (10 μM) and was subtracted from each time point, meaning that <i>t</i> = 0 was always equal to zero. Each time point was taken on the same 384-well plate incubated at 37 °C with orbital mixing (1 s of 100 rpm per cycle). Multiple concentrations of the unlabeled competitor were tested for determination of rate parameters. Data were globally fitted using <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a> to simultaneously calculate <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i184" class="anchor-spacer"></div><h4 class="article-section__title" id="_i184"> Signal Detection and Data Analysis</h4><div class="NLM_p last">Signal detection was performed on a Pherastar FS instrument (BMG Labtech, Offenburg, Germany) using standard HTRF settings. The terbium donor was always excited with three laser flashes at a wavelength of 337 nm. A kinetic TR-FRET signal was collected at 20 s intervals both at 665 and 620 nm, when using a red acceptor. HTRF ratios were obtained by dividing the acceptor signal (665 nm) by the donor signal (620 nm) and multiplying this value by 10 000. All experiments were analyzed by nonlinear regression using Prism 6.0 (GraphPad Software, San Diego). Competition displacement data were fitted to sigmoidal (variable slope) curves using a “four parameter logistic equation”<span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_m001.gif" alt="" id="_i185" /></img><span class="labelSpan">(1)</span></span>IC<sub>50</sub> values obtained from the inhibition curves were converted to <i>K</i><sub>i</sub> values using the method of Cheng and Prusoff.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> PPHT-red association data were fitted as follows to a global fitting model using GraphPad Prism 6.0 to simultaneously calculate <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> using the following equation, where <i>k</i><sub>ob</sub> equals the observed rate of association<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_m002.gif" alt="" id="_i186" /></img><span class="labelSpan">(2)</span></span>Association and dissociation rates for unlabeled compounds were calculated using the equations described by Motulsky and Mahan<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_m003.gif" alt="" id="_i187" /></img><span class="labelSpan">(3)</span></span>where <i>X</i> is the time (min), <i>Y</i> is the specific binding (HTRF ratio 665/620 nm × 10 000), <i>k</i><sub>1</sub> = <i>k</i><sub>on</sub> of PPHT-red, <i>k</i><sub>2</sub> = <i>k</i><sub>off</sub> of PPHT-red, <i>L</i> is the concentration of PPHT-red used (nM), <i>B</i><sub>max</sub> is the total binding (HTRF ratio 665/620 nm × 10 000), and <i>I</i> is the concentration of unlabeled antagonist (nM). Fixing the above parameters allowed the following to be calculated: <i>k</i><sub>3</sub>, that is, the association rate of unlabeled ligand (M<sup>–1</sup> min<sup>–1</sup>), and <i>k</i><sub>4</sub>, that is, dissociation rate of unlabeled ligand (min<sup>–1</sup>). Dissociation of PPHT-red was fitted to a one-phase monoexponential decay function to estimate the dissociation rate of PPHT-red directly. Specific binding was determined by subtracting the nonspecific HTRF ratio from the total HTRF ratio.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i188" class="anchor-spacer"></div><h4 class="article-section__title" id="_i188"> cAMP Assay</h4><div class="NLM_p last">FlpIn CHO cells stably expressing the SNAP-tagged hD<sub>2L</sub>R and the CAMYEL BRET biosensor were plated into 96-well white-walled plates (Greiner, Kremsmünster, Austria) at a density of 40 000 cells per well and grown overnight. The cells were equilibrated in Dulbecco’s phosphate-buffered saline with 5 mM glucose at 37 °C for 30 min before starting the experiment. Coelenterazine (Nanolight, Pinetop, Arizona) was added at a final concentration of 5 μM at 5 min prior to addition of agonist. For the agonist mode experiments, the cells were co-stimulated with the analogues and 3 μM forskolin for 10 min before BRET readings were taken. For the antagonist mode experiments, a 10 μM concentration of each analogue was added prior to cells being co-stimulated with 3 μM forskolin and an EC<sub>80</sub> concentration (30 nM) dopamine for 10 min before BRET readings were taken. The signals were detected at 445–505 and 505–565 nm using a Pherastar FS instrument (BMG LabTech, Offenburg, Germany). Net BRET was determined by subtraction of the vehicle control co-added with 3 μM forskolin.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i189"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00864" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00864" class="ext-link">10.1021/acs.jmedchem.9b00864</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic schemes and characterization data for literature analogues of <b>1</b>; <sup>1</sup>H and <sup>13</sup>C NMR spectra and reverse-phase analytical chromatograms for representative screening compounds; plot of determined PPHT-red equilibrium and kinetic binding parameters; plot of observed association rate (<i>k</i><sub>on</sub>) with calculated topological polar surface are (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all screening compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_001.csv">jm9b00864_si_001.csv (2.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf">jm9b00864_si_002.pdf (3.11 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00864" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Robert Lane</span> - <span class="hlFld-Affiliation affiliation">School
of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7361-7875" title="Orcid link">http://orcid.org/0000-0002-7361-7875</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8ffde0eda1e3eee1eacfe1e0fbfbe6e1e8e7eee2a1eeeca1fae4"><span class="__cf_email__" data-cfemail="3b49545915575a555e7b55544f4f52555c535a56155a58154e50">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven J. Charlton</span> - <span class="hlFld-Affiliation affiliation">School
of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Excellerate
Bioscience Ltd., BioCity, Nottingham NG1 1GF, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#85f6f1e0f3e0ebabe6ede4f7e9f1eaebc5ebeaf1f1ecebe2ede4e8abe4e6abf0ee"><span class="__cf_email__" data-cfemail="91e2e5f4e7f4ffbff2f9f0e3fde5feffd1fffee5e5f8fff6f9f0fcbff0f2bfe4fa">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shailesh N. Mistry</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2252-1689" title="Orcid link">http://orcid.org/0000-0002-2252-1689</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b38232a22272e3823652622383f39320b25243f3f22252c232a26652a28653e20"><span class="__cf_email__" data-cfemail="ee9d868f87828b9d86c083879d9a9c97ae80819a9a878089868f83c08f8dc09b85">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tim J. Fyfe</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, 
    Drug Discovery Biology, Monash Institute of Pharmaceutical
Sciences, 
     and , Monash University, Parkville, Victoria 3052, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barrie Kellam</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0030-9908" title="Orcid link">http://orcid.org/0000-0003-0030-9908</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David A. Sykes</span> - <span class="hlFld-Affiliation affiliation">School
of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
of Membrane Protein and Receptors, University of Nottingham, Nottingham NG7 2UH, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ben Capuano</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry and , Monash University, Parkville, Victoria 3052, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5434-0180" title="Orcid link">http://orcid.org/0000-0001-5434-0180</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter J. Scammells</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry and , Monash University, Parkville, Victoria 3052, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2930-895X" title="Orcid link">http://orcid.org/0000-0003-2930-895X</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e16076-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i190">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was supported by the joint University of Nottingham & Monash University Doctoral Training Centre (DTC). Jackie Glenn is thanked for technical support with the cAMP assays.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">D<sub>2</sub>R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">APD</td><td class="NLM_def"><p class="first last">antipsychotic drug</p></td></tr><tr><td class="NLM_term">EPS</td><td class="NLM_def"><p class="first last">extrapyramidal symptoms</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved fluorescence resonance energy transfer</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>off</sub></td><td class="NLM_def"><p class="first last">dissociation rate constant</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>on</sub></td><td class="NLM_def"><p class="first last">association rate constant</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SKR</td><td class="NLM_def"><p class="first last">structure–kinetic relationship</p></td></tr><tr><td class="NLM_term">FCC</td><td class="NLM_def"><p class="first last">flash column chromatography</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i192">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 74 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau-Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1038/261717a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2F261717a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=945467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors&doi=10.1038%2F261717a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug doses and neuroleptic/dopamine receptors</span></div><div class="casAuthors">Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5562</span>),
    <span class="NLM_cas:pages">717-19</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Clin. effective antipsychotic drugs, e.g., chlorpromazine [50-53-3], blocked the stereospecific binding of 3H-labeled haloperidol [52-86-8] at concns. which correlated directly with their clin. potencies.  In addn., the antipsychotics blocked binding of dopamine [51-61-6], the IC50 values (concns. producing 50% blockade) for this effect correlated quant. with the clin. antipsychotic potencies.  The neuroleptic receptor assay can thus be used to screen potentially useful antipsychotic drugs.  The IC50 values for blockade of haloperidol binding were almost identical to the concns. of drugs in the patients plasma; e.g., 29 and 30nM, resp., for chlorpromazine.  These IC50 values may therefore be of therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIuatc5GaFrVg90H21EOLACvtfcHk0lgoz5l0OsfmAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D&md5=2800e926625d767c976dbf4181fc6ad2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F261717a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F261717a0%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26spage%3D717%26epage%3D719%26doi%3D10.1038%2F261717a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginovart, N.</span>; <span class="NLM_string-name">Kapur, S.</span></span> <span> </span><span class="NLM_article-title">Role of Dopamine D<sub>2</sub> Receptors for Antipsychotic Activity</span>. In  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, G.</span>, <span class="NLM_string-name">Geyer, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">212</span>, pp  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">52</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=27-52&author=N.+Ginovart&author=S.+Kapurauthor=G.+Gross&author=M.+Geyer&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGinovart%26aufirst%3DN.%26atitle%3DRole%2520of%2520Dopamine%2520D2%2520Receptors%2520for%2520Antipsychotic%2520Activity%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DGross%26aufirst%3DG.%26pub%3DSpringer%26date%3D2012%26volume%3D212%26spage%3D27%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarskog, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischhacker, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1038/mp.2012.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fmp.2012.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22584864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1206-1227&author=S.+Miyamotoauthor=N.+Miyakeauthor=L.+F.+Jarskogauthor=W.+W.+Fleischhackerauthor=J.+A.+Lieberman&title=Pharmacological+treatment+of+schizophrenia%3A+a+critical+review+of+the+pharmacology+and+clinical+effects+of+current+and+future+therapeutic+agents&doi=10.1038%2Fmp.2012.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span></div><div class="casAuthors">Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1206-1227</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D2 receptor has been the target for the development of APDs.  Pharmacol. actions to reduce neurotransmission through the D2 receptor have been the only proven therapeutic mechanism for psychoses.  A no. of novel non-D2 mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective.  At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory.  The relative success of antipsychotics in treating pos. symptoms is limited by the fact that a substantial no. of patients are refractory to current medications and by their lack of efficacy for neg. and cognitive symptoms, which often det. the level of functional impairment.  In addn., while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about wt. gain and endocrinopathies have emerged.  Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new mol. targets and develop mechanistically novel compds. that can address the various symptom dimensions of schizophrenia.  In recent years, a variety of new exptl. pharmacol. approaches have emerged, including compds. acting on targets other than the dopamine D2 receptor.  However, there is still an ongoing debate as to whether drugs selective for singe mol. targets (i.e., magic bullets') or drugs selectively non-selective for several mol. targets (i.e., magic shotguns', multifunctional drugs' or intramol. polypharmacy') will lead to more effective new medications for schizophrenia.  In this context, current and future drug development strategies can be seen to fall into three categories: (1) refinement of precedented mechanisms of action to provide drugs of comparable or superior efficacy and side-effect profiles to existing APDs; (2) development of novel (and presumably non-D2) mechanism APDs; (3) development of compds. to be used as adjuncts to APDs to augment efficacy by targeting specific symptom dimensions of schizophrenia and particularly those not responsive to traditional APD treatment.  In addn., efforts are being made to det. if the products of susceptibility genes in schizophrenia, identified by genetic linkage and assocn. studies, may be viable targets for drug development.  Finally, a focus on early detection and early intervention aimed at halting or reversing progressive pathophysiol. processes in schizophrenia has gained great influence.  This has encouraged future drug development and therapeutic strategies that are neuroprotective.  This article provides an update and crit. review of the pharmacol. and clin. profiles of current APDs and drugs acting on novel targets with potential to be therapeutic agents in the future.  Mol. Psychiatry (2012) 17, 1206-1227; doi:10.1038/mp.2012.47; published online 15 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qXbq8buMvLVg90H21EOLACvtfcHk0lieQqQAniXzog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI&md5=f0240f40a88e012daaebd216efc438b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.47%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DN.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DFleischhacker%26aufirst%3DW.%2BW.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacological%2520treatment%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520the%2520pharmacology%2520and%2520clinical%2520effects%2520of%2520current%2520and%2520future%2520therapeutic%2520agents%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26spage%3D1206%26epage%3D1227%26doi%3D10.1038%2Fmp.2012.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span> <span> </span><span class="NLM_article-title">Update on typical and atypical antipsychotic drugs</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050911-161504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1146%2Fannurev-med-050911-161504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=23020880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=393-406&author=H.+Y.+Meltzer&title=Update+on+typical+and+atypical+antipsychotic+drugs&doi=10.1146%2Fannurev-med-050911-161504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Update on typical and atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-406</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic drugs (APDs) are best classified as typical or atypical.  The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD).  The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.  TD increases the death rate and can be minimized by limiting use of typical APDs.  Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for redn. of suicide, and for improving longevity.  The typical and atypical APDs do not differ in improving psychopathol. in non-TRS.  The atypicals vary in metabolic side effects: some have little burden.  Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS.  Overall, choosing among the atypical APDs as first-line treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK6NegaTYH_7Vg90H21EOLACvtfcHk0lieQqQAniXzog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D&md5=cb4d64f893e34f0cf66b92ba97723081</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050911-161504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050911-161504%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DUpdate%2520on%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26spage%3D393%26epage%3D406%26doi%3D10.1146%2Fannurev-med-050911-161504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span> <span> </span><span class="NLM_article-title">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61764-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0140-6736%2808%2961764-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19058842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=31-41&author=S.+Leuchtauthor=C.+Corvesauthor=D.+Arbterauthor=R.+R.+Engelauthor=C.+Liauthor=J.+M.+Davis&title=Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia%3A+a+meta-analysis&doi=10.1016%2FS0140-6736%2808%2961764-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span></div><div class="casAuthors">Leucht, Stefan; Corves, Caroline; Arbter, Dieter; Engel, Rolf R.; Li, Chunbo; Davis, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9657</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-anal. of randomized controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.  We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), pos., neg. and depressive symptoms, relapse, quality of life, extrapyramidal side-effects, wt. gain, and sedation.  We included 150 double-blind, mostly short-term, studies, with 21,533 participants.  We excluded open studies because they systematically favored second-generation drugs.  Four of these drugs were better than first-generation antipsychotic drugs for overall efficacy, with small to medium effect sizes (amisulpride -0.31 [95% CI -0.44 to -0.19, p<0.0001], clozapine -0.52 [-0.75 to -0.29, p<0.0001], olanzapine -0.28 [-0.38 to -0.18, p<0.0001], and risperidone -0.13 [-0.22 to -0.05, p=0.002]).  The other second-generation drugs were not more efficacious than the first-generation drugs, even for neg. symptoms.  Therefore efficacy on neg. symptoms cannot be a core component of atypicality.  Second-generation antipsychotic drugs induced fewer extrapyramidal side-effects than did haloperidol (even at low doses).  Only a few have been shown to induce fewer extrapyramidal side-effects than low-potency first-generation antipsychotic drugs.  With the exception of aripiprazole and ziprasidone, second-generation antipsychotic drugs induced more wt. gain, in various degrees, than did haloperidol but not than low-potency first-generation drugs.  The second-generation drugs also differed in their sedating properties.  We did not note any consistent effects of moderator variables, such as industry sponsorship, comparator dose, or prophylactic antiparkinsonian medication.  Second-generation antipsychotic drugs differ in many properties and are not a homogeneous class.  This meta-anal. provides data for individualized treatment based on efficacy, side-effects, and cost.  Funding: National Institute of Mental Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXIyLwG0IPLVg90H21EOLACvtfcHk0lieQqQAniXzog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D&md5=b36479dbb36763237e2183f3c773e979</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961764-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961764-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DArbter%26aufirst%3DD.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DSecond-generation%2520versus%2520first-generation%2520antipsychotic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS0140-6736%2808%2961764-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordström, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedvall, G.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.1992.01820070032005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1001%2Farchpsyc.1992.01820070032005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1352677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK38zivVKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1992&pages=538-544&author=L.+Fardeauthor=A.+L.+Nordstr%C3%B6mauthor=F.+A.+Wieselauthor=S.+Pauliauthor=C.+Halldinauthor=G.+Sedvall&title=Positron+emission+tomographic+analysis+of+central+D1+and+D2+dopamine+receptor+occupancy+in+patients+treated+with+classical+neuroleptics+and+clozapine.+Relation+to+extrapyramidal+side+effects&doi=10.1001%2Farchpsyc.1992.01820070032005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects</span></div><div class="casAuthors">Farde L; Nordstrom A L; Wiesel F A; Pauli S; Halldin C; Sedvall G</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">538-44</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Positron emission tomography and selective radioligands were used to determine D1 and D2 dopamine receptor occupancy induced by neuroleptics in the basal ganglia of drug-treated schizophrenic patients.  In 22 patients treated with conventional dosages of classical neuroleptics, the D2 occupancy was 70% to 89%.  Patients with acute extrapyramidal syndromes had a higher D2 occupancy than those without side effects.  This finding indicates that neuroleptic-induced extrapyramidal syndromes are related to the degree of central D2 occupancy induced in the basal ganglia.  In five patients treated with clozapine, the prototype atypical antipsychotic drug, a lower D2 occupancy of 38% to 63% was found.  This finding demonstrates that clozapine is also "atypical" with respect to the central D2 occupancy in patients.  During treatment with clozapine, there is a low frequency of extrapyramidal syndromes, which accordingly may reflect the comparatively low D2 occupancy induced by clinical doses of clozapine.  Classical neuroleptics, like haloperidol or sulpiride, did not cause any evident D1 occupancy, but the thioxanthene flupentixol induced a 36% to 44% occupancy.  In four patients treated with clozapine, the D1 occupancy was 38% to 52%.  The D1 occupancy induced by clozapine and flupentixol may contribute to the antipsychotic effect of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8O-69J5LclwvupmecNw_lfW6udTcc2eb_Fs5atUnUrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zivVKgug%253D%253D&md5=9c70724d8c7ca998bd4f0154101b0d7d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1992.01820070032005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1992.01820070032005%26sid%3Dliteratum%253Aachs%26aulast%3DFarde%26aufirst%3DL.%26aulast%3DNordstr%25C3%25B6m%26aufirst%3DA.%2BL.%26aulast%3DWiesel%26aufirst%3DF.%2BA.%26aulast%3DPauli%26aufirst%3DS.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSedvall%26aufirst%3DG.%26atitle%3DPositron%2520emission%2520tomographic%2520analysis%2520of%2520central%2520D1%2520and%2520D2%2520dopamine%2520receptor%2520occupancy%2520in%2520patients%2520treated%2520with%2520classical%2520neuroleptics%2520and%2520clozapine.%2520Relation%2520to%2520extrapyramidal%2520side%2520effects%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1992%26volume%3D49%26spage%3D538%26epage%3D544%26doi%3D10.1001%2Farchpsyc.1992.01820070032005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">2244</span>– <span class="NLM_lpage">2253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=416027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE1cXlslemsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=2244-2253&author=M.+G.+Caronauthor=M.+Beaulieuauthor=V.+Raymondauthor=B.+Gagneauthor=J.+Drouinauthor=R.+J.+Lefkowitzauthor=F.+Labrie&title=Dopaminergic+receptors+in+the+anterior+pituitary+gland.+Correlation+of+%5B3H%5Ddihydroergocryptine+binding+with+the+dopaminergic+control+of+prolactin+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic receptors in the anterior pituitary gland.  Correlation of [3H]-dihydroergocryptine binding with the dopaminergic control of prolactin release</span></div><div class="casAuthors">Caron, Marc G.; Beaulieu, Michele; Raymond, Vincent; Gagne, Bernard; Drouin, Jacques; Lefkowitz, Robert J.; Labrie, Fernand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2244-53</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The ergot alkaloid [3H]-labeled dihydroergocryptine (I)  [25447-66-9], a potent dopaminergic agonist, has been used to study binding sites in bovine anterior pituitary membranes.  One function of the anterior pituitary gland, prolactin  [9002-62-4] secretion, is under typical dopaminergic control and was measured in vitro in another series of expts. using rat anterior pituitary cells in primary culture in order to establish a correlation between binding and a biol. function.  The dopaminergic specificity of ligand binding and the biol. process was demonstrated by the fact that agonists competed for [3H]-I binding and inhibited prolactin release with an identical order of potency: apomorphine > dopamine > epinephrine ≥ norepinephrine » isoproterenol.  Ergot alkaloids, which behave as agonists in this system, potently inhibited prolactin release from pituitary cells to about the same extent as dopamine (80-90% of basal levels) and were potent competitors of [3H]-I binding (KD 0.2-0.5 nM).  Dopaminergic antagonists competed for [3H]-I binding in bovine anterior pituitary membranes in parallel to their ability to reverse either dopamine or dihydroergocornine inhibition of prolactin release from rat anterior pituitary cells.  [3H]-I binding fulfilled another criterion of specific receptor sites in that binding to the anterior pituitary sites was saturable with an apparent dissocn. const. (KD) of 2.2 nM and a mean satn. value of 0.32 pmol/mg of protein.  The close correlation which exists between the properties of [3H]-I binding to pituitary membrane receptors and characteristics of modulation of prolactin secretion by dopaminergic agents suggests that [3H]-I binding sites are assocd. with mammotrophs and that these dopaminergic binding sites modulate prolactin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5xLpyUbMoybVg90H21EOLACvtfcHk0lgLeSrx7MoXTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXlslemsbk%253D&md5=b15b2c147f75780e5faeddb610da7d63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBeaulieu%26aufirst%3DM.%26aulast%3DRaymond%26aufirst%3DV.%26aulast%3DGagne%26aufirst%3DB.%26aulast%3DDrouin%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLabrie%26aufirst%3DF.%26atitle%3DDopaminergic%2520receptors%2520in%2520the%2520anterior%2520pituitary%2520gland.%2520Correlation%2520of%2520%255B3H%255Ddihydroergocryptine%2520binding%2520with%2520the%2520dopaminergic%2520control%2520of%2520prolactin%2520release%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26spage%3D2244%26epage%3D2253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. E.</span></span> <span> </span><span class="NLM_article-title">Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/0920-9964(91)90029-Q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2F0920-9964%2891%2990029-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1674881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK3M3kvVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=109-120&author=D.+E.+Casey&title=Neuroleptic+drug-induced+extrapyramidal+syndromes+and+tardive+dyskinesia&doi=10.1016%2F0920-9964%2891%2990029-Q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia</span></div><div class="casAuthors">Casey D E</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-20</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Neuroleptic (antipsychotic) drug-induced acute extrapyramidal syndromes (EPS) and the late onset tardive dyskinesia (TD) are the major side effects that limit the use of these highly efficacious agents.  The appropriate strategy for controlling these side effects is based on the clinical presentations, pathophysiological mechanisms, and contributions of patient and treatment-related risk factors.  New information about the mechanisms of action of neuroleptics and the long-term outcome of acute EPS and TD provide valuable insights into these syndromes.  The most effective method for maximizing the benefits and minimizing the risks of neuroleptics is to use the lowest effective dose of both neuroleptic and antiEPS drugs in patients who benefit from them.  The next major advancement will be to develop new compounds which effectively control psychotic symptoms and are free of the undesirable acute and tardive motor syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMvSHYz0v3bjMsgLhIoICsfW6udTcc2eb_Fs5atUnUrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3kvVOqsg%253D%253D&md5=6b24bae598ccd63cb71ccd1d7b43b86d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0920-9964%2891%2990029-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0920-9964%252891%252990029-Q%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DD.%2BE.%26atitle%3DNeuroleptic%2520drug-induced%2520extrapyramidal%2520syndromes%2520and%2520tardive%2520dyskinesia%26jtitle%3DSchizophr.%2520Res.%26date%3D1991%26volume%3D4%26spage%3D109%26epage%3D120%26doi%3D10.1016%2F0920-9964%2891%2990029-Q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitschel-Walz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissling, W.</span></span> <span> </span><span class="NLM_article-title">Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/S0920-9964(98)00105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0920-9964%2898%2900105-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=9988841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M7ktlertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1999&pages=51-68&author=S.+Leuchtauthor=G.+Pitschel-Walzauthor=D.+Abrahamauthor=W.+Kissling&title=Efficacy+and+extrapyramidal+side-effects+of+the+new+antipsychotics+olanzapine%2C+quetiapine%2C+risperidone%2C+and+sertindole+compared+to+conventional+antipsychotics+and+placebo.+A+meta-analysis+of+randomized+controlled+trials&doi=10.1016%2FS0920-9964%2898%2900105-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</span></div><div class="casAuthors">Leucht S; Pitschel-Walz G; Abraham D; Kissling W</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-68</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics.  The main results are: (1) All of the 4 new drugs are more effective than placebo, but the magnitude of the effect is only moderate [mean effect size, r, of all antipsychotics vs. placebo = 0.25, with a 95% confidence interval (CI) = 0.22-0.28, n = 2477]. (2) According to the studies published to date, sertindole and quetiapine are as effective as haloperidol, and risperidone and olanzapine are slightly more effective than haloperidol in the treatment of global schizophrenic symptomatology. (3) With respect to negative symptoms, all new antipsychotics are more effective than placebo.  However, contrary to widespread opinion, so is the 'conventional' antipsychotic haloperidol.  Risperidone and olanzapine are slightly superior, sertindole is as effective and--according to the only study fully published to date--quetiapine is even slightly less effective than haloperidol in this regard. (4) All new antipsychotics are associated with less frequent use of antiparkinson medication than haloperidol, with risperidone appearing to have a slightly less favourable EPS-profile than the other new antipsychotics.  The methodological limitations of this review, the generalizability of the results and expectations from future research are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhsUl8IaevAnRxY89Cm6SyfW6udTcc2eYjluaC_rCPbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7ktlertA%253D%253D&md5=25d3d49faa367fabef02c6bcfc5349d6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2898%2900105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252898%252900105-4%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DPitschel-Walz%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DD.%26aulast%3DKissling%26aufirst%3DW.%26atitle%3DEfficacy%2520and%2520extrapyramidal%2520side-effects%2520of%2520the%2520new%2520antipsychotics%2520olanzapine%252C%2520quetiapine%252C%2520risperidone%252C%2520and%2520sertindole%2520compared%2520to%2520conventional%2520antipsychotics%2520and%2520placebo.%2520A%2520meta-analysis%2520of%2520randomized%2520controlled%2520trials%26jtitle%3DSchizophr.%2520Res.%26date%3D1999%26volume%3D35%26spage%3D51%26epage%3D68%26doi%3D10.1016%2FS0920-9964%2898%2900105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halbreich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, L. S.</span></span> <span> </span><span class="NLM_article-title">Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/S0306-4530(02)00112-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0306-4530%2802%2900112-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=12504072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD38jkt1Cltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=53-67&author=U.+Halbreichauthor=B.+J.+Kinonauthor=J.+A.+Gilmoreauthor=L.+S.+Kahn&title=Elevated+prolactin+levels+in+patients+with+schizophrenia%3A+mechanisms+and+related+adverse+effects&doi=10.1016%2FS0306-4530%2802%2900112-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects</span></div><div class="casAuthors">Halbreich U; Kinon B J; Gilmore J A; Kahn L S</div><div class="citationInfo"><span class="NLM_cas:title">Psychoneuroendocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-67</span>
        ISSN:<span class="NLM_cas:issn">0306-4530</span>.
    </div><div class="casAbstract">The neurologic processes involved in schizophrenia are complex and diverse and the mechanisms through which antipsychotic agents exert their effects have been only partly elucidated.  Hyperprolactinemia is a common side effect of treatment with many antipsychotics and is particularly associated with conventional ('typical') agents as well as the atypical antipsychotic risperidone.  In contrast, other atypical agents introduced over the last decade do not elevate prolactin levels.  This article discusses the regulatory mechanisms involved in prolactin secretion, the physiologic role of prolactin, and the etiology of hyperprolactinemia.  Elevated prolactin levels may play important roles, both direct and indirect, in various pathologic states, including breast cancer, osteoporosis, cardiovascular disorders, and sexual disturbances.  Antipsychotic-induced hyperprolactinemia may be associated with similar clinical manifestations; these are examined with particular reference to patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBznfB6Mf3oJdYoSR9eyvsfW6udTcc2eYjluaC_rCPbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jkt1Cltw%253D%253D&md5=5a1215eb750272fc987495ba22e076ae</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0306-4530%2802%2900112-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4530%252802%252900112-9%26sid%3Dliteratum%253Aachs%26aulast%3DHalbreich%26aufirst%3DU.%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DGilmore%26aufirst%3DJ.%2BA.%26aulast%3DKahn%26aufirst%3DL.%2BS.%26atitle%3DElevated%2520prolactin%2520levels%2520in%2520patients%2520with%2520schizophrenia%253A%2520mechanisms%2520and%2520related%2520adverse%2520effects%26jtitle%3DPsychoneuroendocrinology%26date%3D2003%26volume%3D28%26spage%3D53%26epage%3D67%26doi%3D10.1016%2FS0306-4530%2802%2900112-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colasanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragogna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, A. C.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of atypical antipsychotics: an update</span>. <i>EXCLI J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26417330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC283ntFCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1163-1191&author=M.+C.+Mauriauthor=S.+Palettaauthor=M.+Maffiniauthor=A.+Colasantiauthor=F.+Dragognaauthor=C.+Di+Paceauthor=A.+C.+Altamura&title=Clinical+pharmacology+of+atypical+antipsychotics%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of atypical antipsychotics: an update</span></div><div class="casAuthors">Mauri M C; Paletta S; Maffini M; Dragogna F; Di Pace C; Altamura A C; Colasanti A</div><div class="citationInfo"><span class="NLM_cas:title">EXCLI journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1163-91</span>
        ISSN:<span class="NLM_cas:issn">1611-2156</span>.
    </div><div class="casAbstract">This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, que(logical not)tiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine.  A summary of their acute pharmacokinetics properties are also reported.  Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine.  Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine.  Actually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight and metabolic variables.  Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs because there are no unequivocal data supporting a relationship between plasma drug levels and clinical outcomes or side effects.  The exception can be represented by clozapine for which plasma levels of 350-420 ng/ml are reported to be associated with an increased probability of a good clinical response.  Also for olanzapine an established therapeutic range (20-50 ng/ml) is proposed to yield an optimal response and minimize side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdCpEGnFjeucNIRw0GKUoEfW6udTcc2eYjluaC_rCPbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ntFCmsQ%253D%253D&md5=5f02f9f9b62bd78ec8db80168727f5d9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMauri%26aufirst%3DM.%2BC.%26aulast%3DPaletta%26aufirst%3DS.%26aulast%3DMaffini%26aufirst%3DM.%26aulast%3DColasanti%26aufirst%3DA.%26aulast%3DDragogna%26aufirst%3DF.%26aulast%3DDi%2BPace%26aufirst%3DC.%26aulast%3DAltamura%26aufirst%3DA.%2BC.%26atitle%3DClinical%2520pharmacology%2520of%2520atypical%2520antipsychotics%253A%2520an%2520update%26jtitle%3DEXCLI%2520J.%26date%3D2014%26volume%3D13%26spage%3D1163%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lhZREhGpk8t3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span> <span> </span><span class="NLM_article-title">Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(01)01251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0006-3223%2801%2901251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=11743942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2001&pages=873-883&author=S.+Kapurauthor=G.+Remington&title=Dopamine+D%282%29+receptors+and+their+role+in+atypical+antipsychotic+action%3A+still+necessary+and+may+even+be+sufficient&doi=10.1016%2FS0006-3223%2801%2901251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient</span></div><div class="casAuthors">Kapur, Shitij; Remington, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">873-883</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  "Atypical" antipsychotics are assocd. with a much lower propensity for extrapyramidal side effects and, with some exceptions, a lack of sustained prolactin elevation.  The authors propose that a low-affinity and fast dissocn. (in mol. terms) from the dopamine D2 receptor, along with administration of the drug in doses that lead to appropriate levels of dopamine D2 receptor blockade, are the most important requirements for atypicality.  Actions at other receptors (5-HT2, D4, etc.) may not be necessary to achieve atypicality, and while action at these receptors may have benefits on symptoms such as mood and cognition, this is as yet to be conclusively proven.  Why clozapine is effective in refractory patients is still elusive and efforts to make antipsychotics that are devoid of effects on the dopamine D2 receptors so far have been unsuccessful.  In light of this, the authors provide a heuristic model linking pathophysiol. and therapeutics and suggest that the ideal treatment for schizophrenia is unlikely to be single-drug with multireceptor blockade (a sort of one-size-fits-all polypharmacy) but will require several specific and targeted treatment strategies that are titrated to match the variable expression of different dimensions of schizophrenia in each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_C5zIWSvcrrVg90H21EOLACvtfcHk0lhyd8dYd7Ui4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFyqsrk%253D&md5=0f6b6137825f2345542f4531be72d42c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2801%2901251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252801%252901251-3%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DRemington%26aufirst%3DG.%26atitle%3DDopamine%2520D%25282%2529%2520receptors%2520and%2520their%2520role%2520in%2520atypical%2520antipsychotic%2520action%253A%2520still%2520necessary%2520and%2520may%2520even%2520be%2520sufficient%26jtitle%3DBiol.%2520Psychiatry%26date%3D2001%26volume%3D50%26spage%3D873%26epage%3D883%26doi%3D10.1016%2FS0006-3223%2801%2901251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=2571717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=238-246&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=Classification+of+typical+and+atypical+antipsychotic+drugs+on+the+basis+of+dopamine+D-1%2C+D-2+and+serotonin2+pKi+values"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The pKi values of 38 typical and atypical antipsychotic drugs (APD) for 5-HT2, D-1 and D-2 binding sites in rat brain have been detd.  Multivariate analytic techniques demonstrate the importance of the D-2 and 5-HT2 affinities for detg. whether a drug which can block the conditioned avoidance response will have atypical properties as an antipsychotic.  A 5-HT2/D-2 ratio ≥1.12 is characteristic of the atypical APD.  These results may be useful in drug screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCUl6xIvXorVg90H21EOLACvtfcHk0lhyd8dYd7Ui4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D&md5=0f46fdcc98abf7d93d7ea102ac30df84</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DClassification%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520basis%2520of%2520dopamine%2520D-1%252C%2520D-2%2520and%2520serotonin2%2520pKi%2520values%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26spage%3D238%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frånberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konradsson-Geuken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardemark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span> <span> </span><span class="NLM_article-title">Adjunctive alpha(2)-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1017/S1461145709990794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1017%2FS1461145709990794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19835668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Gjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=891-903&author=M.+Marcusauthor=C.+Wikerauthor=O.+Fr%C3%A5nbergauthor=A.+Konradsson-Geukenauthor=X.+Langloisauthor=K.+Jardemarkauthor=T.+Svensson&title=Adjunctive+alpha%282%29-adrenoceptor+blockade+enhances+the+antipsychotic-like+effect+of+risperidone+and+facilitates+cortical+dopaminergic+and+glutamatergic%2C+NMDA+receptor-mediated+transmission&doi=10.1017%2FS1461145709990794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission</span></div><div class="casAuthors">Marcus, Monica M.; Wiker, Charlotte; Franberg, Olivia; Konradsson-Geuken, Aasa; Langlois, Xavier; Jardemark, Kent; Svensson, Torgny H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">891-903</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Compared to both first- and second-generation antipsychotic drugs (APDs), clozapine shows superior efficacy in treatment-resistant schizophrenia.  In contrast to most APDs clozapine possesses high affinity for α2-adrenoceptors, and clin. and preclin. studies provide evidence that the α2-adrenoceptor antagonist idazoxan enhances the antipsychotic efficacy of typical D2 receptor antagonists as well as olanzapine.  Risperidone has lower affinity for α2-adrenoceptors than clozapine but higher than most other APDs.  Here we examd., in rats, the effects of adding idazoxan to risperidone on antipsychotic effect using the conditioned avoidance response (CAR) test, extrapyramidal side-effect (EPS) liability using the catalepsy test, brain dopamine efflux using in-vivo microdialysis in freely moving animals, cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission using intracellular electrophysiol. recording in vitro, and ex-vivo autoradiog. to assess the in-vivo α2A- and α2C-adrenoceptor occupancies by risperidone.  The dose of risperidone needed for antipsychotic effect in the CAR test was ∼0.4 mg/kg, which produced 11% and 17% in-vivo receptor occupancy at α2A- and α2C-adrenoceptors, resp.  Addn. of idazoxan (1.5 mg/kg) to a low dose of risperidone (0.25 mg/kg) enhanced the suppression of CAR, but did not enhance catalepsy.  Both cortical dopamine release and NMDA receptor-mediated responses were enhanced.  These data propose that the therapeutic effect of risperidone in schizophrenia can be enhanced and its EPS liability reduced by adjunctive treatment with an α2-adrenoceptor antagonist, and generally support the notion that the potent α2-adrenoceptor antagonistic action of clozapine may be highly important for its unique efficacy in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1gqInc0lUBLVg90H21EOLACvtfcHk0lhyd8dYd7Ui4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Gjsbk%253D&md5=65bab480c432b66d2cf3b7497ddcfa68</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1017%2FS1461145709990794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145709990794%26sid%3Dliteratum%253Aachs%26aulast%3DMarcus%26aufirst%3DM.%26aulast%3DWiker%26aufirst%3DC.%26aulast%3DFr%25C3%25A5nberg%26aufirst%3DO.%26aulast%3DKonradsson-Geuken%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DJardemark%26aufirst%3DK.%26aulast%3DSvensson%26aufirst%3DT.%26atitle%3DAdjunctive%2520alpha%25282%2529-adrenoceptor%2520blockade%2520enhances%2520the%2520antipsychotic-like%2520effect%2520of%2520risperidone%2520and%2520facilitates%2520cortical%2520dopaminergic%2520and%2520glutamatergic%252C%2520NMDA%2520receptor-mediated%2520transmission%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D891%26epage%3D903%26doi%3D10.1017%2FS1461145709990794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horacek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubenikova-Valesova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palenicek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoschl, C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2165/00023210-200620050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.2165%2F00023210-200620050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=16696579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=389-409&author=J.+Horacekauthor=V.+Bubenikova-Valesovaauthor=M.+Kopecekauthor=T.+Palenicekauthor=C.+Dockeryauthor=P.+Mohrauthor=C.+Hoschl&title=Mechanism+of+action+of+atypical+antipsychotic+drugs+and+the+neurobiology+of+schizophrenia&doi=10.2165%2F00023210-200620050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of atypical antipsychotic drugs and the neurobiology and schizophrenia</span></div><div class="casAuthors">Horacek, Jiri; Bubenikova-Valesova, Vera; Kopecek, Milan; Palenicek, Tomas; Dockery, Colleen; Mohr, Pavel; Hoschl, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">389-409</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics have greatly enhanced the treatment of schizophrenia.  The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained.  This article summarizes the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiol. of schizophrenia.  When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant.  The optimal occupancy of dopamine D2 receptors seems to be crucial to balancing efficacy and adverse effects - transient D2 receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D2 receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms.  Partial D2 receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D2 receptors.  Balancing presynaptic and post-synaptic D2 receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D2 receptors.  Serotonergic modulation is assocd. with a beneficial increase in striatal dopamine release.  Effects on the neg. and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D2 and serotonin 5-HT2A receptor antagonism (e.g. by olanzapine and risperidone), partial D2 receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors.  In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus.  This mechanism may normalize glutamatergic dysfunction and structural abnormalities and affect the core pathophysiol. substrates for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7XN_qERk6M7Vg90H21EOLACvtfcHk0lhTCoYFnc4VsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D&md5=7110d0f95ae4dfd01395ae371feb59e2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2165%2F00023210-200620050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200620050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHoracek%26aufirst%3DJ.%26aulast%3DBubenikova-Valesova%26aufirst%3DV.%26aulast%3DKopecek%26aufirst%3DM.%26aulast%3DPalenicek%26aufirst%3DT.%26aulast%3DDockery%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHoschl%26aufirst%3DC.%26atitle%3DMechanism%2520of%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520the%2520neurobiology%2520of%2520schizophrenia%26jtitle%3DCNS%2520Drugs%26date%3D2006%26volume%3D20%26spage%3D389%26epage%3D409%26doi%3D10.2165%2F00023210-200620050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.158.3.360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1176%2Fappi.ajp.158.3.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=11229973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=360-369&author=S.+Kapurauthor=P.+Seeman&title=Does+fast+dissociation+from+the+dopamine+d%282%29+receptor+explain+the+action+of+atypical+antipsychotics%3F%3A+A+new+hypothesis&doi=10.1176%2Fappi.ajp.158.3.360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear.  This article provides a new hypothesis about the mechanism of action of atypical antipsychotics.  METHOD:  Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis.  Particular attention was paid to data regarding the role of the serotonin 5-HT(2) and dopamine D(4) receptors in atypicality.  RESULTS:  Neuroimaging data show that optimal dopamine D(2) occupancy is sufficient to produce the atypical antipsychotic effect.  Freedom from motor side effects results from low D(2) occupancy, not from high 5-HT(2) occupancy.  If D(2) occupancy is excessive, atypicality is lost even in the presence of high 5-HT(2) occupancy.  Animal data show that a rapid dissociation from the D(2) receptor at a molecular level produces the atypical antipsychotic effect.  In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D(2) receptor, not its high affinity at 5-HT(2), D(4), or another receptor.  CONCLUSIONS:  The authors propose that fast dissociation from the D(2) receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms.  In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D(2) receptor alone; the blockade of other receptors is neither necessary nor sufficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1OTyBcviHdd0Q2ypr7jHkfW6udTcc2eZ4EmPyEtwaqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D&md5=dae2a684b208e0fc09688835b0975c00</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.3.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.3.360%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDoes%2520fast%2520dissociation%2520from%2520the%2520dopamine%2520d%25282%2529%2520receptor%2520explain%2520the%2520action%2520of%2520atypical%2520antipsychotics%253F%253A%2520A%2520new%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D360%26epage%3D369%26doi%3D10.1176%2Fappi.ajp.158.3.360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span> <span> </span><span class="NLM_article-title">Clozapine safety, 35 years later</span>. <i>Curr. Drug. Saf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.2174/157488611797579230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.2174%2F157488611797579230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22122392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSqurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=164-184&author=M.+Raja&title=Clozapine+safety%2C+35+years+later&doi=10.2174%2F157488611797579230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine safety, 35 years later</span></div><div class="casAuthors">Raja, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">164-184</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clozapine is the best treatment option in several clin. circumstances, including treatment-resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease, prevention and treatment of tardive dyskinesia.  However, clozapine is assocd. with many serious side effects.  Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage clozapine use.  Therefore, the drug is underused.  The only way to avoid the underuse of clozapine is full awareness of its side effects and competence to minimize them.  The aim of the paper is reviewing the safety profile of clozapine and the suggested strategies in the management of its side effects, including neutropenia, eosinophilia, seizures, myocarditis, wt. gain, diabetes, metabolic syndrome, hypersalivation, fever, constipation, ileus, urinary incontinence, sweating.  The neuropsychiatric side effects of clozapine are not discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0try1-vfHQrVg90H21EOLACvtfcHk0lhTCoYFnc4VsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSqurvI&md5=87064fbb6bc705af4a4e0b262d7dfcee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F157488611797579230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488611797579230%26sid%3Dliteratum%253Aachs%26aulast%3DRaja%26aufirst%3DM.%26atitle%3DClozapine%2520safety%252C%252035%2520years%2520later%26jtitle%3DCurr.%2520Drug.%2520Saf.%26date%3D2011%26volume%3D6%26spage%3D164%26epage%3D184%26doi%3D10.2174%2F157488611797579230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span>. <i>J. Psychiatry Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10740989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=161-166&author=S.+Kapurauthor=P.+Seeman&title=Antipsychotic+agents+differ+in+how+fast+they+come+off+the+dopamine+D2+receptors.+Implications+for+atypical+antipsychotic+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">RATIONALE AND OBJECTIVE:  While the blockade of dopamine D2 receptors are necessary for antipsychotic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor.  This affinity is determined by the rate at which the antipsychotic agent binds to (kon) and the rate at which it dissociates from (koff) the D2 receptors.  The objective of this study was to determine the relationship between kon, koff and the affinity (Ki) of antipsychotic agents for the D2 receptors, with particular reference to typical and atypical antipsychotic agents.  DESIGN:  The koff of several typical as well as atypical antipsychotic agents (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine and quetiapine) was measured in vitro using the 3H-radiolabelled analogues of these drugs.  The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro.  The kon was derived from values of affinity and ++koff.  MAIN OUTCOME MEASURES:  kon, koff, and the Ki of antipsychotic drugs.  RESULTS:  The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L).  The koff values varied a thousand-fold from 0.002 to 3.013 min-1, with relatively little variation in kon.  The rate at which antipsychotic agents come off the receptor (koff) accounted for 99% of the variation in their affinity for the D2 receptor; differences in kon did not account for differences in affinity.  CONCLUSIONS:  The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor.  These differences in koff may lead to functionally different kinds of dopamine blockade.  Drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission.  Since atypical drugs show a lower affinity and a faster dissociation, a higher koff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiFVfZJOQ7_1UIs6wFK5xJfW6udTcc2eZ4EmPyEtwaqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D&md5=bde1272de3b90ba1fd77b61805c3a39d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520agents%2520differ%2520in%2520how%2520fast%2520they%2520come%2520off%2520the%2520dopamine%2520D2%2520receptors.%2520Implications%2520for%2520atypical%2520antipsychotic%2520action%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2000%26volume%3D25%26spage%3D161%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhZbAdfxuY0Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">The role of target binding kinetics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1796</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fcmdc.201500310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26506404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1793-1796&author=D.+Guoauthor=L.+H.+Heitmanauthor=A.+P.+IJzerman&title=The+role+of+target+binding+kinetics+in+drug+discovery&doi=10.1002%2Fcmdc.201500310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Target Binding Kinetics in Drug Discovery</span></div><div class="casAuthors">Guo, Dong; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1796</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Traditionally structure-activity/affinity relationships (SAR) have dominated research in medicinal chem.  However, structure-kinetics relationships (SKR) can be very informative too.  In this viewpoint we explore the mol. determinants of binding kinetics and discuss challenges for future binding kinetics studies.  A scheme for future kinetics-directed drug design and discovery is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiX7v30ryLZLVg90H21EOLACvtfcHk0lhZbAdfxuY0Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF&md5=8442ba4d4ec014762ed470f7f6131d09</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500310%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DThe%2520role%2520of%2520target%2520binding%2520kinetics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1793%26epage%3D1796%26doi%3D10.1002%2Fcmdc.201500310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sande, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermond, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and kinetic profiling of 7-aryl-1,2,4-triazolo[4,3-a]pyridines: positive allosteric modulators of the metabotropic glutamate receptor 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6704</span>– <span class="NLM_lpage">6720</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKkur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6704-6720&author=M.+L.+J.+Doornbosauthor=J.+M.+Cidauthor=J.+Haubrichauthor=A.+Nunesauthor=J.+W.+van+de+Sandeauthor=S.+C.+Vermondauthor=T.+Mulder-Kriegerauthor=A.+A.+Trabancoauthor=A.+Ahnaouauthor=W.+H.+Drinkenburgauthor=H.+Lavreysenauthor=L.+H.+Heitmanauthor=A.+P.+IJzermanauthor=G.+Tresadern&title=Discovery+and+kinetic+profiling+of+7-aryl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyridines%3A+positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+2&doi=10.1021%2Facs.jmedchem.7b00669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Cid, Jose Maria; Haubrich, Jordi; Nunes, Alexandro; van de Sande, Jasper W.; Vermond, Sophie C.; Mulder-Krieger, Thea; Trabanco, Andres A.; Ahnaou, Abdellah; Drinkenburg, Wilhelmus H.; Lavreysen, Hilde; Heitman, Laura H.; IJzerman, Adriaan P.; Tresadern, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6704-6720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. evaluation of a series of 7-aryl-1,2,4-triazolo[4,3-a]pyridines with mGlu2 pos. allosteric modulator (PAM) activity and affinity.  Besides traditional in vitro parameters of potency and affinity, kinetic parameters kon, koff and residence time (RT) were detd.  The PAMs showed various kinetic profiles; kon values ranged over 2 orders of magnitude, whereas RT values were within a 10-fold range.  Assocn. rate const. kon was linearly correlated to affinity.  Evaluation of a short, medium, and long RT compd. in a label-free assay indicated a correlation between RT and functional effect.  The effects of long RT compd. I on sleep-wake states indicated long RT was translated into sustained inhibition of rapid eye movement (REM) in vivo.  These results show that affinity-only driven selection would have resulted in mGlu2 PAMs with high values for kon but not necessarily optimized RT, which is key to predicting optimal efficacy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL1g_fLH5q87Vg90H21EOLACvtfcHk0lhZbAdfxuY0Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKkur3E&md5=dfecd3e276e08955fd16e68ed27b3c20</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00669%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%2BJ.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DHaubrich%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DA.%26aulast%3Dvan%2Bde%2BSande%26aufirst%3DJ.%2BW.%26aulast%3DVermond%26aufirst%3DS.%2BC.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DTresadern%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520kinetic%2520profiling%2520of%25207-aryl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyridines%253A%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6704%26epage%3D6720%26doi%3D10.1021%2Facs.jmedchem.7b00669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, W. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhoven, J. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duijl, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paasman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Structure–affinity relationships and structure–kinetics relationships of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7555</span>– <span class="NLM_lpage">7568</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00950</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00950" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtleht7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7555-7568&author=L.+Xiaauthor=W.+A.+C.+Burgerauthor=J.+P.+D.+van+Veldhovenauthor=B.+J.+Kuiperauthor=T.+T.+van+Duijlauthor=E.+B.+Lenselinkauthor=E.+Paasmanauthor=L.+H.+Heitmanauthor=A.+P.+Ijzerman&title=Structure%E2%80%93affinity+relationships+and+structure%E2%80%93kinetics+relationships+of+pyrido%5B2%2C1-f%5Dpurine-2%2C4-dione+derivatives+as+human+adenosine+A3+receptor+antagonists&doi=10.1021%2Facs.jmedchem.7b00950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists</span></div><div class="casAuthors">Xia, Lizi; Burger, Wessel A. C.; van Veldhoven, Jacobus P. D.; Kuiper, Boaz J.; van Duijl, Tirsa T.; Lenselink, Eelke B.; Paasman, Ellen; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7555-7568</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivs. as human adenosine A3 receptor (hA3R) antagonists to det. their kinetic profiles and affinities.  Many compds. showed high affinities and a diverse range of kinetic profiles.  We found hA3R antagonists with very short residence time (RT) at the receptor (2.2 min for II 5) and much longer RTs (e.g., 376 min for I or 391 min for 31).  Two representative antagonists (I) and (II) were tested in [35S]GTPγS binding assays, and their RTs appeared correlated to their (in)surmountable antagonism.  From a kon-koff-KD kinetic map, we divided the antagonists into three subgroups, providing a possible direction for the further development of hA3R antagonists.  Addnl., we performed a computational modeling study that sheds light on the crucial receptor interactions, dictating the compds.' binding kinetics.  Knowledge of target binding kinetics appears useful for developing and triaging new hA3R antagonists in the early phase of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiyuuEVYMqbVg90H21EOLACvtfcHk0lhWzDYupv5oTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtleht7fN&md5=a5e396ed21c6d4349d8128e5a590e21b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00950%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DW.%2BA.%2BC.%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJ.%2BP.%2BD.%26aulast%3DKuiper%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BDuijl%26aufirst%3DT.%2BT.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DPaasman%26aufirst%3DE.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DStructure%25E2%2580%2593affinity%2520relationships%2520and%2520structure%25E2%2580%2593kinetics%2520relationships%2520of%2520pyrido%255B2%252C1-f%255Dpurine-2%252C4-dione%2520derivatives%2520as%2520human%2520adenosine%2520A3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7555%26epage%3D7568%26doi%3D10.1021%2Facs.jmedchem.7b00950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilums, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweemer, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wapenaar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, I. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barmare, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brussee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Structure–kinetic relationships—An overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7706</span>– <span class="NLM_lpage">7714</span>, <span class="refDoi"> DOI: 10.1021/jm4011737</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011737" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeksbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7706-7714&author=M.+Vilumsauthor=A.+J.+M.+Zweemerauthor=Z.+Yuauthor=H.+de+Vriesauthor=J.+M.+Hillgerauthor=H.+Wapenaarauthor=I.+A.+E.+Bollenauthor=F.+Barmareauthor=R.+Grossauthor=J.+Clemensauthor=P.+Krenitskyauthor=J.+Brusseeauthor=D.+Stamosauthor=J.+Saundersauthor=L.+H.+Heitmanauthor=A.+P.+Ijzerman&title=Structure%E2%80%93kinetic+relationships%E2%80%94An+overlooked+parameter+in+hit-to-lead+optimization%3A+a+case+of+cyclopentylamines+as+chemokine+receptor+2+antagonists&doi=10.1021%2Fjm4011737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Kinetic Relationships-An Overlooked Parameter in Hit-to-Lead Optimization: A Case of Cyclopentylamines as Chemokine Receptor 2 Antagonists</span></div><div class="casAuthors">Vilums, Maris; Zweemer, Annelien J. M.; Yu, Zhiyi; de Vries, Henk; Hillger, Julia M.; Wapenaar, Hannah; Bollen, Ilse A. E.; Barmare, Farhana; Gross, Raymond; Clemens, Jeremy; Krenitsky, Paul; Brussee, Johannes; Stamos, Dean; Saunders, John; Heitman, Laura H.; Ijzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7706-7714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. models of inflammatory diseases (e.g., neuropathic pain, rheumatoid arthritis, and multiple sclerosis) have pointed to a crit. role of the chemokine receptor 2 (CCR2) and chemokine ligand 2 (CCL2).  However, one of the biggest problems of high-affinity inhibitors of CCR2 is their lack of efficacy in clin. trials.  We report a new approach for the design of high-affinity and long-residence-time CCR2 antagonists.  We developed a new competition assocn. assay for CCR2, which allows us to investigate the relation of the structure of the ligand and its receptor residence time [i.e., structure-kinetic relationship (SKR)] next to a traditional structure-affinity relationship (SAR).  By applying combined knowledge of SAR and SKR, we were able to re-evaluate the hit-to-lead process of cyclopentylamines as CCR2 antagonists.  Affinity-based optimization yielded compd. 1 with good binding (Ki = 6.8 nM) but very short residence time (2.4 min).  However, when the optimization was also based on residence time, the hit-to-lead process yielded compd. 22a, a new high-affinity CCR2 antagonist (3.6 nM), with a residence time of 135 min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsuB8fdAy3j7Vg90H21EOLACvtfcHk0lhWzDYupv5oTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeksbvM&md5=9cd60706c51fa9d58b7674d069d21433</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm4011737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011737%26sid%3Dliteratum%253Aachs%26aulast%3DVilums%26aufirst%3DM.%26aulast%3DZweemer%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3Dde%2BVries%26aufirst%3DH.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DWapenaar%26aufirst%3DH.%26aulast%3DBollen%26aufirst%3DI.%2BA.%2BE.%26aulast%3DBarmare%26aufirst%3DF.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DClemens%26aufirst%3DJ.%26aulast%3DKrenitsky%26aufirst%3DP.%26aulast%3DBrussee%26aufirst%3DJ.%26aulast%3DStamos%26aufirst%3DD.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DStructure%25E2%2580%2593kinetic%2520relationships%25E2%2580%2594An%2520overlooked%2520parameter%2520in%2520hit-to-lead%2520optimization%253A%2520a%2520case%2520of%2520cyclopentylamines%2520as%2520chemokine%2520receptor%25202%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7706%26epage%3D7714%26doi%3D10.1021%2Fjm4011737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span> <span> </span><span class="NLM_article-title">Impact, determination and prediction of drug–receptor residence times for GPCRs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.coph.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27428776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=22-26&author=C.+S.+Tautermann&title=Impact%2C+determination+and+prediction+of+drug%E2%80%93receptor+residence+times+for+GPCRs&doi=10.1016%2Fj.coph.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impact, determination and prediction of drug-receptor residence times for GPCRs</span></div><div class="casAuthors">Tautermann, Christofer S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-26</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The residence time of a ligand on a GPCR of interest has become an optimization parameter in many examples in drug design.  Long residence times can counterbalance unfavorable pharmacokinetic parameters, contributing to compd. safety, and short residence times can be a tool to avoid target related side effects.  Unlike the prediction and interpretation of the structure-activity relationship (SAR) of a ligand class on a receptor, the understanding and prediction of the structure-kinetics relationship (SKR) is much more demanding.  Exptl. and computational approaches are described, which serve to either rationalize SKR or to predict the kinetic parameters such as on-rates and off-rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlEDDF8NqsbLVg90H21EOLACvtfcHk0lhE-4DmKsDQOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr%252FP&md5=fc383a7d2be13b0c0d71d45d0bdba187</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26atitle%3DImpact%252C%2520determination%2520and%2520prediction%2520of%2520drug%25E2%2580%2593receptor%2520residence%2520times%2520for%2520GPCRs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D22%26epage%3D26%26doi%3D10.1016%2Fj.coph.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">In vivo target residence time and kinetic selectivity: The association rate constant as determinant</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.tips.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27394919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=831-842&author=W.+E.+A.+de%0AWitteauthor=M.+Danhofauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=In+vivo+target+residence+time+and+kinetic+selectivity%3A+The+association+rate+constant+as+determinant&doi=10.1016%2Fj.tips.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant</span></div><div class="casAuthors">de Witte, Wilhelmus E. A.; Danhof, Meindert; van der Graaf, Piet H.; de Lange, Elizabeth C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">831-842</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate const. of target dissocn. is a major determinant of the time course and duration of in vivo target occupancy.  Here we show that the second-order rate const. of target assocn. can be equally important.  On the basis of the commonly used math. models for drug-target binding, it is shown that a high target assocn. rate const. can increase the (local) concn. of the drug, which decreases the rate of decline of target occupancy.  The increased drug concn. can also lead to increased off-target binding and decreased selectivity.  Therefore, the kinetics of both target assocn. and dissocn. need to be taken into account in the selection of drug candidates with optimal pharmacodynamic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri0cm4NKLv-7Vg90H21EOLACvtfcHk0lhE-4DmKsDQOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE&md5=e2c077f2c8636214e2f8a77ee5734ad4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DDanhof%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DIn%2520vivo%2520target%2520residence%2520time%2520and%2520kinetic%2520selectivity%253A%2520The%2520association%2520rate%2520constant%2520as%2520determinant%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D831%26epage%3D842%26doi%3D10.1016%2Fj.tips.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knasmueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokh, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nederpelt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Fahrnow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics for drug discovery: an industry-driven effort to target drug residence time</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.drudis.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=28412474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1Kjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=896-911&author=D.+A.+Schuetzauthor=W.+E.+A.+de+Witteauthor=Y.+C.+Wongauthor=B.+Knasmuellerauthor=L.+Richterauthor=D.+B.+Kokhauthor=S.+K.+Sadiqauthor=R.+Bosmaauthor=I.+Nederpeltauthor=L.+H.+Heitmanauthor=E.+Segalaauthor=M.+Amaralauthor=D.+Guoauthor=D.+Andresauthor=V.+Georgiauthor=L.+A.+Stoddartauthor=S.+Hillauthor=R.+M.+Cookeauthor=C.+De+Graafauthor=R.+Leursauthor=M.+Frechauthor=R.+C.+Wadeauthor=E.+C.+M.+de+Langeauthor=A.+P.+IJzermanauthor=A.+Muller-Fahrnowauthor=G.+F.+Ecker&title=Kinetics+for+drug+discovery%3A+an+industry-driven+effort+to+target+drug+residence+time&doi=10.1016%2Fj.drudis.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics for Drug Discovery: an industry-driven effort to target drug residence time</span></div><div class="casAuthors">Schuetz, Doris A.; de Witte, Wilhelmus Egbertus Arnout; Wong, Yin Cheong; Knasmueller, Bernhard; Richter, Lars; Kokh, Daria B.; Sadiq, S. Kashif; Bosma, Reggie; Nederpelt, Indira; Heitman, Laura H.; Segala, Elena; Amaral, Marta; Guo, Dong; Andres, Dorothee; Georgi, Victoria; Stoddart, Leigh A.; Hill, Steve; Cooke, Robert M.; De Graaf, Chris; Leurs, Rob; Frech, Matthias; Wade, Rebecca C.; de Lange, Elizabeth Cunera Maria; IJzerman, Adriaan P.; Mueller-Fahrnow, Anke; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">896-911</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A considerable no. of approved drugs show non-equil. binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy.  Therefore, a detailed understanding of the kinetics of assocn. and dissocn. of a target-ligand complex might provide crucial insight into the mol. mechanism-of-action of a compd.  This deeper understanding will help to improve decision making in drug discovery, thus leading to a better selection of interesting compds. to be profiled further.  In this review, we highlight the contributions of the Kinetics for Drug Discovery (K4DD) Consortium, which targets major open questions related to binding kinetics in an industry-driven public-private partnership.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJRmkYejg8ObVg90H21EOLACvtfcHk0lhE-4DmKsDQOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1Kjs7k%253D&md5=78fce4f850718075ba44b28a20f79195</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchuetz%26aufirst%3DD.%2BA.%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BC.%26aulast%3DKnasmueller%26aufirst%3DB.%26aulast%3DRichter%26aufirst%3DL.%26aulast%3DKokh%26aufirst%3DD.%2BB.%26aulast%3DSadiq%26aufirst%3DS.%2BK.%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DNederpelt%26aufirst%3DI.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DAmaral%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DAndres%26aufirst%3DD.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DFrech%26aufirst%3DM.%26aulast%3DWade%26aufirst%3DR.%2BC.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DMuller-Fahrnow%26aufirst%3DA.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DKinetics%2520for%2520drug%2520discovery%253A%2520an%2520industry-driven%2520effort%2520to%2520target%2520drug%2520residence%2520time%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D896%26epage%3D911%26doi%3D10.1016%2Fj.drudis.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpatrick, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics of ligands acting at GPCRs</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2019.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.mce.2019.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=30738950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=9-19&author=D.+A.+Sykesauthor=L.+A.+Stoddartauthor=L.+E.+Kilpatrickauthor=S.+J.+Hill&title=Binding+kinetics+of+ligands+acting+at+GPCRs&doi=10.1016%2Fj.mce.2019.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics of ligands acting at GPCRs</span></div><div class="casAuthors">Sykes, David A.; Stoddart, Leigh A.; Kilpatrick, Laura E.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The influence of drug-receptor binding kinetics has often been overlooked during the development of new therapeutics that target G protein-coupled receptors (GPCRs).  Over the last decade there has been a growing understanding that an in-depth knowledge of binding kinetics at GPCRs is required to successfully target this class of proteins.  Ligand binding to a GPCR is often not a simple single step process with ligand freely diffusing in soln.  This review will discuss the expts. and equations that are commonly used to measure binding kinetics and how factors such as allosteric regulation, rebinding and ligand interaction with the plasma membrane may influence these measurements.  We will then consider the mol. characteristics of a ligand and if these can be linked to assocn. and dissocn. rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptH1Ujc4eQXrVg90H21EOLACvtfcHk0liLrRg6l--_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFOlu74%253D&md5=17649f726e9540d9e31afedf805f5213</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2019.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2019.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DKilpatrick%26aufirst%3DL.%2BE.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DBinding%2520kinetics%2520of%2520ligands%2520acting%2520at%2520GPCRs%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26spage%3D9%26epage%3D19%26doi%3D10.1016%2Fj.mce.2019.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallerico, T.</span></span> <span> </span><span class="NLM_article-title">Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1176/ajp.156.6.876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1176%2Fajp.156.6.876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10360126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M3ovVequg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=876-884&author=P.+Seemanauthor=T.+Tallerico&title=Rapid+release+of+antipsychotic+drugs+from+dopamine+D2+receptors%3A+an+explanation+for+low+receptor+occupancy+and+early+clinical+relapse+upon+withdrawal+of+clozapine+or+quetiapine&doi=10.1176%2Fajp.156.6.876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine</span></div><div class="casAuthors">Seeman P; Tallerico T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-84</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  In an attempt to understand the basis of early relapse after antipsychotic withdrawal, the objective of this study was to determine whether the low occupancy of dopamine D2 receptors by clozapine and by quetiapine, as seen by brain imaging, could arise from a rapid release of some of the D2-bound clozapine or quetiapine by the brain imaging compounds and by the action of a physiological concentration of dopamine.  METHOD:  Human cloned D2 receptors were first pre-equilibrated with the [3H]antipsychotic drug, after which raclopride, iodobenzamide, or dopamine (at the physiological concentration in the synapse) was added, and the time course of release of the [3H]antipsychotic from the D2 receptor was measured.  RESULTS:  Within 5 minutes, low concentrations of raclopride and iodobenzamide displaced appreciable amounts of [3H]clozapine and [3H]quetiapine from the D2 receptors but, during the course of 1 hour, did not displace any of the other antipsychotic [[3H]ligands. [3H]Clozapine and [3H]quetiapine, moreover, were displaced by dopamine (100 nM) at least 100 times faster than the other antipsychotic [3H]ligands.  CONCLUSIONS:  Clozapine and quetiapine are loosely bound to the D2 receptor, and the injected radioactive ligand at its peak concentration may displace some of the D2-bound antipsychotic drug, resulting in apparently low D2 occupancies.  Therefore, under clinical brain imaging conditions with [11C]raclopride, D2 occupancies by clozapine and by quetiapine may be higher than currently estimated.  These considerations may result in high levels of the D2 receptors being occupied by therapeutic doses of clozapine or quetiapine.  The rapid release of clozapine and quetiapine from D2 receptors by endogenous dopamine may contribute to low D2 receptor occupancy and to early clinical relapse upon withdrawal of these medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShWRknW98LMMvLc4ARHEmzfW6udTcc2ebiR8NK7-zNfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ovVequg%253D%253D&md5=639c7e4719e950adbfdc6ef269693649</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fajp.156.6.876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.156.6.876%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DTallerico%26aufirst%3DT.%26atitle%3DRapid%2520release%2520of%2520antipsychotic%2520drugs%2520from%2520dopamine%2520D2%2520receptors%253A%2520an%2520explanation%2520for%2520low%2520receptor%2520occupancy%2520and%2520early%2520clinical%2520relapse%2520upon%2520withdrawal%2520of%2520clozapine%2520or%2520quetiapine%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D876%26epage%3D884%26doi%3D10.1176%2Fajp.156.6.876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motulsky, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L. C.</span></span> <span> </span><span class="NLM_article-title">The kinetics of competitive radioligand binding predicted by the law of mass action</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+J.+Motulskyauthor=L.+C.+Mahan&title=The+kinetics+of+competitive+radioligand+binding+predicted+by+the+law+of+mass+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2ebiR8NK7-zNfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%2BJ.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26atitle%3DThe%2520kinetics%2520of%2520competitive%2520radioligand%2520binding%2520predicted%2520by%2520the%2520law%2520of%2520mass%2520action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10842</span> <span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=C.+Klein%0AHerenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0ljQS0usIw4o5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albizu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kralikova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span> <span> </span><span class="NLM_article-title">Time-resolved FRET between GPCR ligands reveals oligomers in native tissues</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1038/nchembio.396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnchembio.396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=20622858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=587-594&author=L.+Albizuauthor=M.+Cottetauthor=M.+Kralikovaauthor=S.+Stoevauthor=R.+Seyerauthor=I.+Brabetauthor=T.+Rouxauthor=H.+Bazinauthor=E.+Bourrierauthor=L.+Lamarqueauthor=C.+Bretonauthor=M.-L.+Rivesauthor=A.+Newmanauthor=J.+Javitchauthor=E.+Trinquetauthor=M.+Manningauthor=J.-P.+Pinauthor=B.+Mouillacauthor=T.+Durroux&title=Time-resolved+FRET+between+GPCR+ligands+reveals+oligomers+in+native+tissues&doi=10.1038%2Fnchembio.396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Time-resolved FRET between GPCR ligands reveals oligomers in native tissues</span></div><div class="casAuthors">Albizu, Laura; Cottet, Martin; Kralikova, Michaela; Stoev, Stoytcho; Seyer, Rene; Brabet, Isabelle; Roux, Thomas; Bazin, Herve; Bourrier, Emmanuel; Lamarque, Laurent; Breton, Christophe; Rives, Marie-Laure; Newman, Amy; Javitch, Jonathan; Trinquet, Eric; Manning, Maurice; Pin, Jean-Philippe; Mouillac, Bernard; Durroux, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">587-594</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) oligomers have been proposed to play crit. roles in cell signaling, but confirmation of their existence in a native context remains elusive, as no direct interactions between receptors have been reported.  To demonstrate their presence in native tissues, we developed a time-resolved FRET strategy that is based on receptor labeling with selective fluorescent ligands.  Specific FRET signals were obsd. with four different receptors expressed in cell lines, consistent with their dimeric or oligomeric nature in these transfected cells.  More notably, the comparison between FRET signals measured with sets of fluorescent agonists and antagonists was consistent with an asym. relationship of the two protomers in an activated GPCR dimer.  Finally, we applied the strategy to native tissues and succeeded in demonstrating the presence of oxytocin receptor dimers and/or oligomers in mammary gland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRPFTQQ0GNv7Vg90H21EOLACvtfcHk0ljQS0usIw4o5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ahsbw%253D&md5=7ad4fb48ba7b71d1322e158d7d174b33</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.396%26sid%3Dliteratum%253Aachs%26aulast%3DAlbizu%26aufirst%3DL.%26aulast%3DCottet%26aufirst%3DM.%26aulast%3DKralikova%26aufirst%3DM.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DSeyer%26aufirst%3DR.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DBazin%26aufirst%3DH.%26aulast%3DBourrier%26aufirst%3DE.%26aulast%3DLamarque%26aufirst%3DL.%26aulast%3DBreton%26aufirst%3DC.%26aulast%3DRives%26aufirst%3DM.-L.%26aulast%3DNewman%26aufirst%3DA.%26aulast%3DJavitch%26aufirst%3DJ.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DManning%26aufirst%3DM.%26aulast%3DPin%26aufirst%3DJ.-P.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26atitle%3DTime-resolved%2520FRET%2520between%2520GPCR%2520ligands%2520reveals%2520oligomers%2520in%2520native%2520tissues%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D587%26epage%3D594%26doi%3D10.1038%2Fnchembio.396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">763</span> <span class="refDoi"> DOI: 10.1038/s41467-017-00716-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fs41467-017-00716-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=28970469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=D.+A.+Sykesauthor=H.+Mooreauthor=L.+Stottauthor=N.+Hollidayauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=S.+J.+Charlton&title=Extrapyramidal+side+effects+of+antipsychotics+are+linked+to+their+association+kinetics+at+dopamine+D2+receptors&doi=10.1038%2Fs41467-017-00716-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span></div><div class="casAuthors">Sykes David A; Stott Lisa; Holliday Nicholas; Charlton Steven J; Moore Holly; Javitch Jonathan A; Moore Holly; Javitch Jonathan A; Javitch Jonathan A; Lane J Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">763</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor.  However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions.  Here we show that association rates, but not dissociation rates, correlate with EPS.  We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses.  EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade.  Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side effects compared to first generation drugs.  Here the authors use time-resolved FRET to measure binding kinetics, and show that side effects correlate with drug association rates to the D2 receptor, while dissociation rates correlate with prolactin elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAv7HAvl2UWlVwdslNBF-tfW6udTcc2ebhaWhRD3N-b7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D&md5=6d5c8596da9a3565b7a95b55eceac3cf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00716-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00716-z%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DStott%26aufirst%3DL.%26aulast%3DHolliday%26aufirst%3DN.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExtrapyramidal%2520side%2520effects%2520of%2520antipsychotics%2520are%2520linked%2520to%2520their%2520association%2520kinetics%2520at%2520dopamine%2520D2%2520receptors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-00716-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardenborough, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5739</span>– <span class="NLM_lpage">5742</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmcl.2004.09.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=15501032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5739-5742&author=D.+M.+Sikazweauthor=S.+Liauthor=L.+Mardenboroughauthor=V.+Codyauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Haloperidol%3A+towards+further+understanding+of+the+structural+contributions+of+its+pharmacophoric+elements+at+D2-like+receptors&doi=10.1016%2Fj.bmcl.2004.09.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors</span></div><div class="casAuthors">Sikazwe, Donald M. N.; Li, Shouming; Mardenborough, Leroy; Cody, Vivian; Roth, Brian L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5739-5742</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An attempt to understand the pharmacophore-relevant position of the alc. moiety in haloperidol and the contributions of other pharmacophoric elements led to the resynthesis of its tropane analog (compd. 2).  An anal. of the binding data suggests that haloperidol binds to the DA receptors with the OH group in the axial position and the OH group, while not essential for binding, enhances binding esp. at the D2 receptor.  It also became clear that shortening the butyrophenone chain not only reduces binding affinity at the DA receptors but eliminates subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCqf2yYDY8LVg90H21EOLACvtfcHk0lidr7KBr8sO_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVSnurk%253D&md5=f37a81b9dc77cfe3764b3afdf498fe2c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.046%26sid%3Dliteratum%253Aachs%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMardenborough%26aufirst%3DL.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DHaloperidol%253A%2520towards%2520further%2520understanding%2520of%2520the%2520structural%2520contributions%2520of%2520its%2520pharmacophoric%2520elements%2520at%2520D2-like%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5739%26epage%3D5742%26doi%3D10.1016%2Fj.bmcl.2004.09.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. E. V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7301</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2008.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=18595716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps12jtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7291-7301&author=S.+Y.+Ablordeppeyauthor=R.+Altundasauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=S.+E.+V.+K.+Eyunniauthor=T.+Jacksonauthor=A.+Khanauthor=B.+L.+Roth&title=Identification+of+a+butyrophenone+analog+as+a+potential+atypical+antipsychotic+agent%3A+4-%5B4-%284-chlorophenyl%29-1%2C4-diazepan-1-yl%5D-1-%284-fluorophenyl%29butan-1-one&doi=10.1016%2Fj.bmc.2008.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span></div><div class="casAuthors">Ablordeppey, Seth Y.; Altundas, Ramazan; Bricker, Barbara; Zhu, Xue Y.; Kumar, Eyunni V. K. Suresh; Jackson, Tanise; Khan, Abdul; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7291-7301</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and exploration of novel butyrophenones have led to the identification of a diazepane analog of haloperidol, 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one (compd. 13) with an interesting multireceptor binding profile.  Compd. 13 was evaluated for its binding affinities at DA subtype receptors, 5HT subtype receptors, H-1, M-1 receptors and at NET, DAT, and SERT transporters.  At each of these receptors, compd. 13 (I)was equipotent or better than several of the stds. currently in use.  In in vivo mouse and rat models to evaluate its efficacy and propensity to elicit catalepsy and hence EPS in humans, compd. 13 showed similar efficacy as clozapine and did not produce catalepsy at five times its ED50 value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKWLdcpGfSgbVg90H21EOLACvtfcHk0lidr7KBr8sO_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps12jtLg%253D&md5=fa1d0e1cf2aa8f7ef249d59bbccf8ad8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BE.%2BV.%2BK.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520a%2520butyrophenone%2520analog%2520as%2520a%2520potential%2520atypical%2520antipsychotic%2520agent%253A%25204-%255B4-%25284-chlorophenyl%2529-1%252C4-diazepan-1-yl%255D-1-%25284-fluorophenyl%2529butan-1-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7291%26epage%3D7301%26doi%3D10.1016%2Fj.bmc.2008.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2008.12.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19155177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVyit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1716-1723&author=D.+M.+Sikazweauthor=N.+T.+Nkansahauthor=R.+Altundasauthor=X.+Y.+Zhuauthor=B.+L.+Rothauthor=V.+Setolaauthor=S.+Y.+Ablordeppey&title=Synthesis+and+evaluation+of+ligands+for+D2-like+receptors%3A+the+role+of+common+pharmacophoric+groups&doi=10.1016%2Fj.bmc.2008.12.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups</span></div><div class="casAuthors">Sikazwe, Donald M. N.; Nkansah, Nancy T.; Altundas, Ramazan; Zhu, Xue Y.; Roth, Bryan L.; Setola, Vincent; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1716-1723</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arylcycloalkylamines, such as Ph piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents.  A review of previous reports indicates that arylalkyl substituents can improve the potency and selectivity of the binding affinity at D2-like receptors.  In this paper, we explored the contributions of two key pharmacophoric groups, i.e., 4'-fluorobutyrophenones and 3-methyl-7-azaindoles, to the potency and selectivity of synthesized agents at D2-like receptors.  Preliminary observation of binding affinities indicates that there is little predictability of specific effects of the arylalkyl moieties but the composite structure is responsible for selectivity and potency at these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIG4AM6sMFYrVg90H21EOLACvtfcHk0lidr7KBr8sO_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVyit70%253D&md5=86fd66ce40fbec9375a114518e62f84e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.054%26sid%3Dliteratum%253Aachs%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DNkansah%26aufirst%3DN.%2BT.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520ligands%2520for%2520D2-like%2520receptors%253A%2520the%2520role%2520of%2520common%2520pharmacophoric%2520groups%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1716%26epage%3D1723%26doi%3D10.1016%2Fj.bmc.2008.12.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peprah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamango, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Further evaluation of the tropane analogs of haloperidol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4294</span>– <span class="NLM_lpage">4297</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmcl.2014.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=25070422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gku7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4294-4297&author=D.+Sampsonauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=K.+Peprahauthor=N.+S.+Lamangoauthor=V.+Setolaauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Further+evaluation+of+the+tropane+analogs+of+haloperidol&doi=10.1016%2Fj.bmcl.2014.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Further evaluation of the tropane analogs of haloperidol</span></div><div class="casAuthors">Sampson, Dinithia; Bricker, Barbara; Zhu, Xue Y.; Peprah, Kwakye; Lamango, Nazarius S.; Setola, Vincent; Roth, Bryan L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4294-4297</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous work from our labs has indicated that a tropane analog of haloperidol with potent D2 binding but designed to avoid the formation of MPP+-like metabolites, such as 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridin-1-ium (BCPP+) still produced catalepsy, suggesting a strong role for the D2 receptor in the prodn. of catalepsy in rats, and hence EPS in humans.  This study tested the hypothesis that further modifications of the tropane analog to produce compds. with less potent binding to the D2 receptor than haloperidol, would produce less catalepsy.  These tests have now revealed that while haloperidol produced max. catalepsy, these compds. produced moderate to low levels of catalepsy.  Compd. 9, with the least binding affinity to the D2R, produced the least catalepsy and highest Min. Adverse ED (MAED) of the analogs tested regardless of their affinities at other receptors including the 5-HT1AR.  These observations support the hypothesis that moderation of the D2 binding of the tropane analogs could reduce catalepsy potential in rats and consequently EPS in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5TyDvi6SZ3LVg90H21EOLACvtfcHk0liVyaguSi78jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gku7nN&md5=d8c0bf8678a620c5b6f2d6dc99ebb73b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DD.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DPeprah%26aufirst%3DK.%26aulast%3DLamango%26aufirst%3DN.%2BS.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DFurther%2520evaluation%2520of%2520the%2520tropane%2520analogs%2520of%2520haloperidol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4294%26epage%3D4297%26doi%3D10.1016%2Fj.bmcl.2014.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyles-Eggleston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrihkande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borne, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1021/jm0301033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0301033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=497-508&author=M.+Lyles-Egglestonauthor=R.+Altundasauthor=J.+Xiaauthor=D.+M.+Sikazweauthor=P.+Fanauthor=Q.+Yangauthor=S.+Liauthor=W.+Zhangauthor=X.+Zhuauthor=A.+W.+Schmidtauthor=M.+Vanase-Frawleyauthor=A.+Shrihkandeauthor=A.+Villalobosauthor=R.+F.+Borneauthor=S.+Y.+Ablordeppey&title=Design%2C+synthesis%2C+and+evaluation+of+metabolism-based+analogues+of+haloperidol+incapable+of+forming+MPP%2B-like+species&doi=10.1021%2Fjm0301033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species</span></div><div class="casAuthors">Lyles-Eggleston, M.; Altundas, R.; Xia, J.; Sikazwe, D. M. N.; Fan, P.; Yang, Q.; Li, S.; Zhang, W.; Zhu, X.; Schmidt, A. W.; Vanase-Frawley, M.; Shrihkande, A.; Villalobos, A.; Borne, R. F.; Ablordeppey, S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">497-508</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms.  More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects.  Because BCPP+ and its reduced analog have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, the authors have designed new analogs of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity.  The most potent agent at the D2 receptor, the homopiperidine analog was equipotent to haloperidol.  It was also of interest to identify analogs with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes.  Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by I [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 4-[3-(4-chlorophenyl)-3-hydroxymethylpyrrolidin-1-yl]-1-(4-fluorophenyl)butan-1-one [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2].  A preliminary in-vivo testing of I shows that its behavioral profile is similar to that of clozapine.  This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRXQrMaHciVrVg90H21EOLACvtfcHk0liVyaguSi78jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGks74%253D&md5=b59d2ba383504e51cd81a7007a68b2de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0301033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301033%26sid%3Dliteratum%253Aachs%26aulast%3DLyles-Eggleston%26aufirst%3DM.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DShrihkande%26aufirst%3DA.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DBorne%26aufirst%3DR.%2BF.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520metabolism-based%2520analogues%2520of%2520haloperidol%2520incapable%2520of%2520forming%2520MPP%252B-like%2520species%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D497%26epage%3D508%26doi%3D10.1021%2Fjm0301033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raviña, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casariego, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaguer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montenegro, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villazon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadavid, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demontis, G. C.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4678</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1021/jm0009890</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0009890" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVKhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4678-4693&author=E.+Ravi%C3%B1aauthor=I.+Casariegoauthor=C.+F.+Masaguerauthor=J.+A.+Fontenlaauthor=G.+Y.+Montenegroauthor=M.+E.+Rivasauthor=M.+I.+Lozaauthor=M.+J.+Enguixauthor=M.+Villazonauthor=M.+I.+Cadavidauthor=G.+C.+Demontis&title=Conformationally+constrained+butyrophenones+with+affinity+for+dopamine+%28D%281%29%2C+D%282%29%2C+D%284%29%29+and+serotonin+%285-HT%282A%29%2C+5-HT%282B%29%2C+5-HT%282C%29%29+receptors%3A+synthesis+of+aminomethylbenzo%5Bb%5Dfuranones+and+their+evaluation+as+antipsychotics&doi=10.1021%2Fjm0009890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally Constrained Butyrophenones with Affinity for Dopamine (D1, D2, D4) and Serotonin (5-HT2A, 5-HT2B, 5-HT2C) Receptors: Synthesis of Aminomethylbenzo[b]furanones and Their Evaluation as Antipsychotics</span></div><div class="casAuthors">Ravina, Enrique; Casariego, Isabel; Masaguer, Christian F.; Fontenla, Jose A.; Montenegro, Gisela Y.; Rivas, Maria E.; Loza, M. Isabel; Enguix, Maria J.; Villazon, Maria; Cadavid, Isabel; Demontis, Gian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4678-4693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel conformationally restricted butyrophenones [6-aminomethyl-4,5,6,7-tetrahydrobenzo[b]furan-4-ones bearing 4-(6-fluorobenzisoxazolyl)piperidine, 4-(p-fluorobenzoyl)piperidine, 4-(o-methoxyphenyl)piperazine, 4-(2-pyridyl)piperazine, 4-(2-pyrimidinyl)piperazine, or linear butyro(or valero)phenone fragments] were prepd. and evaluated as antipsychotic agents by in vitro assays for affinity for dopamine receptors (D1, D2, D4) and serotonin receptors (5-HT2A, 5-HT2B, 5-HT2C), by neurochem. studies, and by in vivo assays for antipsychotic potential and the risk of inducing extrapyramidal side effects.  Potency and selectivity depended mainly on the amine fragment connected to the cyclohexanone structure.  QF1003B [I,X = O, R = H] and QF1004B [I, XR = NO] were selective for 5-HT2A receptors.  The in vitro and in vivo pharmacol. profiles of QF1003B and QF1004B suggest that they may be effective as antipsychotic (neuroleptic) drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44HkA5dq_GrVg90H21EOLACvtfcHk0liVyaguSi78jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVKhsbo%253D&md5=e838ae49cfb18c3a6d17dc89ea444977</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0009890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0009890%26sid%3Dliteratum%253Aachs%26aulast%3DRavi%25C3%25B1a%26aufirst%3DE.%26aulast%3DCasariego%26aufirst%3DI.%26aulast%3DMasaguer%26aufirst%3DC.%2BF.%26aulast%3DFontenla%26aufirst%3DJ.%2BA.%26aulast%3DMontenegro%26aufirst%3DG.%2BY.%26aulast%3DRivas%26aufirst%3DM.%2BE.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DEnguix%26aufirst%3DM.%2BJ.%26aulast%3DVillazon%26aufirst%3DM.%26aulast%3DCadavid%26aufirst%3DM.%2BI.%26aulast%3DDemontis%26aufirst%3DG.%2BC.%26atitle%3DConformationally%2520constrained%2520butyrophenones%2520with%2520affinity%2520for%2520dopamine%2520%2528D%25281%2529%252C%2520D%25282%2529%252C%2520D%25284%2529%2529%2520and%2520serotonin%2520%25285-HT%25282A%2529%252C%25205-HT%25282B%2529%252C%25205-HT%25282C%2529%2529%2520receptors%253A%2520synthesis%2520of%2520aminomethylbenzo%255Bb%255Dfuranones%2520and%2520their%2520evaluation%2520as%2520antipsychotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm0009890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishinomiya, H. Y.</span>; <span class="NLM_string-name">Ashiya, T. O.</span>; <span class="NLM_string-name">Sasajima, K.</span>; <span class="NLM_string-name">Minoo, S. K.</span></span> <span> </span><span class="NLM_article-title">Butyrophenone Derivatives</span>. <span class="NLM_patent">US003907812</span>, <span class="NLM_year">1973</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1973&author=H.+Y.+Nishinomiya&author=T.+O.+Ashiya&author=K.+Sasajima&author=S.+K.+Minoo&title=Butyrophenone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNishinomiya%26aufirst%3DH.%2BY.%26atitle%3DButyrophenone%2520Derivatives%26date%3D1973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Westeringh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jageneau, A. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demoen, P. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, B. K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Daele, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Eycken, C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemegeers, C. J. E.</span></span> <span> </span><span class="NLM_article-title">Chemistry and pharmacology of CNS depressants related to 4-(4-Hydroxy-4-phenylpiperidino)butyrophenone. Part I--Synthesis and screening data in mice</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1021/jm50004a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50004a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaF3cXjsValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1959&pages=281-297&author=P.+A.+J.+Janssenauthor=C.+Van+De+Westeringhauthor=A.+H.+M.+Jageneauauthor=P.+J.+A.+Demoenauthor=B.+K.+F.+Hermansauthor=G.+H.+P.+Van+Daeleauthor=K.+H.+L.+Schellekensauthor=C.+A.+M.+Van+Der+Eyckenauthor=C.+J.+E.+Niemegeers&title=Chemistry+and+pharmacology+of+CNS+depressants+related+to+4-%284-Hydroxy-4-phenylpiperidino%29butyrophenone.+Part+I%2D%2DSynthesis+and+screening+data+in+mice&doi=10.1021%2Fjm50004a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice</span></div><div class="casAuthors">Janssen, Paul A. J.; van de Westeringh, Corn.; Jageneau, Anton H. M.; Demoen, Paul J. A.; Hermans, Bert K. F.; van Daele, Georges H. P.; Schellekens, Karel H. L.; van der Eycken, Cyriel A. M.; Niemegeers, Carlos J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-97</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">In general, 4-RC6H4CO(CH2)3N.CH2.CH2.C(OH)-(4-R'C6H4).CH2.CH2 (I) were prepd. by condensation in PhMe of Bz(CH2)3Cl (II) or 4-FC6H4CO(CH2)3Cl (III) with 4-R'C6H4C(OH).CH2.CH2.NH.CH2.CH2 (IV).  Cl(CH2)3CO-Cl (71 g.) in 70 ml. C6H6 underwent the Friedel-Craft reaction in the usual way with C6H6 (or PhF) to yield 80% II, b5 134-7°, n20D 1.541 (or 80-95% III, b6 136-42°, n20D 1.523.  IV were prepd, in 8 steps from α-methylstyrene (V) and its derivs. V (944 g.) added slowly at 60° to 856 g. NH4Cl in 3 1.1.36% H2CO, stirred until the temp. fell to 40°, 2 1. MeOH added, the mixt. stirred 20 hrs., MeOH removed in vacuo, the residue in 3 1. concd. HCl heated at 100°, cooled, dild. with 2 1. H2O, made alk. with 15N NaOH, and extd. with C6H6 yielded 46-50% 4-R'C6H4C:CH.CH2.NH.CH2.CH2 (VI) (R' = H), b1 97-112°, n25D 1.586, HCl salt m. 199-202°, λ 248 mμ (ε 11,700).  Other VI were similarly prepd.  from derivs. of V [R', b.p., λ (mμ) (ε) given]: F, 139-41°/4, 245.5 (10,100); Cl, 167-70°/8, 254.6 (14,100); Me, 162-70°/10, 251 (11,300).  Dry HBr gas passed 7 hrs. at 10-20 through a stirred soln. of 160 g. VI in 500 ml. AcOH, the mixt. kept 16 hrs. at room temp., AcOH and excess HBr removed in vacuo at 40°, and the residue taken up in ether and filtered yielded the HBr salt (VII) of 4-R'C6H4CBr.CH2.CH2.NH.CH2.CH2 (R', m.p. given): H, 209.5-10.5°; F, 143-4°; Cl, 213-15°; Me, 190-2°.  VII (160 g.) in 3 1. H2O was hydrolyzed with 20% NaOH to IV [R', m.p., λ (mμ) (ε) given]: H, 159-60°, 260 (225); F, 116.4-17.6°, 266 (815); Cl, 134.4-6.0°, 269.5 (460); Me, 136-7°, 265.5 (295).  II (8.7 g.) (or III) heated at 100-10° in a closed tube with 14.2 g. IV (R = R' = H), 0.1 g. KI, and 150 ml. PhMe, the cooled reaction mixt. filtered from the sepd. solid, and the filtrate concd. yielded 70% I, m. 129.4-30.6°, λ 246 mμ (ε 12,600), HCl salt m. 182-4°.  Other I were similarly prepd. [R, R', m.p., λ (mμ) (ε), m.p. of HCl salt given]: H, F, 117.4-18.6°, 245 (13,300), 188-90°; H, Cl, 128.2-30.2°, 245.5 (13,400), 216.5-18.0°; H, Me, 101-2.5°, 245 (13,000), 179.6-81.5°; F, H, 135.6-6.2°, 246.5 (12,500), 204.5-5.5.°; F, F, 120-1°, 247 (12,400), 201-3.5°; F, Cl, 148-9.4°, 247 (11,900), 226-7.5°; and F, Me, 118-19.5° 246.5 (12,200), 212-13°.  Some pharmacol. properties in mice of these 8 compds. of structure I were detd. and compared with those of 20 known CNS depressants.  All possessed potent CNS depressant effects in low doses.  Some relations between structure and potency were suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkU436feWFwrVg90H21EOLACvtfcHk0liyT3kL2OFSyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXjsValsw%253D%253D&md5=91eecf5660813684eb3b0ffe3cba2965</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm50004a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50004a007%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DVan%2BDe%2BWesteringh%26aufirst%3DC.%26aulast%3DJageneau%26aufirst%3DA.%2BH.%2BM.%26aulast%3DDemoen%26aufirst%3DP.%2BJ.%2BA.%26aulast%3DHermans%26aufirst%3DB.%2BK.%2BF.%26aulast%3DVan%2BDaele%26aufirst%3DG.%2BH.%2BP.%26aulast%3DSchellekens%26aufirst%3DK.%2BH.%2BL.%26aulast%3DVan%2BDer%2BEycken%26aufirst%3DC.%2BA.%2BM.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%2BE.%26atitle%3DChemistry%2520and%2520pharmacology%2520of%2520CNS%2520depressants%2520related%2520to%25204-%25284-Hydroxy-4-phenylpiperidino%2529butyrophenone.%2520Part%2520I--Synthesis%2520and%2520screening%2520data%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1959%26volume%3D1%26spage%3D281%26epage%3D297%26doi%3D10.1021%2Fjm50004a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leyva-Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrero-Antonino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Marqués, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Resayes, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corma, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the ortho/meta/para isomers of relevant pharmaceutical compounds by coupling a sonogashira reaction with a regioselective hydration</span>. <i>ACS Catal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1021/cs401075z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cs401075z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsleisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=722-731&author=A.+Leyva-P%C3%A9rezauthor=J.+R.+Cabrero-Antoninoauthor=P.+Rubio-Marqu%C3%A9sauthor=S.+I.+Al-Resayesauthor=A.+Corma&title=Synthesis+of+the+ortho%2Fmeta%2Fpara+isomers+of+relevant+pharmaceutical+compounds+by+coupling+a+sonogashira+reaction+with+a+regioselective+hydration&doi=10.1021%2Fcs401075z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the ortho/meta/para Isomers of Relevant Pharmaceutical Compounds by Coupling a Sonogashira Reaction with a Regioselective Hydration</span></div><div class="casAuthors">Leyva-Perez, Antonio; Cabrero-Antonino, Jose R.; Rubio-Marques, Paula; Al-Resayes, Saud I.; Corma, Avelino</div><div class="citationInfo"><span class="NLM_cas:title">ACS Catalysis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722-731</span>CODEN:
                <span class="NLM_cas:coden">ACCACS</span>;
        ISSN:<span class="NLM_cas:issn">2155-5435</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryl ketones substituted in ortho, meta, and para position are prepd. by a palladium-catalyzed Sonogashira reaction followed by a regioselective hydration of the so-formed alkyne with triflimidic acid or a gold catalyst, under catalytic conditions.  This methodol. opens a way to obtain substituted aryl alkyl ketones from readily available starting materials, haloarenes, and terminal alkynes.  The syntheses of the different regioisomers of haloperidol, melperone, pipamperone, and ibuprofen are presented.  Structure-activity relationships for these compds. are studied with dopaminergic and cyclooxygenase binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvGpQwBqp_bVg90H21EOLACvtfcHk0li-chOhomSkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsleisw%253D%253D&md5=fed8458f579052ef029ca9fdb5ae5508</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fcs401075z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcs401075z%26sid%3Dliteratum%253Aachs%26aulast%3DLeyva-P%25C3%25A9rez%26aufirst%3DA.%26aulast%3DCabrero-Antonino%26aufirst%3DJ.%2BR.%26aulast%3DRubio-Marqu%25C3%25A9s%26aufirst%3DP.%26aulast%3DAl-Resayes%26aufirst%3DS.%2BI.%26aulast%3DCorma%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520the%2520ortho%252Fmeta%252Fpara%2520isomers%2520of%2520relevant%2520pharmaceutical%2520compounds%2520by%2520coupling%2520a%2520sonogashira%2520reaction%2520with%2520a%2520regioselective%2520hydration%26jtitle%3DACS%2520Catal.%26date%3D2014%26volume%3D4%26spage%3D722%26epage%3D731%26doi%3D10.1021%2Fcs401075z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrokhzad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diksic, M.</span></span> <span> </span><span class="NLM_article-title">The syntheses of no-carrier-added and carrier-added 18F-labelled haloperidol</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1002/jlcr.2580220713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fjlcr.2580220713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL28Xks1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=721-733&author=S.+Farrokhzadauthor=M.+Diksic&title=The+syntheses+of+no-carrier-added+and+carrier-added+18F-labelled+haloperidol&doi=10.1002%2Fjlcr.2580220713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The syntheses of no-carrier-added and carrier-added fluorine-18-labeled haloperidol</span></div><div class="casAuthors">Farrokhzad, Simin; Diksic, Mirko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">721-33</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    </div><div class="casAbstract">Title compd. I (R = 18F) (II) was prepd. by substitution reactions of I (R = Cl, F) with Bu4N+ 18F- in DMSO.  Alternatively, treatment of 4-O2NC6H4CN or 4-ClC6H4CN with Bu4N+ 18F- in DMSO gave 4-18FC6H4CN, which underwent successive condensation with cyclopropyllithium, ring cleavage by HBr or HCl, and amination by 4-(4-chlorophenyl)-4-piperidinol to give II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKTM0lA_SReLVg90H21EOLACvtfcHk0li-chOhomSkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xks1Snu7s%253D&md5=409d6af72130744311ad8a211b431089</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.2580220713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.2580220713%26sid%3Dliteratum%253Aachs%26aulast%3DFarrokhzad%26aufirst%3DS.%26aulast%3DDiksic%26aufirst%3DM.%26atitle%3DThe%2520syntheses%2520of%2520no-carrier-added%2520and%2520carrier-added%252018F-labelled%2520haloperidol%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1985%26volume%3D22%26spage%3D721%26epage%3D733%26doi%3D10.1002%2Fjlcr.2580220713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-J.</span></span> <span> </span><span class="NLM_article-title">Metal-free Markovnikov-type alkyne hydration under mild conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2187</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b00801</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b00801" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVylsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=2184-2187&author=W.+Liuauthor=H.+Wangauthor=C.-J.+Li&title=Metal-free+Markovnikov-type+alkyne+hydration+under+mild+conditions&doi=10.1021%2Facs.orglett.6b00801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Metal-Free Markovnikov-Type Alkyne Hydration under Mild Conditions</span></div><div class="casAuthors">Liu, Wenbo; Wang, Haining; Li, Chao-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2184-2187</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Markovnikov-type alkyne hydration protocol is presented using 20% F3CSO3H (TfOH) as the catalyst under unprecedented mild conditions applicable to various alkynes, including terminal arylalkynes, terminal nonfunctionalized aliph. alkynes, and internal alkynes with excellent regioselectivity in good to excellent yields (av. yields >85%).  The reaction procedure operates under mild conditions (25-70°), with broad functional group compatibility, and uses only slightly more than a stoichiometric amt. of water in the absence of any transition metal.  The success of this protocol hinges upon the utilization of trifluoroethanol as the solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmF2dw_nhbh7Vg90H21EOLACvtfcHk0li-chOhomSkqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVylsro%253D&md5=1a9fcf604ffb49af6ffd7c5b6a6c1de5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b00801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b00801%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.-J.%26atitle%3DMetal-free%2520Markovnikov-type%2520alkyne%2520hydration%2520under%2520mild%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D2184%26epage%3D2187%26doi%3D10.1021%2Facs.orglett.6b00801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peprah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2011.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22245230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1291-1297&author=K.+Peprahauthor=X.+Y.+Zhuauthor=S.+V.+K.+Eyunniauthor=V.+Setolaauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Multi-receptor+drug+design%3A+Haloperidol+as+a+scaffold+for+the+design+and+synthesis+of+atypical+antipsychotic+agents&doi=10.1016%2Fj.bmc.2011.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents</span></div><div class="casAuthors">Peprah, Kwakye; Zhu, Xue Y.; Eyunni, Suresh V. K.; Setola, Vincent; Roth, Bryan L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1291-1297</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors assocd. with atypical antipsychotic pharmacol.  It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest.  This strategy has resulted in the identification of several new agents, compds. 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics.  This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors assocd. with antipsychotic pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxSs13DajzXLVg90H21EOLACvtfcHk0ljNOnt0t-oVPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSht7c%253D&md5=10cf70b7fe6d5d7fa05967e66e928aa5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DPeprah%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BV.%2BK.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DMulti-receptor%2520drug%2520design%253A%2520Haloperidol%2520as%2520a%2520scaffold%2520for%2520the%2520design%2520and%2520synthesis%2520of%2520atypical%2520antipsychotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1291%26epage%3D1297%26doi%3D10.1016%2Fj.bmc.2011.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinciguerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurdanella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporarello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anfuso, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic effect of (±)-haloperidol metabolite II valproate ester [(±)-MRJF22] in human microvascular retinal endothelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9960</span>– <span class="NLM_lpage">9966</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9960-9966&author=M.+Olivieriauthor=E.+Amataauthor=S.+Vinciguerraauthor=J.+Fioritoauthor=G.+Giurdanellaauthor=F.+Dragoauthor=N.+Caporarelloauthor=O.+Prezzaventoauthor=E.+Arenaauthor=L.+Salernoauthor=A.+Rescifinaauthor=G.+Lupoauthor=C.+D.+Anfusoauthor=A.+Marrazzo&title=Antiangiogenic+effect+of+%28%C2%B1%29-haloperidol+metabolite+II+valproate+ester+%5B%28%C2%B1%29-MRJF22%5D+in+human+microvascular+retinal+endothelial+cells&doi=10.1021%2Facs.jmedchem.6b01039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells</span></div><div class="casAuthors">Olivieri, Melania; Amata, Emanuele; Vinciguerra, Shila; Fiorito, Jole; Giurdanella, Giovanni; Drago, Filippo; Caporarello, Nunzia; Prezzavento, Orazio; Arena, Emanuela; Salerno, Loredana; Rescifina, Antonio; Lupo, Gabriella; Anfuso, Carmelina Daniela; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9960-9966</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(±)-MRJF22 [(±)-2], a novel prodrug of haloperidol metabolite II (sigma-1 receptor antagonist/sigma-2 receptor agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human retinal endothelial cell (HREC) viability in a comparable manner to bevacizumab.  Moreover, (±)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube formation in vascular endothelial growth factor A (VEGF-A) stimulated HREC cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJedDLZWd8jbVg90H21EOLACvtfcHk0ljNOnt0t-oVPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P&md5=f0a092eedd76c583f4dabaa7151774c4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01039%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DM.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DVinciguerra%26aufirst%3DS.%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DGiurdanella%26aufirst%3DG.%26aulast%3DDrago%26aufirst%3DF.%26aulast%3DCaporarello%26aufirst%3DN.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DLupo%26aufirst%3DG.%26aulast%3DAnfuso%26aufirst%3DC.%2BD.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3DAntiangiogenic%2520effect%2520of%2520%2528%25C2%25B1%2529-haloperidol%2520metabolite%2520II%2520valproate%2520ester%2520%255B%2528%25C2%25B1%2529-MRJF22%255D%2520in%2520human%2520microvascular%2520retinal%2520endothelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9960%26epage%3D9966%26doi%3D10.1021%2Facs.jmedchem.6b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reymer, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigeni, V.</span></span> <span> </span><span class="NLM_article-title">Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1906</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1021/jm00393a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00393a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL2sXmtlKntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1906-1910&author=M.+A.+Iorioauthor=T.+P.+Reymerauthor=V.+Frigeni&title=Combined+analgesic%2Fneuroleptic+activity+in+N-butyrophenone+prodine-like+compounds&doi=10.1021%2Fjm00393a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds</span></div><div class="casAuthors">Iorio, M. A.; Paszkowska Reymer, T.; Frigeni, V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-10</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Some 4-phenyl-4-piperidinols I (R = H, HO, EtCO2; R1 = H, Me) synthesized and evaluated in vitro and in vivo tests in order to examine their ability to interact contemporaneously with opioid and dopamine receptors.  The propionyloxy derivs. showed a good combination of analgesic and neuroleptic activity.  With a 3-Me substituent on the piperidine ring, the β-configuration was the more active form not only for analgesic activity, as expected from previous results on prodines, but also for neuroleptic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcgsF-xoet7Vg90H21EOLACvtfcHk0ljNOnt0t-oVPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtlKntbo%253D&md5=84c6d73b0e7a630e1dcf62653923c83d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm00393a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00393a037%26sid%3Dliteratum%253Aachs%26aulast%3DIorio%26aufirst%3DM.%2BA.%26aulast%3DReymer%26aufirst%3DT.%2BP.%26aulast%3DFrigeni%26aufirst%3DV.%26atitle%3DCombined%2520analgesic%252Fneuroleptic%2520activity%2520in%2520N-butyrophenone%2520prodine-like%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1906%26epage%3D1910%26doi%3D10.1021%2Fjm00393a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=4724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE28XktVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1976&pages=251-262&author=L.+L.+Iversenauthor=M.+A.+Rogawskiauthor=R.+J.+Miller&title=Comparison+of+the+effects+of+neuroleptic+drugs+on+pre-+and+postsynaptic+dopaminergic+mechanisms+in+the+rat+striatum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum</span></div><div class="casAuthors">Iversen, L. L.; Rogawski, M. A.; Miller, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-62</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Neuroleptic drugs of various chem. classes were compared as inhibitors of postsynaptic dopamine-sensitive adenylate cyclase [9012-42-4] in rat striatum and for their ability to influence a variety of presyaptic mechanisms in the dopaminergic nerve terminals in the striatum.  Sixteen chem. analogs of the butyrophenone, haloperidol-HCl (I-HCl) [1511-16-6] were tested on the dopamine-sensitive adenylate cyclase, and the results showed a good correlation between inhibitory potency in the system and the known effects of these compds. as(-)-apomorphine-HCl [314-19-2] antagonists in vivo.  In intact synaptosome prepns. from rat striatum, (-)-apomorphine-HCl was a potent inhibitor (IC50 = 0.2 μM) of the conversion of tritiated tyrosine to catechols.  Other dopaminemimetic drugs [epinine [501-15-5], dopamine [51-61-6], 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) [53463-78-8]] also had similar inhibitory effects, although the α adrenoceptor agonist (-)-phenylephrine [59-42-7] and the β agonist (±)-isoprenaline [7683-59-2] were also inhibitory at higher concns.  The inhibitory actions of dopamine, epinine, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene(ADTN), and (+)- [149-95-1] and (-)-noradrenaline [51-41-2] were significantly reduced by the addn. of the dopamine uptake inhibitor, benztropine, suggesting that they act at least in part by inhibition of intrasynaptosomal tyrosine hydroxylase [9036-22-0] after uptake into dopaminergic terminals.  The effects of apomorphine, however, were unaffected by benztropine, suggesting a direct action on presynaptic autoreceptors at dopaminergic terminals.  All the compds. tested were at least 50 times less potent as inhibitors of free tyrosine hydroxylase in detergent-contg. striatal homogenates.  The inhibitory effects of apomorphine on synaptosomal catechol synthesis were partially reversed by various neuroleptic drugs, and this appeared to be due to a competitive interaction between the neuroleptic drugs and apomorphine at the presynaptic receptor sites.  The neuroleptics, however, also tended to inhibit catechol synthesis by themselves.  I, spiroperidol [749-02-0], and pimozide [2062-78-4] were particularly potent in reversing the presynaptic actions of apomorphine on catechol formation, being active at concns. between 10 and 100 nM.  Neuroleptics also had some activity as inhibitors of tritiated dopamine uptake and as dopamine releasers in striatal synaptosomes.  They also antagonized the evoked release of tritiated dopamine elicited by protoveratrine.  None of these effects, however, occurred at very low drug concns., and the butyrophenones were no more potent than chlorpromazine [50-53-3].  Thus, neuroleptics possess action on both pre- and postsynaptic sites in the striatum, but the postsynaptic blocking action on dopamine receptors appears to be more crucial for the clin. activity of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnXiHijtl8W7Vg90H21EOLACvtfcHk0ljq0a2IKxPzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XktVShsb8%253D&md5=5c395b324ac284baedd47765e55e18b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIversen%26aufirst%3DL.%2BL.%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BJ.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520neuroleptic%2520drugs%2520on%2520pre-%2520and%2520postsynaptic%2520dopaminergic%2520mechanisms%2520in%2520the%2520rat%2520striatum%26jtitle%3DMol.%2520Pharmacol.%26date%3D1976%26volume%3D12%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span> <span> </span><span class="NLM_article-title">Ni-catalyzed stereoselective arylation of inert C-O bonds at low temperatures</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6298</span>– <span class="NLM_lpage">6301</span>, <span class="refDoi"> DOI: 10.1021/ol4031815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4031815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=6298-6301&author=J.+Cornellaauthor=R.+Martin&title=Ni-catalyzed+stereoselective+arylation+of+inert+C-O+bonds+at+low+temperatures&doi=10.1021%2Fol4031815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ni-Catalyzed Stereoselective Arylation of Inert C-O bonds at Low Temperatures</span></div><div class="casAuthors">Cornella, Josep; Martin, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6298-6301</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Ni-catalyzed arylation of inert C-O bonds that operates at temps. as low as -40°C is described.  Unlike other methods for C-O bond cleavage utilizing organometallic species, this protocol operates at low temps., thus allowing the presence of sensitive functional groups with exquisite site-selectivity and stereoselectivity.  Thus, e.g., arylation/C-O bond cleavage of 2,3-dihydrofuran with PhMgBr in presence of Ni NHC complex and LiCl afforded quant. (Z)-4-phenyl-3-buten-1-ol at -30°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkz_msEy_aV7Vg90H21EOLACvtfcHk0ljq0a2IKxPzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL3P&md5=5e8c0526cfb4e2c22f18b5cde62163c7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fol4031815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4031815%26sid%3Dliteratum%253Aachs%26aulast%3DCornella%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DR.%26atitle%3DNi-catalyzed%2520stereoselective%2520arylation%2520of%2520inert%2520C-O%2520bonds%2520at%2520low%2520temperatures%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D6298%26epage%3D6301%26doi%3D10.1021%2Fol4031815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span> <span> </span><span class="NLM_article-title">A new synthesis of cyclopropanes from olefins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">5323</span>– <span class="NLM_lpage">5324</span>, <span class="refDoi"> DOI: 10.1021/ja01552a080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01552a080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaG1MXjvFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1958&pages=5323-5324&author=H.+E.+Simmonsauthor=R.+D.+Smith&title=A+new+synthesis+of+cyclopropanes+from+olefins&doi=10.1021%2Fja01552a080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthesis of cyclopropanes from olefins</span></div><div class="casAuthors">Simmons, Howard E.; Smith, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5323-4</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. Howard, C.A. 34, 62153.  A versatile, stereospecific synthesis is reported of cyclopropanes by the reaction of unsatd. compds. with CH2I2 and a Zn-Cu couple.  Cyclohexene (0.30 mole), 0.15 mole CH2I2, and Zn-Cu couple (0.22 mole Zn) refluxed 48 hrs. in Et2O and the product distd. yielded 48% pure bicyclo[4.1.0] heptane, b. 116.5°, n25D 1.4546.  Many functionally substituted olefins gave the corresponding cyclopropanes.  Yields (10-70%) depended greatly on the kind of couple used and in no case were isomeric or rearranged products encountered (starting compd., product, and % yield given): C2H4, cyclopropane, 29; cyclopentene, bicyclo[3.1.0]hexane, 27; bicyclo[2.2.1] hept-2-ene, tricyclo[3,2,1,0]octane, 47; PhCH2CH:CH2, benzylcyclopropane, 49; PhCH:CH2, phenylcyclopropane, 32; ο-MeOC6H4CH:CHMe, 1-(ο-methoxyphenyl)-2-methylcyclopropane, 70; MeCH:CHCO2Me, Me 2-methyl-cyclopropanecarboxylate, 9; AcOCH:CH2, cyclopropyl acetate, 31.  Ethereal solns. from the reaction of the Zn-Cu couple contained ICH2ZnI.  Mechanisms for the reaction are discussed.  The stereospecificity of the reaction is indicated by the following reactions: cis-EtCH:CHEt yielded 35.5% pure cis-1,2-diethylcyclopropane, b. 93.5°, n25D 1.4035; trans-EtCH:CHEt yielded 15.5% trans-1,2-diethylcyclopropane, b. 86.5°, n25D 1.3982.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpnVTzAYovLVg90H21EOLACvtfcHk0ljq0a2IKxPzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXjvFKgug%253D%253D&md5=06d71e46354becf7287751ac835f51f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja01552a080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01552a080%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DH.%2BE.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26atitle%3DA%2520new%2520synthesis%2520of%2520cyclopropanes%2520from%2520olefins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1958%26volume%3D80%26spage%3D5323%26epage%3D5324%26doi%3D10.1021%2Fja01552a080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, K. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, V. M.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-directed ketone hydroacylation: Enantioselective synthesis of benzoxazecinones</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1039/C0SC00469C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1039%2FC0SC00469C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=407-410&author=H.+A.+Khanauthor=K.+G.+M.+Kouauthor=V.+M.+Dong&title=Nitrogen-directed+ketone+hydroacylation%3A+Enantioselective+synthesis+of+benzoxazecinones&doi=10.1039%2FC0SC00469C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrogen-directed ketone hydroacylation: Enantioselective synthesis of benzoxazecinones</span></div><div class="casAuthors">Khan, Hasan A.; Kou, Kevin G. M.; Dong, Vy M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A method for a nitrogen-directed ketone hydroacylation is reported to furnish eight-membered nitrogen-contg. lactone (benzoxazecinone) derivs. in high yield and high enantiomeric excess.  In a model study, a comparison was made between nitrogen, oxygen and sulfur directing groups and it was found that nitrogen promoted faster hydroacylation.  By this catalytic transformation the synthesis of the target compds. (i.e., nitrogen heterocyclic compds., benzoxazepinone derivs. and benzoxazecinone derivs.) was achieved and it was discovered that, moreover, an amine-directing group completely suppressed a competitive decarbonylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSb9rhRu1TZ7Vg90H21EOLACvtfcHk0ljq0a2IKxPzTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvV2isr4%253D&md5=75287a2eaa1323632b47b2fe4bcb3bbd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC0SC00469C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00469C%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DH.%2BA.%26aulast%3DKou%26aufirst%3DK.%2BG.%2BM.%26aulast%3DDong%26aufirst%3DV.%2BM.%26atitle%3DNitrogen-directed%2520ketone%2520hydroacylation%253A%2520Enantioselective%2520synthesis%2520of%2520benzoxazecinones%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D407%26epage%3D410%26doi%3D10.1039%2FC0SC00469C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komissarov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knyazhanskaya, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrokhova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottikh, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kritzyn, A. M.</span></span> <span> </span><span class="NLM_article-title">The search of novel inhibitors of HIV-1 integrase among 5-(4-halogenophenyl)-5-oxopentyl derivatives of nucleic bases</span>. <i>Russ. J. Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1134/S1068162014050094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1134%2FS1068162014050094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCisLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=532-540&author=V.+V.+Komissarovauthor=E.+S.+Knyazhanskayaauthor=A.+V.+Atrokhovaauthor=M.+B.+Gottikhauthor=A.+M.+Kritzyn&title=The+search+of+novel+inhibitors+of+HIV-1+integrase+among+5-%284-halogenophenyl%29-5-oxopentyl+derivatives+of+nucleic+bases&doi=10.1134%2FS1068162014050094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The search of novel inhibitors of HIV-1 integrase among 5-(4-halogenophenyl)-5-oxopentyl derivatives of nucleic bases</span></div><div class="casAuthors">Komissarov, V. V.; Knyazhanskaya, E. S.; Atrokhova, A. V.; Gottikh, M. B.; Kritzyn, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-540</span>CODEN:
                <span class="NLM_cas:coden">RJBCET</span>;
        ISSN:<span class="NLM_cas:issn">1068-1620</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">New nucleic base derivs. were obtained by alkylation of uracil, thymine, cytosine, adenine, 6-chloropurine, and 2-amino-6-chloropurine with 5-chloro-1-(4-halogenophenyl)-1-pentanones, and their phys. and chem. properties were studied.  The influence of the compds. synthesized on the HIV-1 integrase activity was studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOZOAc_VtHdLVg90H21EOLACvtfcHk0ljgPQbpvbIhnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCisLjN&md5=c66f6a30b8f3d093b430e5c2bc5eda5a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1134%2FS1068162014050094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1068162014050094%26sid%3Dliteratum%253Aachs%26aulast%3DKomissarov%26aufirst%3DV.%2BV.%26aulast%3DKnyazhanskaya%26aufirst%3DE.%2BS.%26aulast%3DAtrokhova%26aufirst%3DA.%2BV.%26aulast%3DGottikh%26aufirst%3DM.%2BB.%26aulast%3DKritzyn%26aufirst%3DA.%2BM.%26atitle%3DThe%2520search%2520of%2520novel%2520inhibitors%2520of%2520HIV-1%2520integrase%2520among%25205-%25284-halogenophenyl%2529-5-oxopentyl%2520derivatives%2520of%2520nucleic%2520bases%26jtitle%3DRuss.%2520J.%2520Bioorg.%2520Chem.%26date%3D2014%26volume%3D40%26spage%3D532%26epage%3D540%26doi%3D10.1134%2FS1068162014050094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Visible light-promoted ring-opening functionalization of unstrained cycloalkanols via inert C–C bond scission</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5805</span>– <span class="NLM_lpage">5809</span>, <span class="refDoi"> DOI: 10.1039/C8SC01763H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1039%2FC8SC01763H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=30079191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5805-5809&author=D.+Wangauthor=J.+Maoauthor=C.+Zhu&title=Visible+light-promoted+ring-opening+functionalization+of+unstrained+cycloalkanols+via+inert+C%E2%80%93C+bond+scission&doi=10.1039%2FC8SC01763H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Visible light-promoted ring-opening functionalization of unstrained cycloalkanols via inert C-C bond scission</span></div><div class="casAuthors">Wang, Dongping; Mao, Jincheng; Zhu, Chen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5805-5809</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A novel, useful, visible light-promoted ring-opening functionalization of unstrained cycloalkanols was described.  Upon scission of an inert cyclic C-C σ-bond, a set of medium- and large-sized rings were readily brominated under mild reaction conditions to afford the corresponding distal bromo-substituted alkyl ketones that were hard to synthesize otherwise.  The products were versatile building blocks, which were easily converted to other valuable mols. in one-step operation.  This protocol was also applicable to the unprecedented ring-opening cyanation and alkynylation of unstrained cycloalkanols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXWSzS0exWbVg90H21EOLACvtfcHk0ljgPQbpvbIhnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtbvO&md5=a6c46e60203c1d9fb6bea7cb5503df5a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC8SC01763H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01763H%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DC.%26atitle%3DVisible%2520light-promoted%2520ring-opening%2520functionalization%2520of%2520unstrained%2520cycloalkanols%2520via%2520inert%2520C%25E2%2580%2593C%2520bond%2520scission%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D5805%26epage%3D5809%26doi%3D10.1039%2FC8SC01763H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tummatorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploypradith, P.</span></span> <span> </span><span class="NLM_article-title">A convergent general strategy for the functionalized 2-aryl cycloalkyl-fused chromans: intramolecular hetero-Diels–Alder reactions of ortho-quinone methides</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1448</span>, <span class="refDoi"> DOI: 10.1002/chem.200902403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fchem.200902403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=20039342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1445-1448&author=J.+Tummatornauthor=S.+Ruchirawatauthor=P.+Ploypradith&title=A+convergent+general+strategy+for+the+functionalized+2-aryl+cycloalkyl-fused+chromans%3A+intramolecular+hetero-Diels%E2%80%93Alder+reactions+of+ortho-quinone+methides&doi=10.1002%2Fchem.200902403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A Convergent General Strategy for the Functionalized 2-Aryl Cycloalkyl-Fused Chromans: Intramolecular Hetero-Diels-Alder Reactions of ortho-Quinone Methides</span></div><div class="casAuthors">Tummatorn, Jumreang; Ruchirawat, Somsak; Ploypradith, Poonsakdi</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1445-1448, S1445/1-S1445/44</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A highly efficient and general strategy for the synthesis of cycloalkyl-fused chromans by o-QM/HDA reactions mediated by p-toluenesulfonic acid immobilized on silica (PTS-Si) is described.  The use of PTS-Si in toluene was crit. to suppress styrene polymn.  All stereocenters at C2, C3, and C4 were installed with good to excellent stereocontrol in a single step.  E.g., treatment of precursor I with NaBH4, AcCl, DMAP, then PTS-Si, gave 50% chroman deriv. II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbARkQIYb37rVg90H21EOLACvtfcHk0ljgPQbpvbIhnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsrs%253D&md5=e2025bdbc3599e6cfdb90e7b35ef4ecf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fchem.200902403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200902403%26sid%3Dliteratum%253Aachs%26aulast%3DTummatorn%26aufirst%3DJ.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPloypradith%26aufirst%3DP.%26atitle%3DA%2520convergent%2520general%2520strategy%2520for%2520the%2520functionalized%25202-aryl%2520cycloalkyl-fused%2520chromans%253A%2520intramolecular%2520hetero-Diels%25E2%2580%2593Alder%2520reactions%2520of%2520ortho-quinone%2520methides%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26spage%3D1445%26epage%3D1448%26doi%3D10.1002%2Fchem.200902403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span> <span> </span><span class="NLM_article-title">Catalyst-free annulation of 2-pyridylacetates and ynals with molecular oxygen: an access to 3-acylated indolizines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b02883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b02883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=1630-1639&author=Z.+Chenauthor=P.+Liangauthor=X.+Maauthor=H.+Luoauthor=G.+Xuauthor=T.+Liuauthor=X.+Wenauthor=J.+Zhengauthor=H.+Ye&title=Catalyst-free+annulation+of+2-pyridylacetates+and+ynals+with+molecular+oxygen%3A+an+access+to+3-acylated+indolizines&doi=10.1021%2Facs.joc.8b02883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Catalyst-Free Annulation of 2-Pyridylacetates and Ynals with Molecular Oxygen: An Access to 3-Acylated Indolizines</span></div><div class="casAuthors">Chen, Zhengwang; Liang, Pei; Ma, Xiaoyue; Luo, Haiqing; Xu, Guohai; Liu, Tanggao; Wen, Xiaowei; Zheng, Jing; Ye, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1630-1639</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalyst and additive-free annulation of 2-pyridylacetates and ynals under mol. oxygen was the first developed, affording 3-acylated indolizines in good to excellent yields.  Mol. oxygen was used as the source of the carbonyl oxygen atom in indolizines.  This approach was compatible with a wide range of functional groups, and esp. it has been successfully extended to unsatd. double bonds and triple bonds, which were difficult to prep. by previous methods in a single step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr683h-yftqv7Vg90H21EOLACvtfcHk0liDlcH--euHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslClsw%253D%253D&md5=42003dafba29fc276f3ca5f2019f7ca5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b02883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b02883%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DH.%26atitle%3DCatalyst-free%2520annulation%2520of%25202-pyridylacetates%2520and%2520ynals%2520with%2520molecular%2520oxygen%253A%2520an%2520access%2520to%25203-acylated%2520indolizines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D1630%26epage%3D1639%26doi%3D10.1021%2Facs.joc.8b02883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristianslund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aursnes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. V.</span></span> <span> </span><span class="NLM_article-title">Squaramide catalyzed enantioselective iodolactonization of allenoic acids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5232</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2016.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.tetlet.2016.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=5232-5236&author=R.+Kristianslundauthor=M.+Aursnesauthor=J.+E.+Tungenauthor=T.+V.+Hansen&title=Squaramide+catalyzed+enantioselective+iodolactonization+of+allenoic+acids&doi=10.1016%2Fj.tetlet.2016.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramide catalyzed enantioselective iodolactonization of allenoic acids</span></div><div class="casAuthors">Kristianslund, Renate; Aursnes, Marius; Tungen, Joern Eivind; Hansen, Trond Vidar</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">5232-5236</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An asym. iodolactonization reaction of allenoic acids has been extensively studied.  Eight different chiral squaramides were prepd. in a straightforward manner and investigated as organocatalysts.  The reaction protocol is operationally simple to execute and proceeds with up to 76% enantiomeric excess.  Several conditions, additives, catalysts, and substrates have been investigated.  The best results were obsd. with 3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-(((1R,2R)-2-(dipentylamino)cyclohexyl)amino)-cyclobut-3-ene-1,2-dione as the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx8dRE5nS7wLVg90H21EOLACvtfcHk0liDlcH--euHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGitrjE&md5=e786253a43dce700392584a607615be2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2016.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2016.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DKristianslund%26aufirst%3DR.%26aulast%3DAursnes%26aufirst%3DM.%26aulast%3DTungen%26aufirst%3DJ.%2BE.%26aulast%3DHansen%26aufirst%3DT.%2BV.%26atitle%3DSquaramide%2520catalyzed%2520enantioselective%2520iodolactonization%2520of%2520allenoic%2520acids%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D5232%26epage%3D5236%26doi%3D10.1016%2Fj.tetlet.2016.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1021/tx00019a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00019a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaK3MXnsFSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=123-128&author=B.+Subramanyamauthor=T.+Woolfauthor=N.+Castagnoli&title=Studies+on+the+in+vitro+conversion+of+haloperidol+to+a+potentially+neurotoxic+pyridinium+metabolite&doi=10.1021%2Ftx00019a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite</span></div><div class="casAuthors">Subramanyam, Babu; Woolf, Thomas; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-8</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">Evidence that partially oxidized piperidine derivs. such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats.  The present in vitro studies examine the metabolic pathway governing this overall four-electron oxidn.  Although haloperidol and its 1,2,3,6-tetrahydropyridine dehydration product were not substrates for purified bovine liver MAO-B, both compds. were biotransformed to the pyridinium product by rat liver microsomal prepns.  The dependence on NADPH and the inhibition by SKF-525A argue that one or more liver cytochrome P 450 isoenzymes may catalyze this transformation.  Attempts to detect possible metabolic intermediates were not successful.  Chem. model studies however, suggest that the expected intermediary amino enol and dihydropyridinium species may be too unstable to isolate.  The possible significance of this pathway with respect to haloperidol-induced central nervous system dysfunction is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp65KQZwtgo8bVg90H21EOLACvtfcHk0liDlcH--euHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnsFSksA%253D%253D&md5=35ff88549b6900cc5bdb9f4da1709f58</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Ftx00019a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00019a017%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DWoolf%26aufirst%3DT.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DStudies%2520on%2520the%2520in%2520vitro%2520conversion%2520of%2520haloperidol%2520to%2520a%2520potentially%2520neurotoxic%2520pyridinium%2520metabolite%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1991%26volume%3D4%26spage%3D123%26epage%3D128%26doi%3D10.1021%2Ftx00019a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuriev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span> <span> </span><span class="NLM_article-title">Ligand binding pathways of clozapine and haloperidol in the dopamine D2 and D3 receptors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=308-321&author=T.+Thomasauthor=Y.+Fangauthor=E.+Yurievauthor=D.+K.+Chalmers&title=Ligand+binding+pathways+of+clozapine+and+haloperidol+in+the+dopamine+D2+and+D3+receptors&doi=10.1021%2Facs.jcim.5b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Binding Pathways of Clozapine and Haloperidol in the Dopamine D2 and D3 Receptors</span></div><div class="casAuthors">Thomas, Trayder; Fang, Yu; Yuriev, Elizabeth; Chalmers, David K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-321</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The binding of a small mol. ligand to its protein target is most often characterized by binding affinity and is typically viewed as an on/off switch.  The more complex reality is that binding involves the ligand passing through a series of intermediate states between the soln. phase and the fully bound pose.  We have performed a set of 29 unbiased mol. dynamics simulations to model the binding pathways of the dopamine receptor antagonists clozapine and haloperidol binding to the D2 and D3 dopamine receptors.  Through these simulations we have captured the binding pathways of clozapine and haloperidol from the extracellular vestibule to the orthosteric binding site and thereby, we also predict the bound pose of each ligand.  These are the first long time scale simulations of haloperidol or clozapine binding to dopamine receptors.  From these simulations, we have identified several important stages in the binding pathway, including the involvement of Tyr7.35 in a "handover" mechanism that transfers the ligand between the extracellular vestibule and Asp3.32.  We have also performed interaction and cluster analyses to det. differences in binding pathways between the D2 and D3 receptors and identified metastable states that may be of use in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpimYd-xEW9a7Vg90H21EOLACvtfcHk0liDlcH--euHGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiurzO&md5=b5faf13609b11b8efcfebd3eb5f0a77e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00457%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26atitle%3DLigand%2520binding%2520pathways%2520of%2520clozapine%2520and%2520haloperidol%2520in%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D308%26epage%3D321%26doi%3D10.1021%2Facs.jcim.5b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalani, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanino, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freddolino, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalani, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floriano, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kam, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, W. A.,  3rd</span></span> <span> </span><span class="NLM_article-title">The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3820</span>, <span class="refDoi"> DOI: 10.1073/pnas.0400100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1073%2Fpnas.0400100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=14999101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Kgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3815-3820&author=M.+Y.+Kalaniauthor=N.+Vaidehiauthor=S.+E.+Hallauthor=R.+J.+Trabaninoauthor=P.+L.+Freddolinoauthor=M.+A.+Kalaniauthor=W.+B.+Florianoauthor=V.+W.+Kamauthor=W.+A.+Goddard&title=The+predicted+3D+structure+of+the+human+D2+dopamine+receptor+and+the+binding+site+and+binding+affinities+for+agonists+and+antagonists&doi=10.1073%2Fpnas.0400100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists</span></div><div class="casAuthors">Yashar, M.; Kalani, S.; Vaidehi, Nagarajan; Hall, Spencer E.; Trabanino, Rene J.; Freddolino, Peter L.; Kalani, Maziyar A.; Floriano, Wely B.; Kam, Victor Wai Tak; Goddard, William A., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3815-3820</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dopamine neurotransmitter and its receptors play a crit. role in the cell signaling process responsible for information transfer in neurons functioning in the nervous system.  Development of improved therapeutics for such disorders as Parkinson's disease and schizophrenia would be significantly enhanced with the availability of the 3D structure for the dopamine receptors and of the binding site for dopamine and other agonists and antagonists.  The authors report the 3D structure of the long isoform of the human D2 dopamine receptor, predicted from primary sequence using first-principles theor. and computational techniques (i.e., the authors did not use bioinformatic or exptl. 3D structural information in predicting structures).  The predicted 3D structure is validated by comparison of the predicted binding site and the relative binding affinities of dopamine, three known dopamine agonists (antiparkinsonian), and seven known antagonists (antipsychotic) in the D2 receptor to exptl. detd. values.  These structures correctly predict the crit. residues for binding dopamine and several antagonists, identified by mutation studies, and give relative binding affinities that correlate well with expts.  The predicted binding site for dopamine and agonists is located between transmembrane (TM) helixes 3, 4, 5, and 6, whereas the best antagonists bind to a site involving TM helixes 2, 3, 4, 6, and 7 with minimal contacts to TM helix 5.  The authors identify characteristic differences between the binding sites of agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK0awOUK1verVg90H21EOLACvtfcHk0li3bfrBDhQzeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Kgtbc%253D&md5=429ddad44cb95b2eb78390612346df59</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0400100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0400100101%26sid%3Dliteratum%253Aachs%26aulast%3DKalani%26aufirst%3DM.%2BY.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DHall%26aufirst%3DS.%2BE.%26aulast%3DTrabanino%26aufirst%3DR.%2BJ.%26aulast%3DFreddolino%26aufirst%3DP.%2BL.%26aulast%3DKalani%26aufirst%3DM.%2BA.%26aulast%3DFloriano%26aufirst%3DW.%2BB.%26aulast%3DKam%26aufirst%3DV.%2BW.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26atitle%3DThe%2520predicted%25203D%2520structure%2520of%2520the%2520human%2520D2%2520dopamine%2520receptor%2520and%2520the%2520binding%2520site%2520and%2520binding%2520affinities%2520for%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D3815%26epage%3D3820%26doi%3D10.1073%2Fpnas.0400100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-Horner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1021/cn300142q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300142q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1050-1062&author=R.+R.+Luedtkeauthor=Y.+Mishraauthor=Q.+Wangauthor=S.+A.+Griffinauthor=C.+Bell-Hornerauthor=M.+Taylorauthor=S.+Vangveravongauthor=G.+H.+Dillonauthor=R.-Q.+Huangauthor=D.+E.+Reichertauthor=R.+H.+Mach&title=Comparison+of+the+binding+and+functional+properties+of+two+structurally+different+D2+dopamine+receptor+subtype+selective+compounds&doi=10.1021%2Fcn300142q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds</span></div><div class="casAuthors">Luedtke, Robert R.; Mishra, Yogesh; Wang, Qi; Griffin, Suzy A.; Bell-Horner, Cathy; Taylor, Michelle; Vangveravong, Suwanna; Dillon, Glenn H.; Huang, Ren-Qi; Reichert, David E.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1050-1062</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported on the synthesis of substituted phenyl-4-hydroxy-1-piperidyl indole analogs with nanomolar affinity at D2 dopamine receptors, ranging from 10- to 100-fold selective for D2 compared to the D3 dopamine receptor subtype.  More recently, we evaluated a panel of aripiprazole analogs, identifying several analogs that also exhibit D2 vs D3 dopamine receptor binding selectivity.  These studies further characterize the intrinsic efficacy of the compd. with the greatest binding selectivity from each chem. class, 1-((5-methoxy-1H-indol-3-yl)methyl)-4-(4-(methylthio)phenyl)piperidin-4-ol (SV 293) and 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one (SV-III-130s), using an adenylyl cyclase inhibition assay, a G-protein-coupled inward-rectifying potassium (GIRK) channel activation assay, and a cell based phospho-MAPK (pERK1/2) assay.  SV 293 was found to be a neutral antagonist at D2 dopamine receptors using all three assays.  SV-III-130s is a partial agonist using an adenylyl cyclase inhibition assay but an antagonist in the GIRK and phospho ERK1/2 assays.  To define the mol. basis for the binding selectivity, the affinity of these two compds. was evaluated using (a) wild type human D2 and D3 receptors and (b) a panel of chimeric D2/D3 dopamine receptors.  Computer-assisted modeling techniques were used to dock these compds. to the human D2 and D3 dopamine receptor subtypes.  It is hoped that these studies on D2 receptor selective ligands will be useful in the future design of (a) receptor selective ligands used to define the function of D2-like receptor subtypes, (b) novel pharmacotherapeutic agents, and/or (c) in vitro and in vivo imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkk_Neaj9JrVg90H21EOLACvtfcHk0li3bfrBDhQzeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqtr7O&md5=42fe569c18220a451a3a88716ef44426</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fcn300142q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300142q%26sid%3Dliteratum%253Aachs%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMishra%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGriffin%26aufirst%3DS.%2BA.%26aulast%3DBell-Horner%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DDillon%26aufirst%3DG.%2BH.%26aulast%3DHuang%26aufirst%3DR.-Q.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DComparison%2520of%2520the%2520binding%2520and%2520functional%2520properties%2520of%2520two%2520structurally%2520different%2520D2%2520dopamine%2520receptor%2520subtype%2520selective%2520compounds%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D1050%26epage%3D1062%26doi%3D10.1021%2Fcn300142q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span> <span> </span><span class="NLM_article-title">Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1021/ci1002747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci1002747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OisrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1970-1985&author=Q.+Wangauthor=R.+H.+Machauthor=R.+R.+Luedtkeauthor=D.+E.+Reichert&title=Subtype+selectivity+of+dopamine+receptor+ligands%3A+insights+from+structure+and+ligand-based+methods&doi=10.1021%2Fci1002747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods</span></div><div class="casAuthors">Wang, Qi; Mach, Robert H.; Luedtke, Robert R.; Reichert, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1970-1985</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subtype selective dopamine receptor ligands have long been sought after as therapeutic and/or imaging agents for the treatment and monitoring of neurol. disorders.  We report herein on a combined structure- and ligand-based approach to explore the mol. mechanism of the subtype selectivity for a large class of D2-like dopamine receptor ligands (163 ligands in total).  Homol. models were built for both human D2L and D3 receptors in complex with haloperidol.  Other ligands, which included multiple examples of substituted phenylpiperazines, were aligned against the binding conformations of haloperidol, and three-dimensional quant. structure activity relationship (3D-QSAR) analyses were carried out.  The receptor models show that although D2 and D3 share highly similar folds and 3D conformations, the slight sequence differences at their extracellular loop regions result in the binding cavity in D2 being comparably shallower than in D3, which may explain why some larger ligands bind with greater affinity at D3 compared to D2 receptors.  The QSAR models show excellent correlation and high predictive power even when evaluated by the most stringent criteria.  They confirm that the origins of subtype selectivity for the ligands arise primarily due to differences in the contours of the two binding sites.  The predictive models suggest that while both steric and electrostatic interactions contribute to the compds.' binding affinity, the major contribution arises from hydrophobic interactions, with hydrogen bonding conferring binding specificity.  The current work provides clues for the development of more subtype selective dopamine receptor ligands.  Furthermore, it demonstrates the possibility of being able to apply similar modeling methods to other subtypes or classes of receptors to study GPCR receptor-ligand interactions at a mol. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokZTtMqvRrXbVg90H21EOLACvtfcHk0ljwiUyB0mPX3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OisrzJ&md5=7c923cdaa5e10b1089c7152cedcd9cb0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fci1002747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1002747%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26atitle%3DSubtype%2520selectivity%2520of%2520dopamine%2520receptor%2520ligands%253A%2520insights%2520from%2520structure%2520and%2520ligand-based%2520methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1970%26epage%3D1985%26doi%3D10.1021%2Fci1002747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1124/mol.108.054452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1124%2Fmol.108.054452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19498041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=543-551&author=D.+A.+Sykesauthor=M.+R.+Dowlingauthor=S.+J.+Charlton&title=Exploring+the+mechanism+of+agonist+efficacy%3A+a+relationship+between+efficacy+and+agonist+dissociation+rate+at+the+muscarinic+M3+receptor&doi=10.1124%2Fmol.108.054452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor</span></div><div class="casAuthors">Sykes, David A.; Dowling, Mark R.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-551</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although there are several empirical approaches that enable the comparison of relative agonist efficacy, the mol. basis that underlies differences in the ability of G protein-coupled receptor agonists to elicit a response is still largely unexplained.  Several models have been described that incorporate the kinetics of receptor-mediated initiation of the G protein cycle, but these have not directly addressed the influence of agonist-binding kinetics.  To test this, we investigated the relationship between the efficacy of seven M3 muscarinic receptor agonists and their rate of dissocn. (koff) from the M3 receptor.  The assocn. and dissocn. rate consts. of the agonists were detd. using a I-[N-methyl]-[3H]scopolamine Me chloride competition binding assay in the presence of GTP.  The agonists displayed a range of assocn. and dissocn. rates.  Relative agonist efficacy was measured at two points after M3 receptor activation: the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to Gα subunits, and the subsequent increase in intracellular calcium levels.  These expts. revealed a range of intrinsic efficacy, from the low-efficacy pilocarpine and oxotremorine to high-efficacy acetylcholine.  There was no relationship between agonist efficacy and the equil. binding affinity of each agonist (Kd).  When efficacy was compared with the dissocn. rate const., however, the two were highly correlated, suggesting a relationship between the duration of agonist binding at the receptor and the intrinsic efficacy.  These data suggest that kinetic models incorporating the mean lifetime of specific complexes will be required to fully explain the nature of agonist efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtUbRzBhLnrVg90H21EOLACvtfcHk0ljwiUyB0mPX3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyrsLg%253D&md5=faa8fd2cf265eadd420c943f4033b02f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.054452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.054452%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExploring%2520the%2520mechanism%2520of%2520agonist%2520efficacy%253A%2520a%2520relationship%2520between%2520efficacy%2520and%2520agonist%2520dissociation%2520rate%2520at%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D543%26epage%3D551%26doi%3D10.1124%2Fmol.108.054452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deyrup, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicki, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. P.</span></span> <span> </span><span class="NLM_article-title">Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor</span>. <i>Naunyn-Schmiedebergs Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1007/PL00005339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1007%2FPL00005339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10208303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M3it12rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1999&pages=168-177&author=M.+D.+Deyrupauthor=S.+T.+Nowickiauthor=N.+G.+Richardsauthor=D.+H.+Oteroauthor=J.+K.+Harrisonauthor=S.+P.+Baker&title=Structure-affinity+profile+of+8-hydroxycarbostyril-based+agonists+that+dissociate+slowly+from+the+beta2-adrenoceptor&doi=10.1007%2FPL00005339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor</span></div><div class="casAuthors">Deyrup M D; Nowicki S T; Richards N G; Otero D H; Harrison J K; Baker S P</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's archives of pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">168-77</span>
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">Several carbostyril-based beta-agonists have been shown to bind tightly to and slowly dissociate from the beta2-adrenoceptor (beta2AR).  In the present study, the structural features of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] -carbostyril (11a) which contribute to its binding properties at the beta2AR were investigated using a series of synthesized analogs.  The k(off), estimated by the rate of cAMP decline in DDT1 MF-2 (DDT) cells with a reduced receptor density, Ki and ligand-induced receptor reductions were determined.  All of the derivatives stimulated cAMP accumulation in DDT cells in the sub to mid nanomolar range and elicited the same maximal stimulation as (-)isoproterenol.  Derivatives of 11a with side chain N-substitutions comprising 2-methylbutyl, phenylethyl and isopropyl had higher k(off)-values and lower affinities as compared to 11a.  Increasing the number of methylenes between the side chain tertiary alpha carbon and phenyl from 1 in 11a to 3 or reducing the number to 0 also resulted in derivatives with higher k(off)- and Ki-values.  In addition, replacement of the 8-hydroxycarbostyril nucleus of 11a with catechol reduced the affinity of the compound for the beta2AR by 48-fold and increased its k(off).  Only those derivatives with the lowest k(off)-values induced a decrease in the receptor density of DDT cell membranes following a preincubation and extensive washing.  The data show that the 8-hydroxycarbostyril nucleus in conjunction with substitutions on the tertiary alpha carbon of the side chain and positioning of the phenyl group are important characteristics determining the high affinity and slow dissociation of 11a from the beta2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpXxjlkrrGA6Nc3HjJRoFAfW6udTcc2eYOWO8T5i40ALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3it12rtg%253D%253D&md5=8b0728ee71d74f30c87a7f1381cc3098</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2FPL00005339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005339%26sid%3Dliteratum%253Aachs%26aulast%3DDeyrup%26aufirst%3DM.%2BD.%26aulast%3DNowicki%26aufirst%3DS.%2BT.%26aulast%3DRichards%26aufirst%3DN.%2BG.%26aulast%3DOtero%26aufirst%3DD.%2BH.%26aulast%3DHarrison%26aufirst%3DJ.%2BK.%26aulast%3DBaker%26aufirst%3DS.%2BP.%26atitle%3DStructure-affinity%2520profile%2520of%25208-hydroxycarbostyril-based%2520agonists%2520that%2520dissociate%2520slowly%2520from%2520the%2520beta2-adrenoceptor%26jtitle%3DNaunyn-Schmiedebergs%2520Arch.%2520Pharmacol.%26date%3D1999%26volume%3D359%26spage%3D168%26epage%3D177%26doi%3D10.1007%2FPL00005339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Functional efficacy of adenosine A(2A) receptor agonists is positively correlated to their receptor residence time</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01897.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fj.1476-5381.2012.01897.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22324512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOku7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1846-1859&author=D.+Guoauthor=T.+Mulder-Kriegerauthor=A.+P.+Ijzermanauthor=L.+H.+Heitman&title=Functional+efficacy+of+adenosine+A%282A%29+receptor+agonists+is+positively+correlated+to+their+receptor+residence+time&doi=10.1111%2Fj.1476-5381.2012.01897.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time</span></div><div class="casAuthors">Guo, Dong; Mulder-Krieger, Thea; IJzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1846-1859</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The adenosine A2A receptor belongs to the superfamily of GPCRs and is a promising therapeutic target.  Traditionally, the discovery of novel agents for the A2A receptor has been guided by their affinity for the receptor.  This parameter is detd. under equil. conditions, largely ignoring the kinetic aspects of the ligand-receptor interaction.  The aim of this study was to assess the binding kinetics of A2A receptor agonists and explore a possible relationship with their functional efficacy.  We set up, validated and optimized a kinetic radioligand binding assay (a so-called competition assocn. assay) at the A2A receptor from which the binding kinetics of unlabeled ligands were detd.  Subsequently, functional efficacies of A2A receptor agonists were detd. in two different assays: a novel label-free impedance-based assay and a more traditional cAMP detn.  A simplified competition assocn. assay yielded an accurate detn. of the assocn. and dissocn. rates of unlabeled A2A receptor ligands at their receptor.  A correlation was obsd. between the receptor residence time of A2A receptor agonists and their intrinsic efficacies in both functional assays.  The affinity of A2A receptor agonists was not correlated to their functional efficacy.  This study indicates that the mol. basis of different agonist efficacies at the A2A receptor lies within their different residence times at this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowupsgRlfDkLVg90H21EOLACvtfcHk0ljwiUyB0mPX3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOku7bL&md5=318c22c4a852bc14cb0fac5915ae7e90</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01897.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01897.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DFunctional%2520efficacy%2520of%2520adenosine%2520A%25282A%2529%2520receptor%2520agonists%2520is%2520positively%2520correlated%2520to%2520their%2520receptor%2520residence%2520time%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1846%26epage%3D1859%26doi%3D10.1111%2Fj.1476-5381.2012.01897.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1111/bph.12245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fbph.12245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=23692283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOntrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=351-363&author=R.+Mouldauthor=J.+Brownauthor=F.+H.+Marshallauthor=C.+J.+Langmead&title=Binding+kinetics+differentiates+functional+antagonism+of+orexin-2+receptor+ligands&doi=10.1111%2Fbph.12245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands</span></div><div class="casAuthors">Mould, R.; Brown, J.; Marshall, F. H.; Langmead, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-363</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Orexin receptor antagonism represents a novel approach for the treatment of insomnia that directly targets sleep/wake regulation.  Several such compds. have entered into clin. development, including the dual orexin receptor antagonists, suvorexant and almorexant.  In this study, we have used equil. and kinetic binding studies with the orexin-2 (OX2) selective antagonist radioligand, [3H]-EMPA, to profile several orexin receptor antagonists.  Furthermore, selected compds. were studied in cell-based assays of inositol phosphate accumulation and ERK-1/2 phosphorylation in CHO cells stably expressing the OX2 receptor that employ different agonist incubation times (30 and 5 min, resp.).  EMPA, suvorexant, almorexant and TCS-OX-29 all bind to the OX2 receptor with moderate to high affinity (pKI values ≥ 7.5), whereas the primarily OX1 selective antagonists SB-334867 and SB-408124 displayed low affinity (pKI values ca. 6).  Competition kinetic anal. showed that the compds. displayed a range of dissocn. rates from very fast (TCS-OX2-29, koff = 0.22 min-1) to very slow (almorexant, koff = 0.005 min-1).  Notably, there was a clear correlation between assocn. rate and affinity.  In the cell-based assays, fast-offset antagonists EMPA and TCS-OX2-29 displayed surmountable antagonism of orexin-A agonist activity.  However, both suvorexant and particularly almorexant cause concn.-dependent depression in the maximal orexin-A response, a profile that is more evident with a shorter agonist incubation time.  Anal. according to a hemi-equil. model suggests that antagonist dissocn. is slower in a cellular system than in membrane binding; under these conditions, almorexant effectively acts as a pseudo-irreversible antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKvVgXShAR8rVg90H21EOLACvtfcHk0ljlo9au-Wz8RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOntrvE&md5=1192764ca7f2175956ff57f68e3c9862</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1111%2Fbph.12245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12245%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520kinetics%2520differentiates%2520functional%2520antagonism%2520of%2520orexin-2%2520receptor%2520ligands%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D351%26epage%3D363%26doi%3D10.1111%2Fbph.12245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2683</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01639.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fj.1476-5381.2011.01639.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21883146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVajtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=2672-2683&author=D.+A.+Sykesauthor=S.+J.+Charlton&title=Slow+receptor+dissociation+is+not+a+key+factor+in+the+duration+of+action+of+inhaled+long-acting+beta2-adrenoceptor+agonists&doi=10.1111%2Fj.1476-5381.2011.01639.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists</span></div><div class="casAuthors">Sykes, David A.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2672-2683</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: β2-Adrenoceptor agonists are important bronchodilators used for the treatment of chronic obstructive pulmonary disease and asthma.  Clin. data on β2-adrenoceptor agonists show a range of onset and duration of action.  We have investigated whether the receptor binding kinetics of β2-adrenoceptor agonists can explain their obsd. onset of action and duration of effect in the clinic.  Exptl. Approach: [3H]-DHA was used to label β2-adrenoceptors expressed in CHO-cell membranes (Kd of 0.084 nM).  Competition kinetic expts. were performed in the presence of unlabeled β2 agonists at 37°C in HBSS contg. GTP.  To det. the kinetic parameters, three concns. (10, 3 and 1 × Ki) of the unlabeled compd. were employed against a fixed concn. of [3H]-DHA (0.6 nM).  Key Results: The clin. used β2-adrenoceptor agonists exhibited a range of assocn. and dissocn. rates.  The kinetic Kd and the competition Ki values of the eight β2-adrenoceptor agonists examd. were strongly correlated, suggesting that the method had produced accurate koff and kon rates.  The kinetic on-rate was highly correlated with equil. binding affinity.  Conclusions and Implications: Although the β2-adrenoceptor agonists displayed a range of kinetic rate parameters, simulations at relevant drug concns. suggest that receptor kinetics do not play an important role in detg. onset of action in the clinic.  In addn., it is unlikely that receptor kinetics exert an important influence on the duration of action of these agonists, as indacaterol (once daily dosing) had a shorter residency time at the receptor than salmeterol (twice daily dosing).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSXrYrFofvmrVg90H21EOLACvtfcHk0ljlo9au-Wz8RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVajtLg%253D&md5=c090bf289f61624bbf038f83208b0e07</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01639.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01639.x%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DSlow%2520receptor%2520dissociation%2520is%2520not%2520a%2520key%2520factor%2520in%2520the%2520duration%2520of%2520action%2520of%2520inhaled%2520long-acting%2520beta2-adrenoceptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D2672%26epage%3D2683%26doi%3D10.1111%2Fj.1476-5381.2011.01639.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span> <span> </span><span class="NLM_article-title">Molecular properties affecting fast dissociation from the D2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2011.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21421319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2231-2241&author=G.+Tresadernauthor=J.+M.+Bartolomeauthor=G.+J.+Macdonaldauthor=X.+Langlois&title=Molecular+properties+affecting+fast+dissociation+from+the+D2+receptor&doi=10.1016%2Fj.bmc.2011.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties affecting fast dissociation from the D2 receptor</span></div><div class="casAuthors">Tresadern, Gary; Bartolome, Jose Manuel; MacDonald, Gregor J.; Langlois, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-2241</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonism is the foundation of antipsychotic treatment.  Antipsychotic agents vary in how fast they dissoc. from the D2 receptors.  It has been proposed that the liability to exhibit side effects such as extra pyramidal symptoms may be the result of a slow rate of dissocn.  Compds. with a faster rate of dissocn., while still blocking efficiently the D2 receptors, will subsequently respond better to physiol. surges in dopamine transmission.  Therefore, work in our labs. has focussed on identifying fast dissocg. and selective D2 antagonists.  Biol. screening was performed to measure the affinity and extent of dissocn. for a large dataset of over 1800 D2 antagonists.  Subsequent univariate and multivariate statistical anal. revealed the mol. properties which differentiate fast and slow dissocg. compds.  It is shown that faster dissocg. antagonists are less lipophilic and have lower mol. wt.  There was a clear and expected inverse relationship with extent of dissocn. and binding affinity with more potent compds. tending to be slower dissocg.  However, within a range of comparable affinity both fast and slow dissocg. compds. were identified.  After de-correlating affinity and dissocn. the anal. revealed the important descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilpQ8-EuD-LVg90H21EOLACvtfcHk0ljlo9au-Wz8RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D&md5=574e106853b1cff1b6975c4bba979031</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBartolome%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DLanglois%26aufirst%3DX.%26atitle%3DMolecular%2520properties%2520affecting%2520fast%2520dissociation%2520from%2520the%2520D2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2231%26epage%3D2241%26doi%3D10.1016%2Fj.bmc.2011.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Cell membranes... and how long drugs may exert beneficial pharmacological activity in vivo</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1111/bcp.12996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fbcp.12996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27135195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC28bltFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=673-682&author=G.+Vauquelin&title=Cell+membranes...+and+how+long+drugs+may+exert+beneficial+pharmacological+activity+in+vivo&doi=10.1111%2Fbcp.12996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Cell membranes... and how long drugs may exert beneficial pharmacological activity in vivo</span></div><div class="casAuthors">Vauquelin Georges</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The time course of the beneficial pharmacological effect of a drug has long been considered to depend merely on the temporal fluctuation of its free concentration.  Only in the last decade has it become widely accepted that target-binding kinetics can also affect in vivo pharmacological activity.  Although current reviews still essentially focus on genuine dissociation rates, evidence is accumulating that additional micro-pharmacokinetic (PK) and -pharmacodynamic (PD) mechanisms, in which the cell membrane plays a central role, may also increase the residence time of a drug on its target.  The present review provides a compilation of otherwise widely dispersed information on this topic.  The cell membrane can intervene in drug binding via the following three major mechanisms: (i) by acting as a sink/repository for the drug; (ii) by modulating the conformation of the drug and even by participating in the binding process; and (iii) by facilitating the approach (and rebinding) of the drug to the target.  To highlight these mechanisms, we focus on drugs that are currently used in clinical therapy, such as the antihypertensive angiotensin II type 1 receptor antagonist candesartan, the atypical antipsychotic agent clozapine and the bronchodilator salmeterol.  Although the role of cell membranes in PK-PD modelling is gaining increasing interest, many issues remain unresolved.  It is likely that novel biophysical and computational approaches will provide improved insights in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNNhiIkXw2kevW160gIxP_fW6udTcc2eao6jIonYg5rrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bltFektQ%253D%253D&md5=f30526cdbc86bc81ae55b1fb452b5197</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12996%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DCell%2520membranes...%2520and%2520how%2520long%2520drugs%2520may%2520exert%2520beneficial%2520pharmacological%2520activity%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D82%26spage%3D673%26epage%3D682%26doi%3D10.1111%2Fbcp.12996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0liSC8O0IMG6Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocking, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1124/mol.115.102657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1124%2Fmol.115.102657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26873858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsF2ks7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=485-491&author=D.+Guoauthor=A.+C.+Panauthor=R.+O.+Drorauthor=T.+Mockingauthor=R.+Liuauthor=L.+H.+Heitmanauthor=D.+E.+Shawauthor=A.+P.+IJzerman&title=Molecular+Basis+of+Ligand+Dissociation+from+the+Adenosine+A2A+Receptor&doi=10.1124%2Fmol.115.102657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of ligand dissociation from the adenosine A2A receptor</span></div><div class="casAuthors">Guo, Dong; Pan, Albert C.; Dror, Ron O.; Mocking, Tamara; Liu, Rongfang; Heitman, Laura H.; Shaw, David E.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">How drugs dissoc. from their targets is largely unknown.  We investigated the mol. basis of this process in the adenosine A2A receptor (A2AR), a prototypical G protein-coupled receptor (GPCR).  Through kinetic radioligand binding expts., we characterized mutant receptors selected based on mol. dynamic simulations of the antagonist ZM241385 dissocg. from the A2AR.  We discovered mutations that dramatically altered the ligand's dissocn. rate despite only marginally influencing its binding affinity, demonstrating that even receptor features with little contribution to affinity may prove crit. to the dissocn. process.  Our results also suggest that ZM241385 follows a multistep dissocn. pathway, consecutively interacting with distinct receptor regions, a mechanism that may also be common to many other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFL8Q8IGEZJbVg90H21EOLACvtfcHk0liSC8O0IMG6Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsF2ks7zJ&md5=ae4fb68a895391167db19e72b4f99d72</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.102657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.102657%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DMocking%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DMolecular%2520Basis%2520of%2520Ligand%2520Dissociation%2520from%2520the%2520Adenosine%2520A2A%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D485%26epage%3D491%26doi%3D10.1124%2Fmol.115.102657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlow, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Pathway and mechanism of drug binding to G-protein-coupled receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">13118</span>– <span class="NLM_lpage">13123</span>, <span class="refDoi"> DOI: 10.1073/pnas.1104614108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1073%2Fpnas.1104614108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21778406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=13118-13123&author=R.+O.+Drorauthor=A.+C.+Panauthor=D.+H.+Arlowauthor=D.+W.+Borhaniauthor=P.+Maragakisauthor=Y.+Shanauthor=H.+Xuauthor=D.+E.+Shaw&title=Pathway+and+mechanism+of+drug+binding+to+G-protein-coupled+receptors&doi=10.1073%2Fpnas.1104614108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pathway and mechanism of drug binding to G-protein-coupled receptors</span></div><div class="casAuthors">Dror, Ron O.; Pan, Albert C.; Arlow, Daniel H.; Borhani, David W.; Maragakis, Paul; Shan, Yibing; Xu, Huafeng; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">13118-13123, S13118/1-S13118/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">How drugs bind to their receptors-from initial assocn., through drug entry into the binding pocket, to adoption of the final bound conformation, or "pose"-has remained unknown, even for G-protein-coupled receptor modulators, which constitute 1/3 of all marketed drugs.  Here, the authors captured this pharmaceutically crit. process in at. detail using the 1st unbiased mol. dynamics simulations in which drug mols. spontaneously assoc. with G-protein-coupled receptors to achieve final poses matching those detd. crystallog.  The authors found that several beta blockers and a beta agonist all traversed the same well-defined, dominant pathway as they bound to the β1- and β2-adrenergic receptors, initially making contact with a vestibule on each receptor's extracellular surface.  Surprisingly, assocn. with this vestibule, at a distance of 15 Å from the binding pocket, often presented the largest energetic barrier to binding, despite the fact that subsequent entry into the binding pocket required the receptor to deform and the drug to squeeze through a narrow passage.  The early barrier appeared to reflect the substantial dehydration that takes place as the drug assocs. with the vestibule.  The at.-level description of the binding process suggests opportunities for allosteric modulation and provides a structural foundation for future optimization of drug-receptor binding and unbinding rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUYFtkTGwf7Vg90H21EOLACvtfcHk0lgKXvNKTVTIfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE&md5=9cfa8673217931cacd586321309fa72e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104614108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104614108%26sid%3Dliteratum%253Aachs%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DPathway%2520and%2520mechanism%2520of%2520drug%2520binding%2520to%2520G-protein-coupled%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D13118%26epage%3D13123%26doi%3D10.1073%2Fpnas.1104614108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span>; <span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure–Function Relations in G Protein-Coupled Receptors</span>. In  <i>Methods in Neurosciences</i>;<span class="NLM_contrib-group"><span class="NLM_string-name">Sealfon, S. C.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1995</span>; Vol.  <span class="NLM_volume">25</span>, pp  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=366-428&author=J.+A.+Ballesteros&author=H.+Weinsteinauthor=S.+C.+Sealfon&title=Methods+in+Neurosciences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26atitle%3DIntegrated%2520Methods%2520for%2520the%2520Construction%2520of%2520Three-Dimensional%2520Models%2520and%2520Computational%2520Probing%2520of%2520Structure%25E2%2580%2593Function%2520Relations%2520in%2520G%2520Protein-Coupled%2520Receptors%26btitle%3DMethods%2520in%2520Neurosciences%26aulast%3DSealfon%26aufirst%3DS.%2BC.%26pub%3DAcademic%2520Press%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgKXvNKTVTIfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lgKXvNKTVTIfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Olena Kuleshova, Sobi Asako, <span class="NLM_string-name hlFld-ContribAuthor">Laurean Ilies</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-Enabled, Iridium-Catalyzed ortho-Borylation of Fluoroarenes. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2021,</strong> <em>11 </em>
                                    (10)
                                     , 5968-5973. <a href="https://doi.org/10.1021/acscatal.1c01206" title="DOI URL">https://doi.org/10.1021/acscatal.1c01206</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.1c01206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.1c01206%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DLigand-Enabled%25252C%252BIridium-Catalyzed%252Bortho-Borylation%252Bof%252BFluoroarenes%26aulast%3DKuleshova%26aufirst%3DOlena%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D16032021%26date%3D22042021%26date%3D30042021%26volume%3D11%26issue%3D10%26spage%3D5968%26epage%3D5973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raphaela A.  Lima</span>, <span class="hlFld-ContribAuthor ">Jennyffer S.M.  Quimbayo</span>, <span class="hlFld-ContribAuthor ">Daniel L.M.  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Cristiano B.  Silva</span>, <span class="hlFld-ContribAuthor ">Josias V.  Santana</span>, <span class="hlFld-ContribAuthor ">Geancarlo  Zanatta</span>, <span class="hlFld-ContribAuthor ">Valder N.  Freire</span>, <span class="hlFld-ContribAuthor ">Paulo T.C.  Freire</span>. </span><span class="cited-content_cbyCitation_article-title">Study of the vibrational properties of haloperidol under high-pressure. </span><span class="cited-content_cbyCitation_journal-name">Vibrational Spectroscopy</span><span> <strong>2020,</strong> <em>109 </em>, 103103. <a href="https://doi.org/10.1016/j.vibspec.2020.103103" title="DOI URL">https://doi.org/10.1016/j.vibspec.2020.103103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.vibspec.2020.103103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.vibspec.2020.103103%26sid%3Dliteratum%253Aachs%26jtitle%3DVibrational%2520Spectroscopy%26atitle%3DStudy%252Bof%252Bthe%252Bvibrational%252Bproperties%252Bof%252Bhaloperidol%252Bunder%252Bhigh-pressure%26aulast%3DLima%26aufirst%3DRaphaela%2BA.%26date%3D2020%26volume%3D109%26spage%3D103103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0029.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0001.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Typical APD haloperidol (<b>1</b>) and atypical APD clozapine (<b>2</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0002.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural regions of haloperidol (<b>1</b>) investigated as part of the SKR study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Haloperidol (<b>1</b>) Analogues with Modification to the <i>para</i>-Chlorophenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, tetrahydrofuran (THF), −78 °C, 3–8 h, 50–88% (<b>5a</b>–<b>l</b>); (ii) HCl (4 M), 1,4-dioxane, 1–3 h, 75–98% (<b>6a</b>, <b>6c</b>, <b>6e</b>, <b>6f</b>, <b>6h</b>–<b>l</b> (free base) <b>6b</b>, <b>6d</b>, <b>6g</b> (HCl salt)); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 45–70% (<b>8a</b>–<b>l</b>).</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Biphenyl Side Product and <i>ortho</i>-Cl Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) <i>n</i>-BuLi, THF, −78 °C, 6 h, 55% (<b>5m</b>); (ii) Mg, I<sub>2(cat.)</sub>, Et<sub>2</sub>O, 0 °C to reflux, 3 h, 54% (<b>5n</b>); (iii) HCl, 1,4-dioxane, room temperature (rt), 2 h, 72–96% (<b>6m</b>, <b>6n</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 62–76% (<b>8m</b>, <b>8n</b>).</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Analogues of <b>1</b> with Modification to the <i>p</i>-Fluorophenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) SOCl<sub>2</sub>, pyridine, 0 °C to reflux, 30 min, 82%; (ii) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, Et<sub>3</sub>N, 1,4-dioxane, 50 °C, 1–3 h, 45–85% (<b>12a</b>–<b>j</b>); (iii) TfOH, H<sub>2</sub>O, CF<sub>3</sub>CH<sub>2</sub>OH, 60 °C, 3–8 h, 50–90% (<b>13a</b>–<b>j</b>); (iv) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 50–82% (<b>14a</b>, <b>14b</b>, <b>14d</b>, <b>14e</b>, <b>14g</b>–<b>l</b>); <b>14c</b> and <b>14f</b> were detected but unable to be isolated in appreciable yield.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of 2,3- and 2,6-Difluoro Analogues of <b>1</b> Using Various Protection Strategies<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) trimethylorthoformate, <i>p</i>-TsOH·H<sub>2</sub>O, MeOH, rt, 12 h, 77% (<b>15c</b>); (ii) ethylene glycol, <i>p</i>-TsOH·H<sub>2</sub>O, toluene, reflux (Dean–Stark), 16 h, 83% (<b>15f</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 71–77% (<b>16c</b>, <b>16f</b>); (iv) <i>p</i>-TsOH·H<sub>2</sub>O, 15:1 acetone/H<sub>2</sub>O, reflux, 48 h, 76–82% (<b>14c</b>, <b>14f</b>).</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0003.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Literature analogues of <b>1</b> synthesized using various methodologies. Ether- and thioether analogues<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>17a</b> and <b>17b</b>, respectively); racemic alcohol analogue<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (<b>18</b>); tropanyl analogue<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>42</b>); piperazinyl analogue<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>43</b>); phenyl- and <i>p</i>-chlorophenylpiperidine analogues<a onclick="showRef(event, 'ref38 ref47'); return false;" href="javascript:void(0);" class="ref ref38 ref47">(38,47)</a> (<b>47</b> and <b>48</b>, respectively); reverse substitution analogue<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (<b>53</b>); and <i>des</i>-halo analogue<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>54</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>trans-</i>Olefin Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NaOH, MeOH, 60 °C, 5 h, quantitative; (ii) NaBH<sub>4</sub>, MeOH, 0 °C to rt, 3 h, 99%; (iii) VO(acac)<sub>2</sub>, butylated hydroxytoluene, PhCl, 80 °C, 48 h, 35%; (iv) MsCl, dichloromethane (DCM), Et<sub>3</sub>N, rt, 3 h, 88%; (v) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 82%.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0013.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>cis-</i>Olefin Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Ni[COD]<sub>2</sub>, 1,3-bis-(2,6-diisopropylphenyl)imidazolinium chloride, LiCl, THF, −30 °C, 8 h, 31%; (ii) MsCl, Et<sub>3</sub>N, DCM, rt, 24 h, 90%; (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 75%.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0014.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Both <i>trans</i>- and <i>cis</i>-Cyclopropane Enantiomers of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Et<sub>2</sub>Zn, CH<sub>2</sub>I<sub>2</sub>, DCM, 0 °C to rt, 24 h, 95–98% (<b>29</b>, <b>30</b>); (ii) MsCl, Et<sub>3</sub>N, DCM, rt, 90–95% (<b>29a</b>, <b>30a</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 67–70% (<b>29b</b>, <b>30b</b>).</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0015.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Ketone and Alkane Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) AlCl<sub>3</sub>, DCM, 0 °C to rt, 6 h, 85% (<b>33a</b>, <b>33c</b>); (ii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 75–90% (<b>34a</b>, <b>34c</b>); (iii) triethylsilane, trifluoroacetic acid, 0 °C, 2–3 h, 75–85% (<b>35a</b>–<b>c</b>); (iv) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 72–91% (<b>36a</b>–<b>c</b>).</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0016.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Internal Alkyne Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, CuI, Et<sub>3</sub>N, MeCN, rt, 5 h, 94% (<b>39a</b>, <b>39c</b>); (ii) methanesulfonyl chloride, Et<sub>3</sub>N, DCM, 24 h, 93% (<b>40a</b>, <b>40c</b>); (iii) PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Et<sub>3</sub>N, 1,4-dioxane, 50 °C, 3 h, 75% (<b>40b</b>); (iii) NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 68–74% (<b>41a</b>–<b>c</b>).</p></p></figure><figure data-id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0017.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Dihydropyridyl and Fused Cyclopropane Analogues of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) HCl (conc.), reflux, 5 h, quantitative; (ii) <b>7a</b>, NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 65% (<b>45</b>); (iii) Et<sub>2</sub>Zn, CH<sub>2</sub>I<sub>2</sub>, DCM, 0 °C to rt, 24 h, 75% (<b>46</b>).</p></p></figure><figure data-id="sch11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0018.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Methyl Ether Analogue of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) Boc<sub>2</sub>O, Et<sub>3</sub>N, DCM, rt, 4 h, 85%; (ii) NaH, MeI, DMF, rt, 24 h, 80%; (iii) HCl, 1,4-dioxane, rt, 2 h, 95%; (iv) <b>7a</b>, NaHCO<sub>3</sub>, KI, toluene, reflux, 24 h, 70%.</p></p></figure><figure data-id="fig4" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0004.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Equilibrium and competition association binding. (A) Competition between PPHT-red (12.5 nM) and increasing concentrations of <b>1</b> and representative analogues (<b>8b</b>, <b>8d</b>, <b>8g</b>, <b>8l</b>, <b>14j</b>, <b>14k</b>, <b>45</b>, <b>46</b>, <b>48</b>, <b>52</b>, <b>53</b>) at the hD<sub>2L</sub>R. PPHT-red competition association curves in the presence of (B) <b>30b</b>, (C) <b>34c</b>, and (D) <b>42</b>. All binding reactions were performed at 37 °C in the presence of GppNHp (100 μM) with nonspecific binding levels determined by inclusion of haloperidol (10 μM). Kinetic and equilibrium data were fitted to the equations described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> to calculate <i>K</i><sub>i</sub>, <i>K</i><sub>d</sub>, <i>k</i><sub>on</sub>, and <i>k</i><sub>off</sub> values for the unlabeled ligands: these are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as singlet values from a representative of four experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0005.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Correlating equilibrium and kinetically derived parameters for haloperidol (<b>1</b>) and 51 structural analogues at the dopamine D<sub>2</sub> receptor. Correlation between p<i>K</i><sub>i</sub> and kinetically derived p<i>K</i><sub>d</sub> for the 51 test ligands including haloperidol. p<i>K</i><sub>i</sub> values were taken from PPHT-red competition binding experiments at equilibrium as exemplified in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A. The values composing the kinetically derived p<i>K</i><sub>d</sub> (−log (<i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>)) were taken from competition kinetic association experiments as exemplified in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B–D. All data used in these plots are detailed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as mean ± S.E.M. from four separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0006.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Correlating kinetically derived equilibrium dissociation constants vs kinetic rate constants of haloperidol (<b>1</b>) and 50 structural analogues at the dopamine D<sub>2</sub> receptor. (A) A plot of log <i>k</i><sub>on</sub> vs p<i>K</i><sub>d</sub> demonstrates a statistically significant correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.96, <i>p</i> < 0.0001) between these two variables. (B) Conversely, a plot of p<i>K</i><sub>d</sub> vs log <i>k</i><sub>off</sub> demonstrates a much poorer correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.34, <i>p</i> < 0.0001) despite the traditional scientific consensus that APD affinity is solely driven by changes in <i>k</i><sub>off</sub>. (C) Observed association rate (log <i>k</i><sub>on</sub>) and calculated partition coefficient (cLog <i>P</i>) show no correlation (two-tailed Pearson’s correlation <i>r</i><sup>2</sup> = 0.007, <i>p</i> = 0.562). The central line corresponds to the linear regression of the data, and the dotted lines represent the 95% confidence intervals for the regression. (D) Representing the diversity in affinity and corresponding kinetic profiles for analogues of <b>1</b>. A plot of log <i>k</i><sub>off</sub> vs log <i>k</i><sub>on</sub> represents a spectrum of compounds with various kinetic profiles (∼10-fold difference in <i>k</i><sub>off</sub>, ∼30-fold difference in <i>k</i><sub>on</sub>) identified from this study. Clozapine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (<b>2</b>) and typical APD chlorpromazine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> are also included as reference points. These data identify several compounds with interesting slow on, fast off kinetic profiles (<b>14c</b>, <b>30b</b>, <b>34c</b>, <b>36a</b>). Combinations of <i>k</i><sub>on</sub> and <i>k</i><sub>off</sub> that result in identical affinity (<i>K</i><sub>d</sub>) values are represented by diagonal dotted lines. All data used in these plots apart from chlorpromazine are detailed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Data are presented as mean from at least four separate experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/medium/jm9b00864_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0007.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Summary of the range of kinetic binding parameters obtained for each region of structural modification to haloperidol (<b>1</b>). Values describe the fold-difference between the largest and smallest values for each parameter and grouped by the moiety of <b>1</b> that was modified.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b00864/20191108/images/large/jm9b00864_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00864&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i192">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 74 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau-Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic drug doses and neuroleptic/dopamine receptors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1038/261717a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2F261717a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=945467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1976&pages=717-719&author=P.+Seemanauthor=T.+Leeauthor=M.+Chau-Wongauthor=K.+Wong&title=Antipsychotic+drug+doses+and+neuroleptic%2Fdopamine+receptors&doi=10.1038%2F261717a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic drug doses and neuroleptic/dopamine receptors</span></div><div class="casAuthors">Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5562</span>),
    <span class="NLM_cas:pages">717-19</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Clin. effective antipsychotic drugs, e.g., chlorpromazine [50-53-3], blocked the stereospecific binding of 3H-labeled haloperidol [52-86-8] at concns. which correlated directly with their clin. potencies.  In addn., the antipsychotics blocked binding of dopamine [51-61-6], the IC50 values (concns. producing 50% blockade) for this effect correlated quant. with the clin. antipsychotic potencies.  The neuroleptic receptor assay can thus be used to screen potentially useful antipsychotic drugs.  The IC50 values for blockade of haloperidol binding were almost identical to the concns. of drugs in the patients plasma; e.g., 29 and 30nM, resp., for chlorpromazine.  These IC50 values may therefore be of therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIuatc5GaFrVg90H21EOLACvtfcHk0lj8gf7Ezna__Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XlsFCisbk%253D&md5=2800e926625d767c976dbf4181fc6ad2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2F261717a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F261717a0%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DChau-Wong%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26atitle%3DAntipsychotic%2520drug%2520doses%2520and%2520neuroleptic%252Fdopamine%2520receptors%26jtitle%3DNature%26date%3D1976%26volume%3D261%26spage%3D717%26epage%3D719%26doi%3D10.1038%2F261717a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ginovart, N.</span>; <span class="NLM_string-name">Kapur, S.</span></span> <span> </span><span class="NLM_article-title">Role of Dopamine D<sub>2</sub> Receptors for Antipsychotic Activity</span>. In  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, G.</span>, <span class="NLM_string-name">Geyer, M.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2012</span>; Vol.  <span class="NLM_volume">212</span>, pp  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">52</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=27-52&author=N.+Ginovart&author=S.+Kapurauthor=G.+Gross&author=M.+Geyer&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGinovart%26aufirst%3DN.%26atitle%3DRole%2520of%2520Dopamine%2520D2%2520Receptors%2520for%2520Antipsychotic%2520Activity%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DGross%26aufirst%3DG.%26pub%3DSpringer%26date%3D2012%26volume%3D212%26spage%3D27%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarskog, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischhacker, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, J. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1038/mp.2012.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fmp.2012.47" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22584864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1206-1227&author=S.+Miyamotoauthor=N.+Miyakeauthor=L.+F.+Jarskogauthor=W.+W.+Fleischhackerauthor=J.+A.+Lieberman&title=Pharmacological+treatment+of+schizophrenia%3A+a+critical+review+of+the+pharmacology+and+clinical+effects+of+current+and+future+therapeutic+agents&doi=10.1038%2Fmp.2012.47"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents</span></div><div class="casAuthors">Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1206-1227</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D2 receptor has been the target for the development of APDs.  Pharmacol. actions to reduce neurotransmission through the D2 receptor have been the only proven therapeutic mechanism for psychoses.  A no. of novel non-D2 mechanisms of action of APDs have been explored over the past 40 years but none has definitively been proven effective.  At the same time, the effectiveness of treatments and range of outcomes for patients are far from satisfactory.  The relative success of antipsychotics in treating pos. symptoms is limited by the fact that a substantial no. of patients are refractory to current medications and by their lack of efficacy for neg. and cognitive symptoms, which often det. the level of functional impairment.  In addn., while the newer antipsychotics produce fewer motor side effects, safety and tolerability concerns about wt. gain and endocrinopathies have emerged.  Consequently, there is an urgent need for more effective and better-tolerated antipsychotic agents, and to identify new mol. targets and develop mechanistically novel compds. that can address the various symptom dimensions of schizophrenia.  In recent years, a variety of new exptl. pharmacol. approaches have emerged, including compds. acting on targets other than the dopamine D2 receptor.  However, there is still an ongoing debate as to whether drugs selective for singe mol. targets (i.e., magic bullets') or drugs selectively non-selective for several mol. targets (i.e., magic shotguns', multifunctional drugs' or intramol. polypharmacy') will lead to more effective new medications for schizophrenia.  In this context, current and future drug development strategies can be seen to fall into three categories: (1) refinement of precedented mechanisms of action to provide drugs of comparable or superior efficacy and side-effect profiles to existing APDs; (2) development of novel (and presumably non-D2) mechanism APDs; (3) development of compds. to be used as adjuncts to APDs to augment efficacy by targeting specific symptom dimensions of schizophrenia and particularly those not responsive to traditional APD treatment.  In addn., efforts are being made to det. if the products of susceptibility genes in schizophrenia, identified by genetic linkage and assocn. studies, may be viable targets for drug development.  Finally, a focus on early detection and early intervention aimed at halting or reversing progressive pathophysiol. processes in schizophrenia has gained great influence.  This has encouraged future drug development and therapeutic strategies that are neuroprotective.  This article provides an update and crit. review of the pharmacol. and clin. profiles of current APDs and drugs acting on novel targets with potential to be therapeutic agents in the future.  Mol. Psychiatry (2012) 17, 1206-1227; doi:10.1038/mp.2012.47; published online 15 May 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qXbq8buMvLVg90H21EOLACvtfcHk0lj9wvZ3LLHJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahtrbI&md5=f0240f40a88e012daaebd216efc438b1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmp.2012.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2012.47%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyake%26aufirst%3DN.%26aulast%3DJarskog%26aufirst%3DL.%2BF.%26aulast%3DFleischhacker%26aufirst%3DW.%2BW.%26aulast%3DLieberman%26aufirst%3DJ.%2BA.%26atitle%3DPharmacological%2520treatment%2520of%2520schizophrenia%253A%2520a%2520critical%2520review%2520of%2520the%2520pharmacology%2520and%2520clinical%2520effects%2520of%2520current%2520and%2520future%2520therapeutic%2520agents%26jtitle%3DMol.%2520Psychiatry%26date%3D2012%26volume%3D17%26spage%3D1206%26epage%3D1227%26doi%3D10.1038%2Fmp.2012.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span> <span> </span><span class="NLM_article-title">Update on typical and atypical antipsychotic drugs</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-050911-161504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1146%2Fannurev-med-050911-161504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=23020880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=393-406&author=H.+Y.+Meltzer&title=Update+on+typical+and+atypical+antipsychotic+drugs&doi=10.1146%2Fannurev-med-050911-161504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Update on typical and atypical antipsychotic drugs</span></div><div class="casAuthors">Meltzer, Herbert Y.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">393-406</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Antipsychotic drugs (APDs) are best classified as typical or atypical.  The distinction is based solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia (TD).  The two classes differ in mechanism of action, with atypical APDs providing important modulation of serotonergic neurotransmission.  TD increases the death rate and can be minimized by limiting use of typical APDs.  Clozapine is unique among the atypical APDs in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for redn. of suicide, and for improving longevity.  The typical and atypical APDs do not differ in improving psychopathol. in non-TRS.  The atypicals vary in metabolic side effects: some have little burden.  Cognitive benefits of the atypical APDs may be superior for some domains of cognition and require less use of anticholinergic drugs, which impair memory, for treatment of EPS.  Overall, choosing among the atypical APDs as first-line treatment represents the best course for schizophrenia and most likely other disorders for which APDs are used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK6NegaTYH_7Vg90H21EOLACvtfcHk0lj9wvZ3LLHJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFKltL8%253D&md5=cb4d64f893e34f0cf66b92ba97723081</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-050911-161504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-050911-161504%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26atitle%3DUpdate%2520on%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2013%26volume%3D64%26spage%3D393%26epage%3D406%26doi%3D10.1146%2Fannurev-med-050911-161504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corves, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span> <span> </span><span class="NLM_article-title">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61764-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0140-6736%2808%2961764-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19058842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=31-41&author=S.+Leuchtauthor=C.+Corvesauthor=D.+Arbterauthor=R.+R.+Engelauthor=C.+Liauthor=J.+M.+Davis&title=Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia%3A+a+meta-analysis&doi=10.1016%2FS0140-6736%2808%2961764-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span></div><div class="casAuthors">Leucht, Stefan; Corves, Caroline; Arbter, Dieter; Engel, Rolf R.; Li, Chunbo; Davis, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9657</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-anal. of randomized controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.  We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), pos., neg. and depressive symptoms, relapse, quality of life, extrapyramidal side-effects, wt. gain, and sedation.  We included 150 double-blind, mostly short-term, studies, with 21,533 participants.  We excluded open studies because they systematically favored second-generation drugs.  Four of these drugs were better than first-generation antipsychotic drugs for overall efficacy, with small to medium effect sizes (amisulpride -0.31 [95% CI -0.44 to -0.19, p<0.0001], clozapine -0.52 [-0.75 to -0.29, p<0.0001], olanzapine -0.28 [-0.38 to -0.18, p<0.0001], and risperidone -0.13 [-0.22 to -0.05, p=0.002]).  The other second-generation drugs were not more efficacious than the first-generation drugs, even for neg. symptoms.  Therefore efficacy on neg. symptoms cannot be a core component of atypicality.  Second-generation antipsychotic drugs induced fewer extrapyramidal side-effects than did haloperidol (even at low doses).  Only a few have been shown to induce fewer extrapyramidal side-effects than low-potency first-generation antipsychotic drugs.  With the exception of aripiprazole and ziprasidone, second-generation antipsychotic drugs induced more wt. gain, in various degrees, than did haloperidol but not than low-potency first-generation drugs.  The second-generation drugs also differed in their sedating properties.  We did not note any consistent effects of moderator variables, such as industry sponsorship, comparator dose, or prophylactic antiparkinsonian medication.  Second-generation antipsychotic drugs differ in many properties and are not a homogeneous class.  This meta-anal. provides data for individualized treatment based on efficacy, side-effects, and cost.  Funding: National Institute of Mental Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXIyLwG0IPLVg90H21EOLACvtfcHk0lj9wvZ3LLHJyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D&md5=b36479dbb36763237e2183f3c773e979</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961764-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961764-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DArbter%26aufirst%3DD.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DSecond-generation%2520versus%2520first-generation%2520antipsychotic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS0140-6736%2808%2961764-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordström, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesel, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedvall, G.</span></span> <span> </span><span class="NLM_article-title">Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">538</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.1992.01820070032005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1001%2Farchpsyc.1992.01820070032005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1352677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK38zivVKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1992&pages=538-544&author=L.+Fardeauthor=A.+L.+Nordstr%C3%B6mauthor=F.+A.+Wieselauthor=S.+Pauliauthor=C.+Halldinauthor=G.+Sedvall&title=Positron+emission+tomographic+analysis+of+central+D1+and+D2+dopamine+receptor+occupancy+in+patients+treated+with+classical+neuroleptics+and+clozapine.+Relation+to+extrapyramidal+side+effects&doi=10.1001%2Farchpsyc.1992.01820070032005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects</span></div><div class="casAuthors">Farde L; Nordstrom A L; Wiesel F A; Pauli S; Halldin C; Sedvall G</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">538-44</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Positron emission tomography and selective radioligands were used to determine D1 and D2 dopamine receptor occupancy induced by neuroleptics in the basal ganglia of drug-treated schizophrenic patients.  In 22 patients treated with conventional dosages of classical neuroleptics, the D2 occupancy was 70% to 89%.  Patients with acute extrapyramidal syndromes had a higher D2 occupancy than those without side effects.  This finding indicates that neuroleptic-induced extrapyramidal syndromes are related to the degree of central D2 occupancy induced in the basal ganglia.  In five patients treated with clozapine, the prototype atypical antipsychotic drug, a lower D2 occupancy of 38% to 63% was found.  This finding demonstrates that clozapine is also "atypical" with respect to the central D2 occupancy in patients.  During treatment with clozapine, there is a low frequency of extrapyramidal syndromes, which accordingly may reflect the comparatively low D2 occupancy induced by clinical doses of clozapine.  Classical neuroleptics, like haloperidol or sulpiride, did not cause any evident D1 occupancy, but the thioxanthene flupentixol induced a 36% to 44% occupancy.  In four patients treated with clozapine, the D1 occupancy was 38% to 52%.  The D1 occupancy induced by clozapine and flupentixol may contribute to the antipsychotic effect of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8O-69J5LclwvupmecNw_lfW6udTcc2eZdO1zVOoaHFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zivVKgug%253D%253D&md5=9c70724d8c7ca998bd4f0154101b0d7d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1992.01820070032005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1992.01820070032005%26sid%3Dliteratum%253Aachs%26aulast%3DFarde%26aufirst%3DL.%26aulast%3DNordstr%25C3%25B6m%26aufirst%3DA.%2BL.%26aulast%3DWiesel%26aufirst%3DF.%2BA.%26aulast%3DPauli%26aufirst%3DS.%26aulast%3DHalldin%26aufirst%3DC.%26aulast%3DSedvall%26aufirst%3DG.%26atitle%3DPositron%2520emission%2520tomographic%2520analysis%2520of%2520central%2520D1%2520and%2520D2%2520dopamine%2520receptor%2520occupancy%2520in%2520patients%2520treated%2520with%2520classical%2520neuroleptics%2520and%2520clozapine.%2520Relation%2520to%2520extrapyramidal%2520side%2520effects%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1992%26volume%3D49%26spage%3D538%26epage%3D544%26doi%3D10.1001%2Farchpsyc.1992.01820070032005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefkowitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrie, F.</span></span> <span> </span><span class="NLM_article-title">Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">2244</span>– <span class="NLM_lpage">2253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=416027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE1cXlslemsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1978&pages=2244-2253&author=M.+G.+Caronauthor=M.+Beaulieuauthor=V.+Raymondauthor=B.+Gagneauthor=J.+Drouinauthor=R.+J.+Lefkowitzauthor=F.+Labrie&title=Dopaminergic+receptors+in+the+anterior+pituitary+gland.+Correlation+of+%5B3H%5Ddihydroergocryptine+binding+with+the+dopaminergic+control+of+prolactin+release"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Dopaminergic receptors in the anterior pituitary gland.  Correlation of [3H]-dihydroergocryptine binding with the dopaminergic control of prolactin release</span></div><div class="casAuthors">Caron, Marc G.; Beaulieu, Michele; Raymond, Vincent; Gagne, Bernard; Drouin, Jacques; Lefkowitz, Robert J.; Labrie, Fernand</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2244-53</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The ergot alkaloid [3H]-labeled dihydroergocryptine (I)  [25447-66-9], a potent dopaminergic agonist, has been used to study binding sites in bovine anterior pituitary membranes.  One function of the anterior pituitary gland, prolactin  [9002-62-4] secretion, is under typical dopaminergic control and was measured in vitro in another series of expts. using rat anterior pituitary cells in primary culture in order to establish a correlation between binding and a biol. function.  The dopaminergic specificity of ligand binding and the biol. process was demonstrated by the fact that agonists competed for [3H]-I binding and inhibited prolactin release with an identical order of potency: apomorphine > dopamine > epinephrine ≥ norepinephrine » isoproterenol.  Ergot alkaloids, which behave as agonists in this system, potently inhibited prolactin release from pituitary cells to about the same extent as dopamine (80-90% of basal levels) and were potent competitors of [3H]-I binding (KD 0.2-0.5 nM).  Dopaminergic antagonists competed for [3H]-I binding in bovine anterior pituitary membranes in parallel to their ability to reverse either dopamine or dihydroergocornine inhibition of prolactin release from rat anterior pituitary cells.  [3H]-I binding fulfilled another criterion of specific receptor sites in that binding to the anterior pituitary sites was saturable with an apparent dissocn. const. (KD) of 2.2 nM and a mean satn. value of 0.32 pmol/mg of protein.  The close correlation which exists between the properties of [3H]-I binding to pituitary membrane receptors and characteristics of modulation of prolactin secretion by dopaminergic agents suggests that [3H]-I binding sites are assocd. with mammotrophs and that these dopaminergic binding sites modulate prolactin secretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5xLpyUbMoybVg90H21EOLACvtfcHk0ljj58A2IsahwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXlslemsbk%253D&md5=b15b2c147f75780e5faeddb610da7d63</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBeaulieu%26aufirst%3DM.%26aulast%3DRaymond%26aufirst%3DV.%26aulast%3DGagne%26aufirst%3DB.%26aulast%3DDrouin%26aufirst%3DJ.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DLabrie%26aufirst%3DF.%26atitle%3DDopaminergic%2520receptors%2520in%2520the%2520anterior%2520pituitary%2520gland.%2520Correlation%2520of%2520%255B3H%255Ddihydroergocryptine%2520binding%2520with%2520the%2520dopaminergic%2520control%2520of%2520prolactin%2520release%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1978%26volume%3D253%26spage%3D2244%26epage%3D2253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casey, D. E.</span></span> <span> </span><span class="NLM_article-title">Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/0920-9964(91)90029-Q</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2F0920-9964%2891%2990029-Q" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1674881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK3M3kvVOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=109-120&author=D.+E.+Casey&title=Neuroleptic+drug-induced+extrapyramidal+syndromes+and+tardive+dyskinesia&doi=10.1016%2F0920-9964%2891%2990029-Q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia</span></div><div class="casAuthors">Casey D E</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-20</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">Neuroleptic (antipsychotic) drug-induced acute extrapyramidal syndromes (EPS) and the late onset tardive dyskinesia (TD) are the major side effects that limit the use of these highly efficacious agents.  The appropriate strategy for controlling these side effects is based on the clinical presentations, pathophysiological mechanisms, and contributions of patient and treatment-related risk factors.  New information about the mechanisms of action of neuroleptics and the long-term outcome of acute EPS and TD provide valuable insights into these syndromes.  The most effective method for maximizing the benefits and minimizing the risks of neuroleptics is to use the lowest effective dose of both neuroleptic and antiEPS drugs in patients who benefit from them.  The next major advancement will be to develop new compounds which effectively control psychotic symptoms and are free of the undesirable acute and tardive motor syndromes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQMvSHYz0v3bjMsgLhIoICsfW6udTcc2eZdO1zVOoaHFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3M3kvVOqsg%253D%253D&md5=6b24bae598ccd63cb71ccd1d7b43b86d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0920-9964%2891%2990029-Q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0920-9964%252891%252990029-Q%26sid%3Dliteratum%253Aachs%26aulast%3DCasey%26aufirst%3DD.%2BE.%26atitle%3DNeuroleptic%2520drug-induced%2520extrapyramidal%2520syndromes%2520and%2520tardive%2520dyskinesia%26jtitle%3DSchizophr.%2520Res.%26date%3D1991%26volume%3D4%26spage%3D109%26epage%3D120%26doi%3D10.1016%2F0920-9964%2891%2990029-Q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leucht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitschel-Walz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissling, W.</span></span> <span> </span><span class="NLM_article-title">Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</span>. <i>Schizophr. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/S0920-9964(98)00105-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0920-9964%2898%2900105-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=9988841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M7ktlertA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1999&pages=51-68&author=S.+Leuchtauthor=G.+Pitschel-Walzauthor=D.+Abrahamauthor=W.+Kissling&title=Efficacy+and+extrapyramidal+side-effects+of+the+new+antipsychotics+olanzapine%2C+quetiapine%2C+risperidone%2C+and+sertindole+compared+to+conventional+antipsychotics+and+placebo.+A+meta-analysis+of+randomized+controlled+trials&doi=10.1016%2FS0920-9964%2898%2900105-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</span></div><div class="casAuthors">Leucht S; Pitschel-Walz G; Abraham D; Kissling W</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-68</span>
        ISSN:<span class="NLM_cas:issn">0920-9964</span>.
    </div><div class="casAbstract">The objective of this meta-analysis is to summarize the efficacy and tolerability of the new antipsychotics risperidone, olanzapine, sertindole and quetiapine in schizophrenia compared to placebo and conventional antipsychotics.  The main results are: (1) All of the 4 new drugs are more effective than placebo, but the magnitude of the effect is only moderate [mean effect size, r, of all antipsychotics vs. placebo = 0.25, with a 95% confidence interval (CI) = 0.22-0.28, n = 2477]. (2) According to the studies published to date, sertindole and quetiapine are as effective as haloperidol, and risperidone and olanzapine are slightly more effective than haloperidol in the treatment of global schizophrenic symptomatology. (3) With respect to negative symptoms, all new antipsychotics are more effective than placebo.  However, contrary to widespread opinion, so is the 'conventional' antipsychotic haloperidol.  Risperidone and olanzapine are slightly superior, sertindole is as effective and--according to the only study fully published to date--quetiapine is even slightly less effective than haloperidol in this regard. (4) All new antipsychotics are associated with less frequent use of antiparkinson medication than haloperidol, with risperidone appearing to have a slightly less favourable EPS-profile than the other new antipsychotics.  The methodological limitations of this review, the generalizability of the results and expectations from future research are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhsUl8IaevAnRxY89Cm6SyfW6udTcc2eZCKcQzJlQy17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7ktlertA%253D%253D&md5=25d3d49faa367fabef02c6bcfc5349d6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0920-9964%2898%2900105-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0920-9964%252898%252900105-4%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DPitschel-Walz%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DD.%26aulast%3DKissling%26aufirst%3DW.%26atitle%3DEfficacy%2520and%2520extrapyramidal%2520side-effects%2520of%2520the%2520new%2520antipsychotics%2520olanzapine%252C%2520quetiapine%252C%2520risperidone%252C%2520and%2520sertindole%2520compared%2520to%2520conventional%2520antipsychotics%2520and%2520placebo.%2520A%2520meta-analysis%2520of%2520randomized%2520controlled%2520trials%26jtitle%3DSchizophr.%2520Res.%26date%3D1999%26volume%3D35%26spage%3D51%26epage%3D68%26doi%3D10.1016%2FS0920-9964%2898%2900105-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halbreich, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, L. S.</span></span> <span> </span><span class="NLM_article-title">Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects</span>. <i>Psychoneuroendocrinology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/S0306-4530(02)00112-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0306-4530%2802%2900112-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=12504072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD38jkt1Cltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=53-67&author=U.+Halbreichauthor=B.+J.+Kinonauthor=J.+A.+Gilmoreauthor=L.+S.+Kahn&title=Elevated+prolactin+levels+in+patients+with+schizophrenia%3A+mechanisms+and+related+adverse+effects&doi=10.1016%2FS0306-4530%2802%2900112-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects</span></div><div class="casAuthors">Halbreich U; Kinon B J; Gilmore J A; Kahn L S</div><div class="citationInfo"><span class="NLM_cas:title">Psychoneuroendocrinology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28 Suppl 1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-67</span>
        ISSN:<span class="NLM_cas:issn">0306-4530</span>.
    </div><div class="casAbstract">The neurologic processes involved in schizophrenia are complex and diverse and the mechanisms through which antipsychotic agents exert their effects have been only partly elucidated.  Hyperprolactinemia is a common side effect of treatment with many antipsychotics and is particularly associated with conventional ('typical') agents as well as the atypical antipsychotic risperidone.  In contrast, other atypical agents introduced over the last decade do not elevate prolactin levels.  This article discusses the regulatory mechanisms involved in prolactin secretion, the physiologic role of prolactin, and the etiology of hyperprolactinemia.  Elevated prolactin levels may play important roles, both direct and indirect, in various pathologic states, including breast cancer, osteoporosis, cardiovascular disorders, and sexual disturbances.  Antipsychotic-induced hyperprolactinemia may be associated with similar clinical manifestations; these are examined with particular reference to patients with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBznfB6Mf3oJdYoSR9eyvsfW6udTcc2eZCKcQzJlQy17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jkt1Cltw%253D%253D&md5=5a1215eb750272fc987495ba22e076ae</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS0306-4530%2802%2900112-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4530%252802%252900112-9%26sid%3Dliteratum%253Aachs%26aulast%3DHalbreich%26aufirst%3DU.%26aulast%3DKinon%26aufirst%3DB.%2BJ.%26aulast%3DGilmore%26aufirst%3DJ.%2BA.%26aulast%3DKahn%26aufirst%3DL.%2BS.%26atitle%3DElevated%2520prolactin%2520levels%2520in%2520patients%2520with%2520schizophrenia%253A%2520mechanisms%2520and%2520related%2520adverse%2520effects%26jtitle%3DPsychoneuroendocrinology%26date%3D2003%26volume%3D28%26spage%3D53%26epage%3D67%26doi%3D10.1016%2FS0306-4530%2802%2900112-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mauri, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maffini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colasanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragogna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pace, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, A. C.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of atypical antipsychotics: an update</span>. <i>EXCLI J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26417330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC283ntFCmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1163-1191&author=M.+C.+Mauriauthor=S.+Palettaauthor=M.+Maffiniauthor=A.+Colasantiauthor=F.+Dragognaauthor=C.+Di+Paceauthor=A.+C.+Altamura&title=Clinical+pharmacology+of+atypical+antipsychotics%3A+an+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of atypical antipsychotics: an update</span></div><div class="casAuthors">Mauri M C; Paletta S; Maffini M; Dragogna F; Di Pace C; Altamura A C; Colasanti A</div><div class="citationInfo"><span class="NLM_cas:title">EXCLI journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1163-91</span>
        ISSN:<span class="NLM_cas:issn">1611-2156</span>.
    </div><div class="casAbstract">This review will concentrate on the clinical pharmacology, in particular pharmacodynamic data, related to atypical antipsychotics, clozapine, risperidone, paliperidone, olanzapine, que(logical not)tiapine, amisulpride, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone and cariprazine.  A summary of their acute pharmacokinetics properties are also reported.  Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine.  Similar to ziprasidone and aripiprazole, these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second-generation antipsychotics such as olanzapine or clozapine.  Actually lurasidone seems to be best in terms of minimizing unwanted alterations in body weight and metabolic variables.  Therapeutic drug monitoring is not strictly necessary for all of the new antipsychotic drugs because there are no unequivocal data supporting a relationship between plasma drug levels and clinical outcomes or side effects.  The exception can be represented by clozapine for which plasma levels of 350-420 ng/ml are reported to be associated with an increased probability of a good clinical response.  Also for olanzapine an established therapeutic range (20-50 ng/ml) is proposed to yield an optimal response and minimize side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdCpEGnFjeucNIRw0GKUoEfW6udTcc2eZCKcQzJlQy17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ntFCmsQ%253D%253D&md5=5f02f9f9b62bd78ec8db80168727f5d9</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMauri%26aufirst%3DM.%2BC.%26aulast%3DPaletta%26aufirst%3DS.%26aulast%3DMaffini%26aufirst%3DM.%26aulast%3DColasanti%26aufirst%3DA.%26aulast%3DDragogna%26aufirst%3DF.%26aulast%3DDi%2BPace%26aufirst%3DC.%26aulast%3DAltamura%26aufirst%3DA.%2BC.%26atitle%3DClinical%2520pharmacology%2520of%2520atypical%2520antipsychotics%253A%2520an%2520update%26jtitle%3DEXCLI%2520J.%26date%3D2014%26volume%3D13%26spage%3D1163%26epage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroeze, W. K.</span></span> <span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">353</span>, <span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ljb-8itJtFSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remington, G.</span></span> <span> </span><span class="NLM_article-title">Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(01)01251-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS0006-3223%2801%2901251-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=11743942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFyqsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2001&pages=873-883&author=S.+Kapurauthor=G.+Remington&title=Dopamine+D%282%29+receptors+and+their+role+in+atypical+antipsychotic+action%3A+still+necessary+and+may+even+be+sufficient&doi=10.1016%2FS0006-3223%2801%2901251-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient</span></div><div class="casAuthors">Kapur, Shitij; Remington, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">873-883</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  "Atypical" antipsychotics are assocd. with a much lower propensity for extrapyramidal side effects and, with some exceptions, a lack of sustained prolactin elevation.  The authors propose that a low-affinity and fast dissocn. (in mol. terms) from the dopamine D2 receptor, along with administration of the drug in doses that lead to appropriate levels of dopamine D2 receptor blockade, are the most important requirements for atypicality.  Actions at other receptors (5-HT2, D4, etc.) may not be necessary to achieve atypicality, and while action at these receptors may have benefits on symptoms such as mood and cognition, this is as yet to be conclusively proven.  Why clozapine is effective in refractory patients is still elusive and efforts to make antipsychotics that are devoid of effects on the dopamine D2 receptors so far have been unsuccessful.  In light of this, the authors provide a heuristic model linking pathophysiol. and therapeutics and suggest that the ideal treatment for schizophrenia is unlikely to be single-drug with multireceptor blockade (a sort of one-size-fits-all polypharmacy) but will require several specific and targeted treatment strategies that are titrated to match the variable expression of different dimensions of schizophrenia in each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_C5zIWSvcrrVg90H21EOLACvtfcHk0ljb-8itJtFSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFyqsrk%253D&md5=0f6b6137825f2345542f4531be72d42c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2801%2901251-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252801%252901251-3%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DRemington%26aufirst%3DG.%26atitle%3DDopamine%2520D%25282%2529%2520receptors%2520and%2520their%2520role%2520in%2520atypical%2520antipsychotic%2520action%253A%2520still%2520necessary%2520and%2520may%2520even%2520be%2520sufficient%26jtitle%3DBiol.%2520Psychiatry%26date%3D2001%26volume%3D50%26spage%3D873%26epage%3D883%26doi%3D10.1016%2FS0006-3223%2801%2901251-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=2571717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=238-246&author=H.+Y.+Meltzerauthor=S.+Matsubaraauthor=J.+C.+Lee&title=Classification+of+typical+and+atypical+antipsychotic+drugs+on+the+basis+of+dopamine+D-1%2C+D-2+and+serotonin2+pKi+values"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values</span></div><div class="casAuthors">Meltzer, Herbert Y.; Matsubara, Shigehiro; Lee, Jar Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-46</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The pKi values of 38 typical and atypical antipsychotic drugs (APD) for 5-HT2, D-1 and D-2 binding sites in rat brain have been detd.  Multivariate analytic techniques demonstrate the importance of the D-2 and 5-HT2 affinities for detg. whether a drug which can block the conditioned avoidance response will have atypical properties as an antipsychotic.  A 5-HT2/D-2 ratio ≥1.12 is characteristic of the atypical APD.  These results may be useful in drug screening programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqCUl6xIvXorVg90H21EOLACvtfcHk0ljb-8itJtFSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmt1Cksb4%253D&md5=0f46fdcc98abf7d93d7ea102ac30df84</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer%26aufirst%3DH.%2BY.%26aulast%3DMatsubara%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DClassification%2520of%2520typical%2520and%2520atypical%2520antipsychotic%2520drugs%2520on%2520the%2520basis%2520of%2520dopamine%2520D-1%252C%2520D-2%2520and%2520serotonin2%2520pKi%2520values%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26spage%3D238%26epage%3D246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frånberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konradsson-Geuken, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardemark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, T.</span></span> <span> </span><span class="NLM_article-title">Adjunctive alpha(2)-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1017/S1461145709990794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1017%2FS1461145709990794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19835668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Gjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=891-903&author=M.+Marcusauthor=C.+Wikerauthor=O.+Fr%C3%A5nbergauthor=A.+Konradsson-Geukenauthor=X.+Langloisauthor=K.+Jardemarkauthor=T.+Svensson&title=Adjunctive+alpha%282%29-adrenoceptor+blockade+enhances+the+antipsychotic-like+effect+of+risperidone+and+facilitates+cortical+dopaminergic+and+glutamatergic%2C+NMDA+receptor-mediated+transmission&doi=10.1017%2FS1461145709990794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission</span></div><div class="casAuthors">Marcus, Monica M.; Wiker, Charlotte; Franberg, Olivia; Konradsson-Geuken, Aasa; Langlois, Xavier; Jardemark, Kent; Svensson, Torgny H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">891-903</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">Compared to both first- and second-generation antipsychotic drugs (APDs), clozapine shows superior efficacy in treatment-resistant schizophrenia.  In contrast to most APDs clozapine possesses high affinity for α2-adrenoceptors, and clin. and preclin. studies provide evidence that the α2-adrenoceptor antagonist idazoxan enhances the antipsychotic efficacy of typical D2 receptor antagonists as well as olanzapine.  Risperidone has lower affinity for α2-adrenoceptors than clozapine but higher than most other APDs.  Here we examd., in rats, the effects of adding idazoxan to risperidone on antipsychotic effect using the conditioned avoidance response (CAR) test, extrapyramidal side-effect (EPS) liability using the catalepsy test, brain dopamine efflux using in-vivo microdialysis in freely moving animals, cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission using intracellular electrophysiol. recording in vitro, and ex-vivo autoradiog. to assess the in-vivo α2A- and α2C-adrenoceptor occupancies by risperidone.  The dose of risperidone needed for antipsychotic effect in the CAR test was ∼0.4 mg/kg, which produced 11% and 17% in-vivo receptor occupancy at α2A- and α2C-adrenoceptors, resp.  Addn. of idazoxan (1.5 mg/kg) to a low dose of risperidone (0.25 mg/kg) enhanced the suppression of CAR, but did not enhance catalepsy.  Both cortical dopamine release and NMDA receptor-mediated responses were enhanced.  These data propose that the therapeutic effect of risperidone in schizophrenia can be enhanced and its EPS liability reduced by adjunctive treatment with an α2-adrenoceptor antagonist, and generally support the notion that the potent α2-adrenoceptor antagonistic action of clozapine may be highly important for its unique efficacy in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1gqInc0lUBLVg90H21EOLACvtfcHk0ljb-8itJtFSpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Gjsbk%253D&md5=65bab480c432b66d2cf3b7497ddcfa68</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1017%2FS1461145709990794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145709990794%26sid%3Dliteratum%253Aachs%26aulast%3DMarcus%26aufirst%3DM.%26aulast%3DWiker%26aufirst%3DC.%26aulast%3DFr%25C3%25A5nberg%26aufirst%3DO.%26aulast%3DKonradsson-Geuken%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DX.%26aulast%3DJardemark%26aufirst%3DK.%26aulast%3DSvensson%26aufirst%3DT.%26atitle%3DAdjunctive%2520alpha%25282%2529-adrenoceptor%2520blockade%2520enhances%2520the%2520antipsychotic-like%2520effect%2520of%2520risperidone%2520and%2520facilitates%2520cortical%2520dopaminergic%2520and%2520glutamatergic%252C%2520NMDA%2520receptor-mediated%2520transmission%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2010%26volume%3D13%26spage%3D891%26epage%3D903%26doi%3D10.1017%2FS1461145709990794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horacek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubenikova-Valesova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palenicek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockery, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoschl, C.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">409</span>, <span class="refDoi"> DOI: 10.2165/00023210-200620050-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.2165%2F00023210-200620050-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=16696579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=389-409&author=J.+Horacekauthor=V.+Bubenikova-Valesovaauthor=M.+Kopecekauthor=T.+Palenicekauthor=C.+Dockeryauthor=P.+Mohrauthor=C.+Hoschl&title=Mechanism+of+action+of+atypical+antipsychotic+drugs+and+the+neurobiology+of+schizophrenia&doi=10.2165%2F00023210-200620050-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of atypical antipsychotic drugs and the neurobiology and schizophrenia</span></div><div class="casAuthors">Horacek, Jiri; Bubenikova-Valesova, Vera; Kopecek, Milan; Palenicek, Tomas; Dockery, Colleen; Mohr, Pavel; Hoschl, Cyril</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">389-409</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Atypical antipsychotics have greatly enhanced the treatment of schizophrenia.  The mechanisms underlying the effectiveness and adverse effects of these drugs are, to date, not sufficiently explained.  This article summarizes the hypothetical mechanisms of action of atypical antipsychotics with respect to the neurobiol. of schizophrenia.  When considering treatment models for schizophrenia, the role of dopamine receptor blockade and modulation remains dominant.  The optimal occupancy of dopamine D2 receptors seems to be crucial to balancing efficacy and adverse effects - transient D2 receptor antagonism (such as that attained with, for example, quetiapine and clozapine) is sufficient to obtain an antipsychotic effect, while permanent D2 receptor antagonism (as is caused by conventional antipsychotics) increases the risk of adverse effects such as extrapyramidal symptoms.  Partial D2 receptor agonism (induced by aripiprazole) offers the possibility of maintaining optimal blockade and function of D2 receptors.  Balancing presynaptic and post-synaptic D2 receptor antagonism (e.g. induced by amisulpride) is another mechanism that can, through increased release of endogenous dopamine in the striatum, protect against excessive blockade of D2 receptors.  Serotonergic modulation is assocd. with a beneficial increase in striatal dopamine release.  Effects on the neg. and cognitive symptoms of schizophrenia relate to dopamine release in the prefrontal cortex; this can be modulated by combined D2 and serotonin 5-HT2A receptor antagonism (e.g. by olanzapine and risperidone), partial D2 receptor antagonism or the preferential blockade of inhibitory dopamine autoreceptors.  In the context of the neurodevelopmental disconnection hypothesis of schizophrenia, atypical antipsychotics (in contrast to conventional antipsychotics) induce neuronal plasticity and synaptic remodelling, not only in the striatum but also in other brain areas such as the prefrontal cortex and hippocampus.  This mechanism may normalize glutamatergic dysfunction and structural abnormalities and affect the core pathophysiol. substrates for schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7XN_qERk6M7Vg90H21EOLACvtfcHk0ljxd8hDeHaRSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFyqu78%253D&md5=7110d0f95ae4dfd01395ae371feb59e2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2165%2F00023210-200620050-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00023210-200620050-00004%26sid%3Dliteratum%253Aachs%26aulast%3DHoracek%26aufirst%3DJ.%26aulast%3DBubenikova-Valesova%26aufirst%3DV.%26aulast%3DKopecek%26aufirst%3DM.%26aulast%3DPalenicek%26aufirst%3DT.%26aulast%3DDockery%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DHoschl%26aufirst%3DC.%26atitle%3DMechanism%2520of%2520action%2520of%2520atypical%2520antipsychotic%2520drugs%2520and%2520the%2520neurobiology%2520of%2520schizophrenia%26jtitle%3DCNS%2520Drugs%26date%3D2006%26volume%3D20%26spage%3D389%26epage%3D409%26doi%3D10.2165%2F00023210-200620050-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.158.3.360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1176%2Fappi.ajp.158.3.360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=11229973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2001&pages=360-369&author=S.+Kapurauthor=P.+Seeman&title=Does+fast+dissociation+from+the+dopamine+d%282%29+receptor+explain+the+action+of+atypical+antipsychotics%3F%3A+A+new+hypothesis&doi=10.1176%2Fappi.ajp.158.3.360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">360-9</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear.  This article provides a new hypothesis about the mechanism of action of atypical antipsychotics.  METHOD:  Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis.  Particular attention was paid to data regarding the role of the serotonin 5-HT(2) and dopamine D(4) receptors in atypicality.  RESULTS:  Neuroimaging data show that optimal dopamine D(2) occupancy is sufficient to produce the atypical antipsychotic effect.  Freedom from motor side effects results from low D(2) occupancy, not from high 5-HT(2) occupancy.  If D(2) occupancy is excessive, atypicality is lost even in the presence of high 5-HT(2) occupancy.  Animal data show that a rapid dissociation from the D(2) receptor at a molecular level produces the atypical antipsychotic effect.  In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D(2) receptor, not its high affinity at 5-HT(2), D(4), or another receptor.  CONCLUSIONS:  The authors propose that fast dissociation from the D(2) receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms.  In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D(2) receptor alone; the blockade of other receptors is neither necessary nor sufficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1OTyBcviHdd0Q2ypr7jHkfW6udTcc2ebNKVxFnM20DLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7pslSltg%253D%253D&md5=dae2a684b208e0fc09688835b0975c00</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.158.3.360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.158.3.360%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DDoes%2520fast%2520dissociation%2520from%2520the%2520dopamine%2520d%25282%2529%2520receptor%2520explain%2520the%2520action%2520of%2520atypical%2520antipsychotics%253F%253A%2520A%2520new%2520hypothesis%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2001%26volume%3D158%26spage%3D360%26epage%3D369%26doi%3D10.1176%2Fappi.ajp.158.3.360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raja, M.</span></span> <span> </span><span class="NLM_article-title">Clozapine safety, 35 years later</span>. <i>Curr. Drug. Saf.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.2174/157488611797579230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.2174%2F157488611797579230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22122392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSqurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=164-184&author=M.+Raja&title=Clozapine+safety%2C+35+years+later&doi=10.2174%2F157488611797579230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clozapine safety, 35 years later</span></div><div class="casAuthors">Raja, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Safety</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">164-184</span>CODEN:
                <span class="NLM_cas:coden">CDSUBQ</span>;
        ISSN:<span class="NLM_cas:issn">1574-8863</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clozapine is the best treatment option in several clin. circumstances, including treatment-resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease, prevention and treatment of tardive dyskinesia.  However, clozapine is assocd. with many serious side effects.  Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage clozapine use.  Therefore, the drug is underused.  The only way to avoid the underuse of clozapine is full awareness of its side effects and competence to minimize them.  The aim of the paper is reviewing the safety profile of clozapine and the suggested strategies in the management of its side effects, including neutropenia, eosinophilia, seizures, myocarditis, wt. gain, diabetes, metabolic syndrome, hypersalivation, fever, constipation, ileus, urinary incontinence, sweating.  The neuropsychiatric side effects of clozapine are not discussed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0try1-vfHQrVg90H21EOLACvtfcHk0ljxd8hDeHaRSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSqurvI&md5=87064fbb6bc705af4a4e0b262d7dfcee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F157488611797579230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488611797579230%26sid%3Dliteratum%253Aachs%26aulast%3DRaja%26aufirst%3DM.%26atitle%3DClozapine%2520safety%252C%252035%2520years%2520later%26jtitle%3DCurr.%2520Drug.%2520Saf.%26date%3D2011%26volume%3D6%26spage%3D164%26epage%3D184%26doi%3D10.2174%2F157488611797579230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span> <span> </span><span class="NLM_article-title">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span>. <i>J. Psychiatry Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10740989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=161-166&author=S.+Kapurauthor=P.+Seeman&title=Antipsychotic+agents+differ+in+how+fast+they+come+off+the+dopamine+D2+receptors.+Implications+for+atypical+antipsychotic+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action</span></div><div class="casAuthors">Kapur S; Seeman P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatry & neuroscience : JPN</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-6</span>
        ISSN:<span class="NLM_cas:issn">1180-4882</span>.
    </div><div class="casAbstract">RATIONALE AND OBJECTIVE:  While the blockade of dopamine D2 receptors are necessary for antipsychotic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor.  This affinity is determined by the rate at which the antipsychotic agent binds to (kon) and the rate at which it dissociates from (koff) the D2 receptors.  The objective of this study was to determine the relationship between kon, koff and the affinity (Ki) of antipsychotic agents for the D2 receptors, with particular reference to typical and atypical antipsychotic agents.  DESIGN:  The koff of several typical as well as atypical antipsychotic agents (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine and quetiapine) was measured in vitro using the 3H-radiolabelled analogues of these drugs.  The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro.  The kon was derived from values of affinity and ++koff.  MAIN OUTCOME MEASURES:  kon, koff, and the Ki of antipsychotic drugs.  RESULTS:  The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L).  The koff values varied a thousand-fold from 0.002 to 3.013 min-1, with relatively little variation in kon.  The rate at which antipsychotic agents come off the receptor (koff) accounted for 99% of the variation in their affinity for the D2 receptor; differences in kon did not account for differences in affinity.  CONCLUSIONS:  The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor.  These differences in koff may lead to functionally different kinds of dopamine blockade.  Drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission.  Since atypical drugs show a lower affinity and a faster dissociation, a higher koff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiFVfZJOQ7_1UIs6wFK5xJfW6udTcc2eaEJXaW5_LP5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3gsFWlsA%253D%253D&md5=bde1272de3b90ba1fd77b61805c3a39d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKapur%26aufirst%3DS.%26aulast%3DSeeman%26aufirst%3DP.%26atitle%3DAntipsychotic%2520agents%2520differ%2520in%2520how%2520fast%2520they%2520come%2520off%2520the%2520dopamine%2520D2%2520receptors.%2520Implications%2520for%2520atypical%2520antipsychotic%2520action%26jtitle%3DJ.%2520Psychiatry%2520Neurosci.%26date%3D2000%26volume%3D25%26spage%3D161%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0ljCFldxuTG5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">The role of target binding kinetics in drug discovery</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1796</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fcmdc.201500310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26506404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1793-1796&author=D.+Guoauthor=L.+H.+Heitmanauthor=A.+P.+IJzerman&title=The+role+of+target+binding+kinetics+in+drug+discovery&doi=10.1002%2Fcmdc.201500310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Target Binding Kinetics in Drug Discovery</span></div><div class="casAuthors">Guo, Dong; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1793-1796</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Traditionally structure-activity/affinity relationships (SAR) have dominated research in medicinal chem.  However, structure-kinetics relationships (SKR) can be very informative too.  In this viewpoint we explore the mol. determinants of binding kinetics and discuss challenges for future binding kinetics studies.  A scheme for future kinetics-directed drug design and discovery is also proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiX7v30ryLZLVg90H21EOLACvtfcHk0ljCFldxuTG5pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjurfF&md5=8442ba4d4ec014762ed470f7f6131d09</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500310%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DThe%2520role%2520of%2520target%2520binding%2520kinetics%2520in%2520drug%2520discovery%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1793%26epage%3D1796%26doi%3D10.1002%2Fcmdc.201500310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doornbos, M. L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cid, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haubrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sande, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermond, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanco, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahnaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drinkenburg, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and kinetic profiling of 7-aryl-1,2,4-triazolo[4,3-a]pyridines: positive allosteric modulators of the metabotropic glutamate receptor 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6704</span>– <span class="NLM_lpage">6720</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00669</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00669" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKkur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6704-6720&author=M.+L.+J.+Doornbosauthor=J.+M.+Cidauthor=J.+Haubrichauthor=A.+Nunesauthor=J.+W.+van+de+Sandeauthor=S.+C.+Vermondauthor=T.+Mulder-Kriegerauthor=A.+A.+Trabancoauthor=A.+Ahnaouauthor=W.+H.+Drinkenburgauthor=H.+Lavreysenauthor=L.+H.+Heitmanauthor=A.+P.+IJzermanauthor=G.+Tresadern&title=Discovery+and+kinetic+profiling+of+7-aryl-1%2C2%2C4-triazolo%5B4%2C3-a%5Dpyridines%3A+positive+allosteric+modulators+of+the+metabotropic+glutamate+receptor+2&doi=10.1021%2Facs.jmedchem.7b00669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2</span></div><div class="casAuthors">Doornbos, Maarten L. J.; Cid, Jose Maria; Haubrich, Jordi; Nunes, Alexandro; van de Sande, Jasper W.; Vermond, Sophie C.; Mulder-Krieger, Thea; Trabanco, Andres A.; Ahnaou, Abdellah; Drinkenburg, Wilhelmus H.; Lavreysen, Hilde; Heitman, Laura H.; IJzerman, Adriaan P.; Tresadern, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6704-6720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and biol. evaluation of a series of 7-aryl-1,2,4-triazolo[4,3-a]pyridines with mGlu2 pos. allosteric modulator (PAM) activity and affinity.  Besides traditional in vitro parameters of potency and affinity, kinetic parameters kon, koff and residence time (RT) were detd.  The PAMs showed various kinetic profiles; kon values ranged over 2 orders of magnitude, whereas RT values were within a 10-fold range.  Assocn. rate const. kon was linearly correlated to affinity.  Evaluation of a short, medium, and long RT compd. in a label-free assay indicated a correlation between RT and functional effect.  The effects of long RT compd. I on sleep-wake states indicated long RT was translated into sustained inhibition of rapid eye movement (REM) in vivo.  These results show that affinity-only driven selection would have resulted in mGlu2 PAMs with high values for kon but not necessarily optimized RT, which is key to predicting optimal efficacy in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL1g_fLH5q87Vg90H21EOLACvtfcHk0lhl6qLe3mJ6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKkur3E&md5=dfecd3e276e08955fd16e68ed27b3c20</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00669%26sid%3Dliteratum%253Aachs%26aulast%3DDoornbos%26aufirst%3DM.%2BL.%2BJ.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DHaubrich%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DA.%26aulast%3Dvan%2Bde%2BSande%26aufirst%3DJ.%2BW.%26aulast%3DVermond%26aufirst%3DS.%2BC.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26aulast%3DAhnaou%26aufirst%3DA.%26aulast%3DDrinkenburg%26aufirst%3DW.%2BH.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DTresadern%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520kinetic%2520profiling%2520of%25207-aryl-1%252C2%252C4-triazolo%255B4%252C3-a%255Dpyridines%253A%2520positive%2520allosteric%2520modulators%2520of%2520the%2520metabotropic%2520glutamate%2520receptor%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6704%26epage%3D6720%26doi%3D10.1021%2Facs.jmedchem.7b00669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, W. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veldhoven, J. P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiper, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duijl, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenselink, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paasman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Structure–affinity relationships and structure–kinetics relationships of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7555</span>– <span class="NLM_lpage">7568</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00950</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00950" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtleht7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7555-7568&author=L.+Xiaauthor=W.+A.+C.+Burgerauthor=J.+P.+D.+van+Veldhovenauthor=B.+J.+Kuiperauthor=T.+T.+van+Duijlauthor=E.+B.+Lenselinkauthor=E.+Paasmanauthor=L.+H.+Heitmanauthor=A.+P.+Ijzerman&title=Structure%E2%80%93affinity+relationships+and+structure%E2%80%93kinetics+relationships+of+pyrido%5B2%2C1-f%5Dpurine-2%2C4-dione+derivatives+as+human+adenosine+A3+receptor+antagonists&doi=10.1021%2Facs.jmedchem.7b00950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists</span></div><div class="casAuthors">Xia, Lizi; Burger, Wessel A. C.; van Veldhoven, Jacobus P. D.; Kuiper, Boaz J.; van Duijl, Tirsa T.; Lenselink, Eelke B.; Paasman, Ellen; Heitman, Laura H.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7555-7568</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivs. as human adenosine A3 receptor (hA3R) antagonists to det. their kinetic profiles and affinities.  Many compds. showed high affinities and a diverse range of kinetic profiles.  We found hA3R antagonists with very short residence time (RT) at the receptor (2.2 min for II 5) and much longer RTs (e.g., 376 min for I or 391 min for 31).  Two representative antagonists (I) and (II) were tested in [35S]GTPγS binding assays, and their RTs appeared correlated to their (in)surmountable antagonism.  From a kon-koff-KD kinetic map, we divided the antagonists into three subgroups, providing a possible direction for the further development of hA3R antagonists.  Addnl., we performed a computational modeling study that sheds light on the crucial receptor interactions, dictating the compds.' binding kinetics.  Knowledge of target binding kinetics appears useful for developing and triaging new hA3R antagonists in the early phase of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiyuuEVYMqbVg90H21EOLACvtfcHk0lhl6qLe3mJ6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtleht7fN&md5=a5e396ed21c6d4349d8128e5a590e21b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00950%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DW.%2BA.%2BC.%26aulast%3Dvan%2BVeldhoven%26aufirst%3DJ.%2BP.%2BD.%26aulast%3DKuiper%26aufirst%3DB.%2BJ.%26aulast%3Dvan%2BDuijl%26aufirst%3DT.%2BT.%26aulast%3DLenselink%26aufirst%3DE.%2BB.%26aulast%3DPaasman%26aufirst%3DE.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DStructure%25E2%2580%2593affinity%2520relationships%2520and%2520structure%25E2%2580%2593kinetics%2520relationships%2520of%2520pyrido%255B2%252C1-f%255Dpurine-2%252C4-dione%2520derivatives%2520as%2520human%2520adenosine%2520A3%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7555%26epage%3D7568%26doi%3D10.1021%2Facs.jmedchem.7b00950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilums, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweemer, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wapenaar, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, I. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barmare, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brussee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Structure–kinetic relationships—An overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7706</span>– <span class="NLM_lpage">7714</span>, <span class="refDoi"> DOI: 10.1021/jm4011737</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011737" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeksbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7706-7714&author=M.+Vilumsauthor=A.+J.+M.+Zweemerauthor=Z.+Yuauthor=H.+de+Vriesauthor=J.+M.+Hillgerauthor=H.+Wapenaarauthor=I.+A.+E.+Bollenauthor=F.+Barmareauthor=R.+Grossauthor=J.+Clemensauthor=P.+Krenitskyauthor=J.+Brusseeauthor=D.+Stamosauthor=J.+Saundersauthor=L.+H.+Heitmanauthor=A.+P.+Ijzerman&title=Structure%E2%80%93kinetic+relationships%E2%80%94An+overlooked+parameter+in+hit-to-lead+optimization%3A+a+case+of+cyclopentylamines+as+chemokine+receptor+2+antagonists&doi=10.1021%2Fjm4011737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Kinetic Relationships-An Overlooked Parameter in Hit-to-Lead Optimization: A Case of Cyclopentylamines as Chemokine Receptor 2 Antagonists</span></div><div class="casAuthors">Vilums, Maris; Zweemer, Annelien J. M.; Yu, Zhiyi; de Vries, Henk; Hillger, Julia M.; Wapenaar, Hannah; Bollen, Ilse A. E.; Barmare, Farhana; Gross, Raymond; Clemens, Jeremy; Krenitsky, Paul; Brussee, Johannes; Stamos, Dean; Saunders, John; Heitman, Laura H.; Ijzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7706-7714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Preclin. models of inflammatory diseases (e.g., neuropathic pain, rheumatoid arthritis, and multiple sclerosis) have pointed to a crit. role of the chemokine receptor 2 (CCR2) and chemokine ligand 2 (CCL2).  However, one of the biggest problems of high-affinity inhibitors of CCR2 is their lack of efficacy in clin. trials.  We report a new approach for the design of high-affinity and long-residence-time CCR2 antagonists.  We developed a new competition assocn. assay for CCR2, which allows us to investigate the relation of the structure of the ligand and its receptor residence time [i.e., structure-kinetic relationship (SKR)] next to a traditional structure-affinity relationship (SAR).  By applying combined knowledge of SAR and SKR, we were able to re-evaluate the hit-to-lead process of cyclopentylamines as CCR2 antagonists.  Affinity-based optimization yielded compd. 1 with good binding (Ki = 6.8 nM) but very short residence time (2.4 min).  However, when the optimization was also based on residence time, the hit-to-lead process yielded compd. 22a, a new high-affinity CCR2 antagonist (3.6 nM), with a residence time of 135 min.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsuB8fdAy3j7Vg90H21EOLACvtfcHk0lhl6qLe3mJ6Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeksbvM&md5=9cd60706c51fa9d58b7674d069d21433</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm4011737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011737%26sid%3Dliteratum%253Aachs%26aulast%3DVilums%26aufirst%3DM.%26aulast%3DZweemer%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3Dde%2BVries%26aufirst%3DH.%26aulast%3DHillger%26aufirst%3DJ.%2BM.%26aulast%3DWapenaar%26aufirst%3DH.%26aulast%3DBollen%26aufirst%3DI.%2BA.%2BE.%26aulast%3DBarmare%26aufirst%3DF.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DClemens%26aufirst%3DJ.%26aulast%3DKrenitsky%26aufirst%3DP.%26aulast%3DBrussee%26aufirst%3DJ.%26aulast%3DStamos%26aufirst%3DD.%26aulast%3DSaunders%26aufirst%3DJ.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DStructure%25E2%2580%2593kinetic%2520relationships%25E2%2580%2594An%2520overlooked%2520parameter%2520in%2520hit-to-lead%2520optimization%253A%2520a%2520case%2520of%2520cyclopentylamines%2520as%2520chemokine%2520receptor%25202%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7706%26epage%3D7714%26doi%3D10.1021%2Fjm4011737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tautermann, C. S.</span></span> <span> </span><span class="NLM_article-title">Impact, determination and prediction of drug–receptor residence times for GPCRs</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2016.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.coph.2016.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27428776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=22-26&author=C.+S.+Tautermann&title=Impact%2C+determination+and+prediction+of+drug%E2%80%93receptor+residence+times+for+GPCRs&doi=10.1016%2Fj.coph.2016.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Impact, determination and prediction of drug-receptor residence times for GPCRs</span></div><div class="casAuthors">Tautermann, Christofer S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-26</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The residence time of a ligand on a GPCR of interest has become an optimization parameter in many examples in drug design.  Long residence times can counterbalance unfavorable pharmacokinetic parameters, contributing to compd. safety, and short residence times can be a tool to avoid target related side effects.  Unlike the prediction and interpretation of the structure-activity relationship (SAR) of a ligand class on a receptor, the understanding and prediction of the structure-kinetics relationship (SKR) is much more demanding.  Exptl. and computational approaches are described, which serve to either rationalize SKR or to predict the kinetic parameters such as on-rates and off-rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlEDDF8NqsbLVg90H21EOLACvtfcHk0ljiZRaAQqQuVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyhsr%252FP&md5=fc383a7d2be13b0c0d71d45d0bdba187</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2016.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2016.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DTautermann%26aufirst%3DC.%2BS.%26atitle%3DImpact%252C%2520determination%2520and%2520prediction%2520of%2520drug%25E2%2580%2593receptor%2520residence%2520times%2520for%2520GPCRs%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2016%26volume%3D30%26spage%3D22%26epage%3D26%26doi%3D10.1016%2Fj.coph.2016.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span> <span> </span><span class="NLM_article-title">In vivo target residence time and kinetic selectivity: The association rate constant as determinant</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.tips.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27394919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=831-842&author=W.+E.+A.+de%0AWitteauthor=M.+Danhofauthor=P.+H.+van+der+Graafauthor=E.+C.+M.+de+Lange&title=In+vivo+target+residence+time+and+kinetic+selectivity%3A+The+association+rate+constant+as+determinant&doi=10.1016%2Fj.tips.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant</span></div><div class="casAuthors">de Witte, Wilhelmus E. A.; Danhof, Meindert; van der Graaf, Piet H.; de Lange, Elizabeth C. M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">831-842</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">It is generally accepted that, in conjunction with pharmacokinetics, the first-order rate const. of target dissocn. is a major determinant of the time course and duration of in vivo target occupancy.  Here we show that the second-order rate const. of target assocn. can be equally important.  On the basis of the commonly used math. models for drug-target binding, it is shown that a high target assocn. rate const. can increase the (local) concn. of the drug, which decreases the rate of decline of target occupancy.  The increased drug concn. can also lead to increased off-target binding and decreased selectivity.  Therefore, the kinetics of both target assocn. and dissocn. need to be taken into account in the selection of drug candidates with optimal pharmacodynamic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri0cm4NKLv-7Vg90H21EOLACvtfcHk0ljiZRaAQqQuVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVynur%252FE&md5=e2c077f2c8636214e2f8a77ee5734ad4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DDanhof%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26atitle%3DIn%2520vivo%2520target%2520residence%2520time%2520and%2520kinetic%2520selectivity%253A%2520The%2520association%2520rate%2520constant%2520as%2520determinant%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2016%26volume%3D37%26spage%3D831%26epage%3D842%26doi%3D10.1016%2Fj.tips.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, W. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knasmueller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokh, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadiq, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nederpelt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segala, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaral, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frech, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lange, E. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Fahrnow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G. F.</span></span> <span> </span><span class="NLM_article-title">Kinetics for drug discovery: an industry-driven effort to target drug residence time</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2017.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.drudis.2017.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=28412474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1Kjs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=896-911&author=D.+A.+Schuetzauthor=W.+E.+A.+de+Witteauthor=Y.+C.+Wongauthor=B.+Knasmuellerauthor=L.+Richterauthor=D.+B.+Kokhauthor=S.+K.+Sadiqauthor=R.+Bosmaauthor=I.+Nederpeltauthor=L.+H.+Heitmanauthor=E.+Segalaauthor=M.+Amaralauthor=D.+Guoauthor=D.+Andresauthor=V.+Georgiauthor=L.+A.+Stoddartauthor=S.+Hillauthor=R.+M.+Cookeauthor=C.+De+Graafauthor=R.+Leursauthor=M.+Frechauthor=R.+C.+Wadeauthor=E.+C.+M.+de+Langeauthor=A.+P.+IJzermanauthor=A.+Muller-Fahrnowauthor=G.+F.+Ecker&title=Kinetics+for+drug+discovery%3A+an+industry-driven+effort+to+target+drug+residence+time&doi=10.1016%2Fj.drudis.2017.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics for Drug Discovery: an industry-driven effort to target drug residence time</span></div><div class="casAuthors">Schuetz, Doris A.; de Witte, Wilhelmus Egbertus Arnout; Wong, Yin Cheong; Knasmueller, Bernhard; Richter, Lars; Kokh, Daria B.; Sadiq, S. Kashif; Bosma, Reggie; Nederpelt, Indira; Heitman, Laura H.; Segala, Elena; Amaral, Marta; Guo, Dong; Andres, Dorothee; Georgi, Victoria; Stoddart, Leigh A.; Hill, Steve; Cooke, Robert M.; De Graaf, Chris; Leurs, Rob; Frech, Matthias; Wade, Rebecca C.; de Lange, Elizabeth Cunera Maria; IJzerman, Adriaan P.; Mueller-Fahrnow, Anke; Ecker, Gerhard F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">896-911</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A considerable no. of approved drugs show non-equil. binding characteristics, emphasizing the potential role of drug residence times for in vivo efficacy.  Therefore, a detailed understanding of the kinetics of assocn. and dissocn. of a target-ligand complex might provide crucial insight into the mol. mechanism-of-action of a compd.  This deeper understanding will help to improve decision making in drug discovery, thus leading to a better selection of interesting compds. to be profiled further.  In this review, we highlight the contributions of the Kinetics for Drug Discovery (K4DD) Consortium, which targets major open questions related to binding kinetics in an industry-driven public-private partnership.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJRmkYejg8ObVg90H21EOLACvtfcHk0ljiZRaAQqQuVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1Kjs7k%253D&md5=78fce4f850718075ba44b28a20f79195</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DSchuetz%26aufirst%3DD.%2BA.%26aulast%3Dde%2BWitte%26aufirst%3DW.%2BE.%2BA.%26aulast%3DWong%26aufirst%3DY.%2BC.%26aulast%3DKnasmueller%26aufirst%3DB.%26aulast%3DRichter%26aufirst%3DL.%26aulast%3DKokh%26aufirst%3DD.%2BB.%26aulast%3DSadiq%26aufirst%3DS.%2BK.%26aulast%3DBosma%26aufirst%3DR.%26aulast%3DNederpelt%26aufirst%3DI.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DSegala%26aufirst%3DE.%26aulast%3DAmaral%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DAndres%26aufirst%3DD.%26aulast%3DGeorgi%26aufirst%3DV.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DCooke%26aufirst%3DR.%2BM.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DFrech%26aufirst%3DM.%26aulast%3DWade%26aufirst%3DR.%2BC.%26aulast%3Dde%2BLange%26aufirst%3DE.%2BC.%2BM.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DMuller-Fahrnow%26aufirst%3DA.%26aulast%3DEcker%26aufirst%3DG.%2BF.%26atitle%3DKinetics%2520for%2520drug%2520discovery%253A%2520an%2520industry-driven%2520effort%2520to%2520target%2520drug%2520residence%2520time%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D896%26epage%3D911%26doi%3D10.1016%2Fj.drudis.2017.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoddart, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilpatrick, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. J.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics of ligands acting at GPCRs</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1016/j.mce.2019.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.mce.2019.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=30738950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFOlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=9-19&author=D.+A.+Sykesauthor=L.+A.+Stoddartauthor=L.+E.+Kilpatrickauthor=S.+J.+Hill&title=Binding+kinetics+of+ligands+acting+at+GPCRs&doi=10.1016%2Fj.mce.2019.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics of ligands acting at GPCRs</span></div><div class="casAuthors">Sykes, David A.; Stoddart, Leigh A.; Kilpatrick, Laura E.; Hill, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-19</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The influence of drug-receptor binding kinetics has often been overlooked during the development of new therapeutics that target G protein-coupled receptors (GPCRs).  Over the last decade there has been a growing understanding that an in-depth knowledge of binding kinetics at GPCRs is required to successfully target this class of proteins.  Ligand binding to a GPCR is often not a simple single step process with ligand freely diffusing in soln.  This review will discuss the expts. and equations that are commonly used to measure binding kinetics and how factors such as allosteric regulation, rebinding and ligand interaction with the plasma membrane may influence these measurements.  We will then consider the mol. characteristics of a ligand and if these can be linked to assocn. and dissocn. rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptH1Ujc4eQXrVg90H21EOLACvtfcHk0liOYBOO2UgRqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFOlu74%253D&md5=17649f726e9540d9e31afedf805f5213</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2019.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2019.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DStoddart%26aufirst%3DL.%2BA.%26aulast%3DKilpatrick%26aufirst%3DL.%2BE.%26aulast%3DHill%26aufirst%3DS.%2BJ.%26atitle%3DBinding%2520kinetics%2520of%2520ligands%2520acting%2520at%2520GPCRs%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2019%26spage%3D9%26epage%3D19%26doi%3D10.1016%2Fj.mce.2019.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seeman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallerico, T.</span></span> <span> </span><span class="NLM_article-title">Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1176/ajp.156.6.876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1176%2Fajp.156.6.876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10360126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M3ovVequg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=1999&pages=876-884&author=P.+Seemanauthor=T.+Tallerico&title=Rapid+release+of+antipsychotic+drugs+from+dopamine+D2+receptors%3A+an+explanation+for+low+receptor+occupancy+and+early+clinical+relapse+upon+withdrawal+of+clozapine+or+quetiapine&doi=10.1176%2Fajp.156.6.876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine</span></div><div class="casAuthors">Seeman P; Tallerico T</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">876-84</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  In an attempt to understand the basis of early relapse after antipsychotic withdrawal, the objective of this study was to determine whether the low occupancy of dopamine D2 receptors by clozapine and by quetiapine, as seen by brain imaging, could arise from a rapid release of some of the D2-bound clozapine or quetiapine by the brain imaging compounds and by the action of a physiological concentration of dopamine.  METHOD:  Human cloned D2 receptors were first pre-equilibrated with the [3H]antipsychotic drug, after which raclopride, iodobenzamide, or dopamine (at the physiological concentration in the synapse) was added, and the time course of release of the [3H]antipsychotic from the D2 receptor was measured.  RESULTS:  Within 5 minutes, low concentrations of raclopride and iodobenzamide displaced appreciable amounts of [3H]clozapine and [3H]quetiapine from the D2 receptors but, during the course of 1 hour, did not displace any of the other antipsychotic [[3H]ligands. [3H]Clozapine and [3H]quetiapine, moreover, were displaced by dopamine (100 nM) at least 100 times faster than the other antipsychotic [3H]ligands.  CONCLUSIONS:  Clozapine and quetiapine are loosely bound to the D2 receptor, and the injected radioactive ligand at its peak concentration may displace some of the D2-bound antipsychotic drug, resulting in apparently low D2 occupancies.  Therefore, under clinical brain imaging conditions with [11C]raclopride, D2 occupancies by clozapine and by quetiapine may be higher than currently estimated.  These considerations may result in high levels of the D2 receptors being occupied by therapeutic doses of clozapine or quetiapine.  The rapid release of clozapine and quetiapine from D2 receptors by endogenous dopamine may contribute to low D2 receptor occupancy and to early clinical relapse upon withdrawal of these medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShWRknW98LMMvLc4ARHEmzfW6udTcc2eYjsa_FIJUmKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3ovVequg%253D%253D&md5=639c7e4719e950adbfdc6ef269693649</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1176%2Fajp.156.6.876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.156.6.876%26sid%3Dliteratum%253Aachs%26aulast%3DSeeman%26aufirst%3DP.%26aulast%3DTallerico%26aufirst%3DT.%26atitle%3DRapid%2520release%2520of%2520antipsychotic%2520drugs%2520from%2520dopamine%2520D2%2520receptors%253A%2520an%2520explanation%2520for%2520low%2520receptor%2520occupancy%2520and%2520early%2520clinical%2520relapse%2520upon%2520withdrawal%2520of%2520clozapine%2520or%2520quetiapine%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1999%26volume%3D156%26spage%3D876%26epage%3D884%26doi%3D10.1176%2Fajp.156.6.876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motulsky, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahan, L. C.</span></span> <span> </span><span class="NLM_article-title">The kinetics of competitive radioligand binding predicted by the law of mass action</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=6708928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=1-9&author=H.+J.+Motulskyauthor=L.+C.+Mahan&title=The+kinetics+of+competitive+radioligand+binding+predicted+by+the+law+of+mass+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The kinetics of competitive radioligand binding predicted by the law of mass action</span></div><div class="casAuthors">Motulsky H J; Mahan L C</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored.  The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time.  This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions.  Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments.  Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached.  Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time.  The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above.  When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI.  At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved.  When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCXDwvoK7MbN1QT_1O5WBYfW6udTcc2eYjsa_FIJUmKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7mslOmtQ%253D%253D&md5=f0c09a16d7f8947fe0d72c256e2e4914</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMotulsky%26aufirst%3DH.%2BJ.%26aulast%3DMahan%26aufirst%3DL.%2BC.%26atitle%3DThe%2520kinetics%2520of%2520competitive%2520radioligand%2520binding%2520predicted%2520by%2520the%2520law%2520of%2520mass%2520action%26jtitle%3DMol.%2520Pharmacol.%26date%3D1984%26volume%3D25%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein
Herenbrink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donthamsetti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coudrat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">10842</span> <span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&author=C.+Klein%0AHerenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0ljhcDkLQtTWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albizu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kralikova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoev, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brabet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rives, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouillac, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durroux, T.</span></span> <span> </span><span class="NLM_article-title">Time-resolved FRET between GPCR ligands reveals oligomers in native tissues</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">594</span>, <span class="refDoi"> DOI: 10.1038/nchembio.396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnchembio.396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=20622858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ahsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=587-594&author=L.+Albizuauthor=M.+Cottetauthor=M.+Kralikovaauthor=S.+Stoevauthor=R.+Seyerauthor=I.+Brabetauthor=T.+Rouxauthor=H.+Bazinauthor=E.+Bourrierauthor=L.+Lamarqueauthor=C.+Bretonauthor=M.-L.+Rivesauthor=A.+Newmanauthor=J.+Javitchauthor=E.+Trinquetauthor=M.+Manningauthor=J.-P.+Pinauthor=B.+Mouillacauthor=T.+Durroux&title=Time-resolved+FRET+between+GPCR+ligands+reveals+oligomers+in+native+tissues&doi=10.1038%2Fnchembio.396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Time-resolved FRET between GPCR ligands reveals oligomers in native tissues</span></div><div class="casAuthors">Albizu, Laura; Cottet, Martin; Kralikova, Michaela; Stoev, Stoytcho; Seyer, Rene; Brabet, Isabelle; Roux, Thomas; Bazin, Herve; Bourrier, Emmanuel; Lamarque, Laurent; Breton, Christophe; Rives, Marie-Laure; Newman, Amy; Javitch, Jonathan; Trinquet, Eric; Manning, Maurice; Pin, Jean-Philippe; Mouillac, Bernard; Durroux, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">587-594</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptor (GPCR) oligomers have been proposed to play crit. roles in cell signaling, but confirmation of their existence in a native context remains elusive, as no direct interactions between receptors have been reported.  To demonstrate their presence in native tissues, we developed a time-resolved FRET strategy that is based on receptor labeling with selective fluorescent ligands.  Specific FRET signals were obsd. with four different receptors expressed in cell lines, consistent with their dimeric or oligomeric nature in these transfected cells.  More notably, the comparison between FRET signals measured with sets of fluorescent agonists and antagonists was consistent with an asym. relationship of the two protomers in an activated GPCR dimer.  Finally, we applied the strategy to native tissues and succeeded in demonstrating the presence of oxytocin receptor dimers and/or oligomers in mammary gland.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRPFTQQ0GNv7Vg90H21EOLACvtfcHk0ljhcDkLQtTWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ahsbw%253D&md5=7ad4fb48ba7b71d1322e158d7d174b33</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.396%26sid%3Dliteratum%253Aachs%26aulast%3DAlbizu%26aufirst%3DL.%26aulast%3DCottet%26aufirst%3DM.%26aulast%3DKralikova%26aufirst%3DM.%26aulast%3DStoev%26aufirst%3DS.%26aulast%3DSeyer%26aufirst%3DR.%26aulast%3DBrabet%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DT.%26aulast%3DBazin%26aufirst%3DH.%26aulast%3DBourrier%26aufirst%3DE.%26aulast%3DLamarque%26aufirst%3DL.%26aulast%3DBreton%26aufirst%3DC.%26aulast%3DRives%26aufirst%3DM.-L.%26aulast%3DNewman%26aufirst%3DA.%26aulast%3DJavitch%26aufirst%3DJ.%26aulast%3DTrinquet%26aufirst%3DE.%26aulast%3DManning%26aufirst%3DM.%26aulast%3DPin%26aufirst%3DJ.-P.%26aulast%3DMouillac%26aufirst%3DB.%26aulast%3DDurroux%26aufirst%3DT.%26atitle%3DTime-resolved%2520FRET%2520between%2520GPCR%2520ligands%2520reveals%2520oligomers%2520in%2520native%2520tissues%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D587%26epage%3D594%26doi%3D10.1038%2Fnchembio.396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holliday, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">763</span> <span class="refDoi"> DOI: 10.1038/s41467-017-00716-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fs41467-017-00716-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=28970469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&author=D.+A.+Sykesauthor=H.+Mooreauthor=L.+Stottauthor=N.+Hollidayauthor=J.+A.+Javitchauthor=J.+R.+Laneauthor=S.+J.+Charlton&title=Extrapyramidal+side+effects+of+antipsychotics+are+linked+to+their+association+kinetics+at+dopamine+D2+receptors&doi=10.1038%2Fs41467-017-00716-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors</span></div><div class="casAuthors">Sykes David A; Stott Lisa; Holliday Nicholas; Charlton Steven J; Moore Holly; Javitch Jonathan A; Moore Holly; Javitch Jonathan A; Javitch Jonathan A; Lane J Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">763</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor.  However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions.  Here we show that association rates, but not dissociation rates, correlate with EPS.  We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses.  EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade.  Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side effects compared to first generation drugs.  Here the authors use time-resolved FRET to measure binding kinetics, and show that side effects correlate with drug association rates to the D2 receptor, while dissociation rates correlate with prolactin elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSAv7HAvl2UWlVwdslNBF-tfW6udTcc2eYE64em1W_Tb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksFGgsg%253D%253D&md5=6d5c8596da9a3565b7a95b55eceac3cf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-00716-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-00716-z%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DMoore%26aufirst%3DH.%26aulast%3DStott%26aufirst%3DL.%26aulast%3DHolliday%26aufirst%3DN.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExtrapyramidal%2520side%2520effects%2520of%2520antipsychotics%2520are%2520linked%2520to%2520their%2520association%2520kinetics%2520at%2520dopamine%2520D2%2520receptors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26doi%3D10.1038%2Fs41467-017-00716-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardenborough, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cody, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5739</span>– <span class="NLM_lpage">5742</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2004.09.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmcl.2004.09.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=15501032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=5739-5742&author=D.+M.+Sikazweauthor=S.+Liauthor=L.+Mardenboroughauthor=V.+Codyauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Haloperidol%3A+towards+further+understanding+of+the+structural+contributions+of+its+pharmacophoric+elements+at+D2-like+receptors&doi=10.1016%2Fj.bmcl.2004.09.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Haloperidol: towards further understanding of the structural contributions of its pharmacophoric elements at D2-like receptors</span></div><div class="casAuthors">Sikazwe, Donald M. N.; Li, Shouming; Mardenborough, Leroy; Cody, Vivian; Roth, Brian L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5739-5742</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An attempt to understand the pharmacophore-relevant position of the alc. moiety in haloperidol and the contributions of other pharmacophoric elements led to the resynthesis of its tropane analog (compd. 2).  An anal. of the binding data suggests that haloperidol binds to the DA receptors with the OH group in the axial position and the OH group, while not essential for binding, enhances binding esp. at the D2 receptor.  It also became clear that shortening the butyrophenone chain not only reduces binding affinity at the DA receptors but eliminates subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkCqf2yYDY8LVg90H21EOLACvtfcHk0lj4RvzC59Y8Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVSnurk%253D&md5=f37a81b9dc77cfe3764b3afdf498fe2c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.09.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.09.046%26sid%3Dliteratum%253Aachs%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMardenborough%26aufirst%3DL.%26aulast%3DCody%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DHaloperidol%253A%2520towards%2520further%2520understanding%2520of%2520the%2520structural%2520contributions%2520of%2520its%2520pharmacophoric%2520elements%2520at%2520D2-like%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D5739%26epage%3D5742%26doi%3D10.1016%2Fj.bmcl.2004.09.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. E. V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7291</span>– <span class="NLM_lpage">7301</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.06.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2008.06.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=18595716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps12jtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=7291-7301&author=S.+Y.+Ablordeppeyauthor=R.+Altundasauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=S.+E.+V.+K.+Eyunniauthor=T.+Jacksonauthor=A.+Khanauthor=B.+L.+Roth&title=Identification+of+a+butyrophenone+analog+as+a+potential+atypical+antipsychotic+agent%3A+4-%5B4-%284-chlorophenyl%29-1%2C4-diazepan-1-yl%5D-1-%284-fluorophenyl%29butan-1-one&doi=10.1016%2Fj.bmc.2008.06.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one</span></div><div class="casAuthors">Ablordeppey, Seth Y.; Altundas, Ramazan; Bricker, Barbara; Zhu, Xue Y.; Kumar, Eyunni V. K. Suresh; Jackson, Tanise; Khan, Abdul; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7291-7301</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The synthesis and exploration of novel butyrophenones have led to the identification of a diazepane analog of haloperidol, 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one (compd. 13) with an interesting multireceptor binding profile.  Compd. 13 was evaluated for its binding affinities at DA subtype receptors, 5HT subtype receptors, H-1, M-1 receptors and at NET, DAT, and SERT transporters.  At each of these receptors, compd. 13 (I)was equipotent or better than several of the stds. currently in use.  In in vivo mouse and rat models to evaluate its efficacy and propensity to elicit catalepsy and hence EPS in humans, compd. 13 showed similar efficacy as clozapine and did not produce catalepsy at five times its ED50 value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKWLdcpGfSgbVg90H21EOLACvtfcHk0lj4RvzC59Y8Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps12jtLg%253D&md5=fa1d0e1cf2aa8f7ef249d59bbccf8ad8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.06.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.06.030%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BE.%2BV.%2BK.%26aulast%3DJackson%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DIdentification%2520of%2520a%2520butyrophenone%2520analog%2520as%2520a%2520potential%2520atypical%2520antipsychotic%2520agent%253A%25204-%255B4-%25284-chlorophenyl%2529-1%252C4-diazepan-1-yl%255D-1-%25284-fluorophenyl%2529butan-1-one%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D7291%26epage%3D7301%26doi%3D10.1016%2Fj.bmc.2008.06.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nkansah, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1716</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2008.12.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19155177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVyit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1716-1723&author=D.+M.+Sikazweauthor=N.+T.+Nkansahauthor=R.+Altundasauthor=X.+Y.+Zhuauthor=B.+L.+Rothauthor=V.+Setolaauthor=S.+Y.+Ablordeppey&title=Synthesis+and+evaluation+of+ligands+for+D2-like+receptors%3A+the+role+of+common+pharmacophoric+groups&doi=10.1016%2Fj.bmc.2008.12.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups</span></div><div class="casAuthors">Sikazwe, Donald M. N.; Nkansah, Nancy T.; Altundas, Ramazan; Zhu, Xue Y.; Roth, Bryan L.; Setola, Vincent; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1716-1723</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arylcycloalkylamines, such as Ph piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents.  A review of previous reports indicates that arylalkyl substituents can improve the potency and selectivity of the binding affinity at D2-like receptors.  In this paper, we explored the contributions of two key pharmacophoric groups, i.e., 4'-fluorobutyrophenones and 3-methyl-7-azaindoles, to the potency and selectivity of synthesized agents at D2-like receptors.  Preliminary observation of binding affinities indicates that there is little predictability of specific effects of the arylalkyl moieties but the composite structure is responsible for selectivity and potency at these receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIG4AM6sMFYrVg90H21EOLACvtfcHk0lj4RvzC59Y8Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVyit70%253D&md5=86fd66ce40fbec9375a114518e62f84e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.054%26sid%3Dliteratum%253Aachs%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DNkansah%26aufirst%3DN.%2BT.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520ligands%2520for%2520D2-like%2520receptors%253A%2520the%2520role%2520of%2520common%2520pharmacophoric%2520groups%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1716%26epage%3D1723%26doi%3D10.1016%2Fj.bmc.2008.12.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bricker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peprah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamango, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Further evaluation of the tropane analogs of haloperidol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4294</span>– <span class="NLM_lpage">4297</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.07.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmcl.2014.07.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=25070422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Gku7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=4294-4297&author=D.+Sampsonauthor=B.+Brickerauthor=X.+Y.+Zhuauthor=K.+Peprahauthor=N.+S.+Lamangoauthor=V.+Setolaauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Further+evaluation+of+the+tropane+analogs+of+haloperidol&doi=10.1016%2Fj.bmcl.2014.07.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Further evaluation of the tropane analogs of haloperidol</span></div><div class="casAuthors">Sampson, Dinithia; Bricker, Barbara; Zhu, Xue Y.; Peprah, Kwakye; Lamango, Nazarius S.; Setola, Vincent; Roth, Bryan L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4294-4297</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous work from our labs has indicated that a tropane analog of haloperidol with potent D2 binding but designed to avoid the formation of MPP+-like metabolites, such as 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)pyridin-1-ium (BCPP+) still produced catalepsy, suggesting a strong role for the D2 receptor in the prodn. of catalepsy in rats, and hence EPS in humans.  This study tested the hypothesis that further modifications of the tropane analog to produce compds. with less potent binding to the D2 receptor than haloperidol, would produce less catalepsy.  These tests have now revealed that while haloperidol produced max. catalepsy, these compds. produced moderate to low levels of catalepsy.  Compd. 9, with the least binding affinity to the D2R, produced the least catalepsy and highest Min. Adverse ED (MAED) of the analogs tested regardless of their affinities at other receptors including the 5-HT1AR.  These observations support the hypothesis that moderation of the D2 binding of the tropane analogs could reduce catalepsy potential in rats and consequently EPS in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5TyDvi6SZ3LVg90H21EOLACvtfcHk0lhcjsYTUYQRGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Gku7nN&md5=d8c0bf8678a620c5b6f2d6dc99ebb73b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.07.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.07.018%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DD.%26aulast%3DBricker%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DPeprah%26aufirst%3DK.%26aulast%3DLamango%26aufirst%3DN.%2BS.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DFurther%2520evaluation%2520of%2520the%2520tropane%2520analogs%2520of%2520haloperidol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D4294%26epage%3D4297%26doi%3D10.1016%2Fj.bmcl.2014.07.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyles-Eggleston, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altundas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikazwe, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrihkande, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borne, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1021/jm0301033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0301033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvFGks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=497-508&author=M.+Lyles-Egglestonauthor=R.+Altundasauthor=J.+Xiaauthor=D.+M.+Sikazweauthor=P.+Fanauthor=Q.+Yangauthor=S.+Liauthor=W.+Zhangauthor=X.+Zhuauthor=A.+W.+Schmidtauthor=M.+Vanase-Frawleyauthor=A.+Shrihkandeauthor=A.+Villalobosauthor=R.+F.+Borneauthor=S.+Y.+Ablordeppey&title=Design%2C+synthesis%2C+and+evaluation+of+metabolism-based+analogues+of+haloperidol+incapable+of+forming+MPP%2B-like+species&doi=10.1021%2Fjm0301033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species</span></div><div class="casAuthors">Lyles-Eggleston, M.; Altundas, R.; Xia, J.; Sikazwe, D. M. N.; Fan, P.; Yang, Q.; Li, S.; Zhang, W.; Zhu, X.; Schmidt, A. W.; Vanase-Frawley, M.; Shrihkande, A.; Villalobos, A.; Borne, R. F.; Ablordeppey, S. Y.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">497-508</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms.  More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects.  Because BCPP+ and its reduced analog have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, the authors have designed new analogs of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity.  The most potent agent at the D2 receptor, the homopiperidine analog was equipotent to haloperidol.  It was also of interest to identify analogs with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes.  Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by I [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 4-[3-(4-chlorophenyl)-3-hydroxymethylpyrrolidin-1-yl]-1-(4-fluorophenyl)butan-1-one [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2].  A preliminary in-vivo testing of I shows that its behavioral profile is similar to that of clozapine.  This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRXQrMaHciVrVg90H21EOLACvtfcHk0lhcjsYTUYQRGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvFGks74%253D&md5=b59d2ba383504e51cd81a7007a68b2de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0301033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0301033%26sid%3Dliteratum%253Aachs%26aulast%3DLyles-Eggleston%26aufirst%3DM.%26aulast%3DAltundas%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DSikazwe%26aufirst%3DD.%2BM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DVanase-Frawley%26aufirst%3DM.%26aulast%3DShrihkande%26aufirst%3DA.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DBorne%26aufirst%3DR.%2BF.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520metabolism-based%2520analogues%2520of%2520haloperidol%2520incapable%2520of%2520forming%2520MPP%252B-like%2520species%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D497%26epage%3D508%26doi%3D10.1021%2Fjm0301033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raviña, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casariego, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaguer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontenla, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montenegro, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivas, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enguix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villazon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadavid, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demontis, G. C.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4678</span>– <span class="NLM_lpage">4693</span>, <span class="refDoi"> DOI: 10.1021/jm0009890</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0009890" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVKhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4678-4693&author=E.+Ravi%C3%B1aauthor=I.+Casariegoauthor=C.+F.+Masaguerauthor=J.+A.+Fontenlaauthor=G.+Y.+Montenegroauthor=M.+E.+Rivasauthor=M.+I.+Lozaauthor=M.+J.+Enguixauthor=M.+Villazonauthor=M.+I.+Cadavidauthor=G.+C.+Demontis&title=Conformationally+constrained+butyrophenones+with+affinity+for+dopamine+%28D%281%29%2C+D%282%29%2C+D%284%29%29+and+serotonin+%285-HT%282A%29%2C+5-HT%282B%29%2C+5-HT%282C%29%29+receptors%3A+synthesis+of+aminomethylbenzo%5Bb%5Dfuranones+and+their+evaluation+as+antipsychotics&doi=10.1021%2Fjm0009890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally Constrained Butyrophenones with Affinity for Dopamine (D1, D2, D4) and Serotonin (5-HT2A, 5-HT2B, 5-HT2C) Receptors: Synthesis of Aminomethylbenzo[b]furanones and Their Evaluation as Antipsychotics</span></div><div class="casAuthors">Ravina, Enrique; Casariego, Isabel; Masaguer, Christian F.; Fontenla, Jose A.; Montenegro, Gisela Y.; Rivas, Maria E.; Loza, M. Isabel; Enguix, Maria J.; Villazon, Maria; Cadavid, Isabel; Demontis, Gian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4678-4693</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel conformationally restricted butyrophenones [6-aminomethyl-4,5,6,7-tetrahydrobenzo[b]furan-4-ones bearing 4-(6-fluorobenzisoxazolyl)piperidine, 4-(p-fluorobenzoyl)piperidine, 4-(o-methoxyphenyl)piperazine, 4-(2-pyridyl)piperazine, 4-(2-pyrimidinyl)piperazine, or linear butyro(or valero)phenone fragments] were prepd. and evaluated as antipsychotic agents by in vitro assays for affinity for dopamine receptors (D1, D2, D4) and serotonin receptors (5-HT2A, 5-HT2B, 5-HT2C), by neurochem. studies, and by in vivo assays for antipsychotic potential and the risk of inducing extrapyramidal side effects.  Potency and selectivity depended mainly on the amine fragment connected to the cyclohexanone structure.  QF1003B [I,X = O, R = H] and QF1004B [I, XR = NO] were selective for 5-HT2A receptors.  The in vitro and in vivo pharmacol. profiles of QF1003B and QF1004B suggest that they may be effective as antipsychotic (neuroleptic) drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp44HkA5dq_GrVg90H21EOLACvtfcHk0lhcjsYTUYQRGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVKhsbo%253D&md5=e838ae49cfb18c3a6d17dc89ea444977</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm0009890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0009890%26sid%3Dliteratum%253Aachs%26aulast%3DRavi%25C3%25B1a%26aufirst%3DE.%26aulast%3DCasariego%26aufirst%3DI.%26aulast%3DMasaguer%26aufirst%3DC.%2BF.%26aulast%3DFontenla%26aufirst%3DJ.%2BA.%26aulast%3DMontenegro%26aufirst%3DG.%2BY.%26aulast%3DRivas%26aufirst%3DM.%2BE.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DEnguix%26aufirst%3DM.%2BJ.%26aulast%3DVillazon%26aufirst%3DM.%26aulast%3DCadavid%26aufirst%3DM.%2BI.%26aulast%3DDemontis%26aufirst%3DG.%2BC.%26atitle%3DConformationally%2520constrained%2520butyrophenones%2520with%2520affinity%2520for%2520dopamine%2520%2528D%25281%2529%252C%2520D%25282%2529%252C%2520D%25284%2529%2529%2520and%2520serotonin%2520%25285-HT%25282A%2529%252C%25205-HT%25282B%2529%252C%25205-HT%25282C%2529%2529%2520receptors%253A%2520synthesis%2520of%2520aminomethylbenzo%255Bb%255Dfuranones%2520and%2520their%2520evaluation%2520as%2520antipsychotics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4678%26epage%3D4693%26doi%3D10.1021%2Fjm0009890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishinomiya, H. Y.</span>; <span class="NLM_string-name">Ashiya, T. O.</span>; <span class="NLM_string-name">Sasajima, K.</span>; <span class="NLM_string-name">Minoo, S. K.</span></span> <span> </span><span class="NLM_article-title">Butyrophenone Derivatives</span>. <span class="NLM_patent">US003907812</span>, <span class="NLM_year">1973</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1973&author=H.+Y.+Nishinomiya&author=T.+O.+Ashiya&author=K.+Sasajima&author=S.+K.+Minoo&title=Butyrophenone+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNishinomiya%26aufirst%3DH.%2BY.%26atitle%3DButyrophenone%2520Derivatives%26date%3D1973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Westeringh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jageneau, A. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demoen, P. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, B. K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Daele, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Eycken, C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemegeers, C. J. E.</span></span> <span> </span><span class="NLM_article-title">Chemistry and pharmacology of CNS depressants related to 4-(4-Hydroxy-4-phenylpiperidino)butyrophenone. Part I--Synthesis and screening data in mice</span>. <i>J. Med. Pharm. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1959</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1021/jm50004a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50004a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaF3cXjsValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1959&pages=281-297&author=P.+A.+J.+Janssenauthor=C.+Van+De+Westeringhauthor=A.+H.+M.+Jageneauauthor=P.+J.+A.+Demoenauthor=B.+K.+F.+Hermansauthor=G.+H.+P.+Van+Daeleauthor=K.+H.+L.+Schellekensauthor=C.+A.+M.+Van+Der+Eyckenauthor=C.+J.+E.+Niemegeers&title=Chemistry+and+pharmacology+of+CNS+depressants+related+to+4-%284-Hydroxy-4-phenylpiperidino%29butyrophenone.+Part+I%2D%2DSynthesis+and+screening+data+in+mice&doi=10.1021%2Fjm50004a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)butyrophenone. I. Synthesis and screening data in mice</span></div><div class="casAuthors">Janssen, Paul A. J.; van de Westeringh, Corn.; Jageneau, Anton H. M.; Demoen, Paul J. A.; Hermans, Bert K. F.; van Daele, Georges H. P.; Schellekens, Karel H. L.; van der Eycken, Cyriel A. M.; Niemegeers, Carlos J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">281-97</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">In general, 4-RC6H4CO(CH2)3N.CH2.CH2.C(OH)-(4-R'C6H4).CH2.CH2 (I) were prepd. by condensation in PhMe of Bz(CH2)3Cl (II) or 4-FC6H4CO(CH2)3Cl (III) with 4-R'C6H4C(OH).CH2.CH2.NH.CH2.CH2 (IV).  Cl(CH2)3CO-Cl (71 g.) in 70 ml. C6H6 underwent the Friedel-Craft reaction in the usual way with C6H6 (or PhF) to yield 80% II, b5 134-7°, n20D 1.541 (or 80-95% III, b6 136-42°, n20D 1.523.  IV were prepd, in 8 steps from α-methylstyrene (V) and its derivs. V (944 g.) added slowly at 60° to 856 g. NH4Cl in 3 1.1.36% H2CO, stirred until the temp. fell to 40°, 2 1. MeOH added, the mixt. stirred 20 hrs., MeOH removed in vacuo, the residue in 3 1. concd. HCl heated at 100°, cooled, dild. with 2 1. H2O, made alk. with 15N NaOH, and extd. with C6H6 yielded 46-50% 4-R'C6H4C:CH.CH2.NH.CH2.CH2 (VI) (R' = H), b1 97-112°, n25D 1.586, HCl salt m. 199-202°, λ 248 mμ (ε 11,700).  Other VI were similarly prepd.  from derivs. of V [R', b.p., λ (mμ) (ε) given]: F, 139-41°/4, 245.5 (10,100); Cl, 167-70°/8, 254.6 (14,100); Me, 162-70°/10, 251 (11,300).  Dry HBr gas passed 7 hrs. at 10-20 through a stirred soln. of 160 g. VI in 500 ml. AcOH, the mixt. kept 16 hrs. at room temp., AcOH and excess HBr removed in vacuo at 40°, and the residue taken up in ether and filtered yielded the HBr salt (VII) of 4-R'C6H4CBr.CH2.CH2.NH.CH2.CH2 (R', m.p. given): H, 209.5-10.5°; F, 143-4°; Cl, 213-15°; Me, 190-2°.  VII (160 g.) in 3 1. H2O was hydrolyzed with 20% NaOH to IV [R', m.p., λ (mμ) (ε) given]: H, 159-60°, 260 (225); F, 116.4-17.6°, 266 (815); Cl, 134.4-6.0°, 269.5 (460); Me, 136-7°, 265.5 (295).  II (8.7 g.) (or III) heated at 100-10° in a closed tube with 14.2 g. IV (R = R' = H), 0.1 g. KI, and 150 ml. PhMe, the cooled reaction mixt. filtered from the sepd. solid, and the filtrate concd. yielded 70% I, m. 129.4-30.6°, λ 246 mμ (ε 12,600), HCl salt m. 182-4°.  Other I were similarly prepd. [R, R', m.p., λ (mμ) (ε), m.p. of HCl salt given]: H, F, 117.4-18.6°, 245 (13,300), 188-90°; H, Cl, 128.2-30.2°, 245.5 (13,400), 216.5-18.0°; H, Me, 101-2.5°, 245 (13,000), 179.6-81.5°; F, H, 135.6-6.2°, 246.5 (12,500), 204.5-5.5.°; F, F, 120-1°, 247 (12,400), 201-3.5°; F, Cl, 148-9.4°, 247 (11,900), 226-7.5°; and F, Me, 118-19.5° 246.5 (12,200), 212-13°.  Some pharmacol. properties in mice of these 8 compds. of structure I were detd. and compared with those of 20 known CNS depressants.  All possessed potent CNS depressant effects in low doses.  Some relations between structure and potency were suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkU436feWFwrVg90H21EOLACvtfcHk0lgP7PitVxj6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3cXjsValsw%253D%253D&md5=91eecf5660813684eb3b0ffe3cba2965</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm50004a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50004a007%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DVan%2BDe%2BWesteringh%26aufirst%3DC.%26aulast%3DJageneau%26aufirst%3DA.%2BH.%2BM.%26aulast%3DDemoen%26aufirst%3DP.%2BJ.%2BA.%26aulast%3DHermans%26aufirst%3DB.%2BK.%2BF.%26aulast%3DVan%2BDaele%26aufirst%3DG.%2BH.%2BP.%26aulast%3DSchellekens%26aufirst%3DK.%2BH.%2BL.%26aulast%3DVan%2BDer%2BEycken%26aufirst%3DC.%2BA.%2BM.%26aulast%3DNiemegeers%26aufirst%3DC.%2BJ.%2BE.%26atitle%3DChemistry%2520and%2520pharmacology%2520of%2520CNS%2520depressants%2520related%2520to%25204-%25284-Hydroxy-4-phenylpiperidino%2529butyrophenone.%2520Part%2520I--Synthesis%2520and%2520screening%2520data%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1959%26volume%3D1%26spage%3D281%26epage%3D297%26doi%3D10.1021%2Fjm50004a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leyva-Pérez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrero-Antonino, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubio-Marqués, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Resayes, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corma, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the ortho/meta/para isomers of relevant pharmaceutical compounds by coupling a sonogashira reaction with a regioselective hydration</span>. <i>ACS Catal.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1021/cs401075z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cs401075z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsleisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=722-731&author=A.+Leyva-P%C3%A9rezauthor=J.+R.+Cabrero-Antoninoauthor=P.+Rubio-Marqu%C3%A9sauthor=S.+I.+Al-Resayesauthor=A.+Corma&title=Synthesis+of+the+ortho%2Fmeta%2Fpara+isomers+of+relevant+pharmaceutical+compounds+by+coupling+a+sonogashira+reaction+with+a+regioselective+hydration&doi=10.1021%2Fcs401075z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the ortho/meta/para Isomers of Relevant Pharmaceutical Compounds by Coupling a Sonogashira Reaction with a Regioselective Hydration</span></div><div class="casAuthors">Leyva-Perez, Antonio; Cabrero-Antonino, Jose R.; Rubio-Marques, Paula; Al-Resayes, Saud I.; Corma, Avelino</div><div class="citationInfo"><span class="NLM_cas:title">ACS Catalysis</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">722-731</span>CODEN:
                <span class="NLM_cas:coden">ACCACS</span>;
        ISSN:<span class="NLM_cas:issn">2155-5435</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aryl ketones substituted in ortho, meta, and para position are prepd. by a palladium-catalyzed Sonogashira reaction followed by a regioselective hydration of the so-formed alkyne with triflimidic acid or a gold catalyst, under catalytic conditions.  This methodol. opens a way to obtain substituted aryl alkyl ketones from readily available starting materials, haloarenes, and terminal alkynes.  The syntheses of the different regioisomers of haloperidol, melperone, pipamperone, and ibuprofen are presented.  Structure-activity relationships for these compds. are studied with dopaminergic and cyclooxygenase binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnvGpQwBqp_bVg90H21EOLACvtfcHk0lgP7PitVxj6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsleisw%253D%253D&md5=fed8458f579052ef029ca9fdb5ae5508</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fcs401075z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcs401075z%26sid%3Dliteratum%253Aachs%26aulast%3DLeyva-P%25C3%25A9rez%26aufirst%3DA.%26aulast%3DCabrero-Antonino%26aufirst%3DJ.%2BR.%26aulast%3DRubio-Marqu%25C3%25A9s%26aufirst%3DP.%26aulast%3DAl-Resayes%26aufirst%3DS.%2BI.%26aulast%3DCorma%26aufirst%3DA.%26atitle%3DSynthesis%2520of%2520the%2520ortho%252Fmeta%252Fpara%2520isomers%2520of%2520relevant%2520pharmaceutical%2520compounds%2520by%2520coupling%2520a%2520sonogashira%2520reaction%2520with%2520a%2520regioselective%2520hydration%26jtitle%3DACS%2520Catal.%26date%3D2014%26volume%3D4%26spage%3D722%26epage%3D731%26doi%3D10.1021%2Fcs401075z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farrokhzad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diksic, M.</span></span> <span> </span><span class="NLM_article-title">The syntheses of no-carrier-added and carrier-added 18F-labelled haloperidol</span>. <i>J. Labelled Compd. Radiopharm.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1002/jlcr.2580220713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fjlcr.2580220713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL28Xks1Snu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1985&pages=721-733&author=S.+Farrokhzadauthor=M.+Diksic&title=The+syntheses+of+no-carrier-added+and+carrier-added+18F-labelled+haloperidol&doi=10.1002%2Fjlcr.2580220713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The syntheses of no-carrier-added and carrier-added fluorine-18-labeled haloperidol</span></div><div class="casAuthors">Farrokhzad, Simin; Diksic, Mirko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Labelled Compounds and Radiopharmaceuticals</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">721-33</span>CODEN:
                <span class="NLM_cas:coden">JLCRD4</span>;
        ISSN:<span class="NLM_cas:issn">0362-4803</span>.
    </div><div class="casAbstract">Title compd. I (R = 18F) (II) was prepd. by substitution reactions of I (R = Cl, F) with Bu4N+ 18F- in DMSO.  Alternatively, treatment of 4-O2NC6H4CN or 4-ClC6H4CN with Bu4N+ 18F- in DMSO gave 4-18FC6H4CN, which underwent successive condensation with cyclopropyllithium, ring cleavage by HBr or HCl, and amination by 4-(4-chlorophenyl)-4-piperidinol to give II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKTM0lA_SReLVg90H21EOLACvtfcHk0lgP7PitVxj6ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xks1Snu7s%253D&md5=409d6af72130744311ad8a211b431089</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fjlcr.2580220713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlcr.2580220713%26sid%3Dliteratum%253Aachs%26aulast%3DFarrokhzad%26aufirst%3DS.%26aulast%3DDiksic%26aufirst%3DM.%26atitle%3DThe%2520syntheses%2520of%2520no-carrier-added%2520and%2520carrier-added%252018F-labelled%2520haloperidol%26jtitle%3DJ.%2520Labelled%2520Compd.%2520Radiopharm.%26date%3D1985%26volume%3D22%26spage%3D721%26epage%3D733%26doi%3D10.1002%2Fjlcr.2580220713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-J.</span></span> <span> </span><span class="NLM_article-title">Metal-free Markovnikov-type alkyne hydration under mild conditions</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2187</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.6b00801</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.6b00801" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVylsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=2184-2187&author=W.+Liuauthor=H.+Wangauthor=C.-J.+Li&title=Metal-free+Markovnikov-type+alkyne+hydration+under+mild+conditions&doi=10.1021%2Facs.orglett.6b00801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Metal-Free Markovnikov-Type Alkyne Hydration under Mild Conditions</span></div><div class="casAuthors">Liu, Wenbo; Wang, Haining; Li, Chao-Jun</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2184-2187</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Markovnikov-type alkyne hydration protocol is presented using 20% F3CSO3H (TfOH) as the catalyst under unprecedented mild conditions applicable to various alkynes, including terminal arylalkynes, terminal nonfunctionalized aliph. alkynes, and internal alkynes with excellent regioselectivity in good to excellent yields (av. yields >85%).  The reaction procedure operates under mild conditions (25-70°), with broad functional group compatibility, and uses only slightly more than a stoichiometric amt. of water in the absence of any transition metal.  The success of this protocol hinges upon the utilization of trifluoroethanol as the solvent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmF2dw_nhbh7Vg90H21EOLACvtfcHk0lgUxUQIj6KCPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVylsro%253D&md5=1a9fcf604ffb49af6ffd7c5b6a6c1de5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.6b00801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.6b00801%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.-J.%26atitle%3DMetal-free%2520Markovnikov-type%2520alkyne%2520hydration%2520under%2520mild%2520conditions%26jtitle%3DOrg.%2520Lett.%26date%3D2016%26volume%3D18%26spage%3D2184%26epage%3D2187%26doi%3D10.1021%2Facs.orglett.6b00801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peprah, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyunni, S. V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span> <span> </span><span class="NLM_article-title">Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1297</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2011.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22245230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1291-1297&author=K.+Peprahauthor=X.+Y.+Zhuauthor=S.+V.+K.+Eyunniauthor=V.+Setolaauthor=B.+L.+Rothauthor=S.+Y.+Ablordeppey&title=Multi-receptor+drug+design%3A+Haloperidol+as+a+scaffold+for+the+design+and+synthesis+of+atypical+antipsychotic+agents&doi=10.1016%2Fj.bmc.2011.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents</span></div><div class="casAuthors">Peprah, Kwakye; Zhu, Xue Y.; Eyunni, Suresh V. K.; Setola, Vincent; Roth, Bryan L.; Ablordeppey, Seth Y.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1291-1297</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors assocd. with atypical antipsychotic pharmacol.  It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest.  This strategy has resulted in the identification of several new agents, compds. 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics.  This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors assocd. with antipsychotic pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxSs13DajzXLVg90H21EOLACvtfcHk0lgUxUQIj6KCPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSht7c%253D&md5=10cf70b7fe6d5d7fa05967e66e928aa5</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DPeprah%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DEyunni%26aufirst%3DS.%2BV.%2BK.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26atitle%3DMulti-receptor%2520drug%2520design%253A%2520Haloperidol%2520as%2520a%2520scaffold%2520for%2520the%2520design%2520and%2520synthesis%2520of%2520atypical%2520antipsychotic%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1291%26epage%3D1297%26doi%3D10.1016%2Fj.bmc.2011.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinciguerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorito, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurdanella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drago, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporarello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescifina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anfuso, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span> <span> </span><span class="NLM_article-title">Antiangiogenic effect of (±)-haloperidol metabolite II valproate ester [(±)-MRJF22] in human microvascular retinal endothelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9960</span>– <span class="NLM_lpage">9966</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9960-9966&author=M.+Olivieriauthor=E.+Amataauthor=S.+Vinciguerraauthor=J.+Fioritoauthor=G.+Giurdanellaauthor=F.+Dragoauthor=N.+Caporarelloauthor=O.+Prezzaventoauthor=E.+Arenaauthor=L.+Salernoauthor=A.+Rescifinaauthor=G.+Lupoauthor=C.+D.+Anfusoauthor=A.+Marrazzo&title=Antiangiogenic+effect+of+%28%C2%B1%29-haloperidol+metabolite+II+valproate+ester+%5B%28%C2%B1%29-MRJF22%5D+in+human+microvascular+retinal+endothelial+cells&doi=10.1021%2Facs.jmedchem.6b01039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells</span></div><div class="casAuthors">Olivieri, Melania; Amata, Emanuele; Vinciguerra, Shila; Fiorito, Jole; Giurdanella, Giovanni; Drago, Filippo; Caporarello, Nunzia; Prezzavento, Orazio; Arena, Emanuela; Salerno, Loredana; Rescifina, Antonio; Lupo, Gabriella; Anfuso, Carmelina Daniela; Marrazzo, Agostino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9960-9966</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(±)-MRJF22 [(±)-2], a novel prodrug of haloperidol metabolite II (sigma-1 receptor antagonist/sigma-2 receptor agonist ligand) obtained by conjugation to valproic acid (histone deacetylase inhibitor) via an ester bond, exhibits antiangiogenic activity, being able to reduce human retinal endothelial cell (HREC) viability in a comparable manner to bevacizumab.  Moreover, (±)-2 was able to significantly reduce viable cells count, endothelial cell migration, and tube formation in vascular endothelial growth factor A (VEGF-A) stimulated HREC cultures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJedDLZWd8jbVg90H21EOLACvtfcHk0lgUxUQIj6KCPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yks77P&md5=f0a092eedd76c583f4dabaa7151774c4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01039%26sid%3Dliteratum%253Aachs%26aulast%3DOlivieri%26aufirst%3DM.%26aulast%3DAmata%26aufirst%3DE.%26aulast%3DVinciguerra%26aufirst%3DS.%26aulast%3DFiorito%26aufirst%3DJ.%26aulast%3DGiurdanella%26aufirst%3DG.%26aulast%3DDrago%26aufirst%3DF.%26aulast%3DCaporarello%26aufirst%3DN.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DRescifina%26aufirst%3DA.%26aulast%3DLupo%26aufirst%3DG.%26aulast%3DAnfuso%26aufirst%3DC.%2BD.%26aulast%3DMarrazzo%26aufirst%3DA.%26atitle%3DAntiangiogenic%2520effect%2520of%2520%2528%25C2%25B1%2529-haloperidol%2520metabolite%2520II%2520valproate%2520ester%2520%255B%2528%25C2%25B1%2529-MRJF22%255D%2520in%2520human%2520microvascular%2520retinal%2520endothelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9960%26epage%3D9966%26doi%3D10.1021%2Facs.jmedchem.6b01039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reymer, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frigeni, V.</span></span> <span> </span><span class="NLM_article-title">Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1906</span>– <span class="NLM_lpage">1910</span>, <span class="refDoi"> DOI: 10.1021/jm00393a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00393a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaL2sXmtlKntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1987&pages=1906-1910&author=M.+A.+Iorioauthor=T.+P.+Reymerauthor=V.+Frigeni&title=Combined+analgesic%2Fneuroleptic+activity+in+N-butyrophenone+prodine-like+compounds&doi=10.1021%2Fjm00393a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Combined analgesic/neuroleptic activity in N-butyrophenone prodine-like compounds</span></div><div class="casAuthors">Iorio, M. A.; Paszkowska Reymer, T.; Frigeni, V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1906-10</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Some 4-phenyl-4-piperidinols I (R = H, HO, EtCO2; R1 = H, Me) synthesized and evaluated in vitro and in vivo tests in order to examine their ability to interact contemporaneously with opioid and dopamine receptors.  The propionyloxy derivs. showed a good combination of analgesic and neuroleptic activity.  With a 3-Me substituent on the piperidine ring, the β-configuration was the more active form not only for analgesic activity, as expected from previous results on prodines, but also for neuroleptic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopcgsF-xoet7Vg90H21EOLACvtfcHk0lhoYEcX4df44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtlKntbo%253D&md5=84c6d73b0e7a630e1dcf62653923c83d</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm00393a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00393a037%26sid%3Dliteratum%253Aachs%26aulast%3DIorio%26aufirst%3DM.%2BA.%26aulast%3DReymer%26aufirst%3DT.%2BP.%26aulast%3DFrigeni%26aufirst%3DV.%26atitle%3DCombined%2520analgesic%252Fneuroleptic%2520activity%2520in%2520N-butyrophenone%2520prodine-like%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1987%26volume%3D30%26spage%3D1906%26epage%3D1910%26doi%3D10.1021%2Fjm00393a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogawski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. J.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=4724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE28XktVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1976&pages=251-262&author=L.+L.+Iversenauthor=M.+A.+Rogawskiauthor=R.+J.+Miller&title=Comparison+of+the+effects+of+neuroleptic+drugs+on+pre-+and+postsynaptic+dopaminergic+mechanisms+in+the+rat+striatum"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum</span></div><div class="casAuthors">Iversen, L. L.; Rogawski, M. A.; Miller, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-62</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Neuroleptic drugs of various chem. classes were compared as inhibitors of postsynaptic dopamine-sensitive adenylate cyclase [9012-42-4] in rat striatum and for their ability to influence a variety of presyaptic mechanisms in the dopaminergic nerve terminals in the striatum.  Sixteen chem. analogs of the butyrophenone, haloperidol-HCl (I-HCl) [1511-16-6] were tested on the dopamine-sensitive adenylate cyclase, and the results showed a good correlation between inhibitory potency in the system and the known effects of these compds. as(-)-apomorphine-HCl [314-19-2] antagonists in vivo.  In intact synaptosome prepns. from rat striatum, (-)-apomorphine-HCl was a potent inhibitor (IC50 = 0.2 μM) of the conversion of tritiated tyrosine to catechols.  Other dopaminemimetic drugs [epinine [501-15-5], dopamine [51-61-6], 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) [53463-78-8]] also had similar inhibitory effects, although the α adrenoceptor agonist (-)-phenylephrine [59-42-7] and the β agonist (±)-isoprenaline [7683-59-2] were also inhibitory at higher concns.  The inhibitory actions of dopamine, epinine, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene(ADTN), and (+)- [149-95-1] and (-)-noradrenaline [51-41-2] were significantly reduced by the addn. of the dopamine uptake inhibitor, benztropine, suggesting that they act at least in part by inhibition of intrasynaptosomal tyrosine hydroxylase [9036-22-0] after uptake into dopaminergic terminals.  The effects of apomorphine, however, were unaffected by benztropine, suggesting a direct action on presynaptic autoreceptors at dopaminergic terminals.  All the compds. tested were at least 50 times less potent as inhibitors of free tyrosine hydroxylase in detergent-contg. striatal homogenates.  The inhibitory effects of apomorphine on synaptosomal catechol synthesis were partially reversed by various neuroleptic drugs, and this appeared to be due to a competitive interaction between the neuroleptic drugs and apomorphine at the presynaptic receptor sites.  The neuroleptics, however, also tended to inhibit catechol synthesis by themselves.  I, spiroperidol [749-02-0], and pimozide [2062-78-4] were particularly potent in reversing the presynaptic actions of apomorphine on catechol formation, being active at concns. between 10 and 100 nM.  Neuroleptics also had some activity as inhibitors of tritiated dopamine uptake and as dopamine releasers in striatal synaptosomes.  They also antagonized the evoked release of tritiated dopamine elicited by protoveratrine.  None of these effects, however, occurred at very low drug concns., and the butyrophenones were no more potent than chlorpromazine [50-53-3].  Thus, neuroleptics possess action on both pre- and postsynaptic sites in the striatum, but the postsynaptic blocking action on dopamine receptors appears to be more crucial for the clin. activity of these drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnXiHijtl8W7Vg90H21EOLACvtfcHk0lhoYEcX4df44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XktVShsb8%253D&md5=5c395b324ac284baedd47765e55e18b9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIversen%26aufirst%3DL.%2BL.%26aulast%3DRogawski%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BJ.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520neuroleptic%2520drugs%2520on%2520pre-%2520and%2520postsynaptic%2520dopaminergic%2520mechanisms%2520in%2520the%2520rat%2520striatum%26jtitle%3DMol.%2520Pharmacol.%26date%3D1976%26volume%3D12%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cornella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R.</span></span> <span> </span><span class="NLM_article-title">Ni-catalyzed stereoselective arylation of inert C-O bonds at low temperatures</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6298</span>– <span class="NLM_lpage">6301</span>, <span class="refDoi"> DOI: 10.1021/ol4031815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4031815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=6298-6301&author=J.+Cornellaauthor=R.+Martin&title=Ni-catalyzed+stereoselective+arylation+of+inert+C-O+bonds+at+low+temperatures&doi=10.1021%2Fol4031815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Ni-Catalyzed Stereoselective Arylation of Inert C-O bonds at Low Temperatures</span></div><div class="casAuthors">Cornella, Josep; Martin, Ruben</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6298-6301</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A Ni-catalyzed arylation of inert C-O bonds that operates at temps. as low as -40°C is described.  Unlike other methods for C-O bond cleavage utilizing organometallic species, this protocol operates at low temps., thus allowing the presence of sensitive functional groups with exquisite site-selectivity and stereoselectivity.  Thus, e.g., arylation/C-O bond cleavage of 2,3-dihydrofuran with PhMgBr in presence of Ni NHC complex and LiCl afforded quant. (Z)-4-phenyl-3-buten-1-ol at -30°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkz_msEy_aV7Vg90H21EOLACvtfcHk0lhoYEcX4df44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL3P&md5=5e8c0526cfb4e2c22f18b5cde62163c7</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fol4031815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4031815%26sid%3Dliteratum%253Aachs%26aulast%3DCornella%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DR.%26atitle%3DNi-catalyzed%2520stereoselective%2520arylation%2520of%2520inert%2520C-O%2520bonds%2520at%2520low%2520temperatures%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D6298%26epage%3D6301%26doi%3D10.1021%2Fol4031815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. D.</span></span> <span> </span><span class="NLM_article-title">A new synthesis of cyclopropanes from olefins</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">5323</span>– <span class="NLM_lpage">5324</span>, <span class="refDoi"> DOI: 10.1021/ja01552a080</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01552a080" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaG1MXjvFKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1958&pages=5323-5324&author=H.+E.+Simmonsauthor=R.+D.+Smith&title=A+new+synthesis+of+cyclopropanes+from+olefins&doi=10.1021%2Fja01552a080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">A new synthesis of cyclopropanes from olefins</span></div><div class="casAuthors">Simmons, Howard E.; Smith, Ronald D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5323-4</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">cf. Howard, C.A. 34, 62153.  A versatile, stereospecific synthesis is reported of cyclopropanes by the reaction of unsatd. compds. with CH2I2 and a Zn-Cu couple.  Cyclohexene (0.30 mole), 0.15 mole CH2I2, and Zn-Cu couple (0.22 mole Zn) refluxed 48 hrs. in Et2O and the product distd. yielded 48% pure bicyclo[4.1.0] heptane, b. 116.5°, n25D 1.4546.  Many functionally substituted olefins gave the corresponding cyclopropanes.  Yields (10-70%) depended greatly on the kind of couple used and in no case were isomeric or rearranged products encountered (starting compd., product, and % yield given): C2H4, cyclopropane, 29; cyclopentene, bicyclo[3.1.0]hexane, 27; bicyclo[2.2.1] hept-2-ene, tricyclo[3,2,1,0]octane, 47; PhCH2CH:CH2, benzylcyclopropane, 49; PhCH:CH2, phenylcyclopropane, 32; ο-MeOC6H4CH:CHMe, 1-(ο-methoxyphenyl)-2-methylcyclopropane, 70; MeCH:CHCO2Me, Me 2-methyl-cyclopropanecarboxylate, 9; AcOCH:CH2, cyclopropyl acetate, 31.  Ethereal solns. from the reaction of the Zn-Cu couple contained ICH2ZnI.  Mechanisms for the reaction are discussed.  The stereospecificity of the reaction is indicated by the following reactions: cis-EtCH:CHEt yielded 35.5% pure cis-1,2-diethylcyclopropane, b. 93.5°, n25D 1.4035; trans-EtCH:CHEt yielded 15.5% trans-1,2-diethylcyclopropane, b. 86.5°, n25D 1.3982.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpnVTzAYovLVg90H21EOLACvtfcHk0lhoYEcX4df44A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXjvFKgug%253D%253D&md5=06d71e46354becf7287751ac835f51f7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fja01552a080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01552a080%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DH.%2BE.%26aulast%3DSmith%26aufirst%3DR.%2BD.%26atitle%3DA%2520new%2520synthesis%2520of%2520cyclopropanes%2520from%2520olefins%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1958%26volume%3D80%26spage%3D5323%26epage%3D5324%26doi%3D10.1021%2Fja01552a080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, K. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, V. M.</span></span> <span> </span><span class="NLM_article-title">Nitrogen-directed ketone hydroacylation: Enantioselective synthesis of benzoxazecinones</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1039/C0SC00469C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1039%2FC0SC00469C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvV2isr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=407-410&author=H.+A.+Khanauthor=K.+G.+M.+Kouauthor=V.+M.+Dong&title=Nitrogen-directed+ketone+hydroacylation%3A+Enantioselective+synthesis+of+benzoxazecinones&doi=10.1039%2FC0SC00469C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrogen-directed ketone hydroacylation: Enantioselective synthesis of benzoxazecinones</span></div><div class="casAuthors">Khan, Hasan A.; Kou, Kevin G. M.; Dong, Vy M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-410</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A method for a nitrogen-directed ketone hydroacylation is reported to furnish eight-membered nitrogen-contg. lactone (benzoxazecinone) derivs. in high yield and high enantiomeric excess.  In a model study, a comparison was made between nitrogen, oxygen and sulfur directing groups and it was found that nitrogen promoted faster hydroacylation.  By this catalytic transformation the synthesis of the target compds. (i.e., nitrogen heterocyclic compds., benzoxazepinone derivs. and benzoxazecinone derivs.) was achieved and it was discovered that, moreover, an amine-directing group completely suppressed a competitive decarbonylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSb9rhRu1TZ7Vg90H21EOLACvtfcHk0lhx4rgYBke7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvV2isr4%253D&md5=75287a2eaa1323632b47b2fe4bcb3bbd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1039%2FC0SC00469C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00469C%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DH.%2BA.%26aulast%3DKou%26aufirst%3DK.%2BG.%2BM.%26aulast%3DDong%26aufirst%3DV.%2BM.%26atitle%3DNitrogen-directed%2520ketone%2520hydroacylation%253A%2520Enantioselective%2520synthesis%2520of%2520benzoxazecinones%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D407%26epage%3D410%26doi%3D10.1039%2FC0SC00469C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komissarov, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knyazhanskaya, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atrokhova, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottikh, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kritzyn, A. M.</span></span> <span> </span><span class="NLM_article-title">The search of novel inhibitors of HIV-1 integrase among 5-(4-halogenophenyl)-5-oxopentyl derivatives of nucleic bases</span>. <i>Russ. J. Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1134/S1068162014050094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1134%2FS1068162014050094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCisLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=532-540&author=V.+V.+Komissarovauthor=E.+S.+Knyazhanskayaauthor=A.+V.+Atrokhovaauthor=M.+B.+Gottikhauthor=A.+M.+Kritzyn&title=The+search+of+novel+inhibitors+of+HIV-1+integrase+among+5-%284-halogenophenyl%29-5-oxopentyl+derivatives+of+nucleic+bases&doi=10.1134%2FS1068162014050094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The search of novel inhibitors of HIV-1 integrase among 5-(4-halogenophenyl)-5-oxopentyl derivatives of nucleic bases</span></div><div class="casAuthors">Komissarov, V. V.; Knyazhanskaya, E. S.; Atrokhova, A. V.; Gottikh, M. B.; Kritzyn, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Russian Journal of Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">532-540</span>CODEN:
                <span class="NLM_cas:coden">RJBCET</span>;
        ISSN:<span class="NLM_cas:issn">1068-1620</span>.
    
            (<span class="NLM_cas:orgname">SP MAIK Nauka/Interperiodica</span>)
        </div><div class="casAbstract">New nucleic base derivs. were obtained by alkylation of uracil, thymine, cytosine, adenine, 6-chloropurine, and 2-amino-6-chloropurine with 5-chloro-1-(4-halogenophenyl)-1-pentanones, and their phys. and chem. properties were studied.  The influence of the compds. synthesized on the HIV-1 integrase activity was studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOZOAc_VtHdLVg90H21EOLACvtfcHk0lhx4rgYBke7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCisLjN&md5=c66f6a30b8f3d093b430e5c2bc5eda5a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1134%2FS1068162014050094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS1068162014050094%26sid%3Dliteratum%253Aachs%26aulast%3DKomissarov%26aufirst%3DV.%2BV.%26aulast%3DKnyazhanskaya%26aufirst%3DE.%2BS.%26aulast%3DAtrokhova%26aufirst%3DA.%2BV.%26aulast%3DGottikh%26aufirst%3DM.%2BB.%26aulast%3DKritzyn%26aufirst%3DA.%2BM.%26atitle%3DThe%2520search%2520of%2520novel%2520inhibitors%2520of%2520HIV-1%2520integrase%2520among%25205-%25284-halogenophenyl%2529-5-oxopentyl%2520derivatives%2520of%2520nucleic%2520bases%26jtitle%3DRuss.%2520J.%2520Bioorg.%2520Chem.%26date%3D2014%26volume%3D40%26spage%3D532%26epage%3D540%26doi%3D10.1134%2FS1068162014050094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span> <span> </span><span class="NLM_article-title">Visible light-promoted ring-opening functionalization of unstrained cycloalkanols via inert C–C bond scission</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">5805</span>– <span class="NLM_lpage">5809</span>, <span class="refDoi"> DOI: 10.1039/C8SC01763H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1039%2FC8SC01763H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=30079191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=5805-5809&author=D.+Wangauthor=J.+Maoauthor=C.+Zhu&title=Visible+light-promoted+ring-opening+functionalization+of+unstrained+cycloalkanols+via+inert+C%E2%80%93C+bond+scission&doi=10.1039%2FC8SC01763H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Visible light-promoted ring-opening functionalization of unstrained cycloalkanols via inert C-C bond scission</span></div><div class="casAuthors">Wang, Dongping; Mao, Jincheng; Zhu, Chen</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">5805-5809</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A novel, useful, visible light-promoted ring-opening functionalization of unstrained cycloalkanols was described.  Upon scission of an inert cyclic C-C σ-bond, a set of medium- and large-sized rings were readily brominated under mild reaction conditions to afford the corresponding distal bromo-substituted alkyl ketones that were hard to synthesize otherwise.  The products were versatile building blocks, which were easily converted to other valuable mols. in one-step operation.  This protocol was also applicable to the unprecedented ring-opening cyanation and alkynylation of unstrained cycloalkanols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXWSzS0exWbVg90H21EOLACvtfcHk0lhx4rgYBke7Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSgtbvO&md5=a6c46e60203c1d9fb6bea7cb5503df5a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1039%2FC8SC01763H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8SC01763H%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DC.%26atitle%3DVisible%2520light-promoted%2520ring-opening%2520functionalization%2520of%2520unstrained%2520cycloalkanols%2520via%2520inert%2520C%25E2%2580%2593C%2520bond%2520scission%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D5805%26epage%3D5809%26doi%3D10.1039%2FC8SC01763H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tummatorn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruchirawat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploypradith, P.</span></span> <span> </span><span class="NLM_article-title">A convergent general strategy for the functionalized 2-aryl cycloalkyl-fused chromans: intramolecular hetero-Diels–Alder reactions of ortho-quinone methides</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1448</span>, <span class="refDoi"> DOI: 10.1002/chem.200902403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1002%2Fchem.200902403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=20039342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1445-1448&author=J.+Tummatornauthor=S.+Ruchirawatauthor=P.+Ploypradith&title=A+convergent+general+strategy+for+the+functionalized+2-aryl+cycloalkyl-fused+chromans%3A+intramolecular+hetero-Diels%E2%80%93Alder+reactions+of+ortho-quinone+methides&doi=10.1002%2Fchem.200902403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A Convergent General Strategy for the Functionalized 2-Aryl Cycloalkyl-Fused Chromans: Intramolecular Hetero-Diels-Alder Reactions of ortho-Quinone Methides</span></div><div class="casAuthors">Tummatorn, Jumreang; Ruchirawat, Somsak; Ploypradith, Poonsakdi</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1445-1448, S1445/1-S1445/44</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A highly efficient and general strategy for the synthesis of cycloalkyl-fused chromans by o-QM/HDA reactions mediated by p-toluenesulfonic acid immobilized on silica (PTS-Si) is described.  The use of PTS-Si in toluene was crit. to suppress styrene polymn.  All stereocenters at C2, C3, and C4 were installed with good to excellent stereocontrol in a single step.  E.g., treatment of precursor I with NaBH4, AcCl, DMAP, then PTS-Si, gave 50% chroman deriv. II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbARkQIYb37rVg90H21EOLACvtfcHk0li8zyLk1yPV-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKjsrs%253D&md5=e2025bdbc3599e6cfdb90e7b35ef4ecf</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fchem.200902403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200902403%26sid%3Dliteratum%253Aachs%26aulast%3DTummatorn%26aufirst%3DJ.%26aulast%3DRuchirawat%26aufirst%3DS.%26aulast%3DPloypradith%26aufirst%3DP.%26atitle%3DA%2520convergent%2520general%2520strategy%2520for%2520the%2520functionalized%25202-aryl%2520cycloalkyl-fused%2520chromans%253A%2520intramolecular%2520hetero-Diels%25E2%2580%2593Alder%2520reactions%2520of%2520ortho-quinone%2520methides%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2010%26volume%3D16%26spage%3D1445%26epage%3D1448%26doi%3D10.1002%2Fchem.200902403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, H.</span></span> <span> </span><span class="NLM_article-title">Catalyst-free annulation of 2-pyridylacetates and ynals with molecular oxygen: an access to 3-acylated indolizines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1630</span>– <span class="NLM_lpage">1639</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.8b02883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.8b02883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslClsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=1630-1639&author=Z.+Chenauthor=P.+Liangauthor=X.+Maauthor=H.+Luoauthor=G.+Xuauthor=T.+Liuauthor=X.+Wenauthor=J.+Zhengauthor=H.+Ye&title=Catalyst-free+annulation+of+2-pyridylacetates+and+ynals+with+molecular+oxygen%3A+an+access+to+3-acylated+indolizines&doi=10.1021%2Facs.joc.8b02883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Catalyst-Free Annulation of 2-Pyridylacetates and Ynals with Molecular Oxygen: An Access to 3-Acylated Indolizines</span></div><div class="casAuthors">Chen, Zhengwang; Liang, Pei; Ma, Xiaoyue; Luo, Haiqing; Xu, Guohai; Liu, Tanggao; Wen, Xiaowei; Zheng, Jing; Ye, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1630-1639</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalyst and additive-free annulation of 2-pyridylacetates and ynals under mol. oxygen was the first developed, affording 3-acylated indolizines in good to excellent yields.  Mol. oxygen was used as the source of the carbonyl oxygen atom in indolizines.  This approach was compatible with a wide range of functional groups, and esp. it has been successfully extended to unsatd. double bonds and triple bonds, which were difficult to prep. by previous methods in a single step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr683h-yftqv7Vg90H21EOLACvtfcHk0li8zyLk1yPV-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslClsw%253D%253D&md5=42003dafba29fc276f3ca5f2019f7ca5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.8b02883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.8b02883%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DH.%26atitle%3DCatalyst-free%2520annulation%2520of%25202-pyridylacetates%2520and%2520ynals%2520with%2520molecular%2520oxygen%253A%2520an%2520access%2520to%25203-acylated%2520indolizines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2019%26volume%3D84%26spage%3D1630%26epage%3D1639%26doi%3D10.1021%2Facs.joc.8b02883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristianslund, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aursnes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tungen, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. V.</span></span> <span> </span><span class="NLM_article-title">Squaramide catalyzed enantioselective iodolactonization of allenoic acids</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5232</span>– <span class="NLM_lpage">5236</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2016.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.tetlet.2016.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=5232-5236&author=R.+Kristianslundauthor=M.+Aursnesauthor=J.+E.+Tungenauthor=T.+V.+Hansen&title=Squaramide+catalyzed+enantioselective+iodolactonization+of+allenoic+acids&doi=10.1016%2Fj.tetlet.2016.10.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramide catalyzed enantioselective iodolactonization of allenoic acids</span></div><div class="casAuthors">Kristianslund, Renate; Aursnes, Marius; Tungen, Joern Eivind; Hansen, Trond Vidar</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">5232-5236</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An asym. iodolactonization reaction of allenoic acids has been extensively studied.  Eight different chiral squaramides were prepd. in a straightforward manner and investigated as organocatalysts.  The reaction protocol is operationally simple to execute and proceeds with up to 76% enantiomeric excess.  Several conditions, additives, catalysts, and substrates have been investigated.  The best results were obsd. with 3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-(((1R,2R)-2-(dipentylamino)cyclohexyl)amino)-cyclobut-3-ene-1,2-dione as the catalyst.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx8dRE5nS7wLVg90H21EOLACvtfcHk0li8zyLk1yPV-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGitrjE&md5=e786253a43dce700392584a607615be2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2016.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2016.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DKristianslund%26aufirst%3DR.%26aulast%3DAursnes%26aufirst%3DM.%26aulast%3DTungen%26aufirst%3DJ.%2BE.%26aulast%3DHansen%26aufirst%3DT.%2BV.%26atitle%3DSquaramide%2520catalyzed%2520enantioselective%2520iodolactonization%2520of%2520allenoic%2520acids%26jtitle%3DTetrahedron%2520Lett.%26date%3D2016%26volume%3D57%26spage%3D5232%26epage%3D5236%26doi%3D10.1016%2Fj.tetlet.2016.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagnoli, N.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1021/tx00019a017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx00019a017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaK3MXnsFSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1991&pages=123-128&author=B.+Subramanyamauthor=T.+Woolfauthor=N.+Castagnoli&title=Studies+on+the+in+vitro+conversion+of+haloperidol+to+a+potentially+neurotoxic+pyridinium+metabolite&doi=10.1021%2Ftx00019a017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite</span></div><div class="casAuthors">Subramanyam, Babu; Woolf, Thomas; Castagnoli, Neal, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-8</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    </div><div class="casAbstract">Evidence that partially oxidized piperidine derivs. such as the Parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are biotransformed in a reaction catalyzed by monoamine oxidase B (MAO-B) to neurotoxic pyridinium metabolites led to studies resulting in the identification of the haloperidol-derived pyridinium metabolite in the urine of drug-treated rats.  The present in vitro studies examine the metabolic pathway governing this overall four-electron oxidn.  Although haloperidol and its 1,2,3,6-tetrahydropyridine dehydration product were not substrates for purified bovine liver MAO-B, both compds. were biotransformed to the pyridinium product by rat liver microsomal prepns.  The dependence on NADPH and the inhibition by SKF-525A argue that one or more liver cytochrome P 450 isoenzymes may catalyze this transformation.  Attempts to detect possible metabolic intermediates were not successful.  Chem. model studies however, suggest that the expected intermediary amino enol and dihydropyridinium species may be too unstable to isolate.  The possible significance of this pathway with respect to haloperidol-induced central nervous system dysfunction is considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp65KQZwtgo8bVg90H21EOLACvtfcHk0lhVctYjhiZ_lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXnsFSksA%253D%253D&md5=35ff88549b6900cc5bdb9f4da1709f58</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Ftx00019a017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx00019a017%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanyam%26aufirst%3DB.%26aulast%3DWoolf%26aufirst%3DT.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DStudies%2520on%2520the%2520in%2520vitro%2520conversion%2520of%2520haloperidol%2520to%2520a%2520potentially%2520neurotoxic%2520pyridinium%2520metabolite%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1991%26volume%3D4%26spage%3D123%26epage%3D128%26doi%3D10.1021%2Ftx00019a017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuriev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, D. K.</span></span> <span> </span><span class="NLM_article-title">Ligand binding pathways of clozapine and haloperidol in the dopamine D2 and D3 receptors</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">308</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.5b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.5b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2016&pages=308-321&author=T.+Thomasauthor=Y.+Fangauthor=E.+Yurievauthor=D.+K.+Chalmers&title=Ligand+binding+pathways+of+clozapine+and+haloperidol+in+the+dopamine+D2+and+D3+receptors&doi=10.1021%2Facs.jcim.5b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand Binding Pathways of Clozapine and Haloperidol in the Dopamine D2 and D3 Receptors</span></div><div class="casAuthors">Thomas, Trayder; Fang, Yu; Yuriev, Elizabeth; Chalmers, David K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">308-321</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The binding of a small mol. ligand to its protein target is most often characterized by binding affinity and is typically viewed as an on/off switch.  The more complex reality is that binding involves the ligand passing through a series of intermediate states between the soln. phase and the fully bound pose.  We have performed a set of 29 unbiased mol. dynamics simulations to model the binding pathways of the dopamine receptor antagonists clozapine and haloperidol binding to the D2 and D3 dopamine receptors.  Through these simulations we have captured the binding pathways of clozapine and haloperidol from the extracellular vestibule to the orthosteric binding site and thereby, we also predict the bound pose of each ligand.  These are the first long time scale simulations of haloperidol or clozapine binding to dopamine receptors.  From these simulations, we have identified several important stages in the binding pathway, including the involvement of Tyr7.35 in a "handover" mechanism that transfers the ligand between the extracellular vestibule and Asp3.32.  We have also performed interaction and cluster analyses to det. differences in binding pathways between the D2 and D3 receptors and identified metastable states that may be of use in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpimYd-xEW9a7Vg90H21EOLACvtfcHk0lhVctYjhiZ_lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiurzO&md5=b5faf13609b11b8efcfebd3eb5f0a77e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.5b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.5b00457%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DYuriev%26aufirst%3DE.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26atitle%3DLigand%2520binding%2520pathways%2520of%2520clozapine%2520and%2520haloperidol%2520in%2520the%2520dopamine%2520D2%2520and%2520D3%2520receptors%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2016%26volume%3D56%26spage%3D308%26epage%3D321%26doi%3D10.1021%2Facs.jcim.5b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalani, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidehi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trabanino, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freddolino, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalani, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floriano, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kam, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, W. A.,  3rd</span></span> <span> </span><span class="NLM_article-title">The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3815</span>– <span class="NLM_lpage">3820</span>, <span class="refDoi"> DOI: 10.1073/pnas.0400100101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1073%2Fpnas.0400100101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=14999101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Kgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=3815-3820&author=M.+Y.+Kalaniauthor=N.+Vaidehiauthor=S.+E.+Hallauthor=R.+J.+Trabaninoauthor=P.+L.+Freddolinoauthor=M.+A.+Kalaniauthor=W.+B.+Florianoauthor=V.+W.+Kamauthor=W.+A.+Goddard&title=The+predicted+3D+structure+of+the+human+D2+dopamine+receptor+and+the+binding+site+and+binding+affinities+for+agonists+and+antagonists&doi=10.1073%2Fpnas.0400100101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists</span></div><div class="casAuthors">Yashar, M.; Kalani, S.; Vaidehi, Nagarajan; Hall, Spencer E.; Trabanino, Rene J.; Freddolino, Peter L.; Kalani, Maziyar A.; Floriano, Wely B.; Kam, Victor Wai Tak; Goddard, William A., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3815-3820</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dopamine neurotransmitter and its receptors play a crit. role in the cell signaling process responsible for information transfer in neurons functioning in the nervous system.  Development of improved therapeutics for such disorders as Parkinson's disease and schizophrenia would be significantly enhanced with the availability of the 3D structure for the dopamine receptors and of the binding site for dopamine and other agonists and antagonists.  The authors report the 3D structure of the long isoform of the human D2 dopamine receptor, predicted from primary sequence using first-principles theor. and computational techniques (i.e., the authors did not use bioinformatic or exptl. 3D structural information in predicting structures).  The predicted 3D structure is validated by comparison of the predicted binding site and the relative binding affinities of dopamine, three known dopamine agonists (antiparkinsonian), and seven known antagonists (antipsychotic) in the D2 receptor to exptl. detd. values.  These structures correctly predict the crit. residues for binding dopamine and several antagonists, identified by mutation studies, and give relative binding affinities that correlate well with expts.  The predicted binding site for dopamine and agonists is located between transmembrane (TM) helixes 3, 4, 5, and 6, whereas the best antagonists bind to a site involving TM helixes 2, 3, 4, 6, and 7 with minimal contacts to TM helix 5.  The authors identify characteristic differences between the binding sites of agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK0awOUK1verVg90H21EOLACvtfcHk0lhVctYjhiZ_lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Kgtbc%253D&md5=429ddad44cb95b2eb78390612346df59</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0400100101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0400100101%26sid%3Dliteratum%253Aachs%26aulast%3DKalani%26aufirst%3DM.%2BY.%26aulast%3DVaidehi%26aufirst%3DN.%26aulast%3DHall%26aufirst%3DS.%2BE.%26aulast%3DTrabanino%26aufirst%3DR.%2BJ.%26aulast%3DFreddolino%26aufirst%3DP.%2BL.%26aulast%3DKalani%26aufirst%3DM.%2BA.%26aulast%3DFloriano%26aufirst%3DW.%2BB.%26aulast%3DKam%26aufirst%3DV.%2BW.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26atitle%3DThe%2520predicted%25203D%2520structure%2520of%2520the%2520human%2520D2%2520dopamine%2520receptor%2520and%2520the%2520binding%2520site%2520and%2520binding%2520affinities%2520for%2520agonists%2520and%2520antagonists%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D3815%26epage%3D3820%26doi%3D10.1073%2Fpnas.0400100101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell-Horner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1021/cn300142q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn300142q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqtr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1050-1062&author=R.+R.+Luedtkeauthor=Y.+Mishraauthor=Q.+Wangauthor=S.+A.+Griffinauthor=C.+Bell-Hornerauthor=M.+Taylorauthor=S.+Vangveravongauthor=G.+H.+Dillonauthor=R.-Q.+Huangauthor=D.+E.+Reichertauthor=R.+H.+Mach&title=Comparison+of+the+binding+and+functional+properties+of+two+structurally+different+D2+dopamine+receptor+subtype+selective+compounds&doi=10.1021%2Fcn300142q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the Binding and Functional Properties of Two Structurally Different D2 Dopamine Receptor Subtype Selective Compounds</span></div><div class="casAuthors">Luedtke, Robert R.; Mishra, Yogesh; Wang, Qi; Griffin, Suzy A.; Bell-Horner, Cathy; Taylor, Michelle; Vangveravong, Suwanna; Dillon, Glenn H.; Huang, Ren-Qi; Reichert, David E.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1050-1062</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported on the synthesis of substituted phenyl-4-hydroxy-1-piperidyl indole analogs with nanomolar affinity at D2 dopamine receptors, ranging from 10- to 100-fold selective for D2 compared to the D3 dopamine receptor subtype.  More recently, we evaluated a panel of aripiprazole analogs, identifying several analogs that also exhibit D2 vs D3 dopamine receptor binding selectivity.  These studies further characterize the intrinsic efficacy of the compd. with the greatest binding selectivity from each chem. class, 1-((5-methoxy-1H-indol-3-yl)methyl)-4-(4-(methylthio)phenyl)piperidin-4-ol (SV 293) and 7-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one (SV-III-130s), using an adenylyl cyclase inhibition assay, a G-protein-coupled inward-rectifying potassium (GIRK) channel activation assay, and a cell based phospho-MAPK (pERK1/2) assay.  SV 293 was found to be a neutral antagonist at D2 dopamine receptors using all three assays.  SV-III-130s is a partial agonist using an adenylyl cyclase inhibition assay but an antagonist in the GIRK and phospho ERK1/2 assays.  To define the mol. basis for the binding selectivity, the affinity of these two compds. was evaluated using (a) wild type human D2 and D3 receptors and (b) a panel of chimeric D2/D3 dopamine receptors.  Computer-assisted modeling techniques were used to dock these compds. to the human D2 and D3 dopamine receptor subtypes.  It is hoped that these studies on D2 receptor selective ligands will be useful in the future design of (a) receptor selective ligands used to define the function of D2-like receptor subtypes, (b) novel pharmacotherapeutic agents, and/or (c) in vitro and in vivo imaging agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkk_Neaj9JrVg90H21EOLACvtfcHk0lglQwS0-445aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqtr7O&md5=42fe569c18220a451a3a88716ef44426</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fcn300142q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn300142q%26sid%3Dliteratum%253Aachs%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DMishra%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGriffin%26aufirst%3DS.%2BA.%26aulast%3DBell-Horner%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DDillon%26aufirst%3DG.%2BH.%26aulast%3DHuang%26aufirst%3DR.-Q.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DComparison%2520of%2520the%2520binding%2520and%2520functional%2520properties%2520of%2520two%2520structurally%2520different%2520D2%2520dopamine%2520receptor%2520subtype%2520selective%2520compounds%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D1050%26epage%3D1062%26doi%3D10.1021%2Fcn300142q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, D. E.</span></span> <span> </span><span class="NLM_article-title">Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1985</span>, <span class="refDoi"> DOI: 10.1021/ci1002747</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci1002747" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OisrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1970-1985&author=Q.+Wangauthor=R.+H.+Machauthor=R.+R.+Luedtkeauthor=D.+E.+Reichert&title=Subtype+selectivity+of+dopamine+receptor+ligands%3A+insights+from+structure+and+ligand-based+methods&doi=10.1021%2Fci1002747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods</span></div><div class="casAuthors">Wang, Qi; Mach, Robert H.; Luedtke, Robert R.; Reichert, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1970-1985</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subtype selective dopamine receptor ligands have long been sought after as therapeutic and/or imaging agents for the treatment and monitoring of neurol. disorders.  We report herein on a combined structure- and ligand-based approach to explore the mol. mechanism of the subtype selectivity for a large class of D2-like dopamine receptor ligands (163 ligands in total).  Homol. models were built for both human D2L and D3 receptors in complex with haloperidol.  Other ligands, which included multiple examples of substituted phenylpiperazines, were aligned against the binding conformations of haloperidol, and three-dimensional quant. structure activity relationship (3D-QSAR) analyses were carried out.  The receptor models show that although D2 and D3 share highly similar folds and 3D conformations, the slight sequence differences at their extracellular loop regions result in the binding cavity in D2 being comparably shallower than in D3, which may explain why some larger ligands bind with greater affinity at D3 compared to D2 receptors.  The QSAR models show excellent correlation and high predictive power even when evaluated by the most stringent criteria.  They confirm that the origins of subtype selectivity for the ligands arise primarily due to differences in the contours of the two binding sites.  The predictive models suggest that while both steric and electrostatic interactions contribute to the compds.' binding affinity, the major contribution arises from hydrophobic interactions, with hydrogen bonding conferring binding specificity.  The current work provides clues for the development of more subtype selective dopamine receptor ligands.  Furthermore, it demonstrates the possibility of being able to apply similar modeling methods to other subtypes or classes of receptors to study GPCR receptor-ligand interactions at a mol. level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokZTtMqvRrXbVg90H21EOLACvtfcHk0lglQwS0-445aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OisrzJ&md5=7c923cdaa5e10b1089c7152cedcd9cb0</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fci1002747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci1002747%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26aulast%3DReichert%26aufirst%3DD.%2BE.%26atitle%3DSubtype%2520selectivity%2520of%2520dopamine%2520receptor%2520ligands%253A%2520insights%2520from%2520structure%2520and%2520ligand-based%2520methods%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1970%26epage%3D1985%26doi%3D10.1021%2Fci1002747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1124/mol.108.054452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1124%2Fmol.108.054452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=19498041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=543-551&author=D.+A.+Sykesauthor=M.+R.+Dowlingauthor=S.+J.+Charlton&title=Exploring+the+mechanism+of+agonist+efficacy%3A+a+relationship+between+efficacy+and+agonist+dissociation+rate+at+the+muscarinic+M3+receptor&doi=10.1124%2Fmol.108.054452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor</span></div><div class="casAuthors">Sykes, David A.; Dowling, Mark R.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-551</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although there are several empirical approaches that enable the comparison of relative agonist efficacy, the mol. basis that underlies differences in the ability of G protein-coupled receptor agonists to elicit a response is still largely unexplained.  Several models have been described that incorporate the kinetics of receptor-mediated initiation of the G protein cycle, but these have not directly addressed the influence of agonist-binding kinetics.  To test this, we investigated the relationship between the efficacy of seven M3 muscarinic receptor agonists and their rate of dissocn. (koff) from the M3 receptor.  The assocn. and dissocn. rate consts. of the agonists were detd. using a I-[N-methyl]-[3H]scopolamine Me chloride competition binding assay in the presence of GTP.  The agonists displayed a range of assocn. and dissocn. rates.  Relative agonist efficacy was measured at two points after M3 receptor activation: the stimulation of guanosine 5'-O-(3-[35S]thio)triphosphate binding to Gα subunits, and the subsequent increase in intracellular calcium levels.  These expts. revealed a range of intrinsic efficacy, from the low-efficacy pilocarpine and oxotremorine to high-efficacy acetylcholine.  There was no relationship between agonist efficacy and the equil. binding affinity of each agonist (Kd).  When efficacy was compared with the dissocn. rate const., however, the two were highly correlated, suggesting a relationship between the duration of agonist binding at the receptor and the intrinsic efficacy.  These data suggest that kinetic models incorporating the mean lifetime of specific complexes will be required to fully explain the nature of agonist efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPtUbRzBhLnrVg90H21EOLACvtfcHk0lglQwS0-445aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyrsLg%253D&md5=faa8fd2cf265eadd420c943f4033b02f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.054452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.054452%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDowling%26aufirst%3DM.%2BR.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DExploring%2520the%2520mechanism%2520of%2520agonist%2520efficacy%253A%2520a%2520relationship%2520between%2520efficacy%2520and%2520agonist%2520dissociation%2520rate%2520at%2520the%2520muscarinic%2520M3%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D543%26epage%3D551%26doi%3D10.1124%2Fmol.108.054452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deyrup, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowicki, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. P.</span></span> <span> </span><span class="NLM_article-title">Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor</span>. <i>Naunyn-Schmiedebergs Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1007/PL00005339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1007%2FPL00005339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10208303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADyaK1M3it12rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=1999&pages=168-177&author=M.+D.+Deyrupauthor=S.+T.+Nowickiauthor=N.+G.+Richardsauthor=D.+H.+Oteroauthor=J.+K.+Harrisonauthor=S.+P.+Baker&title=Structure-affinity+profile+of+8-hydroxycarbostyril-based+agonists+that+dissociate+slowly+from+the+beta2-adrenoceptor&doi=10.1007%2FPL00005339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor</span></div><div class="casAuthors">Deyrup M D; Nowicki S T; Richards N G; Otero D H; Harrison J K; Baker S P</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's archives of pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">168-77</span>
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">Several carbostyril-based beta-agonists have been shown to bind tightly to and slowly dissociate from the beta2-adrenoceptor (beta2AR).  In the present study, the structural features of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] -carbostyril (11a) which contribute to its binding properties at the beta2AR were investigated using a series of synthesized analogs.  The k(off), estimated by the rate of cAMP decline in DDT1 MF-2 (DDT) cells with a reduced receptor density, Ki and ligand-induced receptor reductions were determined.  All of the derivatives stimulated cAMP accumulation in DDT cells in the sub to mid nanomolar range and elicited the same maximal stimulation as (-)isoproterenol.  Derivatives of 11a with side chain N-substitutions comprising 2-methylbutyl, phenylethyl and isopropyl had higher k(off)-values and lower affinities as compared to 11a.  Increasing the number of methylenes between the side chain tertiary alpha carbon and phenyl from 1 in 11a to 3 or reducing the number to 0 also resulted in derivatives with higher k(off)- and Ki-values.  In addition, replacement of the 8-hydroxycarbostyril nucleus of 11a with catechol reduced the affinity of the compound for the beta2AR by 48-fold and increased its k(off).  Only those derivatives with the lowest k(off)-values induced a decrease in the receptor density of DDT cell membranes following a preincubation and extensive washing.  The data show that the 8-hydroxycarbostyril nucleus in conjunction with substitutions on the tertiary alpha carbon of the side chain and positioning of the phenyl group are important characteristics determining the high affinity and slow dissociation of 11a from the beta2AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpXxjlkrrGA6Nc3HjJRoFAfW6udTcc2eaRJql5s_gD1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3it12rtg%253D%253D&md5=8b0728ee71d74f30c87a7f1381cc3098</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2FPL00005339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00005339%26sid%3Dliteratum%253Aachs%26aulast%3DDeyrup%26aufirst%3DM.%2BD.%26aulast%3DNowicki%26aufirst%3DS.%2BT.%26aulast%3DRichards%26aufirst%3DN.%2BG.%26aulast%3DOtero%26aufirst%3DD.%2BH.%26aulast%3DHarrison%26aufirst%3DJ.%2BK.%26aulast%3DBaker%26aufirst%3DS.%2BP.%26atitle%3DStructure-affinity%2520profile%2520of%25208-hydroxycarbostyril-based%2520agonists%2520that%2520dissociate%2520slowly%2520from%2520the%2520beta2-adrenoceptor%26jtitle%3DNaunyn-Schmiedebergs%2520Arch.%2520Pharmacol.%26date%3D1999%26volume%3D359%26spage%3D168%26epage%3D177%26doi%3D10.1007%2FPL00005339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder-Krieger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijzerman, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span> <span> </span><span class="NLM_article-title">Functional efficacy of adenosine A(2A) receptor agonists is positively correlated to their receptor residence time</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">1846</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.01897.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fj.1476-5381.2012.01897.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=22324512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOku7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1846-1859&author=D.+Guoauthor=T.+Mulder-Kriegerauthor=A.+P.+Ijzermanauthor=L.+H.+Heitman&title=Functional+efficacy+of+adenosine+A%282A%29+receptor+agonists+is+positively+correlated+to+their+receptor+residence+time&doi=10.1111%2Fj.1476-5381.2012.01897.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time</span></div><div class="casAuthors">Guo, Dong; Mulder-Krieger, Thea; IJzerman, Adriaan P.; Heitman, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1846-1859</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The adenosine A2A receptor belongs to the superfamily of GPCRs and is a promising therapeutic target.  Traditionally, the discovery of novel agents for the A2A receptor has been guided by their affinity for the receptor.  This parameter is detd. under equil. conditions, largely ignoring the kinetic aspects of the ligand-receptor interaction.  The aim of this study was to assess the binding kinetics of A2A receptor agonists and explore a possible relationship with their functional efficacy.  We set up, validated and optimized a kinetic radioligand binding assay (a so-called competition assocn. assay) at the A2A receptor from which the binding kinetics of unlabeled ligands were detd.  Subsequently, functional efficacies of A2A receptor agonists were detd. in two different assays: a novel label-free impedance-based assay and a more traditional cAMP detn.  A simplified competition assocn. assay yielded an accurate detn. of the assocn. and dissocn. rates of unlabeled A2A receptor ligands at their receptor.  A correlation was obsd. between the receptor residence time of A2A receptor agonists and their intrinsic efficacies in both functional assays.  The affinity of A2A receptor agonists was not correlated to their functional efficacy.  This study indicates that the mol. basis of different agonist efficacies at the A2A receptor lies within their different residence times at this receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowupsgRlfDkLVg90H21EOLACvtfcHk0ljawhO5XsBBNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOku7bL&md5=318c22c4a852bc14cb0fac5915ae7e90</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01897.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01897.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26atitle%3DFunctional%2520efficacy%2520of%2520adenosine%2520A%25282A%2529%2520receptor%2520agonists%2520is%2520positively%2520correlated%2520to%2520their%2520receptor%2520residence%2520time%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1846%26epage%3D1859%26doi%3D10.1111%2Fj.1476-5381.2012.01897.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langmead, C. J.</span></span> <span> </span><span class="NLM_article-title">Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1111/bph.12245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fbph.12245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=23692283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFOntrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=351-363&author=R.+Mouldauthor=J.+Brownauthor=F.+H.+Marshallauthor=C.+J.+Langmead&title=Binding+kinetics+differentiates+functional+antagonism+of+orexin-2+receptor+ligands&doi=10.1111%2Fbph.12245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands</span></div><div class="casAuthors">Mould, R.; Brown, J.; Marshall, F. H.; Langmead, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">351-363</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Orexin receptor antagonism represents a novel approach for the treatment of insomnia that directly targets sleep/wake regulation.  Several such compds. have entered into clin. development, including the dual orexin receptor antagonists, suvorexant and almorexant.  In this study, we have used equil. and kinetic binding studies with the orexin-2 (OX2) selective antagonist radioligand, [3H]-EMPA, to profile several orexin receptor antagonists.  Furthermore, selected compds. were studied in cell-based assays of inositol phosphate accumulation and ERK-1/2 phosphorylation in CHO cells stably expressing the OX2 receptor that employ different agonist incubation times (30 and 5 min, resp.).  EMPA, suvorexant, almorexant and TCS-OX-29 all bind to the OX2 receptor with moderate to high affinity (pKI values ≥ 7.5), whereas the primarily OX1 selective antagonists SB-334867 and SB-408124 displayed low affinity (pKI values ca. 6).  Competition kinetic anal. showed that the compds. displayed a range of dissocn. rates from very fast (TCS-OX2-29, koff = 0.22 min-1) to very slow (almorexant, koff = 0.005 min-1).  Notably, there was a clear correlation between assocn. rate and affinity.  In the cell-based assays, fast-offset antagonists EMPA and TCS-OX2-29 displayed surmountable antagonism of orexin-A agonist activity.  However, both suvorexant and particularly almorexant cause concn.-dependent depression in the maximal orexin-A response, a profile that is more evident with a shorter agonist incubation time.  Anal. according to a hemi-equil. model suggests that antagonist dissocn. is slower in a cellular system than in membrane binding; under these conditions, almorexant effectively acts as a pseudo-irreversible antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKvVgXShAR8rVg90H21EOLACvtfcHk0ljawhO5XsBBNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFOntrvE&md5=1192764ca7f2175956ff57f68e3c9862</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1111%2Fbph.12245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12245%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DF.%2BH.%26aulast%3DLangmead%26aufirst%3DC.%2BJ.%26atitle%3DBinding%2520kinetics%2520differentiates%2520functional%2520antagonism%2520of%2520orexin-2%2520receptor%2520ligands%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D351%26epage%3D363%26doi%3D10.1111%2Fbph.12245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span> <span> </span><span class="NLM_article-title">Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">2672</span>– <span class="NLM_lpage">2683</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01639.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fj.1476-5381.2011.01639.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21883146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVajtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=2672-2683&author=D.+A.+Sykesauthor=S.+J.+Charlton&title=Slow+receptor+dissociation+is+not+a+key+factor+in+the+duration+of+action+of+inhaled+long-acting+beta2-adrenoceptor+agonists&doi=10.1111%2Fj.1476-5381.2011.01639.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists</span></div><div class="casAuthors">Sykes, David A.; Charlton, Steven J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2672-2683</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose: β2-Adrenoceptor agonists are important bronchodilators used for the treatment of chronic obstructive pulmonary disease and asthma.  Clin. data on β2-adrenoceptor agonists show a range of onset and duration of action.  We have investigated whether the receptor binding kinetics of β2-adrenoceptor agonists can explain their obsd. onset of action and duration of effect in the clinic.  Exptl. Approach: [3H]-DHA was used to label β2-adrenoceptors expressed in CHO-cell membranes (Kd of 0.084 nM).  Competition kinetic expts. were performed in the presence of unlabeled β2 agonists at 37°C in HBSS contg. GTP.  To det. the kinetic parameters, three concns. (10, 3 and 1 × Ki) of the unlabeled compd. were employed against a fixed concn. of [3H]-DHA (0.6 nM).  Key Results: The clin. used β2-adrenoceptor agonists exhibited a range of assocn. and dissocn. rates.  The kinetic Kd and the competition Ki values of the eight β2-adrenoceptor agonists examd. were strongly correlated, suggesting that the method had produced accurate koff and kon rates.  The kinetic on-rate was highly correlated with equil. binding affinity.  Conclusions and Implications: Although the β2-adrenoceptor agonists displayed a range of kinetic rate parameters, simulations at relevant drug concns. suggest that receptor kinetics do not play an important role in detg. onset of action in the clinic.  In addn., it is unlikely that receptor kinetics exert an important influence on the duration of action of these agonists, as indacaterol (once daily dosing) had a shorter residency time at the receptor than salmeterol (twice daily dosing).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSXrYrFofvmrVg90H21EOLACvtfcHk0ljMIkRDvQkKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVajtLg%253D&md5=c090bf289f61624bbf038f83208b0e07</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01639.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01639.x%26sid%3Dliteratum%253Aachs%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26atitle%3DSlow%2520receptor%2520dissociation%2520is%2520not%2520a%2520key%2520factor%2520in%2520the%2520duration%2520of%2520action%2520of%2520inhaled%2520long-acting%2520beta2-adrenoceptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D2672%26epage%3D2683%26doi%3D10.1111%2Fj.1476-5381.2011.01639.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tresadern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, X.</span></span> <span> </span><span class="NLM_article-title">Molecular properties affecting fast dissociation from the D2 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2231</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2Fj.bmc.2011.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21421319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=2231-2241&author=G.+Tresadernauthor=J.+M.+Bartolomeauthor=G.+J.+Macdonaldauthor=X.+Langlois&title=Molecular+properties+affecting+fast+dissociation+from+the+D2+receptor&doi=10.1016%2Fj.bmc.2011.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular properties affecting fast dissociation from the D2 receptor</span></div><div class="casAuthors">Tresadern, Gary; Bartolome, Jose Manuel; MacDonald, Gregor J.; Langlois, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2231-2241</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Dopamine D2 receptor antagonism is the foundation of antipsychotic treatment.  Antipsychotic agents vary in how fast they dissoc. from the D2 receptors.  It has been proposed that the liability to exhibit side effects such as extra pyramidal symptoms may be the result of a slow rate of dissocn.  Compds. with a faster rate of dissocn., while still blocking efficiently the D2 receptors, will subsequently respond better to physiol. surges in dopamine transmission.  Therefore, work in our labs. has focussed on identifying fast dissocg. and selective D2 antagonists.  Biol. screening was performed to measure the affinity and extent of dissocn. for a large dataset of over 1800 D2 antagonists.  Subsequent univariate and multivariate statistical anal. revealed the mol. properties which differentiate fast and slow dissocg. compds.  It is shown that faster dissocg. antagonists are less lipophilic and have lower mol. wt.  There was a clear and expected inverse relationship with extent of dissocn. and binding affinity with more potent compds. tending to be slower dissocg.  However, within a range of comparable affinity both fast and slow dissocg. compds. were identified.  After de-correlating affinity and dissocn. the anal. revealed the important descriptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqilpQ8-EuD-LVg90H21EOLACvtfcHk0ljMIkRDvQkKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFeht70%253D&md5=574e106853b1cff1b6975c4bba979031</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DTresadern%26aufirst%3DG.%26aulast%3DBartolome%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DLanglois%26aufirst%3DX.%26atitle%3DMolecular%2520properties%2520affecting%2520fast%2520dissociation%2520from%2520the%2520D2%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D2231%26epage%3D2241%26doi%3D10.1016%2Fj.bmc.2011.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vauquelin, G.</span></span> <span> </span><span class="NLM_article-title">Cell membranes... and how long drugs may exert beneficial pharmacological activity in vivo</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.1111/bcp.12996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1111%2Fbcp.12996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=27135195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A280%3ADC%252BC28bltFektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2016&pages=673-682&author=G.+Vauquelin&title=Cell+membranes...+and+how+long+drugs+may+exert+beneficial+pharmacological+activity+in+vivo&doi=10.1111%2Fbcp.12996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Cell membranes... and how long drugs may exert beneficial pharmacological activity in vivo</span></div><div class="casAuthors">Vauquelin Georges</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-82</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The time course of the beneficial pharmacological effect of a drug has long been considered to depend merely on the temporal fluctuation of its free concentration.  Only in the last decade has it become widely accepted that target-binding kinetics can also affect in vivo pharmacological activity.  Although current reviews still essentially focus on genuine dissociation rates, evidence is accumulating that additional micro-pharmacokinetic (PK) and -pharmacodynamic (PD) mechanisms, in which the cell membrane plays a central role, may also increase the residence time of a drug on its target.  The present review provides a compilation of otherwise widely dispersed information on this topic.  The cell membrane can intervene in drug binding via the following three major mechanisms: (i) by acting as a sink/repository for the drug; (ii) by modulating the conformation of the drug and even by participating in the binding process; and (iii) by facilitating the approach (and rebinding) of the drug to the target.  To highlight these mechanisms, we focus on drugs that are currently used in clinical therapy, such as the antihypertensive angiotensin II type 1 receptor antagonist candesartan, the atypical antipsychotic agent clozapine and the bronchodilator salmeterol.  Although the role of cell membranes in PK-PD modelling is gaining increasing interest, many issues remain unresolved.  It is likely that novel biophysical and computational approaches will provide improved insights in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNNhiIkXw2kevW160gIxP_fW6udTcc2ebMoCrMK8cpjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bltFektQ%253D%253D&md5=f30526cdbc86bc81ae55b1fb452b5197</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12996%26sid%3Dliteratum%253Aachs%26aulast%3DVauquelin%26aufirst%3DG.%26atitle%3DCell%2520membranes...%2520and%2520how%2520long%2520drugs%2520may%2520exert%2520beneficial%2520pharmacological%2520activity%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D82%26spage%3D673%26epage%3D682%26doi%3D10.1111%2Fbcp.12996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wacker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>555</i></span>,  <span class="NLM_fpage">269</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1038/nature25758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1038%2Fnature25758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=29466326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=555&publication_year=2018&pages=269-273&author=S.+Wangauthor=T.+Cheauthor=A.+Levitauthor=B.+K.+Shoichetauthor=D.+Wackerauthor=B.+L.+Roth&title=Structure+of+the+D2+dopamine+receptor+bound+to+the+atypical+antipsychotic+drug+risperidone&doi=10.1038%2Fnature25758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</span></div><div class="casAuthors">Wang, Sheng; Che, Tao; Levit, Anat; Shoichet, Brian K.; Wacker, Daniel; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">555</span>
        (<span class="NLM_cas:issue">7695</span>),
    <span class="NLM_cas:pages">269-273</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metab. and hormonal secretion.  Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting.  The actions of dopamine are mediated by a family of five G-protein-coupled receptors.  The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease.  Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors.  Accordingly, a mol. understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications.  Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone.  The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeo4Ov49kft7Vg90H21EOLACvtfcHk0ljMIkRDvQkKcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFKqt7c%253D&md5=2842adc1893293ea8dbf98ae3270a1b2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fnature25758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25758%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DChe%26aufirst%3DT.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DWacker%26aufirst%3DD.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DStructure%2520of%2520the%2520D2%2520dopamine%2520receptor%2520bound%2520to%2520the%2520atypical%2520antipsychotic%2520drug%2520risperidone%26jtitle%3DNature%26date%3D2018%26volume%3D555%26spage%3D269%26epage%3D273%26doi%3D10.1038%2Fnature25758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mocking, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitman, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">IJzerman, A. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1124/mol.115.102657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1124%2Fmol.115.102657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=26873858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsF2ks7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=485-491&author=D.+Guoauthor=A.+C.+Panauthor=R.+O.+Drorauthor=T.+Mockingauthor=R.+Liuauthor=L.+H.+Heitmanauthor=D.+E.+Shawauthor=A.+P.+IJzerman&title=Molecular+Basis+of+Ligand+Dissociation+from+the+Adenosine+A2A+Receptor&doi=10.1124%2Fmol.115.102657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of ligand dissociation from the adenosine A2A receptor</span></div><div class="casAuthors">Guo, Dong; Pan, Albert C.; Dror, Ron O.; Mocking, Tamara; Liu, Rongfang; Heitman, Laura H.; Shaw, David E.; IJzerman, Adriaan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">485-491</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">How drugs dissoc. from their targets is largely unknown.  We investigated the mol. basis of this process in the adenosine A2A receptor (A2AR), a prototypical G protein-coupled receptor (GPCR).  Through kinetic radioligand binding expts., we characterized mutant receptors selected based on mol. dynamic simulations of the antagonist ZM241385 dissocg. from the A2AR.  We discovered mutations that dramatically altered the ligand's dissocn. rate despite only marginally influencing its binding affinity, demonstrating that even receptor features with little contribution to affinity may prove crit. to the dissocn. process.  Our results also suggest that ZM241385 follows a multistep dissocn. pathway, consecutively interacting with distinct receptor regions, a mechanism that may also be common to many other GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFL8Q8IGEZJbVg90H21EOLACvtfcHk0lgPoC_8_KQR0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsF2ks7zJ&md5=ae4fb68a895391167db19e72b4f99d72</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.102657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.102657%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DMocking%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHeitman%26aufirst%3DL.%2BH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26atitle%3DMolecular%2520Basis%2520of%2520Ligand%2520Dissociation%2520from%2520the%2520Adenosine%2520A2A%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D485%26epage%3D491%26doi%3D10.1124%2Fmol.115.102657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arlow, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhani, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragakis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Pathway and mechanism of drug binding to G-protein-coupled receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">13118</span>– <span class="NLM_lpage">13123</span>, <span class="refDoi"> DOI: 10.1073/pnas.1104614108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1073%2Fpnas.1104614108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21778406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=13118-13123&author=R.+O.+Drorauthor=A.+C.+Panauthor=D.+H.+Arlowauthor=D.+W.+Borhaniauthor=P.+Maragakisauthor=Y.+Shanauthor=H.+Xuauthor=D.+E.+Shaw&title=Pathway+and+mechanism+of+drug+binding+to+G-protein-coupled+receptors&doi=10.1073%2Fpnas.1104614108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Pathway and mechanism of drug binding to G-protein-coupled receptors</span></div><div class="casAuthors">Dror, Ron O.; Pan, Albert C.; Arlow, Daniel H.; Borhani, David W.; Maragakis, Paul; Shan, Yibing; Xu, Huafeng; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">13118-13123, S13118/1-S13118/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">How drugs bind to their receptors-from initial assocn., through drug entry into the binding pocket, to adoption of the final bound conformation, or "pose"-has remained unknown, even for G-protein-coupled receptor modulators, which constitute 1/3 of all marketed drugs.  Here, the authors captured this pharmaceutically crit. process in at. detail using the 1st unbiased mol. dynamics simulations in which drug mols. spontaneously assoc. with G-protein-coupled receptors to achieve final poses matching those detd. crystallog.  The authors found that several beta blockers and a beta agonist all traversed the same well-defined, dominant pathway as they bound to the β1- and β2-adrenergic receptors, initially making contact with a vestibule on each receptor's extracellular surface.  Surprisingly, assocn. with this vestibule, at a distance of 15 Å from the binding pocket, often presented the largest energetic barrier to binding, despite the fact that subsequent entry into the binding pocket required the receptor to deform and the drug to squeeze through a narrow passage.  The early barrier appeared to reflect the substantial dehydration that takes place as the drug assocs. with the vestibule.  The at.-level description of the binding process suggests opportunities for allosteric modulation and provides a structural foundation for future optimization of drug-receptor binding and unbinding rates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKUYFtkTGwf7Vg90H21EOLACvtfcHk0lgPoC_8_KQR0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKit7bE&md5=9cfa8673217931cacd586321309fa72e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104614108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104614108%26sid%3Dliteratum%253Aachs%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DPan%26aufirst%3DA.%2BC.%26aulast%3DArlow%26aufirst%3DD.%2BH.%26aulast%3DBorhani%26aufirst%3DD.%2BW.%26aulast%3DMaragakis%26aufirst%3DP.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DPathway%2520and%2520mechanism%2520of%2520drug%2520binding%2520to%2520G-protein-coupled%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D13118%26epage%3D13123%26doi%3D10.1073%2Fpnas.1104614108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span>; <span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure–Function Relations in G Protein-Coupled Receptors</span>. In  <i>Methods in Neurosciences</i>;<span class="NLM_contrib-group"><span class="NLM_string-name">Sealfon, S. C.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1995</span>; Vol.  <span class="NLM_volume">25</span>, pp  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=366-428&author=J.+A.+Ballesteros&author=H.+Weinsteinauthor=S.+C.+Sealfon&title=Methods+in+Neurosciences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26atitle%3DIntegrated%2520Methods%2520for%2520the%2520Construction%2520of%2520Three-Dimensional%2520Models%2520and%2520Computational%2520Probing%2520of%2520Structure%25E2%2580%2593Function%2520Relations%2520in%2520G%2520Protein-Coupled%2520Receptors%26btitle%3DMethods%2520in%2520Neurosciences%26aulast%3DSealfon%26aufirst%3DS.%2BC.%26pub%3DAcademic%2520Press%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javitch, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherezov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span> <span> </span><span class="NLM_article-title">Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">1091</span>– <span class="NLM_lpage">1095</span>, <span class="refDoi"> DOI: 10.1126/science.1197410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1126%2Fscience.1197410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=21097933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=1091-1095&author=E.+Y.+Chienauthor=W.+Liuauthor=Q.+Zhaoauthor=V.+Katritchauthor=G.+W.+Hanauthor=M.+A.+Hansonauthor=L.+Shiauthor=A.+H.+Newmanauthor=J.+A.+Javitchauthor=V.+Cherezovauthor=R.+C.+Stevens&title=Structure+of+the+human+dopamine+D3+receptor+in+complex+with+a+D2%2FD3+selective+antagonist&doi=10.1126%2Fscience.1197410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist</span></div><div class="casAuthors">Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Won Han, Gye; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6007</span>),
    <span class="NLM_cas:pages">1091-1095</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain.  The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small mol. D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops.  On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are obsd.  Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R.  This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOEcfSdjMm-7Vg90H21EOLACvtfcHk0lgSk7wghxNEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVahurvM&md5=12c6f343daea9fb14ca605a092f28533</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1126%2Fscience.1197410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1197410%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DStructure%2520of%2520the%2520human%2520dopamine%2520D3%2520receptor%2520in%2520complex%2520with%2520a%2520D2%252FD3%2520selective%2520antagonist%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D1091%26epage%3D1095%26doi%3D10.1126%2Fscience.1197410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50+per+cent+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lgSk7wghxNEjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2520per%2520cent%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NM_000795" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NM_000795','Genbank','NM_000795'); return false;">Genbank: NM_000795</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i189"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00864">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18466"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00864">10.1021/acs.jmedchem.9b00864</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic schemes and characterization data for literature analogues of <b>1</b>; <sup>1</sup>H and <sup>13</sup>C NMR spectra and reverse-phase analytical chromatograms for representative screening compounds; plot of determined PPHT-red equilibrium and kinetic binding parameters; plot of observed association rate (<i>k</i><sub>on</sub>) with calculated topological polar surface are (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for all screening compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_001.csv">jm9b00864_si_001.csv (2.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00864/suppl_file/jm9b00864_si_002.pdf">jm9b00864_si_002.pdf (3.11 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00864&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00864%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00864" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d84d1c7a3c2e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
